question_text,nct_id,retrieval_score,matching_terms,trial_title,trial_phase,trial_age_range,diseases_targeted,inclusion_criteria,exclusion_criteria,prior_therapies,gender,model_grade,reasoning,patient_diseases_targeted,patient_biomarkers,patient_inclusion_criteria,patient_exclusion_criteria,patient_prior_therapies,patient_disease_stage,patient_line_of_therapy,patient_age,patient_age_unit,patient_sex,patient_trial_phase_preference,judge_accuracy,judge_correct_grade,judge_comment,human_grade,human_notes
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT00102648,0.8363680839538574,Recurrent Glioblastoma,Phase I/Ib Study of Sarasar and Temodar in Patients with Recurrent or Temodar-Refractory Glioblastoma Multiforme,PHASE1,18 years,Glioblastoma (recurrent); Gliosarcoma (recurrent),"Histologically proven supratentorial glioblastoma multiforme or gliosarcoma | Radiographic evidence of tumor recurrence or progression by MRI/CT after radiation therapy | Imaging within 14 days prior to registration with stable or decreasing steroid dose for >=5 days | Post-resection patients: >=2 weeks from surgery, recovered with adequate wound healing | Post-resection imaging: CT/MRI within 96 hours post-op or >=4 weeks post-op (within 14 days of registration) with stable steroids for 5 days | Karnofsky performance status >=60 | Recovered from prior therapy toxicities | Washouts: >=4 weeks from prior cytotoxic therapy; >=2 weeks from vincristine; >=6 weeks from nitrosoureas; >=3 weeks from procarbazine; >=1 week from non-cytotoxic agents","Current use of enzyme-inducing anticonvulsants (primidone, carbamazepine, phenobarbital, phenytoin) or not off them for at least 72 hours prior to treatment | History of another cancer (except non-melanoma skin cancer or cervical carcinoma in situ) unless in complete remission and off all therapy for >=3 years | Uncontrolled active infection | Serious intercurrent medical illness or conditions that could obscure toxicity or alter drug metabolism | Any prior treatment with farnesyl transferase inhibitors | Prior recurrence while receiving a farnesyl transferase inhibitor | Use of oral contraceptives or other hormonal birth control methods (e.g., depot medroxyprogesterone)",Prior temozolomide required; No prior farnesyl transferase inhibitor therapy allowed; Up to 2 prior chemotherapy regimens for recurrent/progressive disease allowed; Phase 1b expansion: at least 2 cycles of adjuvant temozolomide required; Washout: >=4 weeks from prior cytotoxic therapy; Washout: >=2 weeks from vincristine; Washout: >=6 weeks from nitrosoureas; Washout: >=3 weeks from procarbazine; Washout: >=1 week from non-cytotoxic agents,ALL,A,"Disease and setting align (recurrent glioblastoma post-radiation/temozolomide), and prior-exposure requirements are met (prior temozolomide, no prior farnesyl transferase inhibitor). Age/sex fit eligibility, and no explicit exclusions are evident from the provided data.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,No hard exclusions. Disease matches (recurrent GBM). Stage/setting matches (recurrent). Line/prior exposure matches (prior temozolomide; no prior FTI). No required biomarkers or metastatic pattern constraints. ≥2 core anchors match with no soft conflicts → A.,,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT01012817,0.7590675354003906,Recurrent Clear Cell Ovarian Carcinoma,"A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) After Prior Platinum Containing First-Line Chemotherapy",PHASE1/PHASE2,18 years,Solid Tumor (metastatic); Solid Tumor (unresectable); Ovarian Cancer (recurrent); Fallopian Tube Cancer (recurrent); Primary Peritoneal Cancer (recurrent),"Phase I: Histologically confirmed solid tumor that is metastatic or unresectable and lacks standard curative or life-extending therapy | Phase II: Biopsy-proven ovarian, fallopian tube, or primary peritoneal cancer | Fewer than 3 prior lines of therapy and relapse less than 1 year from last platinum regimen | Measurable disease with at least one lesion >= 2.0 cm (conventional) or >= 1.0 cm (spiral CT) | Absolute neutrophil count >= 1500/µL | Hemoglobin >= 9.0 g/dL | Platelets >= 100,000/µL | Total bilirubin <= 1.5 x ULN | AST or ALT <= 2.5 x ULN (stricter general threshold) | Creatinine <= 1.5 x ULN | INR <= 1.4 unless on therapeutic warfarin | PTT <= 48 s | ECOG performance status 0-2 | Life expectancy >= 12 weeks | Negative pregnancy test for females of childbearing potential | Able to swallow and absorb oral medication","Standard therapy exists that is potentially curative or capable of extending life expectancy | Prior treatment with a PARP inhibitor or topotecan | Uncontrolled intercurrent illness (e.g., active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, significant psychiatric illness) | Chemotherapy within 4 weeks | Mitomycin C or nitrosoureas within 6 weeks | Immunotherapy within 4 weeks | Biologic therapy within 4 weeks | Radiation therapy within 4 weeks | Radiation to > 25% of bone marrow | Investigational therapy within 4 weeks (hormone therapy for prostate cancer allowed) | Failure to recover from acute reversible effects of prior chemotherapy | NYHA class III or IV heart failure | Known CNS metastases or seizure disorder unless treated and stable >= 6 months without steroids and without seizures | Pregnant or nursing | Men or women of childbearing potential unwilling to use adequate contraception | Significant co-morbid systemic illness that would interfere with safety assessment | Immunocompromised state or known HIV positive | Receiving another investigational agent for the primary neoplasm | Other active malignancy except non-melanoma skin cancer or carcinoma in situ of the cervix | History of myocardial infarction within 6 months | Congestive heart failure requiring ongoing maintenance therapy for life-threatening ventricular arrhythmias | More than 2 prior chemotherapy regimens for the current malignancy",< 3 prior lines of therapy and relapse < 1 year from last platinum regimen; No chemotherapy within 4 weeks prior to registration; No mitomycin C or nitrosoureas within 6 weeks prior to registration; No immunotherapy within 4 weeks prior to registration; No biologic therapy within 4 weeks prior to registration; No radiation therapy within 4 weeks prior to registration; No investigational therapy within 4 weeks prior to registration,ALL,A,"The trial targets relapsed ovarian cancer and the patient (36-year-old female with recurrent clear cell ovarian cancer) fits the disease/setting and age/sex. She has only one prior platinum-based regimen and no prior PARP/topotecan exposure, aligning with line/prior requirements; other specifics (e.g., relapse interval, measurable disease, labs) are unspecified but not conflicting.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),INCORRECT,B,"No hard exclusions. Disease and stage/setting (recurrent ovarian cancer post-platinum) match. However, a key line-of-therapy requirement—relapse <1 year from last platinum—is unknown, so the Line/prior anchor cannot be counted as a clear match. With exactly one clear anchor (stage/setting) and no soft conflicts, the correct grade is B, not A.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT01107522,0.8286269903182983,Recurrent Glioblastoma,A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas,PHASE1,18 years,Solid Tumor (advanced/metastatic); Glioblastoma; Malignant Glioma (recurrent),"Histologically confirmed advanced or metastatic solid tumor refractory to or without standard therapy (Arm A) | Measurable disease per RECIST 1.1 (Arm A) | Received prior anticancer therapy or not eligible for established conventional therapy (Arm A) | Recovered from acute adverse effects of prior therapies to baseline or <= grade 1 (all applicable arms) | ECOG performance status 0–2 (all arms) | Age >= 18 years (all arms) | Adequate bone marrow, renal, and hepatic function (see labs) (Arm A) | Life expectancy >= 12 weeks (Arm A) | Histologically proven malignant glioblastoma or other recurrent malignant gliomas (Arm B) | Measurable tumor on gadolinium-enhanced MRI (Arm B) | Life expectancy >= 8 weeks (Arm B) | Unequivocal radiographic progression by MRI within 14 days; on stable steroid dose >= 5 days or new baseline MRI if dose increased (Arm B) | Postoperative eligibility if recovered from surgery and residual disease assessed by MRI within required windows (Arm B) | Prior radiation therapy with or without chemotherapy and progressed; interval >= 12 weeks from completion of radiation to registration (Arm B) | On stable dose of non–CYP3A4-inhibiting/inducing antiepileptic drugs for >= 2 weeks with no seizures at registration (Arms B and C) | Histologically proven newly diagnosed glioblastoma or other malignant gliomas (Arm C) | Life expectancy >= 8 weeks (Arm C) | MRI within 14 days prior to registration; on stable steroid dose >= 5 days or new baseline MRI if dose increased (Arm C)","Prior chemotherapy, hormonal therapy, radiation therapy, or biologic therapy within 4 weeks (6 weeks for mitomycin C or nitrosoureas); for targeted therapy, < 5 half-lives or < 28 days (whichever is shorter) (Arms A and B) | For Arm B, shorter washouts allowed: 14 days vincristine; 21 days procarbazine; 7 days for non-cytotoxic agents (interferon, tamoxifen, thalidomide, cis-retinoic acid) | Any concomitant condition compromising study objectives/compliance or ability to tolerate therapy (e.g., CHF, uncontrolled angina, MI within 1 year, uncontrolled hypertension, dysrhythmias, active infection, unstable diabetes, psychiatric disorder) (all arms) | Pregnant or breastfeeding (all arms) | Another malignancy within 3 years except curatively treated non-melanoma skin cancer or carcinoma in situ of cervix or breast not requiring further treatment (all arms) | Known HIV, HBV, or HCV infection (all arms) | Underlying diagnosis/disease state with increased risk of bleeding (all arms) | Central nervous system metastases, leptomeningeal disease, brain involvement, or seizure disorder (Arm A) | Uncontrolled seizure activity (Arms B and C) | Treatment with known CYP3A4 inhibitors or inducers (all arms) | No prior chemotherapy, hormonal therapy, or biologic therapy for gliomas (Arm C) | Anaplastic oligodendroglioma with 1p/19q deletion or unknown 1p/19q status (Arm C)","Prior anticancer therapy allowed or ineligible for standard therapy (Arm A); Washout >= 4 weeks from prior chemotherapy, hormonal therapy, radiation therapy, or biologic therapy (>= 6 weeks for mitomycin C or nitrosoureas) (Arms A and B); For prior targeted therapy, washout >= 5 half-lives or 28 days (whichever is shorter) (Arms A and B); Shorter washouts permitted in Arm B: 14 days vincristine; 21 days procarbazine; 7 days non-cytotoxic agents (interferon, tamoxifen, thalidomide, cis-retinoic acid); Prior radiation therapy required with progression; >= 12 weeks since completion of radiation (Arm B); No prior chemotherapy, hormonal therapy, or biologic therapy for gliomas (Arm C); Recovery to baseline or <= grade 1 from prior therapy adverse effects before enrollment (all arms)",ALL,A,"Disease and setting match Arm B (recurrent glioblastoma after prior radiation/temozolomide); age ≥18 and ECOG 1 meet criteria with no stated conflicting exclusions. Some required details (measurable MRI lesion, steroid stability, washout intervals, AED use) are unspecified but not hard mismatches.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches Arm B (recurrent glioblastoma). Stage/setting matches (recurrent) and prior-exposure compatibility matches (post-RT/TMZ, prior RT required). Other specifics (measurable MRI lesion, steroid stability, washout, AEDs) are unknown, not mismatches. Thus ≥2 core anchors match with no soft conflicts → A.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT01140373,0.8512437343597412,Metastatic Castration-Resistant Prostate Cancer,Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC),PHASE1,18 years,"Prostate Cancer (metastatic, castration-resistant)","Male, age >= 18 years | Karnofsky >= 70% | Histologic confirmation of prostate cancer at MSKCC | Progressive castrate metastatic prostate cancer | Soft tissue progression per RECIST 1.0 | Bone disease progression per PCWG2 with >= 2 new lesions on bone scan | Rising PSA on >= 3 successive determinations >= 2 weeks apart meeting protocol thresholds (and evidence of metastases present) | PSA rise timing after anti-androgen discontinuation: within 2 weeks if second-line therapy | PSA rise timing after anti-androgen discontinuation: after 4 weeks if first-line therapy | Evidence of metastatic disease on imaging (bone scan, CT, and/or MRI) at any time after initial diagnosis | Castrate serum testosterone < 50 ng/mL achieved by prior orchiectomy or LHRH agonist with or without anti-androgen | WBC >= 3000/µL | Absolute neutrophil count >= 1500/µL | Platelets >= 100000/µL | Hemoglobin >= 10 g/dL | Bilirubin < 1.5 x ULN (Gilbert's permitted) | ALT < 2.5 x ULN | AST < 2.5 x ULN | Creatinine < 1.5 x ULN | Negative screening for HIV, HBV antigen, and HCV","History of non-prostate primary malignant cancer (except non-melanoma skin cancer) within 5 years | History of splenectomy | Autoimmune or antibody-mediated disease (e.g., SLE, rheumatoid arthritis, ulcerative colitis, Crohn's disease, temporal arteritis, thyroiditis) | Clinically significant cardiac disease (NYHA Class III/IV) or severe debilitating pulmonary disease | Radiation therapy within 4 weeks prior to Day -1 | More than one prior chemotherapy regimen | Use within 4 weeks before Week 1: systemic radiopharmaceuticals (e.g., samarium-153), hematopoietic growth factors other than erythropoietin, medroxyprogesterone as appetite stimulant, or alternative prostate cancer treatments (e.g., Prostasol, saw palmetto, Zyflamend) | Active CNS or symptomatic epidural metastatic disease | Infection requiring antibiotics within 7 days of Day -1 | Requirement for daily systemic corticosteroids or other immunosuppressive/immunomodulatory agents (topical/nasal/physiologic steroids permitted) | Live attenuated vaccines within 8 weeks prior to Day -1 and throughout the study | Subunit or killed vaccines within 2 weeks prior to Day -1 and throughout the study (influenza vaccination permitted between Week 12–16 and after Week 20) | Positive stool guaiac (excluding hemorrhoids or documented radiation-induced proctitis if tested) | Participation in a therapeutic study or receipt of an investigational drug within 4 weeks of leukapheresis | Allergy to ganciclovir or acyclovir","Prior orchiectomy or LHRH agonist to achieve castrate testosterone required; If anti-androgen discontinued: document PSA rise within 2 weeks (second-line) or after 4 weeks (first-line) before enrollment; Washout: radiation therapy >= 4 weeks before Day -1; Washout: systemic radiopharmaceuticals, non-erythropoietin hematopoietic growth factors, medroxyprogesterone as appetite stimulant, and alternative prostate cancer treatments >= 4 weeks before Week 1; Washout: live attenuated vaccines >= 8 weeks before Day -1; subunit/killed vaccines >= 2 weeks before Day -1; Washout: investigational drug >= 4 weeks before leukapheresis",MALE,A,"Disease and stage match mCRPC; the patient is a 66-year-old male with prior LHRH therapy and progression on AR-targeted therapy, fitting the trial’s progressive castrate metastatic setting. Metastatic pattern (bone/liver) is allowed, and no explicit exclusion is triggered based on provided data.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches mCRPC. Stage/setting matches (progressive castrate metastatic). Line/prior exposure compatible (prior LHRH and AR-targeted therapy; no disallowed chemo). Metastatic pattern acceptable (no CNS). Required biomarkers not specified; none contradicted. ≥2 core anchors match with no soft conflicts, so A is appropriate.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT01366144,0.8285872340202332,Metastatic Urothelial Carcinoma,An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors,PHASE1,18 years,Breast Cancer; Carcinoma of Unknown Primary; Endometrial Cancer; Esophageal Cancer; Lung Cancer; Head and Neck Cancer; Testicular Cancer; Melanoma; Ovarian Cancer; Urothelial Carcinoma,"Histologically confirmed metastatic or unresectable malignancy with expected responsiveness to carboplatin/paclitaxel | ECOG <=2 | Life expectancy >12 weeks | Absolute neutrophil count >= 1,500/µL | Platelets >= 100,000/µL | Hemoglobin >= 8.0 g/dL | All degrees of renal dysfunction allowed, including hemodialysis | Mild to severe hepatic dysfunction allowed | Total bilirubin <= 5 x ULN | AST and ALT <= 10 x ULN | For patients with biliary stent: stable labs within hepatic group from two readings 3 days apart, taken >=10 days after stent placement; no obstruction within last 2 months if stent placed >2 months ago","Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or unresolved toxicities from prior therapy | Concurrent treatment with other investigational agents | Allergy to veliparib or compounds of similar chemical/biologic composition or to study agents | Peripheral neuropathy > grade 1 | Inability to take oral medications continuously | Bleeding diathesis | Active or unstable CNS metastases or requirement for steroid treatment | Uncontrolled intercurrent illness (e.g., active infection, symptomatic congestive heart failure, unstable angina, significant arrhythmia, psychiatric illness limiting compliance) | Pregnant or breastfeeding | HIV-positive on combination antiretroviral therapy with potential for PK interactions | Concurrent hepatic and renal dysfunction | Progressed on prior carboplatin plus paclitaxel therapy | Active seizure or history of seizure disorder",Prior chemotherapy or radiotherapy allowed with washout >=4 weeks (>=6 weeks for nitrosoureas or mitomycin C); Prior veliparib permitted,ALL,A,"Urothelial carcinoma is included, and the patient’s metastatic setting aligns with the trial’s metastatic/unresectable population; prior therapies are permitted with washout, and age/sex fit. No known exclusion is triggered, though prior progression on carboplatin+paclitaxel would exclude if present (unknown here).",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),INCORRECT,B,"No hard exclusions are confirmed. Disease matches and the metastatic setting matches (1 anchor). Line/prior-exposure compatibility is uncertain due to the trial’s explicit exclusion for prior progression on carboplatin+paclitaxel; the patient’s prior exposure is unknown, so this anchor cannot be counted as a match. With exactly one anchor matched and no soft conflicts, the correct grade is B, not A.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT01552434,0.7144888639450073,Recurrent Glioblastoma,"A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications",PHASE1,Not specified,Advanced Malignant Neoplasm; Metastatic Malignant Neoplasm; Recurrent Malignant Neoplasm; Refractory Malignant Neoplasm; Lymphangioleiomyomatosis; Neurofibromatosis Type 2; Erdheim-Chester Disease; Castleman Disease,"Advanced or metastatic cancer refractory to standard therapy, relapsed after standard therapy, or without effective standard therapy | Relentlessly progressive benign diseases eligible: lymphangioleiomyomatosis, neurofibromatosis type 2, Erdheim-Chester disease, Castleman disease | >= 4 weeks since last therapeutic radiation or cytotoxic chemotherapy or antibody therapy | >= 5 half-lives since last non-cytotoxic targeted or biologic therapy | Palliative radiation allowed if not to the only target lesion | ECOG performance status <=2 | Karnofsky >= 60% | Lansky >= 60% (for participants <=16 years) | Absolute neutrophil count >= 1,000/µL | Platelets >= 50,000/µL | Creatinine <= 3 x ULN | Total bilirubin <= 3.0 mg/dL | AST <= 5 x ULN | ALT <= 5 x ULN | Fasting total cholesterol <= 350 mg/dL | Triglycerides <= 400 mg/dL","Clinically significant unexplained bleeding within 28 days prior to enrollment | Uncontrolled hypertension (systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg on medication) | History of cerebrovascular accident within 6 months | Myocardial infarction within 6 months | Unstable angina or unstable angina pectoris | Pregnant or breast-feeding | Hypersensitivity to bevacizumab or murine products or any component of its formulation | Hypersensitivity to temsirolimus, sirolimus, polysorbate 80, or any component of its formulation | Hypersensitivity to cetuximab, murine products, or any component of its formulation | Concurrent use of CYP3A4 inducers or inhibitors | Colorectal cancer with known KRAS mutation (for cetuximab-containing arm) | Major surgery within 6 weeks of enrollment | Receiving other investigational agents or other concurrent anticancer agents or therapies",">= 4-week washout from therapeutic radiation, cytotoxic chemotherapy, or antibody therapy; >= 5 half-life washout from non-cytotoxic targeted or biologic therapy; Palliative radiation permitted if not to the only target lesion",ALL,A,"Recurrent glioblastoma fits the basket trial’s advanced/recurrent malignancy scope, and the patient is relapsed after standard therapy with ECOG 1, matching stage/setting and prior-therapy anchors. No explicit exclusions are evident from the provided data (age/sex acceptable; other labs/timing unknown but not disqualifying).",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,No hard exclusions identified; disease fits broad advanced/recurrent malignancy basket. Stage/setting (recurrent/relapsed after standard therapy) and line/prior exposure anchors both match. No required biomarkers or mets pattern constraints. Unknown washout/labs are not grounds for downgrade per rubric. Grade A is appropriate.,,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT01906385,0.7714822888374329,Recurrent Glioblastoma,"A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC# 12-02)",PHASE1/PHASE2,18 years,Glioma (recurrent),"Age >= 18 years | Histologically confirmed recurrent Grade III/IV glioma (e.g., Astrocytoma, IDH-mutant grade 3 or 4; Glioblastoma, IDH-wildtype grade 4) | Disease progression by RANO or other accepted neuro-oncology criteria after standard treatment options with known survival benefit for any recurrence, or medically unable/unwilling to receive them | Stable dose of antiepileptic medication for >= 2 weeks without seizures prior to dosing (if on antiepileptics) | Corticosteroid dose stable or decreasing for >= 2 weeks without symptom progression prior to dosing (if on corticosteroids) | Tumor within the treatment field volume | ECOG performance status 0–2 | Karnofsky Performance Status >= 60% | Life expectancy >= 2 months | Bilirubin <= 1.5 x ULN | AST <= 3.0 x ULN | ALT <= 3.0 x ULN | Serum creatinine <= 1.5 x ULN | ANC >= 1000/µL (without hematologic support) | Platelet count >= 100000/µL (without hematologic support) | Hemoglobin >= 9.0 g/dL (without hematologic support)","Acute intracranial or intratumoral hemorrhage on MRI or CT (resolving changes/punctate/hemosiderin allowed) | Contraindication or inability to undergo MRI | Not recovered to CTCAE v4.0 Grade <= 1 from prior therapy-related adverse events (except alopecia, anemia, lymphopenia) | Pregnant or breastfeeding | Uncontrolled hypertension (>150/100 mmHg on two readings) despite optimal treatment | Active medically significant infection unresponsive to antibiotics or uncontrolled systemic infection | Clinically significant cardiac arrhythmias not controlled by medications | Untreated hypothyroidism | Symptomatic congestive heart failure or unstable angina within 3 months prior to study drug | Myocardial infarction within 6 months prior to study drug | Stroke or transient ischemic attack within 6 months prior to study drug | Known active malignancy other than glioma (except non-melanoma skin cancer or cervical carcinoma in situ unless deemed not impactful by PI) | Inherited bleeding diathesis or coagulopathy with bleeding risk | Prior treatment with bevacizumab | Prior non-standard radiation to target site (brachytherapy, systemic radioisotope therapy, or intra-operative radiotherapy) | External beam radiation therapy within 12 weeks of screening | Systemic therapy (including investigational agents and small-molecule kinase inhibitors) or non-cytotoxic hormonal therapy within 14 days or 5 half-lives (whichever is shorter) prior to dosing | Biologic agents (antibodies, immune modulators, vaccines, cytokines) within 21 days prior to dosing | Nitrosoureas or mitomycin C within 42 days prior to dosing | Metronomic/protracted low-dose chemotherapy within 14 days prior to dosing | Other cytotoxic chemotherapy within 28 days prior to dosing | Prior treatment with carmustine wafers | Receipt of another investigational agent within 28 days prior to dosing or currently receiving investigational therapy | Multifocal progression or leptomeningeal involvement | Psychiatric illness or social situations limiting compliance | Infratentorial disease | Tumor within 1–2 cm of a ventricle with risk for extravasation to subarachnoid space per surgeon/PI/sponsor assessment | Phase 2 only: tumor volume > 20 cm3","Received standard treatments with known survival benefit for recurrence (e.g., surgery, temozolomide, radiation, tumor treating fields) or medically unable/unwilling to receive them; Washout: external beam radiation >= 12 weeks before screening; Washout: systemic therapy or non-cytotoxic hormonal therapy >= 14 days or 5 half-lives (whichever is shorter) before dosing; Washout: biologic agents >= 21 days before dosing; Washout: nitrosoureas or mitomycin C >= 42 days before dosing; Washout: metronomic/protracted low-dose chemotherapy >= 14 days before dosing; Washout: other cytotoxic chemotherapy >= 28 days before dosing; No investigational agents within 28 days before dosing",ALL,A,"The trial targets recurrent high-grade glioma including IDH-wildtype GBM; the patient is a 40-year-old with recurrent GBM after standard chemoradiation and ECOG 1, matching stage/setting and prior-therapy requirements. No explicit exclusions (e.g., prior bevacizumab or recent radiation) are reported, though labs and tumor location/volume would need confirmation at screening.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,No hard exclusions identified. Disease matches (recurrent GBM within recurrent high-grade glioma cohort). Stage/setting matches (recurrent). Line/prior exposure compatible (post-standard chemoradiation; no bevacizumab/carmustine wafers noted). Required subtype acceptable (IDH-wildtype GBM is explicitly included). Unknown labs/tumor location are neutral per rubric. Thus ≥2 core anchors match with no soft conflicts → A.,,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT02062827,0.7754822969436646,Recurrent Glioblastoma,"A Phase 1 Study of M032 (NSC 733972), a Genetically Engineered HSV-1 Expressing IL-12, in Patients With Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma",PHASE1,18 years,Glioblastoma (recurrent/progressive); Anaplastic Astrocytoma; Gliosarcoma,"Histologically or cytologically confirmed glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma | Failed external beam radiotherapy to the brain | If eligible and tolerated, prior temozolomide chemotherapy | All radiation and additional chemotherapies completed >=4 weeks before enrollment | Prior nitrosoureas completed >=6 weeks before enrollment | Age >=18 years | Karnofsky Performance Status >=70% | Life expectancy >4 weeks | Leukocytes >3000/µL | Absolute neutrophil count >1500/µL | Platelets >100000/µL | Total bilirubin within normal limits | AST/ALT <2.5 x ULN | Creatinine within normal limits or creatinine clearance >60 mL/min | Residual lesion >=1.0 cm and <5.5 cm in diameter without bilateral corpus callosum extension, suitable for local catheter-based delivery by MRI | Women of childbearing potential: negative serum pregnancy test within 14 days prior to treatment | Use of adequate contraception; barrier method required for 6 months after M032 | Steroid use allowed if dose not increased within 2 weeks; preferably <=2 mg dexamethasone daily at treatment","Chemotherapy, cytotoxic therapy, or immunotherapy within 4 weeks (6 weeks for nitrosoureas) prior to enrollment | Surgical resection within 4 weeks prior to enrollment | Any prior experimental viral therapy or gene therapy (e.g., adenovirus, retrovirus, herpes virus) | Not recovered from adverse events from prior therapy administered >4 weeks earlier | Receiving other investigational agents | History of allergic reactions to compounds similar to M032 or to interleukin-12 | Tumor location requiring ventricular, brainstem, basal ganglia, or posterior fossa inoculation, or requiring ventricular access for delivery | Bilateral extension through the corpus callosum, actively growing multifocal disease by MRI, or CSF/leptomeningeal dissemination | Prior history of encephalitis, multiple sclerosis, or other CNS infection | Required steroid dose increase within 2 weeks of scheduled M032 administration | Active oral herpes lesion | Concurrent therapy with anti-HSV drugs (e.g., acyclovir, valacyclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir) | Uncontrolled intercurrent illness (e.g., active infection, symptomatic heart failure, unstable angina, cardiac arrhythmia) or any condition precluding surgery | Psychiatric illness or social situation limiting compliance | Pregnant or breastfeeding | HIV-seropositive | Allergy to IV contrast not amenable to premedication | MRI contraindications (e.g., pacemaker, ferromagnetic aneurysm clips, metal infusion pumps, metal/shrapnel fragments, certain stents) | Receipt of Gliadel therapy | Receipt of bevacizumab within 4 weeks of scheduled M032 administration | Any other reason deemed unfit by investigator","Must have failed external beam radiotherapy to the brain; If eligible and tolerated, prior temozolomide chemotherapy required; Washout: radiation and additional chemotherapies completed >=4 weeks before enrollment; Washout: prior nitrosoureas completed >=6 weeks before enrollment; Washout: surgical resection completed >=4 weeks before enrollment; Washout: bevacizumab >=4 weeks before M032 administration",ALL,A,"The trial targets recurrent GBM and requires prior radiation/temozolomide, which this 40-year-old patient with recurrent IDH-wildtype GBM has completed; ECOG 1 is consistent with KPS ≥70 and age criteria are met. Some procedural details (lesion size/location, washout intervals, steroid dose) are not provided but are not hard exclusions.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches (recurrent GBM). Stage/setting matches (recurrent/progressive). Line/prior exposure matches (failed EBRT and prior temozolomide). Age/sex compatible. Other requirements (lesion size/location, washouts, steroids) are unknown, not soft mismatches. Thus ≥2 core anchors match with no soft conflicts → A.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT02099058,0.7885686755180359,Metastatic Non-Small Cell Lung Cancer,"A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors",PHASE1,18 years,Non-Small Cell Lung Cancer (advanced/metastatic),"Advanced non-small cell lung cancer not amenable to surgery or other approved therapy with clinical benefit | ECOG performance status 0–2 (Monotherapy Expansion Cohort: ECOG 0–1) | Measurable disease per RECIST v1.1 | Archived FFPE tumor tissue available for analyses | Adequate bone marrow, renal, and hepatic function | Women of childbearing potential have a negative serum pregnancy test at baseline | Eligible to receive erlotinib or nivolumab per local labeling (for Arms A and D) | Arm E: Metastatic/locally advanced nonsquamous NSCLC with EGFR del19 or L858R (with or without T790M) and no EGFR mutations known to be resistant to osimertinib | Arm E: Received 1–2 prior regimens, one containing osimertinib, with progression on osimertinib (only 1 prior regimen may have contained chemotherapy; consecutive EGFR TKIs count as 1) | Arm E: Post-progression tumor tissue available for central c-MET IHC testing | Monotherapy Expansion: Locally advanced or metastatic, nonsquamous, EGFR wild-type, c-MET positive NSCLC (no adenosquamous histology) | Monotherapy Expansion: No more than 2 prior systemic therapies in advanced setting (no more than 1 line of cytotoxic chemotherapy) | Monotherapy Expansion: Progressed on cytotoxic chemotherapy (or ineligible) and on an immune checkpoint inhibitor (or ineligible), and prior targeted therapy for driver alterations if applicable","Radiation therapy to the lung within 6 months before first dose | Anticancer therapy (chemotherapy, immunotherapy, biologic, investigational) within 21 days before first dose | Herbal therapy within 7 days before first dose | Uncontrolled CNS metastases; eligible 2–4 weeks after definitive therapy if asymptomatic and steroid dose stable/not increasing and not on anticonvulsants for progressive CNS metastases | History of interstitial lung disease or pneumonitis requiring systemic steroids | Pulmonary fibrosis on imaging or any history of pneumonitis/ILD within 3 months of first dose | Unresolved clinically significant adverse events >= Grade 2 from prior anticancer therapy (except alopecia or anemia) | Major surgery within 21 days before first dose | History of major immunologic reaction to any IgG-containing agent | Pregnant or lactating female | Known active COVID-19 infection or recent exposure/signs within 14 days prior to screening | Combination arms: Any condition placing participant at unacceptably high risk for toxicities from the combination | Nivolumab: Active autoimmune disease (except vitiligo, type 1 diabetes, hypothyroidism, psoriasis) | Nivolumab: Systemic corticosteroids >10 mg prednisone equivalent or other immunosuppressants within 14 days (except inhaled/locally injected/topical) | Nivolumab: Known immunosuppressive disease (e.g., HIV infection, history of bone marrow transplant, chronic lymphocytic leukemia) | Osimertinib: Hypersensitivity to osimertinib or excipients | Osimertinib: History of osimertinib dose reduction | Osimertinib: Conditions interfering with absorption (refractory nausea/vomiting, chronic GI disease, inability to swallow, prior significant bowel resection) | Osimertinib: QTc >470 ms, significant ECG conduction abnormalities (e.g., LBBB, 2nd/3rd degree block, PR >250 ms), or risk factors for QT prolongation/arrhythmia (e.g., heart failure, hypokalemia, congenital long QT, QT-prolonging meds) | Monotherapy Expansion: Prior c-MET–targeted antibody-based therapies",Arm E: 1–2 prior regimens with mandatory prior osimertinib and progression on osimertinib; only 1 prior chemotherapy-containing regimen allowed; Monotherapy Expansion: <=2 prior systemic therapies in advanced setting with <=1 cytotoxic chemotherapy line; Monotherapy Expansion: Progression on cytotoxic chemotherapy and on an immune checkpoint inhibitor or ineligible for these therapies; Washout: No anticancer therapy within 21 days before first dose; Washout: No herbal therapy within 7 days before first dose; Washout: No major surgery within 21 days before first dose,ALL,A,"Metastatic NSCLC with EGFR exon 19 deletion matches the Arm E cohort, and the patient meets general eligibility (age ≥18, ECOG 0). Prior osimertinib exposure aligns with arm requirements; progression status and tissue/testing availability are unknown but not conflicting.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),INCORRECT,B,"Disease and metastatic setting match. However, Arm E requires nonsquamous histology and progression on prior osimertinib—both are unknown. Thus only one clear CORE ANCHOR (stage/setting) can be counted; biomarker/subtype anchor is uncertain due to unknown histology, and line/prior is unknown due to progression requirement. No soft mismatches or hard exclusions. Correct grade is B, not A.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT02123758,0.8754674792289734,Metastatic Castration-Resistant Prostate Cancer,"A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer",PHASE1,18 years to 99 years,Prostate Cancer (metastatic castration-resistant),ECOG performance status <= 2 | Histologically or cytologically confirmed adenocarcinoma of the prostate | Documented metastatic disease | Evidence of prostate cancer progression | Surgically or medically castrated with testosterone < 50 ng/dL | Adequate bone marrow and organ function,"Known brain metastases | Pathology consistent with small cell carcinoma of the prostate | Investigational agent within 4 weeks prior to Cycle 1 Day 1 | Chemotherapy or immunotherapy for prostate cancer within 4 weeks prior to Cycle 1 Day 1 | Concomitant medications that lower the seizure threshold | Use of herbal or non-herbal products that may decrease PSA levels (e.g., saw palmetto, pomegranate products) | Use of strong enzyme inducers (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort) or dexamethasone | Use of potent inhibitors of CYP3A4 or CYP2C8",Surgical or medical castration required (testosterone < 50 ng/dL); Washout >= 4 weeks since last investigational agent; Washout >= 4 weeks since last chemotherapy or immunotherapy for prostate cancer,MALE,A,"Disease and stage match (mCRPC), and the patient’s age/sex fit the trial window; prior AR-targeted therapy is not prohibited in the listed criteria and the metastatic pattern (liver/bone, no brain mets reported) is acceptable. No explicit exclusion is triggered based on available data.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions. Disease and stage (mCRPC) match. Line/prior exposure is compatible (trial does not prohibit prior AR-targeted therapy; only washouts/chemo-immuno noted). No identified soft mismatches; other anchors (biomarker, brain mets) are neutral/unknown. Thus ≥2 anchors (stage and line/prior) → A.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02142803,0.7360695004463196,Recurrent Clear Cell Ovarian Carcinoma,A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors,PHASE1,18 years,Glioblastoma; Endometrial Clear Cell Carcinoma; Endometrial Serous Carcinoma; Ovarian Clear Cell Carcinoma; Ovarian Endometrioid Carcinoma; Ovarian Mucinous Carcinoma; Ovarian Serous Carcinoma; Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Malignant Uterine Corpus Neoplasm,"Histologically/cytologically confirmed recurrent glioblastoma or advanced solid tumor where bevacizumab has shown benefit and no standard/curative options remain | Measurable or evaluable disease (RECIST 1.1 for non-GBM; RANO for GBM) | Prior therapy: Stage 1 and Stage 2 endometrial/ovarian cohorts allow unlimited prior therapy; Stage 2 GBM: no more than 2 prior relapses (intent: no more than 3 prior therapies total) | Recovery from prior therapy toxicities to grade <= 1 or baseline | Washouts before day 1: 12 weeks from completion of radiation for recurrent GBM (unless surgical diagnosis of recurrence or new non-irradiated lesion) | Washouts before day 1: 6 weeks from nitrosourea chemotherapy | Washouts before day 1: 3 weeks from non-nitrosourea chemotherapy | Washouts before day 1: 4 weeks from an investigational (non-FDA-approved) agent or 5 half-lives (whichever is shorter) | Washouts before day 1: 2 weeks from a non-cytotoxic FDA-approved agent or 5 half-lives (whichever is shorter) | ECOG performance status <= 2 (Karnofsky >= 60%) | Absolute neutrophil count >= 1,500/µL | Platelets >= 100,000/µL | Hemoglobin >= 9.0 g/dL | Total bilirubin < 1.5 x ULN (direct bilirubin normal; exception: Gilbert's disease) | AST <= 2.5 x ULN (<= 5 x ULN with liver metastases) | ALT <= 2.5 x ULN (<= 5 x ULN with liver metastases) | Creatinine < 1.5 x ULN or creatinine clearance >= 50 mL/min | Fasting serum glucose <= 130 mg/dL | Fasting triglycerides <= 300 mg/dL | Solid tumor patients off corticosteroids prior to registration; GBM: on stable or decreasing corticosteroid dose >= 5 days before baseline imaging; new/increased steroids require new baseline imaging | Able to swallow whole capsules | Stage 2 GBM: archival tissue (block or 30 unstained slides) available | Stage 2 endometrial/ovarian: at least one lesion amenable to biopsy | Stage 2 solid tumor histologies limited to specified endometrial (papillary serous, endometrioid, clear cell) and ovarian/fallopian/primary peritoneal (high-grade serous, clear cell, endometrioid, mucinous) carcinoma","Concurrent investigational agents | Allergy to compounds similar to sapanisertib or bevacizumab | Stage 2: prior mTOR/PI3K/Akt inhibitors not allowed (allowed in Stage 1 only) | Stage 2 GBM: prior bevacizumab/VEGFR inhibitors not allowed (allowed in Stage 1 and Stage 2 endometrial/ovarian) | Stage 1 solid tumor and Stage 2 endometrial/ovarian: symptomatic or progressing CNS metastases (treated, asymptomatic, stable >= 1 month allowed) | Concurrent enzyme-inducing antiepileptic drugs (must be off >= 10 days); non-enzyme–inducing AEDs allowed | Strong CYP3A4/CYP2C19 inhibitors/inducers require caution; avoid if possible | Concurrent herbal supplements or non-traditional medications (must stop before registration) | Concurrent anticoagulants other than LMWH (must stop before registration); if recently on warfarin, INR <= 2 required | Significant intracranial hemorrhage within 6 weeks or on screening MRI | Uncontrolled intercurrent illness (active infection, symptomatic CHF, unstable angina, significant arrhythmia, psychiatric illness limiting compliance) | Cardiac exclusions within 6 months: LVEF <= 55%, NYHA class >= 3 heart failure, significant ischemic changes, complete LBBB, bifascicular block, congenital long QT, QTcF > 450 ms, inotropic support (excluding digoxin), clinically significant tachyarrhythmias or cardiac arrest, clinically significant bradycardia, unstable atrial fibrillation (>100 bpm), arrhythmia requiring ICD, angina within 12 months, acute MI within 12 months, significant valvular disease, ischemic events requiring therapy or revascularization, pacemaker placement, pulmonary embolism, ischemic cerebrovascular events or revascularization | GI impairment that may alter absorption (e.g., active ulcerative disease, uncontrolled N/V/D, malabsorption, small bowel resection requiring nutritional support) | Use of hematopoietic growth factors <= 2 weeks before start (ESAs allowed if started >= 2 weeks prior) | Pregnant or nursing women | HIV-positive on combination antiretroviral therapy with strong CYP inhibitors are ineligible (eligible if CD4 adequate and ART without strong CYP inhibitors) | Uncontrolled hypertension (SBP >= 160 mmHg or DBP >= 90 mmHg) | Pulmonary hypertension | Uncontrolled asthma or O2 saturation < 90% on room air | Poorly controlled diabetes (HbA1c > 7%) | Proteinuria: if urine dipstick >= 2+, 24-hour urine protein must be < 1000 mg for enrollment | Serious or non-healing wound, ulcer, or bone fracture | History of abdominal fistula, GI perforation, or intra-abdominal abscess within 6 months | Recent invasive procedures: major surgery/open biopsy/significant trauma within 28 days; anticipated major surgery; core biopsy within 7 days | Significant vascular disease within 6 months (e.g., aortic aneurysm requiring repair, recent peripheral arterial thrombosis) | Bleeding diathesis or coagulopathy | Hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies",Stage 1 and Stage 2 endometrial/ovarian: unlimited prior therapy allowed; Stage 2 GBM: no more than 2 prior relapses (no more than 3 prior therapies total including initial); Recovery from prior therapy toxicities to grade <= 1 required before enrollment; Washout: >= 12 weeks since radiation for recurrent GBM (unless surgical diagnosis of recurrence or new non-irradiated lesion); Washout: >= 6 weeks since nitrosourea chemotherapy; Washout: >= 3 weeks since non-nitrosourea chemotherapy; Washout: >= 4 weeks or 5 half-lives (whichever shorter) since investigational non-FDA-approved agent; Washout: >= 2 weeks or 5 half-lives (whichever shorter) since non-cytotoxic FDA-approved agent,ALL,A,"Disease and setting match the ovarian clear cell cohort, and prior therapy (including bevacizumab) is allowed; age and sex are within bounds. Required histology is satisfied and there are no explicit exclusions based on the provided profile.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,"No hard exclusions. Disease (ovarian clear cell) is explicitly included. Stage/setting (recurrent/advanced) fits. Prior therapy (including bevacizumab) is allowed for the ovarian cohort. Required subtype/histology satisfied; no soft conflicts identified from provided data. Unknowns (e.g., measurable disease/biopsy amenable, no standard options) cannot be inferred, so do not reduce the grade. A is appropriate.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT02192359,0.7554003000259399,Recurrent Glioblastoma,A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination With Intravenous Irinotecan in Patients With Recurrent High-Grade Gliomas,PHASE1,18 years to 69 years,Anaplastic Astrocytoma (recurrent); Anaplastic Oligoastrocytoma (recurrent); Anaplastic Oligodendroglioma (recurrent); Glioblastoma (recurrent); Gliosarcoma (recurrent),"Karnofsky performance status >= 70% | Life expectancy >= 3 months | Histologically confirmed grade III or IV glioma or prior grade II glioma now with radiographic high-grade (grade III or IV) | Radiographic evidence of recurrent tumor | Recurrent or progressive high-grade glioma after prior brain radiation and temozolomide | Requires craniotomy for tumor resection or stereotactic brain biopsy | No anticipated connection between post-resection cavity and cerebral ventricles | Medically able to undergo neurosurgery | Any number of prior therapies permitted with washouts: >= 6 weeks from nitrosoureas; >= 4 weeks from non-nitrosourea cytotoxic chemotherapy (23 days from last daily temozolomide in 5/28 regimen); >= 2 weeks from last targeted agent (>= 4 weeks for bevacizumab) | Toxicities from prior therapy improved to grade 0 or 1 | ANC >= 1,500/µL | Platelets > 100,000/µL | Total bilirubin <= 2.0 mg/dL | AST <= 4 x ULN | Serum creatinine <= 1.5 x ULN | Homozygous negative for UGT1A1*28 | Absence of anti-HLA class I antibodies specific for the NSCs | Negative pregnancy test (women of childbearing potential) | Effective contraception during study (women of childbearing potential and sexually active men) | For enrollment at dose level >= 2: presence of supratentorial disease amenable to resection or biopsy for Rickham reservoir/catheter placement","Prior therapy with neural stem cells | Use of CYP3A4 inducers (including enzyme-inducing anticonvulsants) within 2 weeks prior to start of study treatment | Use of moderate to strong CYP3A4 inhibitors within 2 weeks prior to start of study treatment | Use of drugs that inhibit UGT1A1 (e.g., atazanavir, gemfibrozil, indinavir, ketoconazole) within 2 weeks prior to start of study treatment | Use of systemic immunosuppressive agents other than corticosteroids (e.g., cyclosporine, tacrolimus) | Flucytosine within 2 weeks prior to start of study treatment | Use of herbal medications | Concurrent use or planned use of other investigational agents or anti-tumor therapy (biologic, chemotherapy, or radiation) | Known HIV infection or hepatitis C infection | Unable to undergo MRI with contrast | Known chronic or active CNS viral infections | Clinically significant uncontrolled illness | Active infection requiring antibiotics | Diagnosis of Gilbert's disease | History of allergic reactions to compounds similar to irinotecan | Known sensitivity to any study products | Any other active malignancy | Pregnant or breastfeeding | Serious medical or psychiatric illness that may interfere with safety monitoring or treatment completion | Investigator deems participant may be unable to comply with study procedures",Prior brain radiation and temozolomide required; Any number of prior therapies permitted; Washout: >= 6 weeks from nitrosoureas; Washout: >= 4 weeks from non-nitrosourea cytotoxic chemotherapy (23 days from last daily temozolomide in 5/28 regimen); Washout: >= 2 weeks from last targeted agent (>= 4 weeks for bevacizumab),ALL,A,"Disease and setting match (recurrent glioblastoma after prior radiation/temozolomide), and prior-exposure requirements are met; age/sex and ECOG imply acceptable performance status for KPS ≥70. Key eligibility details (e.g., need for planned craniotomy/biopsy, UGT1A1*28 homozygous negative, and anti-HLA antibody status) are unknown but not conflicting.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches (recurrent GBM within trial’s recurrent high-grade glioma cohorts). Stage/setting matches (recurrent post RT/TMZ) and Line/prior exposure matches (prior RT+TMZ required and allowed). Biomarker requirements (UGT1A1*28 negative, anti-HLA antibodies) and surgical requirement (planned craniotomy/biopsy) are unknown, not mismatches. With ≥2 core anchors matching and no soft conflicts, A is appropriate.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02208375,0.7823781371116638,Recurrent Clear Cell Ovarian Carcinoma,"A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",PHASE1,18 years,Endometrial Adenocarcinoma (recurrent); High-Grade Serous Ovarian Carcinoma (recurrent); Primary Peritoneal Carcinoma (recurrent); Fallopian Tube Carcinoma (recurrent); Ovarian Carcinoma (recurrent); Triple-Negative Breast Cancer (metastatic),"Recurrent endometrial adenocarcinoma (no carcinosarcoma) with no curative option | Recurrent high-grade serous ovarian, primary peritoneal, or fallopian tube carcinoma; or deleterious BRCA-mutant recurrent ovarian/primary peritoneal/fallopian tube cancer | Metastatic triple-negative breast cancer (ER and PR < 10% by IHC and HER2 negative) | Unlimited prior regimens allowed; frontline therapy for metastatic disease allowed | Measurable disease by RECIST 1.1 or assessable disease (e.g., effusion/ascites per CA125 GCIG criteria) | ECOG performance status 0-1 | Women of childbearing potential: negative pregnancy test and agree to effective contraception during treatment and for 30 days after last dose | Able to swallow and tolerate oral medications; no GI illnesses precluding absorption | Life expectancy > 4 months | Absolute neutrophil count >= 1,500/µL | Hemoglobin >= 10 g/dL | Platelets >= 100,000/µL | Blasts < 4% on hematologic studies | Total bilirubin <= 1.5 x ULN | AST/ALT <= 2.5 x ULN (<= 5 x ULN if liver involvement) | Creatinine clearance > 50 mL/min (Cockcroft-Gault) | Type II diabetes eligible if diet-controlled with HbA1c < 8% | FOR EXPANSION PHASE ONLY: Measurable disease accessible for biopsy | FOR EXPANSION PHASE ONLY: Archival tumor specimens available","Receipt of other investigational agents or additional anti-cancer agents | Endometrial carcinosarcoma | Ovarian cancer histology other than high-grade serous without a deleterious BRCA mutation | Recurrences amenable to potentially curative radiation therapy or surgery | History of other malignancy within 5 years except adequately treated basal/squamous skin cancer or in situ cervical cancer (dual primaries of endometrial, ovarian, or breast cancer allowed) | History of myelodysplastic syndrome | Symptomatic, uncontrolled spinal cord compression and/or brain metastases | Prior chemotherapy, biologic therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents, or investigational agents within 28 days before starting study treatment (palliative focal RT excepted as noted) | Prohibited corticosteroids within 14 days prior to starting study treatment | Major surgery within 28 days or minor surgery within 2 weeks prior to study entry, or not recovered from surgery | QTcF >= 470 ms at 2 or more time points within 24 hours or family history of long QT syndrome | Blood transfusion required within 28 days prior to study start | Receipt of hematopoietic growth factors (e.g., G-CSF, GM-CSF) within 2 weeks prior to study start | Concomitant prohibited medications/substances within specified washout periods | Known hypersensitivity to olaparib, capivasertib (AZD5363), vistusertib (AZD2014), or their excipients; or to drugs of similar class | Intolerable adverse events to prior PARP, mTOR, PI3K, or AKT inhibitors per investigator | Within 12 months: CABG, angioplasty, vascular stent, myocardial infarction, angina pectoris, CHF NYHA >= 2, ventricular arrhythmias requiring continuous therapy, uncontrolled supraventricular arrhythmias including atrial fibrillation, hemorrhagic or thrombotic stroke including TIA or other CNS bleeding | Abnormal ECHO or MUGA with LVEF < 50% | Torsades de pointes within 12 months | Uncontrolled hypotension (SBP < 90 mmHg and/or DBP < 50 mmHg) | Proteinuria (>= 3+ dipstick or 300 mg/dL on urinalysis or > 500 mg/24 hours) | Type I diabetes or uncontrolled type II diabetes (HbA1c > 8%) | Severe or uncontrolled systemic disease (e.g., severe hepatic impairment, interstitial lung disease, uncontrolled chronic renal disease), unstable/uncompensated respiratory or cardiac conditions, uncontrolled hypertension (>= 140/90), active bleeding diathesis, or active infection including hepatitis B, hepatitis C, or HIV | Investigator deems patient unsuitable or unlikely to comply | FOR EXPANSION PHASE ONLY: No accessible tumor for biopsy | No archival tumor specimens available",Unlimited prior chemotherapy allowed; Prior PARP inhibitor allowed if not discontinued for toxicity (progression allowed); Prior mTOR inhibitor allowed if not discontinued for toxicity (progression allowed); Prior AKT inhibitor allowed if not discontinued for toxicity (progression allowed); Frontline therapy for metastatic disease permitted; No anticancer therapy or investigational agents within 28 days before study start; No prohibited corticosteroids within 14 days before study start; No hematopoietic growth factors within 14 days before study start; No major surgery within 28 days or minor surgery within 2 weeks before study start,FEMALE,A,"Recurrent ovarian cancer with BRCA1 positivity fits the trial cohort allowing BRCA-mutant recurrent ovarian cancer; female age 36 meets eligibility. Stage/setting (recurrent) and prior therapy exposure are compatible, and pleural effusion qualifies as assessable disease.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,"No hard exclusions. Disease matches a recurrent ovarian carcinoma cohort. Stage/setting (recurrent) matches and prior-therapy exposure is compatible (unlimited prior allowed). BRCA1 positivity satisfies the BRCA-mutant recurrent ovarian cohort requirement. No soft mismatches identified, so ≥2 core anchors match and A is appropriate.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT02312557,0.8073949217796326,Metastatic Castration-Resistant Prostate Cancer,Addition of Pembrolizumab Upon Progression on Enzalutamide in Men With mCRPC,PHASE2,18 years,Prostate Adenocarcinoma (castration-resistant),"Metastatic castration-resistant prostate cancer progressing on enzalutamide after initial response | Histologically or cytologically confirmed prostate adenocarcinoma (no pure small cell) | Age >= 18 years | Metastatic disease | Lesion amenable to biopsy | ECOG performance status 0–1 | ANC >= 1,500/µL within 28 days of treatment initiation | Platelets >= 100,000/µL within 28 days of treatment initiation | Hemoglobin >= 9 g/dL within 28 days of treatment initiation | Serum creatinine <= 1.5 x ULN or creatinine clearance >= 60 mL/min within 28 days of treatment initiation | Total bilirubin <= 1.5 x ULN or direct bilirubin <= ULN within 28 days of treatment initiation | AST <= 2.5 x ULN (<= 5 x ULN with liver metastases) within 28 days of treatment initiation | ALT <= 2.5 x ULN (<= 5 x ULN with liver metastases) within 28 days of treatment initiation | INR or PT <= 1.5 x ULN unless on therapeutic anticoagulation (if undergoing biopsy) within 28 days of treatment initiation | aPTT <= 1.5 x ULN unless on therapeutic anticoagulation (if undergoing biopsy) within 28 days of treatment initiation | PSA or radiographic progression on enzalutamide per RECIST 1.1 or >= 2 new bone lesions | Prior surgical castration or ongoing LHRH agonist/antagonist with serum testosterone < 50 ng/dL and agreement to continue LHRH therapy","Participation in another investigational study or use of an investigational device within 4 weeks before first dose | Immunodeficiency or systemic steroid/immunosuppressive therapy within 7 days before first dose (physiologic corticosteroid doses may be permitted) | Prior monoclonal antibody within 4 weeks before day 1 or unresolved toxicities > grade 1 from prior therapies; denosumab prohibited within 4 weeks before day 1 and on study | Prior chemotherapy for castration-resistant disease | Prior chemotherapy, targeted small molecule therapy, or radiation within 2 weeks before day 1 or unresolved toxicities > grade 1 (<= grade 2 neuropathy allowed) | Major surgery without adequate recovery before starting therapy | Another active malignancy requiring treatment (except certain skin cancers or in situ bladder cancer after curative therapy) | Known brain metastases or carcinomatous meningitis | History of seizure | Allergy to enzalutamide | Active autoimmune disease requiring systemic treatment within the past 3 months or history of clinically severe autoimmune disease requiring systemic therapy (exceptions: vitiligo, resolved childhood asthma/atopy, stable hypothyroidism on replacement, Sjogren's syndrome) | History of non-infectious pneumonitis requiring steroids or current pneumonitis | Active infection requiring systemic therapy | Prior therapy with PD-1, PD-L1, PD-L2, CD137, or CTLA-4 inhibitors | Plans to receive cytotoxic chemotherapy, immune checkpoint inhibitors, sipuleucel-T, radiopharmaceuticals, abiraterone, or other experimental therapy during the study | Known HIV infection | Active hepatitis B or active hepatitis C infection | Receipt of a live vaccine within 30 days before first dose | Rapidly progressive visceral disease making the patient a candidate for docetaxel per treating physician judgment",Prior enzalutamide with initial response followed by progression; Prior surgical castration or ongoing LHRH agonist/antagonist therapy,MALE,A,"Disease/setting match mCRPC and the patient progressed on enzalutamide as required; age and male sex align. No explicit exclusions are evident from the data; other eligibility elements (initial response to enzalutamide, ECOG, labs, biopsy-amenable lesion) are unspecified.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),INCORRECT,B,"No hard exclusions. Stage/setting clearly matches (mCRPC). However, the trial requires progression on enzalutamide after an initial response; the patient’s initial response status is unknown, so the line/prior-exposure anchor is not a clear match (unknown). With exactly one confirmed anchor (stage) and no soft conflicts, the correct grade is B, not A.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT02420847,0.8805067539215088,Metastatic Urothelial Carcinoma,"A Phase I Two-Dimensional Dose-Finding Study of Ixazomib in Combination With Gemcitabine and Doxorubicin, Followed by a Phase II Extension to Assess the Efficacy of This Combination in Metastatic, Surgically Unresectable Urothelial Cancer",PHASE1/PHASE2,18 years,Urothelial Carcinoma (metastatic); Urothelial Carcinoma (unresectable),"Histologically confirmed metastatic or locally unresectable urothelial (transitional cell) carcinoma; variant histology allowed with urothelial component | Measurable or evaluable disease | At least one prior therapy unless not candidates for or refuse cisplatin-based therapy | Phase I: any number of prior regimens allowed | Phase II: no prior proteasome inhibitor (e.g., bortezomib, carfilzomib) and no prior gemcitabine >= 800 mg/m^2 plus doxorubicin >= 30 mg/m^2 in the same regimen | Prior neoadjuvant chemotherapy failure eligible | If prior ischemic heart disease or >= 200 mg/m^2 prior doxorubicin, left ventricular ejection fraction >= 45% | ALT <= 3 x ULN | AST <= 3 x ULN | ECOG performance status <= 2; PS 3 allowed if due to malignancy","Platelet count < 100 x 10^9/L | Absolute neutrophil count < 1.0 x 10^9/L | Creatinine clearance < 30 mL/min | Peripheral neuropathy >= grade 3 or grade 2 with pain | Total bilirubin >= 1.5 x ULN | Allergy to study drugs or excipients | Pregnant or breastfeeding | Participation in other investigational trials within 30 days | Myocardial infarction within 6 months, NYHA class III/IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, acute ischemia or active conduction abnormalities | Symptomatic congestive heart failure | Claudication limiting activity | Cerebrovascular event within the last year (including TIA) | Unstable angina | Active brain metastases (previously treated and stable allowed) | Radiotherapy within 28 days (14 days if small field) | Another malignancy within 2 years unless meeting specified exceptions | Strong CYP1A2/3A inhibitors or strong CYP3A inducers within 14 days of first ixazomib dose; use of Ginkgo biloba or St. John's wort | Not recovered to <= grade 1 from prior chemotherapy toxicities | Major surgery within 14 days | Infection requiring current IV antibiotics | Active systemic infection, active hepatitis B or C, or HIV positive | Serious medical or psychiatric illness interfering with protocol treatment | GI disease or procedure interfering with oral absorption of ixazomib","At least one prior systemic therapy required unless cisplatin-ineligible or refuse cisplatin-based therapy; Phase I: any number of prior regimens permitted, including prior bortezomib or gemcitabine+doxorubicin; Phase II: exclude prior proteasome inhibitor therapy and exclude prior combination gemcitabine >= 800 mg/m^2 plus doxorubicin >= 30 mg/m^2; Prior neoadjuvant chemotherapy allowed; Radiotherapy washout: >= 28 days (>= 14 days if small field); Other investigational agents washout: >= 30 days; Major surgery washout: >= 14 days; Recovered to <= grade 1 from prior chemotherapy toxicities before enrollment",ALL,A,"Disease and stage match (metastatic urothelial carcinoma), and the patient has the required prior therapy history (after second line), which is allowed (Phase I permits any number of prior regimens). Age/sex fit; unknown labs/comorbidities and prior-exposure specifics for Phase II do not create explicit exclusions.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,A,"No hard exclusions. Disease and stage match (metastatic urothelial carcinoma). Line/prior exposure compatible (≥1 prior line required; Phase I allows any number, patient is post-2L). No required biomarker. Metastatic pattern constraints unknown. ≥2 core anchors match with no soft conflicts, so A is appropriate.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT02442297,0.7249406576156616,Recurrent Glioblastoma,Phase I Study of Intracranial Injection of T Cells Expressing HER2-specific Chimeric Antigen Receptors (CAR) in Subjects With HER2-Positive Tumors of the Central Nervous System (iCAR),PHASE1,3 years,Brain Tumor (recurrent/refractory),Recurrent or refractory HER2-positive primary CNS tumor or HER2-positive tumor metastatic to the CNS (procurement) | Karnofsky/Lansky score >= 60 (procurement) | Recurrent or refractory HER2-positive primary CNS tumor or HER2-positive solid tumor metastatic to the CNS (treatment) | HER2 positivity by IHC or RT-PCR; IHC >= grade 1 and >= 1+ intensity | Intracranial catheter in place | Age >= 3 years | Life expectancy >= 6 weeks | Karnofsky/Lansky score >= 60 | Bilirubin <= 3 x ULN | AST <= 5 x ULN | ALT <= 5 x ULN | Serum creatinine <= 2 x ULN (age-adjusted) | Hemoglobin >= 7.0 g/dL | Oxygen saturation >= 90% on room air | Available autologous transduced T lymphocytes with >= 15% HER2 CAR expression and >= 20% killing of HER2-positive targets | Recovered from tumor resection with stable neurological deficits for >= 1 week prior to treatment | Off other investigational antineoplastic therapy for 2 weeks prior to CAR T-cell infusion | Temozolomide allowed up to 48 hours pre-infusion | Dexamethasone allowed up to 2 mg/day if medically indicated,Diagnosis of diffuse intrinsic pontine glioma (DIPG) (procurement) | Bulky tumors causing midline shift and/or signs of impending herniation (procurement) | Known HIV positivity (procurement) | Severe intercurrent infection (treatment) | Known HIV positivity (treatment) | Pregnant or lactating (treatment) | History of hypersensitivity reactions to murine protein-containing products (treatment) | Diagnosis of diffuse intrinsic pontine glioma (DIPG) (treatment) | Dexamethasone dose > 2 mg/day or equivalent (treatment),Off other investigational antineoplastic therapy >= 2 weeks before infusion; Temozolomide permitted up to 48 hours pre-infusion; Dexamethasone <= 2 mg/day permitted if medically indicated,ALL,A,"Recurrent glioblastoma fits the trial’s recurrent/refractory CNS tumor setting, and prior standard RT/TMZ is allowed; age/sex are within range. HER2 positivity is required but currently unknown, so eligibility depends on confirming HER2 expression and meeting procedural requirements.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),INCORRECT,C,"HER2-positivity is a required biomarker for this trial and is unknown for the patient. Per rubric, an A requires required biomarkers satisfied when applicable, so A is not allowed. No hard exclusions apply; stage/setting matches and prior-therapy compatibility likely matches, but with the key required biomarker unknown there is insufficient information to award A. This fits C (relevant/uncertain) rather than A.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02446600,0.8971394300460815,Recurrent Clear Cell Ovarian Carcinoma,"A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",PHASE3,18 years,Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Tumor; Ovarian Seromucinous Carcinoma; Ovarian Serous Tumor; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Primary Peritoneal Carcinoma,"Platinum-sensitive recurrent high-grade serous or high-grade endometrioid ovarian, primary peritoneal, or fallopian tube cancer; other high-risk histologies (clear cell, mixed epithelial, undifferentiated, or transitional cell) allowed if deleterious germline BRCA1 or BRCA2 mutation is present | Platinum-sensitive disease: > 6 months since last platinum and complete clinical response to prior platinum; no progression through prior platinum therapy | Measurable disease by RECIST 1.1 OR evaluable disease with CA-125 doubled from nadir and > 2 x ULN | Prior chemotherapy must have included a first-line platinum-based regimen; unlimited prior platinum-based regimens in the recurrent setting allowed | Up to 1 prior non-platinum-based line in the recurrent setting allowed; prior hormonal therapy does not count toward this limit | ECOG performance status 0–2 (Karnofsky >= 60%) | Able to swallow and retain oral medications; no gastrointestinal illness precluding absorption | Blood pressure <= 140/90 mmHg on up to three antihypertensive medications; able and willing to record daily BP | Toxicities from prior therapy resolved to <= grade 1 (except alopecia); long-standing stable grade 2 neuropathy may be allowed (will not receive carboplatin/paclitaxel if randomized to that arm) | Adequately controlled thyroid function; TSH within normal limits without symptoms of thyroid dysfunction | Women of childbearing potential: negative pregnancy test and agreement to use two reliable forms of contraception | Age >= 18 years","Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to starting treatment, or unresolved toxicities from prior therapy > grade 1 | Hormonal therapy within 2 weeks prior to study entry (except raloxifene for bone health) | Concurrent investigational agents or investigational trial participation within 4 weeks | Medications that may markedly affect renal function (e.g., vancomycin, amphotericin, pentamidine) | Prior treatment affecting the VEGF pathway (e.g., thalidomide, sunitinib, pazopanib, sorafenib, nintedanib) in the recurrent setting; upfront bevacizumab allowed | Prior PARP inhibitor | CA-125–only disease without RECIST 1.1 measurable or otherwise evaluable disease | Untreated or symptomatic brain metastases, spinal cord compression, or leptomeningeal disease; treated brain metastases must be radiographically stable >= 6 months and asymptomatic | Strong CYP3A4 inhibitors or inducers; strong UGT/P-gp modulators should be used with caution | History of gastrointestinal perforation; abdominal fistula unless healed and no evidence for >= 6 months and low risk of recurrence | Intra-abdominal abscess within 3 months | Current signs/symptoms of bowel obstruction or within 3 months prior to starting study drugs | Dependency on IV hydration or total parenteral nutrition | Other invasive malignancy unless meeting specified curatively treated exceptions and disease-free >= 3 years | Myocardial infarction within 6 months, unstable angina, clinically significant ECG abnormalities, or NYHA class III/IV heart failure | Left ventricular ejection fraction below institutional normal or < 55% if no institutional threshold | History of stroke or transient ischemic attack within 6 months | Any prior hypertensive crisis or hypertensive encephalopathy | Clinically significant peripheral or other vascular disease (including aortic aneurysm or dissection) | Major surgery, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib | Uncontrolled intercurrent illness (active infection, symptomatic CHF, unstable angina, significant arrhythmia other than controlled AF, or psychiatric/social conditions limiting compliance) | Pregnancy or breastfeeding | Known HIV-positive status | Use of complementary or alternative medicines (natural herbal products or folk remedies) | Features suggestive of myelodysplastic syndrome or acute myelogenous leukemia on smear or marrow (if evaluated) | Prior allogeneic bone marrow transplant or double umbilical cord blood transplantation",Required prior first-line platinum-based chemotherapy (with or without IV consolidation); Unlimited prior platinum-based regimens in the recurrent setting allowed; Up to 1 prior non-platinum-based line in the recurrent setting allowed; Prior hormonal therapy allowed and does not count toward non-platinum limit; Washout: chemotherapy or radiotherapy >= 4 weeks (>= 6 weeks for nitrosoureas or mitomycin C) before study treatment; Washout: hormonal therapy >= 2 weeks before study entry,FEMALE,A,"Recurrent ovarian cancer with clear cell histology and BRCA1 positivity fits the trial (clear cell allowed with BRCA), and she meets age/sex and prior exposure requirements (received first-line platinum; upfront bevacizumab allowed). Platinum-sensitive interval and measurable/evaluable disease are not provided but no conflicts are evident.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),INCORRECT,B,"No hard exclusions. Disease matches and recurrent setting matches (1 core anchor). Platinum-sensitive status and deleterious germline BRCA requirement are unknown, so Line/prior and Biomarker anchors cannot be counted as matches. No soft mismatch identified. Therefore B, not A.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT02484404,0.8601292371749878,Metastatic Castration-Resistant Prostate Cancer,"Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers",PHASE1/PHASE2,18 years,Solid Tumor; Ovarian Cancer; Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Prostate Cancer (metastatic castrate-resistant); Triple Negative Breast Cancer; Colorectal Cancer,"Age >= 18 years | Adequately controlled blood pressure on <= 3 antihypertensive medications | Phase I: Advanced or recurrent solid tumor | ECOG performance status 0–2 | Adequate organ and marrow function | Off prior chemotherapy, radiation therapy, or biologic therapy >= 3 weeks | Ovarian/fallopian tube/primary peritoneal cancer: persistent or recurrent disease with >= 2 prior regimens or platinum-resistant/refractory after first platinum | Ovarian/fallopian tube/primary peritoneal cancer: at least one lesion safe to biopsy and willing to undergo mandatory baseline biopsy | Ovarian cancer: prior PARP inhibitor and/or prior anti-angiogenesis therapy allowed (but not both olaparib and cediranib previously) | Triple negative breast cancer: histologically confirmed persistent or recurrent TNBC | Triple negative breast cancer: ER/PR/HER2 status documented | Triple negative breast cancer: documentation of germline BRCA1/2 mutation status required | Triple negative breast cancer: measurable disease per RECIST v1.1 | Triple negative breast cancer: at least one lesion safe to biopsy and willing to undergo mandatory baseline biopsy | NSCLC: histologically or cytologically confirmed advanced disease with >= 1 prior line of platinum-based chemotherapy or appropriate targeted therapy for EGFR/ALK/BRAF alterations | NSCLC: measurable disease per RECIST v1.1 | NSCLC: at least one lesion safe to biopsy and willing to undergo mandatory baseline biopsy | mCRPC: metastatic, progressive, castrate-resistant prostate cancer | mCRPC: at least one lesion safe to biopsy and willing to undergo mandatory baseline biopsy | mCRPC: prior treatment with enzalutamide and/or abiraterone (exceptions for prior docetaxel with ADT in castrate-sensitive disease as specified) | mCRPC: ongoing GnRH agonist/antagonist therapy or prior bilateral orchiectomy | SCLC: advanced or recurrent disease eligible for Durvalumab + olaparib cohort | CRC: advanced or recurrent colorectal cancer eligible for Durvalumab + cediranib cohort","Cardiac events within 1 year: myocardial infarction, pericardial effusion, or myocarditis | Cardiac arrhythmia (e.g., atrial fibrillation or flutter) or need for pro-arrhythmic drugs/biologics within 1 year | NYHA Class II or greater heart failure | Left ventricular ejection fraction < 55% or below institutional normal if assessed | QTc > 470 ms or other significant ECG abnormality within 14 days of treatment | Hypertensive crisis or hypertensive encephalopathy | Clinically significant peripheral or vascular disease, including rapidly growing aortic aneurysm, abdominal aortic aneurysm > 5 cm, or aortic dissection | Unstable angina | Cerebrovascular accident or transient ischemic attack within 1 year | History of tuberculosis | Autoimmune disease requiring steroid maintenance or primary immunodeficiency | HIV-positive on antiretroviral therapy ineligible unless long-standing (> 5 years), undetectable viral load, CD4 > 150/µL, and no anticipated drug-drug interactions per PI | HBV-positive or HCV-positive due to risk of viral reactivation | History of severe allergic reactions to MEDI4736 (durvalumab), olaparib, cediranib, other humanized monoclonal antibodies, or similar compounds; history of anaphylaxis, angioedema, laryngeal edema, serum sickness, or uncontrolled asthma | Pregnant or breastfeeding | Any other concomitant or prior invasive malignancy | NSCLC: prior treatment with cediranib (monotherapy or combination) not eligible | NSCLC: current or prior immunosuppressive medication within 28 days before first durvalumab dose (except allowed low-dose steroids and inhaled/intranasal corticosteroids) | NSCLC: prior history of pneumonitis and/or interstitial lung disease | NSCLC: prior PARP inhibitor not eligible | Triple negative breast cancer: prior PARP inhibitor not eligible | Triple negative breast cancer: CNS metastasis or leptomeningeal disease within 1 year | mCRPC: progression on prior docetaxel for castrate-sensitive disease | mCRPC: prior PARP inhibitor not eligible | mCRPC: radionuclide treatment within 6 weeks prior to first dose | Ovarian cancer: prior treatment with both olaparib and cediranib (combination or sequentially) not eligible","Phase II Ovarian cancer: >= 2 prior regimens or platinum-resistant/refractory after first platinum; Ovarian cancer: prior PARP inhibitor allowed; Ovarian cancer: prior anti-angiogenesis therapy allowed; NSCLC: at least one prior line of platinum-based chemotherapy or prior EGFR/ALK/BRAF-targeted therapy when indicated by tumor genotype; mCRPC: prior treatment with enzalutamide and/or abiraterone required (with specified exceptions); mCRPC: continue GnRH agonist/antagonist therapy during study; All cohorts: washout from prior chemotherapy, radiation therapy, or biologic therapy >= 3 weeks",ALL,A,"Disease matches the mCRPC cohort and key anchors align: metastatic/castration-resistant setting and prior enzalutamide/abiraterone exposure meet requirements; age and sex are eligible with no explicit exclusions noted. Other criteria (e.g., ongoing GnRH therapy, biopsy willingness) are unknown but not contradicted.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions identified. Disease matches mCRPC cohort. Two core anchors match: stage/setting (metastatic, castration-resistant, progressive) and prior exposure (enzalutamide/abiraterone required and present). No soft conflicts evident; other requirements (ongoing GnRH, biopsy willingness) are unknown, which is neutral per rubric. Grade A is appropriate.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT02496208,0.84734046459198,Metastatic Urothelial Carcinoma,A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors,PHASE1,18 years,Urothelial Carcinoma (bladder); Urethral Urothelial Carcinoma; Ureter Urothelial Carcinoma; Renal Pelvis Urothelial Carcinoma; Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Sarcomatoid Urothelial Carcinoma; Plasmacytoid Urothelial Carcinoma; Renal Medullary Carcinoma; Penile Squamous Cell Carcinoma; Small Cell Neuroendocrine Carcinoma (bladder),"Age >= 18 years | Histologically confirmed metastatic genitourinary solid tumor (phase I) | Expansion: metastatic urothelial carcinoma (bladder, urethra, ureter, renal pelvis), or clear cell renal cell carcinoma, or adenocarcinoma of the bladder, or non-resectable penile squamous cell carcinoma, or rare GU histologies (squamous or small cell bladder carcinoma, renal medullary carcinoma, sarcomatoid bladder or renal cell carcinoma, plasmacytoid bladder carcinoma, or other rare bladder/kidney histology) | Metastatic disease with at least one evaluable/measurable site or new bone lesion (per cohort definitions) | For urothelial carcinoma or renal cell carcinoma expansion: progressive metastatic disease with at least one measurable site (RECIST) or bone disease by NaF PET/CT | Progressed on >= 1 standard therapy or no standard therapy conferring survival benefit; cisplatin-ineligible urothelial carcinoma may receive protocol therapy first-line | Any number of prior cytotoxic agents permitted | Karnofsky performance status >= 70% | Tissue available for PD-L1 expression (archival or consent to pre/post-treatment biopsies)","Cytotoxic chemotherapy or biologic therapy within 3 weeks (nitrosoureas/mitomycin C within 6 weeks) before first dose | Radiation therapy to thorax/abdomen within 3 months; to bone or brain within 3 weeks; to any other site within 28 days | Radionuclide treatment within 6 weeks | Small molecule kinase inhibitor within 14 days or 5 half-lives (whichever longer) | Hormonal therapy within 14 days or 5 half-lives (GnRH agonists/antagonists allowed) | Investigational agent within 28 days | Unresolved toxicities from prior therapy > grade 1 (except alopecia and asymptomatic lab abnormalities) | Prior MET or VEGFR inhibitors excluded from expansion cohorts (allowed in phase I) | Prior PD-1/PD-L1 or CTLA-4 therapy excluded unless enrolling in designated cohort | Active brain metastases or epidural disease unless previously treated and stable off steroids >= 2 weeks; baseline contrast brain imaging required if history present | PT/INR or PTT >= 1.5 x ULN within 7 days before first dose | Concurrent warfarin prohibited (except <= 1 mg/day); aspirin up to 325 mg/day, factor Xa/thrombin inhibitors, and LMWH permitted | Chronic treatment with strong CYP3A4 inducers not permitted | Clinically significant gastrointestinal bleeding within 6 months; hemoptysis >= 2.5 mL within 3 months; signs of pulmonary hemorrhage within 3 months | Tumor invading major blood vessels | Tumor invasion of GI tract or endotracheal/endobronchial tumor within 28 days before cabozantinib | Cardiovascular disorders: NYHA class III/IV heart failure; uncontrolled hypertension > 140/90 mmHg; QTcF > 500 ms; history of congenital long QT; within 6 months: unstable angina, clinically significant arrhythmias, stroke/TIA, myocardial infarction, or cardiomyopathy | GI disorders at high risk for perforation/fistula: unresolved mucosal invasion, active peptic ulcer disease, diverticulitis, cholecystitis, symptomatic cholangitis, appendicitis, malabsorption; within 6 months: abdominal fistula, GI perforation, bowel or gastric outlet obstruction, intra-abdominal abscess | PEG tube placement within 3 months | Severe active infection requiring systemic therapy within 14 days | Serious non-healing wound/ulcer/bone fracture within 28 days | History of organ transplant | Uncontrolled thyroid dysfunction within 7 days (replacement allowed if indicated) | Recent major surgery within 3 months (or as early as 6 weeks if completely healed and no complications); minor surgery within 1 month (or within 3 months if wound complications); complete wound healing required >= 28 days pre-cabozantinib | Unable to swallow tablets | Severe hypersensitivity to monoclonal antibodies or to cabozantinib, nivolumab, ipilimumab | Another malignancy within 2 years requiring systemic treatment (disease-specific studies) | Pregnancy or breastfeeding | Active hepatitis B (HBsAg positive) or active hepatitis C infection (HCV RNA positive) | Active autoimmune disease or history at risk for recurrence requiring systemic immunosuppression; exceptions include vitiligo, type 1 diabetes, residual hypothyroidism on replacement, psoriasis not requiring systemic therapy, and stable minor autoimmune conditions | Systemic corticosteroids > 10 mg/day prednisone equivalents or other immunosuppressives within 14 days (physiologic or topical/inhaled allowed) | Conditions predisposing to bowel perforation (e.g., active diverticulitis, intra-abdominal abscess, GI obstruction, abdominal carcinomatosis) without appropriate management",Progressed on >= 1 standard therapy or no available standard therapy; cisplatin-ineligible urothelial carcinoma allowed first-line; Any number of prior cytotoxic agents allowed; Washout: cytotoxic/biologic therapy >= 3 weeks (nitrosoureas/mitomycin C >= 6 weeks); Washout: radiation therapy per site (thorax/abdomen >= 3 months; bone/brain >= 3 weeks; other sites >= 28 days); Washout: radionuclide therapy >= 6 weeks; Washout: small molecule kinase inhibitors >= 14 days or 5 half-lives (whichever longer); Washout: hormonal therapy >= 14 days or 5 half-lives (GnRH agonists/antagonists allowed); Washout: other investigational agents >= 28 days,ALL,A,"Disease and metastatic setting match the trial’s urothelial carcinoma cohorts, and the patient is post ≥1 line of therapy as required. Age/sex fit, and there are no known exclusions; prior PD-1 exposure is unknown and only restricts certain cohorts.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches. Stage/setting (metastatic) matches, and line/prior therapy requirement (≥1 prior) is satisfied. Biomarker requirements none; mets pattern constraints unknown without conflict. Prior PD-1 exposure is unknown and not an automatic exclusion due to designated cohorts. Grade A is appropriate per rubric.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT02730338,0.7901040315628052,Metastatic Castration-Resistant Prostate Cancer,"INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4): a Multicentre, Randomised, Controlled, Phase III Study",NA,18 years,Metastatic Prostate Cancer,Metastatic castration-resistant prostate cancer (mCRPC): adenocarcinoma with systemic metastatic disease despite castrate testosterone (<50 ng/dL). | mCRPC progression by measurable disease: >20% increase in sum of diameters or new lesion(s). | mCRPC progression by bone scan: new lesion(s) attributable to prostate cancer. | mCRPC progression by PSA: PSA >= 2 ng/mL with three rising values at least 1 week apart (PSA1 < PSA2 < PSA3). | mCRPC progression by PSMA PET/CT: new lesion(s) attributable to prostate cancer. | mCRPC treatment status category allowed: treatment-naive for mCRPC (<=4 weeks on approved therapies still considered naive). | mCRPC treatment status category allowed: on abiraterone/enzalutamide/apalutamide with stable or declining PSA after >=4 weeks. | mCRPC treatment status category allowed: PSA progression on abiraterone/enzalutamide/apalutamide if asymptomatic and no intent to start chemotherapy within 6 months. | mCRPC treatment status category allowed: prior first-line docetaxel/cabazitaxel or other approved chemotherapy for mCRPC if asymptomatic without evidence of progression. | mCRPC treatment status category allowed: progressed after first-line docetaxel/cabazitaxel and now on abiraterone/enzalutamide/apalutamide with stable or responding PSA; life expectancy >1 year. | Metastatic hormone-sensitive prostate cancer (mHSPC): high-risk (>=2 of: Gleason score >=8; >=3 bone lesions; measurable visceral lesions) or high-volume (visceral metastases and/or >=4 bone metastases with >=1 outside vertebral column/pelvis). | On androgen deprivation therapy during study or prior bilateral orchiectomy. | >=4 weeks since last major surgery and fully recovered. | Halabi Nomogram score < 1951 (low or intermediate risk). | Age >= 18 years. | ECOG performance status 0-1. | Medical clearance to undergo symptom-limited cardiopulmonary exercise test and vigorous aerobic and resistance training; able to complete an acceptable cardiopulmonary exercise test.,"Small cell neuroendocrine prostate cancer or features of small cell disease. | Known contraindications to high-intensity exercise (e.g., brain metastases; current congestive heart failure NYHA class II–IV; serious or non-healing wound, ulcer, or bone fracture; spinal cord compromise or instrumentation due to metastatic disease; peripheral neuropathy >= grade 3). | Serious cardiovascular events within 12 months (e.g., transient ischemic attack, cerebrovascular accident, myocardial infarction). | Uncontrolled hypertension (blood pressure >=160/90). | Engaging in vigorous aerobic exercise >60 minutes/week or structured resistance exercise >=2 days/week.",On androgen deprivation therapy during study or prior bilateral orchiectomy required.; Treatment-naive for mCRPC allowed (<=4 weeks on approved CRPC therapies considered naive).; On abiraterone or enzalutamide or apalutamide for mCRPC with stable or declining PSA allowed.; PSA progression on abiraterone/enzalutamide/apalutamide allowed if asymptomatic and no intent to start chemotherapy within 6 months.; Prior first-line docetaxel or cabazitaxel or other approved chemotherapy for mCRPC allowed if asymptomatic and without progression.; Progressed after first-line chemotherapy and now on abiraterone/enzalutamide/apalutamide with stable or responding PSA allowed; life expectancy >1 year.; >=4 weeks since last major surgery.,MALE,A,"Disease/setting matches mCRPC, and prior exposure/progression on enzalutamide is an allowed cohort; age and sex also fit. Final eligibility depends on factors not provided (e.g., being asymptomatic with no near-term chemotherapy intent, ongoing ADT/low testosterone, ECOG 0–1, Halabi risk threshold, and medical clearance for vigorous exercise).",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches mCRPC. Stage/setting matches (metastatic CRPC). Line/prior exposure is compatible (progression on enzalutamide is an allowed cohort), though contingent factors are unknown but not mismatches. No required biomarkers. No soft conflicts identified. Thus ≥2 anchors (stage and line/prior) → A. Grader’s reasoning appropriately notes conditional factors without inferring.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02834013,0.7218245267868042,Recurrent Clear Cell Ovarian Carcinoma,DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors,PHASE2,18 years,Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortical Carcinoma; Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Metaplastic Breast Carcinoma; Cervical Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Cervical Adenocarcinoma (HPV-independent); Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Neuroendocrine Tumor; Sarcomatoid Lung Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Testicular Sex Cord-Stromal Tumor; Pituitary Neuroendocrine Tumor (metastatic); Minimally Invasive Lung Adenocarcinoma; Mixed Mullerian Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Low Grade Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; PEComa; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Carcinoma; Penile Squamous Cell Carcinoma; Peritoneal Mesothelial Neoplasm; Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Spindle Cell Neoplasm; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma; Vulvar Carcinoma; Cancer of Unknown Primary,"Rare cancer histologically and/or biochemically confirmed (specimen submission required; GTD confirmed by quantitative serum beta-hCG) | PD-L1 amplification cohort: solid tumors (excluding lymphoma) with PD-L1 amplification defined as DNA copy number >= 6 by CLIA-approved assay performed in advanced disease | Cancer of unknown primary: metastatic malignancy with no discernible primary after standard evaluation | Progressed after at least one line of standard systemic therapy or no standard therapy exists that prolongs overall survival | Measurable disease by RECIST v1.1 on CT or MRI within 28 days (cohorts except GTD) | Age >= 18 years | Zubrod performance status 0-2 | Prior malignancy allowed if stage I-II in complete remission, or any cancer disease-free >= 1 year; stage I-II follicular thyroid or prostate cancer eligible without complete remission requirement | Prior anti-CTLA-4 or prior anti-PD-1/PD-L1 allowed (but not both); must be completed >= 4 weeks before registration (except PD-L1 amplified cohort must be PD-1/PD-L1 naive; prior CTLA-4 allowed >= 4 weeks) | Adequate thyroid function (TSH or free T4 within normal range) or on stable replacement | Adequate adrenal axis function (cortisol within normal range or ACTH within normal range) | Brain metastases or primary brain tumors treated and stable; local therapy completed >= 28 days before registration; off steroids >= 7 days | Off other systemic anti-cancer therapy >= 7 days before registration with toxicities recovered to <= grade 1 (except alopecia and <= grade 2 neuropathy) | Hormonal/endocrine blockade permitted if progressed on prior therapy; long-acting somatostatin analogs and androgen deprivation therapy permitted during protocol therapy","Prior grade >= 3 immune-related adverse event with prior immunotherapy | History of or planned solid organ transplant | Active autoimmune disease requiring systemic treatment in the past 2 years (except replacement therapy); autoimmune patients must not have received steroids or immunosuppressives within 28 days prior to registration | Currently receiving investigational agents or systemic anti-cancer therapy (including radiation); planned radiation must be completed before registration | Known hypersensitivity or allergy to nivolumab or ipilimumab | Pregnant or nursing | Active hepatitis B or C infection (allowed if viral load undetectable and no residual hepatic impairment) | HIV-positive patients ineligible if CD4+ < 250 cells/mm^3 or history of non-malignancy AIDS-defining conditions (other than historical low CD4) | Uncontrolled intercurrent illness including symptomatic CHF (NYHA III/IV), unstable angina or coronary angioplasty/stenting within 24 weeks, unstable cardiac arrhythmia (CTCAE v4 grade >= 2), known cardiac metastases, abnormal cardiac valve morphology (>= grade 3), or psychiatric illness limiting compliance | Symptomatic interstitial lung disease or pneumonitis | Not fully recovered from major surgery to <= grade 1 within 14 days before registration","Progressed after >= 1 prior line of standard systemic therapy or no standard OS-prolonging therapy exists; Prior anti-CTLA-4 or prior anti-PD-1/PD-L1 allowed, but not both; must be completed >= 4 weeks before registration; PD-L1 amplified cohort: no prior anti-PD-1/PD-L1; prior anti-CTLA-4 allowed if completed >= 4 weeks; Off other systemic anti-cancer therapy >= 7 days before registration with toxicities recovered to <= grade 1 (except alopecia and <= grade 2 neuropathy); Brain metastases local therapy completed >= 28 days before registration; off steroids >= 7 days; Major surgery recovered to <= grade 1 at least 14 days before registration; Planned radiation must be completed before registration; Hormonal/endocrine therapy may continue if progressed on prior therapy (e.g., GnRH, somatostatin analogs, androgen deprivation)",ALL,A,"Disease matches the trial’s ovarian adenocarcinoma cohort, and the patient has recurrent disease after at least one prior standard systemic therapy, aligning with the stage/setting and prior-therapy requirements. Age and sex fit, and no explicit exclusions are triggered by the available data.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,"No hard exclusions. Disease reasonably matches the trial’s ovarian adenocarcinoma cohort. Stage/setting (recurrent/advanced) and line/prior therapy (progressed after standard systemic therapy) both match, satisfying ≥2 core anchors. Biomarker not required; other requirements (e.g., measurable disease, rare designation) are unknown and not disqualifying per rubric. Grade A is appropriate.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03237780,0.7900701761245728,Metastatic Urothelial Carcinoma,"A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option",PHASE2,18 years,Urothelial Carcinoma of Bladder; Urothelial Carcinoma of Renal Pelvis; Urothelial Carcinoma of Ureter; Urothelial Carcinoma of Urethra,"Age >= 18 years | Histologically or cytologically confirmed locally advanced/unresectable and/or metastatic transitional cell urothelial carcinoma of the renal pelvis, ureter, urinary bladder, or urethra | Measurable disease per RECIST 1.1 | Post-radiotherapy lesions must show progression to be targetable | Archival or newly obtained invasive tumor tissue available for biomarker analysis; sequential biopsies at baseline and 6 weeks if safe | PD-L1 status determined centrally (SP142) available before randomization | New, progressive or recurrent disease during or within 12 months of platinum therapy, or first-line cisplatin-ineligible due to creatinine clearance < 60 mL/min, grade >= 2 hearing loss, and/or ECOG 2 | Up to two prior lines of chemotherapy for advanced disease allowed | Adequate recovery from prior anti-neoplastic treatment toxicities (generally <= grade 1; exceptions: any grade alopecia, grade 2 neuropathy, any grade hearing loss) | Brain metastases allowed if treated or stable, asymptomatic, and off steroids >= 28 days | Life expectancy >= 12 weeks | ECOG performance status 0-2 (Karnofsky >= 60%) | HIV-positive allowed if on stable HAART without CYP3A4 inducers/inhibitors, no need for opportunistic infection prophylaxis, CD4 > 250 cells/µL, and undetectable HIV viral load","Prior allogeneic bone marrow transplantation or prior solid organ transplantation | Chemotherapy within 3 weeks prior to cycle 1 day 1 | Radiotherapy or targeted therapy within 2 weeks prior to cycle 1 day 1 (6 weeks for nitrosoureas or mitomycin C) | Not recovered from prior therapy adverse events beyond allowable exceptions | Prior treatment with anti-PD-1 or anti-PD-L1 agents or prior eribulin | Prior anti-CTLA-4 unless >= 12 weeks from first dose, > 6 weeks from last dose, and no history of severe immune-related adverse events | Investigational agent within 4 weeks prior to cycle 1 day 1 | Systemic immunostimulatory agents (e.g., IFN-alpha, IL-2) within 6 weeks prior to cycle 1 day 1 | Systemic immunosuppressive medications within 2 weeks prior to cycle 1 day 1 (exceptions for acute low-dose use, inhaled steroids, mineralocorticoids) | Bisphosphonate therapy for symptomatic hypercalcemia | Requirement for RANKL inhibitor (e.g., denosumab) that cannot be discontinued before atezolizumab | Primary CNS malignancy or symptomatic CNS metastases | Hypersensitivity to Chinese hamster ovary cell products, humanized antibodies, fusion proteins, or eribulin | Additional malignancy that is progressing or requires active treatment (exceptions: certain skin cancers or in situ cancers in remission >= 2 years) | Congestive heart failure > NYHA class III | Unstable angina or myocardial infarction within 6 months | Serious cardiac arrhythmia | QTcF > 450 ms or risk factors/medications predisposing to torsade de pointes | Autoimmune disease requiring systemic treatment in past 2 years | Clinically significant illness requiring medical treatment within 8 weeks or clinically significant infection within 4 weeks of dosing | History of organ allograft | Active hepatitis B (HBsAg positive) or active hepatitis C infection (PCR positive) | Clinically significant liver disease (active hepatitis, cirrhosis, fatty liver, inherited liver disease) | History or risk of autoimmune diseases (e.g., SLE, RA, IBD, vasculitis, multiple sclerosis) unless meeting specified exceptions | Idiopathic pulmonary fibrosis, pneumonitis (including drug-induced), organizing pneumonia, or active pneumonitis on screening CT | Active tuberculosis | Severe infections within 4 weeks prior to cycle 1 day 1 | Signs or symptoms of infection within 2 weeks prior to cycle 1 day 1 | Oral or IV antibiotics within 2 weeks prior to cycle 1 day 1 (except prophylactic use) | Major surgery within 28 days prior to cycle 1 day 1 or anticipated during the study | Live attenuated vaccine within 4 weeks before cycle 1 day 1 or planned during treatment and up to 5 months after last atezolizumab dose | Uncontrolled intercurrent illness that would limit compliance | Pregnant or breastfeeding",Progression during or within 12 months of platinum-based therapy or first-line cisplatin-ineligible status; Up to two prior lines of chemotherapy for advanced disease allowed; No chemotherapy within 3 weeks before cycle 1 day 1; No radiotherapy or targeted therapy within 2 weeks before cycle 1 day 1 (6 weeks for nitrosoureas or mitomycin C); No investigational agents within 4 weeks before cycle 1 day 1; No systemic immunostimulatory agents within 6 weeks before cycle 1 day 1; No systemic immunosuppressive medications within 2 weeks before cycle 1 day 1 (with specified exceptions); Prior anti-CTLA-4 allowed with washout (>= 12 weeks from first dose and > 6 weeks from last dose) and no severe immune-related adverse events,ALL,A,"Disease and metastatic setting match; age/sex fit, and the trial allows up to two prior lines, consistent with being post–second line. Prior PD-1/PD-L1 exposure and platinum/cisplatin-status requirements are unspecified and could affect eligibility, but no conflicts are stated.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),INCORRECT,B,"No hard exclusion is confirmed. Disease and metastatic setting match (1 anchor). Line/prior-exposure cannot be counted as a clear match because prior PD-1/PD-L1 exposure is disallowed and platinum progression/timing is required—both are unknown. With exactly one anchor match and no soft conflicts, the correct grade is B, not A.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT03355976,0.7311202883720398,Recurrent Clear Cell Ovarian Carcinoma,BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas,PHASE2,18 years,Ovarian Clear Cell Carcinoma; Fallopian Tube Clear Cell Carcinoma; Primary Peritoneal Clear Cell Carcinoma; Clear Cell Carcinoma (extra-renal),"Recurrent, advanced, or metastatic pure clear cell carcinoma of ovarian, fallopian tube, primary peritoneal, or extra-renal origin | Measurable disease by RECIST: >=20 mm by conventional imaging or >=10 mm by spiral CT/MRI/clinical calipers | Progressed after >=1 prior platinum- and taxane-based regimen (ovarian/fallopian tube/primary peritoneal) | Extra-renal clear cell cancer: progressed after >=1 prior systemic regimen for advanced/metastatic disease | Age >=18 years | ECOG performance status 0-1 | Adequate organ and marrow function | Adequate thyroid function (TSH within normal range) | Resting oxygen saturation >=92% at rest","Prior therapy with nivolumab, anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 | Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C); endocrine therapy within 7 days | Not recovered from clinically significant adverse events to < grade 2 from prior therapies | Concurrent investigational agents | Known brain metastases | History of severe hypersensitivity reaction to any monoclonal antibody | Uncontrolled intercurrent illness (active infection requiring antibiotics, symptomatic CHF, unstable angina, serious arrhythmia, or significant psychiatric illness) | Pregnancy or breastfeeding | Other invasive malignancy within 3 years (exceptions for low-risk conditions as specified) | Prior chemotherapy within the last 3 years for cancers other than clear cell cancer | HIV infection not meeting: stable HAART, CD4 >350/µL, and undetectable viral load | Hepatitis B or C with detectable viral load or not definitively treated >=6 months | Active autoimmune disease or history likely to recur affecting vital organs or requiring immunosuppression | Systemic corticosteroids >10 mg prednisone equivalents daily or other immunosuppressive medications within 14 days prior to day 1 | Planned concomitant, non-protocol anti-cancer therapy | Grade >=2 peripheral neuropathy",Prior platinum- and taxane-based chemotherapy required (ovarian/fallopian tube/primary peritoneal); At least one prior systemic regimen required (extra-renal clear cell carcinoma); Washout: chemotherapy or radiotherapy >=4 weeks (>=6 weeks for nitrosoureas or mitomycin C); Washout: endocrine therapy >=7 days,ALL,A,"Disease and setting match (recurrent ovarian clear cell carcinoma), and the patient received prior platinum/taxane therapy as required; age and sex are eligible with no conflicting exclusions noted. Measurable disease status is not provided but its absence here is not a hard exclusion.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,"No hard exclusions. Disease matches ovarian clear cell. Stage/setting matches (recurrent allowed). Prior exposure requirement met (prior platinum/taxane and recurrence). No soft mismatches on core anchors. Measurable disease is required but unknown, which per rubric remains neutral. Grade A is appropriate.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03473743,0.8215460181236267,Metastatic Urothelial Carcinoma,"A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Various Regimens of Erdafitinib in Subjects With Metastatic or Locally Advanced Urothelial Cancer",PHASE1/PHASE2,18 years,Urothelial Carcinoma (metastatic or locally advanced),"Histologic urothelial carcinoma (transitional cell); variant histologies allowed (glandular, squamous, sarcomatoid, micropapillary) | Metastatic or locally advanced disease | Measurable disease by RECIST v1.1 at baseline | Phase 1b erdafitinib + cetrelimab cohort: any number of prior therapy lines for metastatic disease allowed | Phase 1b erdafitinib + cetrelimab + platinum cohort: no prior systemic therapy for metastatic disease | Renal function to receive platinum: creatinine clearance >30 mL/min for carboplatin eligibility and >60 mL/min for cisplatin eligibility (Cockcroft-Gault) | Phase 2: no prior systemic therapy for metastatic disease and cisplatin-ineligible (ECOG 0-1 with at least one: CrCl <60 mL/min, grade >=2 neuropathy, grade >=2 hearing loss; or ECOG 2) | ECOG performance status as follows: Phase 1b erdafitinib + cetrelimab cohort ECOG 0-2; Phase 1b platinum cohort ECOG 0-1 for cisplatin and 0-2 for carboplatin; Phase 2 ECOG 0-2","Investigational agent or therapeutic clinical study participation within 30 days prior to Cycle 1 Day 1 | Phase 1b: prior nitrosoureas or mitomycin C within 6 weeks | Phase 1b erdafitinib + cetrelimab cohort: chemotherapy within 3 weeks of Cycle 1 Day 1 | Phase 1b platinum cohort and Phase 2: prior neoadjuvant/adjuvant chemotherapy allowed only if last dose >12 months before recurrence and no discontinuation due to drug-related toxicity | Prior PD-1, PD-L1, or PD-L2 therapy (exceptions: neoadjuvant/adjuvant >12 months without toxicity leading to discontinuation; PD-1 for non–muscle-invasive bladder cancer allowed) | Active malignancy requiring concurrent therapy other than urothelial cancer | Symptomatic central nervous system metastases",Phase 1b erdafitinib + cetrelimab cohort: any number of prior systemic therapy lines allowed for metastatic disease; Phase 1b erdafitinib + cetrelimab + platinum cohort: no prior systemic therapy for metastatic disease; Phase 2: no prior systemic therapy for metastatic disease (cisplatin-ineligible); Prior neoadjuvant/adjuvant chemotherapy allowed if last dose >12 months before recurrent disease and no discontinuation due to drug-related toxicity; Washout: investigational agents within 30 days prohibited; Washout: nitrosoureas or mitomycin C within 6 weeks prohibited (Phase 1b); Washout: chemotherapy within 3 weeks prohibited (Phase 1b erdafitinib + cetrelimab cohort),ALL,A,"Disease and metastatic setting match, and a Phase 1b cohort allows any number of prior lines—compatible with post–second-line status. No hard exclusions are triggered based on available data (age/sex ok; biomarker not required), though prior PD-1 exposure is unknown.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,A,"A is appropriate: Disease and metastatic setting match, and a Phase 1b cohort allows any number of prior lines, satisfying two core anchors (stage/setting and line/prior). No hard exclusions are triggered from available data; prior PD-1 exposure is unknown and should not be inferred. Presence of other cohorts with stricter prior-therapy rules does not negate eligibility given at least one matching cohort.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03601455,0.7949102520942688,Metastatic Urothelial Carcinoma,"Phase II Study of Radiation Therapy and Anti-PD-L1 Checkpoint Inhibitor (Durvalumab) With or Without Anti-CTLA-4 Inhibition (Tremelimumab) in Patients With Unresectable, Locally Advanced, or Metastatic Urothelial Bladder Cancer That Are Ineligible or Refusing Chemotherapy",PHASE2,18 years,Urothelial Bladder Cancer (unresectable or metastatic),"cT2–T4 or metastatic (N+ or M+) urothelial bladder cancer; mixed histology allowed if predominantly urothelial. | Localized disease: patient refuses cystectomy or is not an ideal cystectomy candidate. | If metastatic: intact, symptomatic bladder tumor appropriate for palliative bladder RT. | Measurable metastatic disease per RECIST v1.1 (>=1 non-irradiated lesion; longest diameter >=10 mm or lymph node short axis >=15 mm). | ECOG performance status 0–1. | Life expectancy >= 12 weeks. | Ineligible for or refusal of cisplatin-based chemotherapy (CrCl < 60 mL/min, CTCAE grade >=2 hearing loss, CTCAE grade >=2 peripheral neuropathy, NYHA class III heart failure, or other investigator-determined reason). | Provision of archived tumor tissue within 12 months or willingness to undergo pre-treatment fresh tumor biopsy; additional older archival tissue requested if available. | Hemoglobin >= 9.0 g/dL. | ANC >= 1500/µL. | Platelets >= 100000/µL. | Total bilirubin <= 1.5 x ULN (Gilbert syndrome allowed per physician). | AST/ALT <= 2.5 x ULN (<= 5 x ULN if liver metastases). | Creatinine clearance > 30 mL/min (Cockcroft-Gault or 24-hour collection). | Women of childbearing potential: negative pregnancy test; or non-reproductive potential as defined.","ECOG performance status >=2. | Prior cystectomy or definitive radiotherapy to the bladder. | Active or prior autoimmune or inflammatory disorders (e.g., myasthenia gravis, autoimmune hepatitis, SLE, rheumatoid arthritis, IBD, sarcoidosis, vasculitis, multiple sclerosis) with specified exceptions. | HIV infection, active hepatitis B or active hepatitis C (exceptions for resolved/past HBV and HCV RNA-negative). | History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced or idiopathic pneumonitis, or active pneumonitis on screening imaging. | Prior radiation therapy to the abdomen or pelvis, including bladder, prostate, or rectum. | Concurrent systemic chemotherapy, biologic, or hormonal therapy for cancer treatment (non-cancer hormonal therapy allowed). | Major surgery within 28 days before first dose (biopsy and TURBT allowed). | Another primary malignancy not meeting allowed exceptions. | QTcF >= 470 ms or clinically significant ECG abnormalities. | Current or prior immunosuppressive medication within 14 days before first dose (with specified corticosteroid exceptions). | History of primary immunodeficiency. | History of allogeneic organ transplant. | Hypersensitivity to durvalumab, tremelimumab, or their combination/excipients. | Uncontrolled intercurrent illness (e.g., infection, CHF, uncontrolled hypertension, unstable angina, arrhythmia, active PUD/gastritis, bleeding diathesis, psychiatric/social conditions limiting compliance). | Active infection including tuberculosis. | History of leptomeningeal carcinomatosis. | Receipt of live attenuated vaccine within 30 days before study entry or within 30 days of receiving study drugs. | Brain metastases or spinal cord compression unless stable, asymptomatic, and off steroids for >=14 days prior to treatment. | Uncontrolled seizures. | Pregnant or breastfeeding; unwilling to use effective contraception for the required period.",Prior systemic therapies allowed with washout >= 45 days,ALL,A,"Disease and metastatic setting match, and prior systemic therapy after second line is allowed; age and sex fit. Specific requirements (cisplatin ineligibility/refusal, intact symptomatic bladder for RT, ECOG/labs) are unknown but present no explicit conflicts.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),INCORRECT,B,"No hard exclusions. Disease matches and prior-therapy/line compatibility matches. However, stage/setting is uncertain because the trial requires metastatic patients to have an intact, symptomatic bladder tumor appropriate for palliative RT (and cisplatin ineligibility/refusal), which are unknown. Thus only 1 CORE ANCHOR clearly matches (Line/prior), yielding grade B, not A.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT03724136,0.7121427655220032,Dementia,Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study,NA,18 years,Alzheimer Disease; Autism Spectrum Disorder; CADASIL; Chronic Traumatic Encephalopathy; Mixed Dementia; Huntington's Dementia; LATE (limbic-predominant age-related TDP-43 encephalopathy); Lewy Body Dementia; Parkinson-Dementia Syndrome; Traumatic Brain Injury; Vascular Dementia; Wernicke-Korsakoff Syndrome,"Documented cognitive impairment or a diagnosis associated with cognitive impairment (e.g., Alzheimer's disease, autism spectrum disorder) | If on current medical therapy for the condition, be stable and unlikely to have reversal of impairment from ongoing treatment | Investigator judges potential for improvement with BMSC and minimal procedural risk | Age >= 18 years | Medically stable and cleared by a primary care practitioner for the procedure",Not medically stable or at significant health risk to undergo the procedure | Pregnant or planning pregnancy within 3 months post treatment | Investigator deems BMSC collection/treatment poses significant risk to general health or neurologic function,(none),ALL,A,"Disease matches, as the trial enrolls adults with documented cognitive impairment/dementia, and the patient is a 68-year-old male with moderate dementia (MMSE 19). There are no biomarker or prior-therapy requirements, age/gender fit, and no exclusion criteria are triggered based on available data.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),INCORRECT,C,"No hard exclusions. Disease broadly matches, but none of the CORE ANCHORS can be counted as matches: stage/setting not specified, line/prior not specified, no required biomarkers, and no metastatic pattern constraints. With 0 anchors matched and no soft conflicts, rubric dictates C, not A.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03866382,0.7712603807449341,Metastatic Urothelial Carcinoma,"A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)",PHASE2,18 years,Bladder Adenocarcinoma; Bladder Clear Cell Adenocarcinoma; Bladder Squamous Cell Carcinoma; Bladder Neuroendocrine Carcinoma; Bladder Small Cell Neuroendocrine Carcinoma; Urothelial Carcinoma; Micropapillary Urothelial Carcinoma; Plasmacytoid Urothelial Carcinoma; Giant Cell Urothelial Carcinoma; Lipid-Rich Urothelial Carcinoma; Nested Variant Urothelial Carcinoma; Lymphoepithelioma-Like Carcinoma; Large Cell Neuroendocrine Carcinoma; Chromophobe Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Collecting Duct Carcinoma; Renal Medullary Carcinoma; Urachal Adenocarcinoma; Urethral Carcinoma; Urethral Clear Cell Adenocarcinoma; Penile Carcinoma; Prostate Small Cell Neuroendocrine Carcinoma; Malignant Testicular Leydig Cell Tumor; Malignant Testicular Sertoli Cell Tumor,"Metastatic disease with new or progressive lesions on imaging | At least one measurable lesion per RECIST v1.1 | For bone-only cohort: at least one bone lesion on bone scan/CT/MRI | Histologically confirmed metastatic small cell/neuroendocrine carcinoma of the bladder | Histologically confirmed metastatic bladder adenocarcinoma, urachal adenocarcinoma, or bladder/urethra clear cell adenocarcinoma (pure) | Histologically confirmed metastatic squamous cell carcinoma of the bladder (pure) | Histologically confirmed metastatic plasmacytoid urothelial carcinoma (>= ~50% plasmacytoid/discohesive) | Any penile cancer | Sarcomatoid renal cell carcinoma (predominantly ~50%, including rhabdoid) and unclassified high-grade RCC; malignant angiomyolipoma allowed | Other variant urothelial carcinomas (e.g., micropapillary >= ~50%, giant cell, lipid-rich, clear cell, nested), large cell neuroendocrine carcinoma, lymphoepithelioma-like carcinoma, mixed patterns; treatment-naive primary prostate small cell allowed; malignant testicular Sertoli or Leydig cell tumors; papillary and chromophobe RCC | Sarcomatoid urothelial carcinoma (predominantly ~50%) | Renal medullary carcinoma | Bone-only metastatic genitourinary tumors (non-prostate) | Renal collecting duct carcinoma (WHO definition) | Urethral carcinoma (any histology; if urothelial, isolated to urethra) | Availability of H&E slides from diagnostic tumor tissue for central review | Up to 2 prior systemic anticancer treatments allowed or treatment naive; small cell carcinoma should have received a platinum-based combination regimen; bone-only cohort must receive cisplatin-based chemotherapy if eligible | Age >= 18 years | Able to swallow oral tablets | Karnofsky performance status >= 80% | ANC >= 1,000/µL | Platelets >= 75,000/µL | Total bilirubin <= 1.5 x ULN (<= 3.0 mg/dL allowed with Gilbert syndrome) | AST/ALT <= 3 x ULN (<= 5 x ULN with liver metastases or Gilbert syndrome) | Creatinine <= 1.5 x ULN or creatinine clearance >= 40 mL/min/1.73 m2 | Hemoglobin >= 9 g/dL (PRBC transfusion allowed) | Serum albumin >= 3.2 g/dL | Lipase and amylase <= 2 x ULN and no clinical/radiologic pancreatitis | HIV-positive allowed if on stable HAART, CD4 > 350/µL, and viral load undetectable | Select stable autoimmune/rheumatologic conditions on topical therapy allowed; controlled endocrine deficiencies allowed; vitiligo allowed | Women of childbearing potential: negative pregnancy test within 7 days prior to registration | Recovery to baseline or CTCAE <= grade 1 from prior therapy toxicities (except alopecia, neuropathy, or non-clinically significant lab AEs) | Previously treated brain metastases eligible if asymptomatic and off steroids >= 2 weeks; baseline contrast brain imaging required if known brain metastases","Prior cabozantinib | Both prior MET/VEGF inhibitor exposure and prior PD-1/PD-L1/CTLA-4 therapy (sequentially or in combination) | Prior PD-1/PD-L1 or CTLA-4 therapy (except allowed for urothelial carcinoma cohorts D, H, J, L) | Active or acute diverticulitis, intra-abdominal abscess, or GI obstruction within 12 months | Pregnancy or breastfeeding | Cytotoxic chemotherapy or biologic agents within 2 weeks before first dose | Radiation therapy to lungs/mediastinum/abdomen within 4 weeks before first dose or with ongoing complications | Radiation to brain metastasis within 3 weeks (WBRT) or 2 weeks (SBRT) before first dose | Radiation to any other site within 2 weeks before first dose | Radionuclide treatment within 6 weeks before first dose | Small molecule kinase inhibitor within 14 days or 5 half-lives (whichever longer) before first dose | Hormonal therapy within 14 days or 5 half-lives (whichever longer) before first dose (GnRH agonists/antagonists allowed) | Other investigational agent within 14 days before first dose | Not recovered to baseline or CTCAE > grade 1 from prior therapy toxicities (except allowed conditions) | Active brain metastases or epidural disease requiring steroids within 2 weeks | Concomitant warfarin (except <= 1 mg/day); aspirin up to 325 mg/day, thrombin or factor Xa inhibitors, and LMWH permitted | Chronic concomitant strong CYP3A4 inducers or strong inhibitors | Clinically significant GI bleeding within 6 months | Hemoptysis >= 2.5 mL/day within 1 month | Signs of pulmonary hemorrhage within 3 months | Tumor invading major blood vessels | Tumor invading GI tract or endotracheal/endobronchial tumor within 28 days; rectal tumor masses | Congestive heart failure NYHA class III or IV | Uncontrolled hypertension (sustained BP > 150/90 mmHg) despite therapy within 7 days of first dose | QTcF > 500 ms (unless average of 3 repeat ECGs <= 500 ms) | History of congenital long QT syndrome | Within 6 months: unstable angina, clinically significant arrhythmias, stroke/TIA/ischemic event, myocardial infarction, or cardiomyopathy | Unresolved active peptic ulcer disease, acute diverticulitis/cholecystitis/cholangitis/appendicitis, or malabsorption within 28 days before first dose | Within 2 years: abdominal or genitourinary fistula, GI perforation, bowel or gastric outlet obstruction, or intra-abdominal abscess (must be fully resolved) | High fistula risk conditions (e.g., recent PEG tube placement) | Severe active infection requiring IV therapy within 14 days | Serious non-healing wound, ulcer, or bone fracture within 28 days | History of organ transplant or allogeneic stem cell transplant | Uncompensated hypothyroidism or thyroid dysfunction within 7 days (unless replacement started) | Major surgery within 3 months (or >= 6 weeks if completely healed) before first cabozantinib dose; minor surgery within 1 month (or 3 months if wound complications); wounds must be fully healed | Severe hypersensitivity to any monoclonal antibody | Active malignancy requiring systemic treatment within 2 years | Allergic reactions to compounds of similar chemical or biologic composition to cabozantinib, nivolumab, or ipilimumab | Active hepatitis B (HBsAg positive with detectable HBV DNA) or active hepatitis C infection | Active autoimmune disease or history with risk of recurrence requiring systemic immunosuppression (e.g., SLE, MS, myasthenia gravis, IBD, autoimmune hepatitis, TEN, Stevens-Johnson syndrome, antiphospholipid syndrome)","Up to 2 prior systemic anticancer treatments allowed; treatment naive allowed; Small cell carcinoma: prior platinum-based combination regimen required (neoadjuvant, adjuvant, or first line); Bone-only cohort: must receive standard cisplatin-based chemotherapy if cisplatin-eligible; Prior MET or VEGFR inhibitors allowed; No cytotoxic chemotherapy or biologic agents within 2 weeks before first dose; No radiation within protocol-specified windows before first dose (lungs/mediastinum/abdomen within 4 weeks; brain WBRT within 3 weeks or SBRT within 2 weeks; other sites within 2 weeks); No radionuclide therapy within 6 weeks before first dose; No small molecule kinase inhibitors within 14 days or 5 half-lives (whichever longer) before first dose; No hormonal therapy within 14 days or 5 half-lives (whichever longer) before first dose (GnRH agonists/antagonists allowed); No other investigational agents within 14 days before first dose; Toxicities from prior therapies recovered to baseline or CTCAE <= grade 1 (exceptions apply)",ALL,A,"Disease and stage match (metastatic urothelial carcinoma), and the trial allows up to two prior systemic therapies, aligning with the patient being after second line. Age/sex fit and no explicit exclusions are triggered based on available data; other required labs/performance details are unknown.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,A,"Disease (urothelial carcinoma) and metastatic setting match; trial permits up to 2 prior systemic therapies and patient is post–second line (2 prior), so line/prior exposure matches. No hard exclusions triggered from available data. Meets ≥2 core anchors without soft conflicts → Grade A per rubric.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT04092270,0.9287108778953552,Recurrent Clear Cell Ovarian Carcinoma,A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC),PHASE1,18 years,Endometrial Endometrioid Adenocarcinoma (FIGO Grade 1); Endometrial Endometrioid Adenocarcinoma (FIGO Grade 2); Endometrial High Grade Endometrioid Adenocarcinoma; Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian High Grade Serous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Undifferentiated Carcinoma; Platinum-Sensitive Ovarian Carcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Primary Peritoneal Transitional Cell Carcinoma; Primary Peritoneal Undifferentiated Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Ovarian Carcinosarcoma; Recurrent Ovarian Clear Cell Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Ovarian Low Grade Serous Adenocarcinoma; Recurrent Ovarian Mucinous Adenocarcinoma; Recurrent Ovarian Transitional Cell Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma,"Recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer (dose-escalation). | Expansion cohorts: recurrent or persistent low grade serous ovarian cancer (LGSOC) or high grade serous ovarian cancer (HGSOC). | Measurable disease per RECIST 1.1. | Prior therapy: at least one prior line of platinum-based chemotherapy required. | Prior therapy: unlimited additional lines of chemotherapy, targeted, biologic, or hormonal therapy allowed. | Washout: prior anti-cancer therapy discontinued >= 4 weeks, one cycle, or 5 half-lives (whichever is shortest) before study treatment. | Age >= 18 years. | Platinum-sensitive ovarian cancer eligible for dose expansion if PLD is appropriate. | ECOG performance status <= 2 (Karnofsky >= 60%). | Cardiac ejection fraction >= lower limit of normal. | Hemoglobin >= 9 g/dL. | Absolute neutrophil count >= 1,500/µL. | Platelets >= 100,000/µL. | Total bilirubin <= 1.5 x ULN. | AST/ALT <= 3 x ULN. | Alkaline phosphatase <= 2.5 x ULN. | Creatinine clearance > 30 mL/min. | HIV-infected patients eligible if on effective ART with undetectable viral load within 6 months. | Chronic hepatitis B eligible if viral load undetectable on suppressive therapy, if indicated. | Hepatitis C eligible if cured or on treatment with undetectable viral load. | Treated brain metastases eligible if no progression on follow-up imaging, off steroids, and clinically stable. | Women of childbearing potential: negative urine or serum pregnancy test within 72 hours prior to first dose. | Contraception required during treatment and for 6 months after last dose. | Prior or concurrent malignancy allowed if it will not interfere with assessment of safety or efficacy. | Cardiac risk assessment NYHA class 2B or better. | Availability of archival FFPE tissue (within past 36 months) for DNA/RNA analysis.","Eligible for available therapies known to confer clinical benefit (dose-escalation phase). | Inability to swallow or absorb oral medication (e.g., drainage PEG). | Prior anthracycline exposure for ovarian cancer (doxorubicin or pegylated liposomal doxorubicin). | Unresolved toxicities from prior therapy > grade 1 (except alopecia, thyroid dysfunction, or neuropathy). | Receipt of other investigational agents within 28 days prior to start of treatment. | Allergic reactions to compounds similar to peposertib or pegylated liposomal doxorubicin. | Unable to discontinue interacting medications or herbal supplements with peposertib (strong CYP3A4/5, CYP2C9, CYP2C19 modulators; narrow TI substrates of CYP3A4/5, CYP1A2, CYP2B6; narrow TI transport substrates of P-gp, BCRP, OCT1, OATP1B1, OATP1B3). | Unable to discontinue proton-pump inhibitors >= 5 days prior to treatment (calcium carbonate allowed). | Concurrent sorivudine or brivudine use. | Live attenuated vaccine within 30 days prior to peposertib dosing. | Uncontrolled intercurrent illness, including active infection. | Psychiatric illness or social situations limiting compliance. | Pregnant or breastfeeding. | Significant uncontrolled cardiac conduction abnormalities.","At least one prior line of platinum-based chemotherapy required.; Unlimited additional prior lines of chemotherapy, targeted therapy, biologic therapy, or hormonal therapy allowed.; Washout required: prior anti-cancer therapy stopped >= 4 weeks, one cycle, or 5 half-lives before study start (whichever is shortest).",FEMALE,A,"Disease and setting match (recurrent clear cell ovarian carcinoma is included), and the patient has prior platinum-based chemotherapy; age and sex fit trial requirements. No exclusion criteria are triggered by the provided data.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,Disease matches (recurrent ovarian clear cell included). Stage/setting matches (trial requires recurrent/persistent; patient labeled recurrent). Line/prior-exposure matches (≥1 prior platinum-based regimen). Age and sex fit. No explicit exclusions identified from provided data. Meets ≥2 core anchors with no soft conflicts → A.,,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT04145115,0.7489166259765625,Recurrent Glioblastoma,A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma,PHASE2,18 years,"Glioblastoma (IDH-wildtype); Astrocytoma (IDH-mutant, grade 4); Secondary Glioblastoma; Diffuse Glioma","Histologically confirmed WHO grade 4 glioma at first or second recurrence, including secondary glioblastoma | Glioblastoma IDH-wildtype CNS WHO grade 4 per 2021 WHO criteria | Astrocytoma IDH-mutant CNS WHO grade 4 | Measurable disease on MRI with a bidimensionally measurable lesion >= 10 mm | Tumor tissue available from resection or biopsy of recurrent tumor within 28 days before pre-registration or planned within 28 days after pre-registration | Age >= 18 years | ECOG performance status <= 2 | Able to undergo brain MRI with contrast","Active autoimmune disease or history of autoimmune disease at risk for exacerbation | Prior treatment with checkpoint blockade therapies (anti-CTLA-4, anti-PD-1/PD-L1) | Prior bevacizumab | Prior laser ablation at the time of recurrent tumor tissue sampling (allowed if performed >= 4 months before sampling) | Requires > 4 mg dexamethasone beyond the perioperative period (> 2 weeks after surgery) | History of another active malignancy requiring treatment within the previous 2 years (except in situ cancers or basal/squamous cell skin cancers)",Prior laser ablation allowed if >= 4 months before recurrent tumor tissue sampling,ALL,A,"Recurrent IDH‑wildtype glioblastoma at age 40 with ECOG 1 and prior standard chemoradiation fits the trial’s recurrent GBM (IDH‑wildtype) cohort, with no prior checkpoint inhibitors or bevacizumab reported and age/sex criteria met. Measurable disease and recent recurrent-tumor tissue are not specified but no disqualifying conflicts are evident.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches (IDH‑wildtype GBM). Core anchors: stage/setting = recurrent (match); line/prior exposure = no prior CPI/bevacizumab and standard SOC only (match); required subtype IDH‑wildtype satisfied (match). Measurable disease and recent recurrent tissue availability are unknown, not soft mismatches per rubric. Grade A is appropriate.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04145622,0.7947959899902344,Metastatic Castration-Resistant Prostate Cancer,"Phase I/II, Two-Part, Multicenter First-in-Human Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Subjects With Advanced Solid Malignant Tumors (IDeate-PanTumor01)",PHASE1/PHASE2,18 years,"Head and Neck Squamous Cell Carcinoma; Esophageal Squamous Cell Carcinoma; Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Bladder Cancer; Sarcoma; Endometrial Cancer; Melanoma; Prostate Cancer (castration-resistant, adenocarcinoma); Breast Cancer","ECOG performance status 0–1 | At least one measurable lesion per RECIST v1.1 on CT or MRI; lesions should not be from a previously irradiated site unless progression is documented | Adequate cardiac, hematopoietic, renal, and hepatic function | Adequate treatment washout period prior to study treatment | Pathologically confirmed advanced/unresectable or metastatic: head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, non-small cell lung cancer (squamous or adenocarcinoma), small cell lung cancer, bladder cancer, sarcoma, endometrial cancer, melanoma, adenocarcinoma castration-resistant prostate cancer, or breast cancer refractory/intolerant to standard therapy or without standard options | Expansion Cohort (2L ESCC): Disease progression after platinum-based therapy and an immune checkpoint inhibitor; maximum one prior line of systemic therapy for unresectable/metastatic ESCC","Prior treatment with a B7-H3–targeted agent, including ifinatamab deruxtecan | Prior discontinuation of an antibody-drug conjugate containing an exatecan derivative due to treatment-related toxicities | Multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, superficial GI tract tumors, and non-muscle invasive bladder cancer curatively resected by endoscopic surgery | Uncontrolled significant cardiovascular disease | Clinically severe pulmonary compromise, including underlying pulmonary disorders; autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement; prior pneumonectomy; or requirement for supplemental oxygen | Uncontrolled infection requiring systemic therapy | Substance abuse or other medical conditions increasing safety risk or interfering with study participation or evaluation",Treatment washout required before study start; ESCC expansion: disease progression after platinum-based therapy; ESCC expansion: prior immune checkpoint inhibitor required; ESCC expansion: maximum one prior line of systemic therapy for unresectable/metastatic disease,ALL,A,"Disease matches (metastatic castration-resistant prostate cancer is included), and the stage/setting and prior-therapy context align (metastatic, refractory after standard AR-targeted therapies). No explicit exclusions are triggered; other eligibility items (ECOG, measurable disease, organ function) are unknown but not conflicting.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches (trial includes castration-resistant prostate cancer). Core anchors: Stage/setting matches (metastatic/advanced), and prior-therapy context aligns (refractory to standard AR-targeted therapy). No identified soft conflicts. Thus A is appropriate.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT04196257,0.7105957269668579,Recurrent Clear Cell Ovarian Carcinoma,A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors,PHASE1,18 years,Solid Tumor; Ovarian Epithelial Carcinoma; Endometrial Cancer; Fallopian Tube Neoplasm; Peritoneal Cancer,"Age >= 18 years | Advanced or recurrent solid tumor not a candidate for regimens known to confer clinical benefit | ECOG 0–1 | Willing to undergo pre-treatment and post-treatment biopsies (if applicable) | Dose expansion: recurrent or persistent epithelial ovarian, primary peritoneal, fallopian tube, or endometrial tumor and suitable for single-agent paclitaxel | Endometrial cancer eligible histologies include endometrioid, serous, undifferentiated, clear cell, mixed epithelial, adenocarcinoma NOS, mucinous, squamous cell, transitional cell, mesonephric | Ovarian tumor eligible histologies include high-grade serous, endometrioid, clear cell, squamous, transitional (Brenner), mixed epithelial-stromal, undifferentiated or other epithelial | Uterine carcinosarcoma and other uterine sarcomas are not eligible | Estimated life expectancy > 3 months | Measurable disease per RECIST v1.1 | At least one target lesion per RECIST v1.1; previously irradiated lesions are non-target unless progression or biopsy confirms persistence >= 90 days after RT | Adequate bone marrow, hepatic, renal, neurologic, and coagulation function per protocol thresholds | Prior docetaxel allowed | Dose expansion: prior paclitaxel allowed if no progression on therapy and no relapse within 6 months after completing therapy; persistent disease at completion of primary paclitaxel is not eligible | Free of active infection requiring antibiotics (except uncomplicated UTI) | Discontinue hormonal therapy directed at the tumor >= 2 weeks before first dose | Discontinue other prior anti-tumor therapy, including immunologic agents, >= 4 weeks before first dose (6 weeks for nitrosoureas or mitomycin C)","Dose expansion: low-grade serous ovarian carcinoma or mucinous ovarian carcinoma | Dose expansion: use of strong inhibitor, inducer, or substrate of both CYP3A4 and CYP2C8 within 2 weeks before investigational drug | Prior bone marrow or hematopoietic stem cell transplant | Concurrent treatment with other investigational agents | Pregnant or breastfeeding | CNS disease including primary brain tumor, uncontrolled seizures, any brain metastases, or cerebrovascular accident/transient ischemic attack/subarachnoid hemorrhage within 6 months | Within 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, cerebrovascular accident, or transient ischemic attack | Uncontrolled significant cardiovascular conditions (e.g., unstable angina, NYHA class III–IV heart failure, uncontrolled sustained hypertension, clinically significant arrhythmia) or QTcF > 470 msec | Active symptomatic pleural or pericardial effusion | Ineligible for MRI or history of allergic reaction to gadolinium contrast | History of >= Grade 3 hypersensitivity to paclitaxel, docetaxel, or products mixed in Cremophor EL or Tween 80 | Unresolved > CTCAE Grade 1 toxicity from prior therapy (excluding alopecia) | Substance abuse or medical/psychological/social conditions that may interfere with study participation | HIV infection with CD4+ T-cell count < 350 cells/µL or clinically active hepatitis B or C | Major surgery, open biopsy, dental extractions or other dental surgery with open wound, or significant traumatic injury within 28 days before first dose; placement of vascular access device or core biopsy within 7 days before registration | Dose expansion: ineligible or unable to receive paclitaxel","Prior docetaxel allowed; Prior paclitaxel allowed if no progression on therapy and no relapse within 6 months after completing therapy; persistent disease at completion of primary paclitaxel is not eligible; Discontinue hormonal therapy directed at the tumor >= 2 weeks before first dose; Discontinue prior anti-tumor therapy, including immunologic agents, >= 4 weeks before first dose (6 weeks for nitrosoureas or mitomycin C)",ALL,A,Recurrent clear cell ovarian carcinoma matches the trial’s ovarian epithelial cohort (clear cell allowed) and the advanced/recurrent setting; adult age and sex fit. No explicit exclusions are triggered; factors like symptomatic status of pleural effusion and paclitaxel-related dose-expansion criteria are unknown.,Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),INCORRECT,B,"No hard exclusions are clearly triggered. Disease and stage/setting (recurrent ovarian epithelial clear cell) match, but line-of-therapy/prior exposure compatibility is uncertain (requirements around paclitaxel suitability and relapse timing; “not a candidate for regimens with known benefit” unknown). Biomarkers not required; mets pattern constraint about symptomatic pleural effusion is unknown. Thus exactly one core anchor matches → B, not A.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT04214392,0.7626857757568359,Recurrent Glioblastoma,A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for Patients With MMP2+ Recurrent or Progressive Glioblastoma,PHASE1,18 years,Glioblastoma (recurrent); Malignant Glioma (recurrent); WHO Grade II Glioma (recurrent); WHO Grade III Glioma (recurrent),"Karnofsky performance status >= 60% | ECOG <= 2 | Life expectancy >= 4 weeks | Histologically confirmed grade IV glioblastoma, or prior grade II/III malignant brain tumor with radiographic progression consistent with grade IV glioblastoma | Relapsed/progressive measurable disease after standard therapy and >= 12 weeks after completion of frontline radiation therapy | MMP2-positive tumor by IHC (>= 20% moderate/high staining) | No known contraindications to leukapheresis, steroids, or tocilizumab | WBC > 2000/µL or ANC >= 1000/µL (pre-leukapheresis) | Platelets >= 75,000/µL (pre-leukapheresis) | Hemoglobin >= 8 g/dL (pre-leukapheresis) | Total bilirubin <= 1.5 x ULN (pre-leukapheresis) | AST <= 2.5 x ULN (pre-leukapheresis) | ALT <= 2.5 x ULN (pre-leukapheresis) | Serum creatinine <= 1.6 mg/dL (pre-leukapheresis) | Oxygen saturation >= 95% on room air (pre-leukapheresis) | Seronegative for HIV Ag/Ab combo | Women of childbearing potential: negative pregnancy test | Females and males of childbearing potential agree to effective contraception or abstinence during study and for >= 3 months after last dose","Prior bevacizumab within 3 months before enrollment | Not recovered from toxicities of prior therapy | Uncontrolled seizure activity and/or clinically evident progressive encephalopathy | History of allergic reactions to compounds of similar composition to study agent | Active diarrhea | Clinically significant uncontrolled illness | Active infection requiring antibiotics | Known HIV, hepatitis B, or hepatitis C infection | Other active malignancy | Pregnant or breastfeeding | Any condition that, in the investigator's judgment, contraindicates participation due to safety concerns | Participant may be unable to comply with study procedures",Prior standard therapy required; >= 12 weeks since completion of frontline radiation therapy,ALL,A,"Disease and setting match (recurrent glioblastoma), and prior standard therapy aligns with trial requirements; ECOG 1 and age 40 meet eligibility. MMP2 status is unknown (required but not provided), yet no explicit exclusions or other mismatches are evident.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),INCORRECT,C,"The trial requires MMP2-positive tumor by IHC; the patient’s MMP2 status is unknown. Per the rubric, unknown required biomarker status should not cause F but prevents awarding A (which requires required biomarkers satisfied). Disease and setting/prior therapy align, with no soft conflicts, so this is relevant but uncertain → C.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT04449549,0.7859024405479431,Recurrent Clear Cell Ovarian Carcinoma,Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel,PHASE2,18 years to 120 years,Granulosa Cell Ovarian Cancer; Clear Cell Ovarian Cancer; Anal Cancer; Ewing Sarcoma,Histologically confirmed rare solid tumor progressed on standard therapy known to prolong survival or with no standard treatment options | Measurable and evaluable disease | Age >= 18 years | ECOG performance status <=2 | Adequate organ and marrow function per protocol-defined labs | Completion of radiation therapy or major surgery >=3 weeks prior to enrollment | Completion of biologic therapy or chemotherapy >=5 half-lives or 3 weeks (whichever is shorter); 6 weeks for nitrosoureas or mitomycin C | >=2 weeks since prior Phase 0 (or equivalent) study drug | >=1 week from palliative radiation therapy to non-target lesions (after 2 cycles may be permitted at PI discretion) | Recovered to eligibility levels from prior therapy-related toxicity/adverse events | Women of childbearing potential and men agree to use adequate contraception during treatment and for 3 months after last dose | HIV-infected patients on effective antiretroviral therapy with undetectable viral load within 6 months are eligible; HIV viral load test within 28 days prior to enrollment,"QTcF interval >=450 msec at study entry or congenital long QT syndrome | Sensory or motor neuropathy >= Grade 2 | Concurrent treatment with other investigational agents | Primary CNS malignancy or symptomatic CNS metastases (exceptions for asymptomatic untreated or treated CNS disease meeting protocol criteria) | History of allergic reactions to compounds of similar chemical or biologic composition to study drugs | Uncontrolled intercurrent illness (e.g., serious untreated infection, symptomatic respiratory failure, congestive heart failure, unstable angina, significant arrhythmia, or psychiatric/social conditions limiting compliance) | Pregnancy or breastfeeding",Progressed on prior standard therapy known to prolong survival or no standard options available; Washout: radiation therapy or major surgery >=3 weeks before enrollment; Washout: biologic therapy or chemotherapy >=5 half-lives or 3 weeks (whichever is shorter); 6 weeks for nitrosoureas or mitomycin C; Washout: >=2 weeks since prior Phase 0 or equivalent study drug; Washout: >=1 week from palliative radiation therapy to non-target lesions; Recovery to eligibility levels from prior treatment-related toxicity,ALL,A,"Disease matches (clear cell ovarian cancer) and the patient has recurrent disease after standard therapy, meeting the trial’s setting and prior-therapy requirements. Age and sex fit, and no explicit exclusions are evident; biomarker is not required.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,"Disease matches (clear cell ovarian cancer). Patient has recurrent disease after standard therapy, satisfying both stage/setting and prior-therapy anchors. Age/sex within bounds; no hard exclusions evident; no required biomarker unmet. No soft conflicts identified. Grade A is appropriate per rubric.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04471974,0.6950737237930298,Metastatic Castration-Resistant Prostate Cancer,A Phase 2 Study of BET Bromodomain Inhibitor ZEN-3694 in Combination With Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate Cancer,PHASE2,18 years,Prostate Cancer (metastatic castration-resistant); Small Cell Prostate Carcinoma (metastatic),"Histologically confirmed prostate adenocarcinoma at diagnosis with subsequent metastatic castration-resistant prostate cancer (mCRPC) | Evidence of disease progression by PSA and/or radiographic progression per PCWG3 at study entry | PSA > 2 ng/mL during screening and/or measurable disease by RECIST 1.1 | Safety lead-in: mCRPC with PCWG3 progression, progression on >=1 prior androgen signaling inhibitor, and no prior chemotherapy for mCRPC (prior chemo in castration-sensitive allowed if last dose > 6 months before C1D1) | Cohort A (transdifferentiated mCRPC): clinicogenomic evidence of t-SCNC by one or more of: small cell NEPC on metastatic biopsy; RB1 loss-of-function mutation or deletion; low PSA secretor profile (PSA >= 2 ng/mL, radiographic progression, and > 5 metastases); at least one soft tissue lesion > 1 cm that is PSMA PET-negative | Cohort A: <= 2 prior lines of chemotherapy in the mCRPC setting | Cohort A: measurable disease by RECIST 1.1 | Cohort B (without transdifferentiation): does not meet transdifferentiation criteria | Cohort B: progression on >=1 prior androgen signaling inhibitor | Cohort B: no prior chemotherapy for mCRPC (prior chemo in castration-sensitive allowed if last dose > 6 months before C1D1) | Castrate level of serum testosterone at entry (< 50 ng/dL); continue LHRH therapy unless prior orchiectomy | No other systemic anti-cancer therapies (other than LHRH) within 14 days or 5 half-lives prior to C1D1; prior-treatment AEs recovered to <= grade 1 (except any grade alopecia and <= grade 2 neuropathy) | Age >= 18 years | ECOG performance status <= 1 (Karnofsky >= 70%) | Adequate organ function per protocol thresholds","Participation in another investigational study and received study treatment/device within 2 weeks of C1D1 | Hypersensitivity to ZEN-3694, pembrolizumab, enzalutamide, or excipients | Prior radiotherapy within 2 weeks of C1D1 (>= 1 week allowed for palliative RT <= 2 weeks to non-CNS sites); unresolved radiation toxicities, steroid requirement, or radiation pneumonitis | Prior pembrolizumab or other immune checkpoint inhibitor (e.g., nivolumab, ipilimumab) | Radiopharmaceutical therapy (e.g., radium-223, 177Lu-PSMA) within 6 weeks prior to C1D1 | Prior treatment with a BET bromodomain inhibitor | Concurrent second malignancy requiring active treatment (exceptions: non-melanoma skin cancer, non–muscle-invasive bladder cancer, other carcinoma in situ) | Active autoimmune disease requiring systemic treatment within 2 years (exceptions noted, e.g., replacement therapy; low-dose weekly methotrexate allowed) | Live or live-attenuated vaccine within 30 days prior to first dose (killed vaccines allowed) | Cardiac conditions: QTcF > 480 ms; uncontrolled arrhythmia requiring treatment; NYHA class III/IV heart failure; recent MI, unstable angina, or CVA within 6 months | History of seizure or predisposing condition (e.g., brain metastases) | Immunodeficiency or systemic steroids > 10 mg prednisone equivalent daily or other immunosuppressive therapy within 7 days prior to first dose | Chronic HBV allowed only if viral load undetectable; chronic HCV infection with positive viral load excluded | History of or current pneumonitis/interstitial lung disease requiring steroids, or active pneumonitis/ILD | Active infection requiring IV antibiotics within 7 days prior to C1D1 | Use of prohibited concomitant medications within 7 days of C1D1 | Major surgery within 28 days prior to C1D1 (minor procedures allowed) | Any condition, therapy, or lab abnormality that could confound results or is not in the subject’s best interest per investigator | Psychiatric or substance abuse disorders interfering with protocol compliance | De novo small cell prostate cancer at initial diagnosis","Progression on at least one prior androgen signaling inhibitor required (e.g., abiraterone/prednisone, enzalutamide, apalutamide, darolutamide) for safety lead-in and Cohort B (and per phase 2 description); No prior chemotherapy for mCRPC for Cohort B; Cohort A allows up to two prior chemotherapy lines in mCRPC; Prior chemotherapy in the castration-sensitive setting allowed if last dose > 6 months before C1D1; No other systemic anti-cancer therapy within 14 days or 5 half-lives before C1D1 (except LHRH); Prior radiotherapy washout >= 2 weeks (>= 1 week for short-course palliative RT <= 2 weeks); Radiopharmaceuticals washout >= 6 weeks before C1D1; Investigational agents/device washout >= 2 weeks before C1D1; Enzalutamide may be continued at current dose without washout",MALE,A,"Disease/setting (mCRPC) and prior-exposure requirements match (progressed on enzalutamide; prior abiraterone; no mCRPC chemo noted), with age/sex compatible and no explicit exclusions (e.g., prior PD-1) evident. Final eligibility depends on PSA > 2 ng/mL or measurable disease, castrate testosterone/ECOG, and absence of transdifferentiation features for Cohort B—these are not specified but not contradicted.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches mCRPC; stage/setting matches; prior ARSI exposure (progressed on enzalutamide, prior abiraterone) matches line/prior requirements; sex/age fit. No soft conflicts identified (no prior ICI or mCRPC chemo noted). Other criteria (PSA >2 or measurable disease, castrate T, ECOG, non-transdifferentiated for Cohort B) are unknown but not contradicted. Thus ≥2 core anchors match → A.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04592237,0.7824387550354004,Metastatic Castration-Resistant Prostate Cancer,Randomized Phase II Study of Platinum-Taxane-Cetrelimab Induction Followed by Niraparib Plus or Minus Cetrelimab Maintenance in Men With Aggressive Variant Prostate Cancers,PHASE2,18 years,Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Small Cell Carcinoma; Stage IV Prostate Cancer,"Histologically or cytologically confirmed prostate carcinoma | Metastatic disease documented on imaging (bone scan, CT and/or MRI) | Meets at least one aggressive variant prostate carcinoma (AVPC) criterion | Histologically proven small cell (neuroendocrine) prostate carcinoma (AVPC criterion) | Exclusive visceral metastases (AVPC criterion) | Predominantly lytic bone metastases by x-ray or CT (AVPC criterion) | Bulky (>= 5 cm) lymphadenopathy or high-grade tumor mass in prostate/pelvis (AVPC criterion) | Low PSA (<= 10 ng/mL) at initial presentation or at symptomatic progression in the castrate-setting plus high-volume (>= 20) bone metastases (AVPC criterion) | Elevated LDH (>= 2 x ULN) or elevated CEA (>= 2 x ULN) without other etiologies (AVPC criterion) | Short interval (<= 180 days) to castration-resistant progression after initiation of hormonal therapy (AVPC criterion) | Loss or mutation in at least 2 of TP53, RB1, and PTEN by CLIA-certified testing, IHC and/or DNA sequencing (AVPC criterion) | Castration-resistant progression per RECIST without PSA rising to >= 1.0 ng/mL per PCWG3 (AVPC criterion) | Documented progressive disease by PSA progression (3 measurements >= 7 days apart with last >= 1.0 ng/mL), or new/increasing measurable disease (RECIST), or >= 2 new bone lesions (PCWG3), or increasing symptoms attributed to progression | Surgically or medically castrated with baseline testosterone <= 50 ng/dL | ECOG performance status <= 2 | Hemoglobin >= 10.0 g/dL (>= 8 g/dL if due to marrow infiltration) | Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1.0 x 10^9/L if due to marrow infiltration) | White blood cells (WBC) > 3 x 10^9/L (> 2 x 10^9/L if due to marrow infiltration) | Platelet count >= 100 x 10^9/L (>= 50 x 10^9/L if due to marrow infiltration) | Total bilirubin <= 1.5 x ULN (except Gilbert syndrome) | AST and ALT <= 2.5 x ULN (<= 5 x ULN with liver metastases) | Calculated creatinine clearance (Cockcroft-Gault) >= 30 mL/min | No features suggestive of MDS/AML on peripheral blood smear | Able to swallow study drugs whole (tablet/capsule)","Any prior treatment for CRPC with carboplatin, cisplatin, cabazitaxel, a PARP inhibitor, or an anti-PD-1/PD-L1 inhibitor | More than one prior line of chemotherapy | Unresolved toxicity from prior therapy > CTCAE grade 2 (except allowed ongoing LHRH therapy, bisphosphonates, or RANK ligand inhibitors) | Any unresolved CTCAE grade >= 2 toxicity from previous anti-cancer therapy (irreversible toxicities not expected to be exacerbated may be allowed) | History or current diagnosis of myelodysplastic syndrome or acute myeloid leukemia | Active uncontrolled infection | Active or symptomatic viral hepatitis or chronic liver disease | History of pneumonitis or extensive bilateral non-malignant lung disease | Another malignancy with >= 30% probability of recurrence within 24 months (except adequately treated non-melanoma skin cancer, curatively treated in-situ cervical cancer, or Ta urothelial carcinoma) | Serious underlying medical or psychiatric condition that would make study drug hazardous or confound adverse event interpretation (e.g., uncontrolled ventricular arrhythmia, recent myocardial infarction, superior vena cava syndrome, uncontrolled seizures, history of allogeneic transplant, primary immunodeficiency) | Unable to swallow oral medication or gastrointestinal disorders likely to interfere with absorption | Symptomatic uncontrolled brain metastases or spinal cord compression | Known hypersensitivity to niraparib, carboplatin, cabazitaxel, or anti-PD-1/PD-L1 inhibitors | Current or prior use of systemic immunosuppressive medication within 28 days before first cetrelimab dose (with specified corticosteroid exceptions) | Active or prior documented autoimmune or inflammatory disorders requiring systemic therapy (with specified exceptions such as vitiligo, alopecia, controlled hypothyroidism, certain inactive diseases, or celiac disease controlled by diet) | Receipt of live attenuated vaccine within 30 days prior to cetrelimab | Compulsory detention for treatment of psychiatric or physical illness",(none),MALE,A,"Stage/setting matches mCRPC and prior therapies (enzalutamide/abiraterone) do not violate exclusions; age and sex fit. Eligibility depends on meeting at least one aggressive-variant criterion, which is not documented here and needs confirmation but is not an explicit conflict.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),INCORRECT,C,"Disease matches and stage/setting and prior exposure are compatible, but the trial requires meeting an AVPC criterion (a required subtype). The patient’s AVPC status is unknown. Per rubric, A requires required biomarkers/subtype satisfied when applicable; this is not satisfied/unknown. With anchor info insufficient on a required criterion and no soft conflicts, the correct grade is C, not A.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT04925960,0.5074912309646606,PMM2-CDG,"A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of Oral Epalrestat Therapy in Pediatric Subjects With Phosphomannomutase 2-congenital Disorder of Glycosylation (PMM2-CDG)",PHASE3,2 years to 17 years,Phosphomannomutase 2 Congenital Disorder of Glycosylation,Age >= 2 and < 18 years | Molecularly confirmed biallelic PMM2 pathogenic variants | Negative urine pregnancy test (females of child-bearing potential) | Agrees to effective contraception or abstinence from prior to randomization through 3 months after treatment (subjects of child-bearing potential),"Other known congenital disorders of glycosylation | Allergy to aldose reductase inhibitors | Hypersensitivity to epalrestat | AST > 5 x ULN within 6 months prior to screening | ALT > 5 x ULN within 6 months prior to screening | Total bilirubin > 2 x ULN within 6 months prior to screening | Albumin < 2.8 mmol/L at screening | Liver fibrosis by elastography (Fibroscan > 7 kPa) at screening | Serum creatinine > 0.5 mg/dL (<= 6 years) | Serum creatinine > 0.7 mg/dL (7-10 years) | Serum creatinine > 1.24 mg/dL (>= 11 years) | Platelet count < 125 x10^9/L | Hemoglobin < 10 g/dL | Any other clinically significant laboratory abnormality per investigator | Use of an investigational drug (including acetazolamide) within 28 days | Use of an investigational biologic within 12 months | Concurrent or planned participation in another interventional protocol or use of other unapproved therapeutics | Any other medical condition that interferes with protocol compliance, compromises safety, or interferes with interpretation of results",Washout from investigational drugs >= 28 days; Washout from investigational biologics >= 12 months,ALL,A,"Disease and required biomarker (biallelic PMM2 variants) match, and the patient’s age (8) is within the 2–<18 range. No prior investigational therapy or known exclusion criteria are present, so line/prior exposure is compatible.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,A,"No hard exclusions. Disease and required biomarker match; age within window; prior exposure/washout compatible. At least two core anchors match (biomarker and line/prior), with no soft conflicts, so A is appropriate.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT05086692,0.7260557413101196,Recurrent Clear Cell Ovarian Carcinoma,"A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors",PHASE1/PHASE2,18 years,Acral Melanoma; Basal Cell Carcinoma; Bladder Cancer; Cervical Cancer; Clear Cell Renal Cell Carcinoma; Colorectal Cancer (MSI-H); Cutaneous Melanoma; Cutaneous Squamous Cell Carcinoma; Endometrial Cancer; Epithelial Ovarian Carcinoma; Esophageal Cancer; Fallopian Tube Cancer; Gastric Cancer; Gastroesophageal Junction Cancer; Merkel Cell Carcinoma; Mucosal Melanoma; Non-Small Cell Lung Cancer (non-squamous); Non-Small Cell Lung Cancer (squamous); Pancreatic Adenocarcinoma (MSI-H); Pleural Mesothelioma; Primary Peritoneal Cancer; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Cancer,Age >= 18 years | ECOG 0–1 | Histologically or cytologically confirmed locally advanced or metastatic solid tumor | Adequate organ function | Measurable disease per RECIST v1.1 | Life expectancy >= 12 weeks | Women of childbearing potential: negative pregnancy test at screening and within 72 hours before first dose | Women must not be breastfeeding | Use of highly effective contraception,"Prior systemic anti-cancer therapy within 4 weeks before start of treatment | Prior radiotherapy within 2 weeks before start of treatment | History of radiation pneumonitis | Radiation therapy to the lung > 30 Gy within 6 months before start of treatment | Participation in an investigational agent/device study within 4 weeks before start of treatment | Active central nervous system metastases or carcinomatous meningitis | Active malignancy other than the disease under treatment within the previous 3 years (except curable cancers) | Requirement for systemic corticosteroids > 10 mg prednisone equivalent daily or other immunosuppressive therapy within 7 days prior to treatment | Clinically significant active, known or suspected autoimmune disease or conditions exacerbated by immunotherapy | Severe pulmonary, cardiac, or other systemic disease | Known hepatitis B or hepatitis C virus infection | Pregnant or lactating or planning to become pregnant during the study | History of allogeneic tissue/solid organ transplant | Active infection requiring systemic therapy | Severe hypersensitivity to components of study drugs",Washout >= 4 weeks from prior systemic anti-cancer therapy (shorter interval may be considered for kinase inhibitors or short half-life drugs); Washout >= 2 weeks from prior radiotherapy; Washout >= 1 week for palliative radiotherapy (< 2 weeks of RT) to non-CNS disease; No radiation therapy to the lung > 30 Gy within 6 months prior to treatment; No participation in an investigational agent or device study within 4 weeks prior to treatment,ALL,A,"Epithelial ovarian carcinoma (including clear cell subtype) is included, and her recurrent advanced disease fits the locally advanced/metastatic setting. Age/sex are eligible and prior platinum-taxane-bevacizumab is compatible with only standard washout required; no explicit exclusions are evident.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,"Disease (epithelial ovarian, clear cell) matches the trial’s listed diseases. Stage/setting (recurrent/advanced) fits locally advanced/metastatic requirement, and prior therapy is compatible with only a washout—thus two core anchors (stage/setting and line/prior) match. No hard exclusions or soft mismatches are evident; unknowns like measurable disease/ECOG are neutral. Grade A is appropriate.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT05215574,0.7893146276473999,Metastatic Urothelial Carcinoma,A Phase 1 Dose Escalation/Dose Finding Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors,PHASE1,18 years,Bladder Urothelial Cancer; Breast Cancer; Cervical Cancer; Cholangiocarcinoma; Colorectal Carcinoma; Endocervical Cancer; Esophageal Cancer; Gastric Cancer; Melanoma; Mesothelioma; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Renal Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck,"Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy. | Adequate bone marrow, kidney and liver function. | Performance status of 0 or 1. | Acute effects of prior therapy resolved to baseline severity or CTCAE Grade 1 (except AEs not constituting a safety risk per investigator).",Prior treatment targeting ILT3. | Prior treatment targeting LAIR1.,Prior anticancer therapy permitted if acute effects have resolved to baseline or CTCAE Grade 1.,ALL,A,"Bladder urothelial cancer is explicitly included and the metastatic setting fits. Prior therapy after ≥2 lines is acceptable for this Phase 1 trial, and age/sex meet eligibility with no known conflicting exclusions.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches (bladder/urothelial included). Stage/setting matches (metastatic). Prior therapy allowed and compatible with trial (no cap; only excludes prior ILT3/LAIR1, which is unknown). At least two core anchors match (stage and line/prior), no soft conflicts. Grade A is appropriate.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05236036,1.0,Recurrent Glioblastoma,A Phase 1/1b Adaptive Dose Escalation Study of Mycophenolate Mofetil (MMF) in Combination With Standard of Care for Patients With Glioblastoma,PHASE1,18 years,Glioblastoma (IDH-wildtype); Recurrent Glioblastoma; Astrocytoma,"Histologically confirmed glioblastoma, IDH wild-type (IHC R132H negative or sequencing); astrocytoma with molecular features of GBM eligible | Newly diagnosed glioblastoma with prior surgical resection or biopsy; cohort-specific requirements per Group 1-3 | Group 2: Documented MGMT-unmethylated glioblastoma | Group S: Newly suspected or recurrent glioblastoma and scheduled for standard-of-care surgical resection or biopsy | Stable or decreasing corticosteroids at <= 8 mg dexamethasone daily for >= 7 days prior to registration | Age >= 18 years | Karnofsky performance status >= 70% | WBC >= 3,000/µL (within 14 days) | ANC >= 1,500/µL (within 14 days) | Hemoglobin >= 8 g/dL (within 14 days) | Platelets >= 100,000/µL (within 14 days) | Total bilirubin <= 2 x ULN (within 14 days) | AST/ALT <= 3 x ULN (within 14 days) | Creatinine <= 1.5 x ULN (within 14 days) | INR <= 1.5 x ULN (within 14 days) | PT/PTT <= 1.5 x ULN (within 14 days) | Females of childbearing potential: negative pregnancy test within 14 days prior to registration","Receiving other investigational agents (COVID-19 vaccine or treatment allowed) | Prior or concurrent malignancy that may interfere with study treatment or safety (per investigator discretion) | History of allergic reactions to temozolomide or mycophenolate mofetil or similar compounds | Spinal cord and diffuse leptomeningeal disease glioblastoma | Live vaccination within 2 weeks before initiation of MMF and/or TMZ | Current viral-vector based therapy | Uncontrolled epilepsy | Uncontrolled intercurrent illness | Concurrent malignancy outside of glioblastoma requiring tumor-directed treatment | Known hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency (e.g., Lesch-Nyhan or Kelley-Seegmiller syndromes) | Known concurrent shingles, herpes, or cytomegalovirus (CMV) infection | Known concurrent opportunistic fungal infection | Known concurrent or history of unexplained opportunistic infection | Known immunodeficiency that could predispose to opportunistic infections | Psychiatric illness or social conditions limiting compliance or compromising safety | Pregnant or nursing | Unable to swallow oral medication or conditions affecting absorption of oral medication | Known history of HIV, HBV, or HCV infection",Prior surgical resection or biopsy required for Groups 1-3; Group 1: Prior chemoradiation completed; Group 2: Surgical resection or biopsy only (no prior chemoradiation); Group 3: Surgical resection or biopsy only; Group S: Planned standard-of-care surgical resection or biopsy,ALL,A,"Disease and biomarker match (recurrent IDH-wildtype GBM), age fits, and prior standard chemoradiation/temozolomide is compatible with allowed cohorts. No explicit exclusions are triggered; stage/setting is appropriate for the trial’s recurrent cohort.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease and required biomarker (IDH-wildtype) match; age/sex acceptable. Line/prior exposure compatible (prior RT/TMZ allowed). Stage/setting for recurrent is broadly supported by trial cohorts, though the recurrent cohort may require planned surgery, which is unknown—not a soft mismatch. With ≥2 anchors matched (biomarker and line/prior; stage/setting not clearly mismatched), grade A is appropriate.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05347095,0.702629566192627,Crohn's Disease,"A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease",PHASE3,18 years,Perianal Crohn's Disease,"Diagnosis of Crohn's disease for >= 3 months | At least one active draining perianal fistula confirmed by screening MRI | Previously had inadequate initial response, loss of response, or intolerance to therapy from up to 2 classes of advanced drug therapies approved for Crohn's disease (e.g., infliximab, adalimumab, certolizumab pegol, vedolizumab or approved biosimilars) or a JAK inhibitor licensed for Crohn's disease (e.g., upadacitinib)","Very severe luminal Crohn's disease activity | History of rectovaginal fistulas, rectal and/or anal stenosis, stoma or functioning ostomy, undrained abscess/collections, colonic mucosal dysplasia or pre-cancerous lesions not removed, demyelinating disease, or systemic lupus erythematosus | Complications of Crohn's disease anticipated to require surgery or preclude fistula evaluation (e.g., symptomatic strictures/stenoses, short gut syndrome) | Any medical contraindications preventing study participation | History of ongoing, chronic, or recurrent enteral or systemic infectious disease","Prior exposure to up to 2 classes of advanced therapies for Crohn's disease (anti-TNF agents, vedolizumab, or JAK inhibitor such as upadacitinib); Documented inadequate response, loss of response, or intolerance to the above therapies",ALL,A,"The trial targets fistulizing perianal Crohn's disease, which matches the patient's active perianal fistula, and the patient has prior inadequate response to an anti-TNF (infliximab) as required. Age/sex are eligible and no explicit exclusion is evident.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,A,No hard exclusions. Disease/phenotype matches (perianal fistulizing CD) and prior-exposure anchor matches (failed anti-TNF). Age/sex eligible. MRI confirmation is unknown but not a hard exclusion. ≥2 anchors (line/prior and required phenotype) → A. Grader’s reasoning aligns with rubric.,,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT05394831,0.7731086015701294,Metastatic Non-Small Cell Lung Cancer,"A Phase 1/2, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of JIN-A02 in Patients With EGFR Mutant Advanced Non-small Cell Lung Cancer",PHASE1/PHASE2,18 years,Non-small Cell Lung Cancer (advanced/metastatic),"Age >= 18 years (>= 19 years in South Korea) | Pathologically confirmed advanced and/or metastatic non-small cell lung cancer with active EGFR mutation | Disease progression after standard therapy including an approved EGFR-TKI and/or up to 1 line of platinum-based chemotherapy | For Part C: prior approved EGFR-TKI active against T790M (e.g., osimertinib) required | Locally confirmed EGFR mutation by sponsor-approved test from tumor tissue and/or plasma ctDNA | Part A/B: EGFR C797S or EGFR T790M positive | Part C Cohort 1: EGFR C797S and T790M positive | Part C Cohort 2: EGFR C797S positive and T790M negative | Part C Cohort 3: EGFR T790M positive and C797S negative | Part C Cohort 4: any EGFR mutation with stable brain metastasis | Part C Cohort 5: EGFR-dependent mutation other than C797S or T790M | For Part C: at least one measurable lesion per RECIST v1.1 not previously irradiated | ECOG performance status 0–1 | Toxicities from prior therapy recovered to baseline or <= grade 1 (exceptions allowed for chronic <= grade 2 conditions per investigator) | Adequate bone marrow and organ function","NSCLC with mixed squamous histology or histologic transformation (e.g., transition to small cell lung cancer or epithelial–mesenchymal transition) | For Part A/B and Part C Cohort 4: uncontrolled CNS metastases, leptomeningeal disease, or need for steroid escalation within 28 days (unless stable after local CNS therapy per protocol timeframe) | EGFR-TKI treatment within 7 days before first dose | Systemic anticancer therapy within 14 days or 5 half-lives (whichever is shorter) before first dose | Limited field radiotherapy within 7 days or extended field chest radiotherapy within 14 days before first dose | Immunotherapy or other antibody therapy within 28 days before first dose | Not recovered from major surgery or its side effects within 28 days before first dose (excluding vascular access placement) | QTcF > 470 ms | Clinically significant and uncontrolled cardiac arrhythmia (e.g., type II second-degree or third-degree heart block) | Risk factors for QT prolongation or torsades de pointes (e.g., hypokalemia, congenital long QT, pertinent family history, or concomitant QT-prolonging drugs) | Uncontrolled hypertension: systolic blood pressure > 180 mmHg or diastolic blood pressure > 100 mmHg | Congestive heart failure NYHA class III–IV or hospitalization for heart failure within 6 months | Acute myocardial infarction or unstable angina within 6 months | Active second malignancy within 2 years (except adequately treated basal/squamous skin cancer or carcinoma in situ) | History/evidence of interstitial lung disease or steroid-requiring pneumonitis (COVID-19-related prior ILD may be eligible with approval) | Inability to swallow oral medication or significant gastrointestinal disorder causing malabsorption | Uncontrolled active infections including HIV, HBV, HCV, or tuberculosis | Known hypersensitivity to JIN-A02 or its components | History of drug abuse or unstable medical, mental, or social conditions interfering with study participation | Unable to comply with study procedures",Progression after an approved EGFR-TKI; Up to one prior line of platinum-based chemotherapy; For Part C: prior osimertinib (or another T790M-active EGFR-TKI) required,ALL,A,"Metastatic EGFR-mutant NSCLC with prior osimertinib, age ≥18, and ECOG 0 matches the study’s setting, biomarker, and prior-therapy requirements (Part C allows various EGFR mutations). No explicit exclusion conflicts are identified; progression/resistance details are not provided but are not a hard mismatch.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches. Core anchors: Stage/setting matches (metastatic), and required biomarker (EGFR-mutant) is satisfied (cohort allowing EGFR-dependent mutations other than C797S/T790M). Line/prior exposure has unknown progression status but prior osimertinib aligns with Part C requirement; unknown does not create a soft conflict. With ≥2 anchors matched and no soft mismatches, A is appropriate.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05465954,0.7280203104019165,Recurrent Glioblastoma,Efficacy and Safety Study of Neoadjuvant Efineptakin Alfa (NT-I7) and Pembrolizumab in Recurrent Glioblastoma,PHASE2,18 years,"Glioblastoma (recurrent, IDH-wildtype); Gliosarcoma (recurrent)","Age >= 18 years | WHO Grade IV IDH-wildtype glioblastoma or gliosarcoma with tissue-confirmed progressive or recurrent disease | Previously treated with maximal feasible resection or biopsy, radiation, and temozolomide | Enhancing mass on MRI amenable to resection or biopsy | ECOG performance status 0–1 | Karnofsky performance status >= 70","Life-threatening raised intracranial pressure requiring immediate surgery | Bevacizumab use within <= 4 months prior to registration | Live vaccine within <= 30 days prior to registration | Requirement for dexamethasone dose > 2 mg/day within <= 2 days prior to registration | Failure to recover from adverse events of prior major surgery within <= 28 days | Failure to recover from adverse events of prior radiation therapy within <= 14 days | Severe uncontrolled systemic illness or condition that would interfere with study assessments | Known HIV infection | Uncontrolled intercurrent illness (active infection, symptomatic CHF, unstable angina, cardiac arrhythmia, significant psychiatric or social illness) | Concurrent treatment with another investigational agent | Another active malignancy requiring systemic treatment within <= 1 year | Myocardial infarction within <= 6 months or congestive heart failure requiring maintenance therapy for life-threatening ventricular arrhythmias | Active autoimmune disease requiring systemic treatment within <= 2 years | Concurrent known active hepatitis B and active hepatitis C infection | Known active tuberculosis | History of (non-infectious) pneumonitis or interstitial lung disease that required steroids, or current pneumonitis/interstitial lung disease | Hypersensitivity to pembrolizumab or its excipients | Prior anti-PD-1/PD-L1/PD-L2 therapy within < 12 months prior to registration | History of allogeneic tissue/solid organ transplant",Prior maximal feasible resection or biopsy required; Prior radiation therapy required; Prior temozolomide required; No bevacizumab within 4 months prior to registration; No live vaccine within 30 days prior to registration; No major surgery within 28 days prior to registration; No radiation therapy within 14 days prior to registration; No prior anti-PD-1/PD-L1/PD-L2 therapy within 12 months prior to registration,ALL,A,"Recurrent IDH-wildtype glioblastoma matches the trial’s disease/setting, and the patient meets age/ECOG with required prior resection, radiation, and temozolomide and no PD-1 exposure. No exclusions are evident; items like a resectable/biopsiable enhancing mass are unknown rather than conflicting.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,"Disease and biomarker match (recurrent IDH-wildtype GBM). Stage/setting matches (recurrent), and prior therapy/exposure requirements align (surgery, RT, temozolomide; no prior PD-1). No hard exclusions identified; unmet specifics like resectable/biopsiable enhancing mass are unknown, not conflicts. Meets ≥2 core anchors including stage/line, so A is appropriate.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT05549219,0.46254658699035645,PMM2-CDG,"A Phase 2, Randomized, Open-Label, 24-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult, Adolescent, and Pediatric Participants With PMM2-CDG",PHASE2,2 years to 65 years,Phosphomannomutase 2 Deficiency,"Age 2–65 years (cohort dependent) | Molecularly confirmed PMM2-CDG (biallelic pathogenic/likely pathogenic PMM2 variants, or bi-allelic variants plus deficient PMM2 enzyme activity)","Diagnosis of a congenital disorder of glycosylation other than PMM2-CDG | Active infection requiring parenteral antibiotics/antivirals/antifungals or systemic steroids within 7 days prior to screening | Active COVID-19 or positive SARS-CoV-2 test at screening | ALT >3 x ULN | AST >3 x ULN | Total bilirubin >2 x ULN | INR >1.5 | History of severe allergic reaction to GLM101 or its excipients | Known poor venous access | History of liver transplant | Drug or alcohol use disorder within 12 months | Major surgery within 30 days prior to screening | Clinically significant lab abnormalities not related to PMM2-CDG | Positive pregnancy test (female) | Breastfeeding (female) | Hepatitis B surface antigen positive or hepatitis C antibody positive | Any illness that might impact infusion safety or evaluability per investigator/medical monitor | QTc >=450 ms or clinically significant ECG abnormalities | Uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric, or other significant disease | Participation in another interventional study or investigational product within 30 days or 5 half-lives | Weight >75 kg",(none),ALL,A,"Disease (PMM2-CDG) and required biomarker (biallelic PMM2 variants) match, and age (8) falls within the 2–65-year window; no line-of-therapy restrictions apply. No explicit exclusion criteria are triggered based on the provided data.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),INCORRECT,B,"No hard exclusions. Disease and required biomarker match. However, only one CORE ANCHOR (biomarker) clearly matches; stage/setting and line/prior are unspecified/neutral, and metastatic pattern is not relevant. Age fit is not a core anchor. Thus B, not A.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT05681780,0.8000652194023132,Metastatic Non-Small Cell Lung Cancer,Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients With Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC),PHASE1,18 years,Non-small Cell Lung Cancer (metastatic/recurrent),"Age >= 18 years | Stage IV or recurrent non-small cell lung cancer | Activating genomic alteration in EGFR, ALK, ROS1, or ERBB2 | ECOG performance status 0–1 | Expected survival >= 4 months | Progression after >= 1 prior line of systemic therapy for NSCLC | Prior appropriate targeted therapy for the relevant genomic alteration | Measurable disease (excluding lesion used for TIL harvest) prior to nivolumab start | Safely accessible tumor for TIL harvest by excisional biopsy expected to yield >= 1.5 cm3 of tissue (aggregate) | Brain metastases allowed if treated or clinically stable <= 10 mm or not requiring immediate CNS-specific therapy | Adequate organ and marrow function | DLCO >= 45% predicted within past 4 months | HIV: on effective ART >= 6 months with undetectable viral load and normal CD4 count | Chronic HBV: undetectable viral load on suppressive therapy if indicated and no overt cirrhosis | HCV: treated and cured, or on treatment with undetectable viral load and no overt cirrhosis | Prior or concurrent malignancy allowed if it will not interfere with safety or efficacy assessment","More than six prior lines of systemic therapy for NSCLC | Any prior PD-1 or PD-L1 inhibitor for metastatic NSCLC | Rapidly progressing tumors per investigator judgment | Active or prior documented autoimmune disease within the past 2 years (except allowed limited conditions with approval) | Active leptomeningeal or pachymeningeal metastases, or carcinomatous meningitis | Primary immunodeficiency | Chronic systemic steroid therapy or other immunosuppressive therapy within 7 days prior to enrollment (except allowed physiologic or topical/inhaled steroids) | Uncontrolled intercurrent illness (e.g., symptomatic congestive heart failure, unstable angina, significant arrhythmia other than AF/SVT, >= 85% carotid artery stenosis) | Unresolved >= grade 2 toxicity from prior anticancer therapy (unless irreversible and not expected to be exacerbated) | QTc >= 480 ms (Bazett) | Active systemic infection requiring intravenous antibiotics within 1 week prior to nivolumab | History of allogeneic organ transplant | Psychiatric illness or social situation limiting compliance | History of anaphylaxis to beta-lactam antibiotics",At least one prior line of systemic therapy for NSCLC required; Appropriate prior targeted therapy required for the relevant genomic alteration,ALL,A,"Metastatic NSCLC with activating EGFR exon 19 deletion matches the trial’s disease and biomarker requirements; the patient is age-eligible with ECOG 0 and has received appropriate prior targeted therapy (osimertinib) without prior PD-1 exposure. Some procedural/response details (progression status, measurable disease, accessible tumor for TIL harvest) are unspecified but not contradictory.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,A,"No hard exclusions. Disease and stage/setting match; required biomarker (EGFR exon 19) matches. Line/prior exposure partially unknown regarding progression, but prior appropriate targeted therapy and no PD-1 exposure are compatible; no soft conflicts identified. With ≥2 anchors (stage and biomarker) matching, A is appropriate.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT05920798,0.847095251083374,Recurrent Clear Cell Ovarian Carcinoma,"MC220601, Folate Receptor Alpha Dendritic Cells (FRαDCs) Plus Pembrolizumab for Patients With Advanced Stage Ovarian Cancer (FRAPPE)",PHASE1/PHASE2,18 years,Ovarian Carcinoma (recurrent); Ovarian Clear Cell Adenocarcinoma (recurrent); Ovarian Endometrioid Adenocarcinoma (recurrent); Ovarian High Grade Serous Adenocarcinoma (recurrent); Ovarian Carcinosarcoma (recurrent); Fallopian Tube Carcinoma (recurrent); Fallopian Tube Clear Cell Adenocarcinoma (recurrent); Fallopian Tube Endometrioid Adenocarcinoma (recurrent); Fallopian Tube High Grade Serous Adenocarcinoma (recurrent); Fallopian Tube Carcinosarcoma; Primary Peritoneal Carcinoma (recurrent); Primary Peritoneal Clear Cell Adenocarcinoma (recurrent); Primary Peritoneal Endometrioid Adenocarcinoma (recurrent); Primary Peritoneal High Grade Serous Adenocarcinoma (recurrent); Primary Peritoneal Carcinosarcoma (recurrent),"Age >= 18 years | Histologically confirmed recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (high grade serous, endometrioid, or clear cell; mixed carcinomas/carcinosarcomas eligible if >= 50% high grade serous and/or endometrioid and/or clear cell) | Platinum-refractory, platinum-resistant, or platinum-sensitive recurrence | Measurable disease per RECIST v1.1 and/or CA-125-evaluable disease by GCIG | ECOG performance status 0-1 | Hemoglobin >= 8.5 g/dL | Absolute neutrophil count >= 1000/µL | Platelet count >= 75000/µL | Lymphocytes >= 300/µL | Monocytes >= 250/µL | Total bilirubin <= 1.5 x ULN (if Gilbert's, direct bilirubin <= ULN) | AST <= 3 x ULN | Creatinine clearance >= 30 mL/min","Pregnant or nursing | Persons of childbearing potential or able to father a child unwilling to use adequate contraception | Prior anti-PD-1 or anti-PD-L1 therapy for ovarian cancer | IV anti-cancer therapy <= 3 weeks or oral anti-cancer therapy <= 1 week prior to registration | Grade >= 2 ovarian cancer-related symptoms, or lesion > 5 cm (non-nodal long axis or nodal short axis), or disease likely to become symptomatic within 8 weeks | Significant comorbid illness that would interfere with study treatment or assessments | Uncontrolled HIV infection; HIV must be well controlled on ART with CD4 >= 350/µL and suppressed HIV RNA | Ongoing or active serious infection requiring systemic therapy | Current or prior immune-related pneumonitis or interstitial lung disease requiring steroids | Active autoimmune disease requiring systemic treatment within 2 years (except replacement therapy) | Active hepatitis B (unless on antivirals with undetectable HBV DNA) or active hepatitis C (unless successfully treated with undetectable HCV RNA) | Other active malignancy requiring palliative systemic therapy within 3 years or likely to require treatment in next 2 years (except non-melanoma skin cancer, papillary thyroid cancer not requiring therapy, or carcinoma in situ) | Myocardial infarction within 6 months or congestive heart failure requiring ongoing maintenance therapy for life-threatening ventricular arrhythmias | Systemic immunosuppressive medication within 7 days prior to registration (except permitted low-dose or inhaled steroids) | History of allogeneic stem cell transplant","Any number of prior therapies or maintenance regimens for ovarian cancer allowed; Eligible regardless of platinum status (platinum-refractory, -resistant, or -sensitive); Washout required: last IV anti-cancer therapy >= 3 weeks; last oral anti-cancer therapy >= 1 week before registration",FEMALE,A,"Recurrent clear cell ovarian carcinoma matches the trial’s disease and setting, and the patient (female, 36) meets age/sex with allowed prior therapies and no prior PD-1/PD-L1. Clear cell subtype is eligible and no explicit exclusions are evident from the provided data.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,No hard exclusions. Disease matches (recurrent clear cell ovarian cancer). Core anchors: stage/setting matches recurrence and prior exposure is compatible (any prior lines allowed; no prior PD-1/PD-L1). Required histology/subtype is satisfied. No identified soft conflicts. Grade A is appropriate.,,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT05942300,0.7157944440841675,Recurrent Clear Cell Ovarian Carcinoma,Phase I Trial of CPI-0209 in Combination With Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer,PHASE1,18 years,"Ovarian Cancer (recurrent, platinum-sensitive); Fallopian Tube Cancer (recurrent, platinum-sensitive); Primary Peritoneal Cancer (recurrent, platinum-sensitive)","Platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer (>6 months after last platinum) eligible for platinum-based chemotherapy | Documented disease recurrence/progression per GCIG-RECIST | At least 1 prior line of platinum-based therapy; prior bevacizumab or PARP inhibitor allowed | ECOG performance status 0-2 and life expectancy >=3 months | Adequate organ function | Able to swallow oral CPI-0209 | Treated CNS metastases allowed if therapy completed >=8 weeks prior, asymptomatic off systemic corticosteroids >=4 weeks, and stable/regressed on imaging >=4 weeks after therapy","Borderline or low malignant potential histology | Platinum-resistant disease (progressive disease within 6 months of completing platinum therapy) | Known hypersensitivity to CPI-0209 excipients | Gastrointestinal dysfunction or disease that may significantly alter absorption of study drugs | Concurrent malignancy or malignancy within 3 years except adequately treated basal or squamous cell carcinoma, non-melanomatous skin cancer, or curatively resected cervical cancer, or if deemed cured per investigator | History of HIV infection | Active infection requiring systemic treatment | Severe or uncontrolled medical conditions that pose unacceptable risk (e.g., chronic pancreatitis, chronic active hepatitis, significant cardiac or pulmonary disease) | Current treatment with warfarin or other coumadin-derived anticoagulants (heparin/LMWH/fondaparinux allowed) | Use of herbal supplements unless discontinued >=7 days prior to study drug | Consumption of strong CYP3A4/5 inducers or inhibitors not discontinued >=7 days prior; unwilling to avoid Seville oranges, grapefruit, and related products during study | Pregnant or breastfeeding | Participation in another investigational study within 30 days or within 5 half-lives of the investigational product, whichever is longer | Radiotherapy <=4 weeks prior to study drug (<=2 weeks if limited field for palliation) or not recovered to <=Grade 1; or >=25% of bone marrow irradiated | Major surgery within 14 days prior to study drug or not recovered from major surgery | Not recovered from prior anticancer therapy toxicities to <=Grade 1 (exceptions: any grade alopecia; controlled endocrine toxicities; neuropathy <=Grade 2) | Grade 3 baseline neuropathy | Child-Pugh class B or C hepatic impairment",At least 1 prior platinum-based chemotherapy required; Prior bevacizumab allowed; Prior PARP inhibitor allowed,FEMALE,A,"Disease and setting match (recurrent ovarian cancer), patient is an adult female, and she has had prior platinum-based therapy with bevacizumab allowed. Platinum sensitivity interval (>6 months) is unspecified but not an explicit exclusion, and no other exclusions are evident.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),INCORRECT,B,"No hard exclusions. Disease matches and recurrent setting matches (1 anchor). However, the trial requires platinum-sensitive recurrence (>6 months since last platinum), which is unknown for the patient, so the Line/prior anchor cannot be counted as a clear match. With only one confirmed anchor match and no soft conflicts, the correct grade is B, not A.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT06177964,0.7748099565505981,Recurrent Glioblastoma,Randomized Phase 2 Clinical Trial of Repeated Intratumoral and Cervical Perilymphatic Lerapolturev Injections Versus Lomustine in Recurrent Glioblastoma (GBM),PHASE2,18 years,"Glioblastoma (recurrent, supratentorial)","Age >= 18 years | Histopathologically confirmed recurrent supratentorial glioblastoma (WHO grade 4) | Karnofsky Performance Score >= 70% | Hemoglobin >= 9 g/dL prior to biopsy | Platelet count >= 100,000/µL prior to biopsy (unsupported) | Neutrophil count >= 1000/µL prior to biopsy | Creatinine <= 1.5 x ULN prior to biopsy | Total bilirubin <= 1.5 x ULN prior to biopsy (Gilbert's syndrome exception) | AST/ALT <= 2.5 x ULN | Prothrombin time and partial thromboplastin time <= 1.2 x ULN prior to biopsy | If on warfarin, INR < 2.0 prior to biopsy | Recurrent tumor presence confirmed by histopathology at time of biopsy prior to first lerapolturev infusion | Able to undergo brain MRI with and without contrast | Completed CDC-recommended poliovirus vaccination series and received IPV booster 1–6 weeks before lerapolturev (or evidence of anti-poliovirus immunity)","Pregnant or breastfeeding | Impending, life-threatening cerebral herniation syndrome | Active infection requiring IV therapy or unexplained febrile illness (Tmax > 99.5°F/37.5°C) | Known immunosuppressive disease or HIV infection | Severe heart disease (NYHA class III or IV) | Known lung disease (FEV1 < 50%) or uncontrolled diabetes mellitus | Known albumin allergy | History of agammaglobulinemia | Chemotherapy or bevacizumab within 4 weeks (nitrosourea within 6 weeks; metronomic daily etoposide or cyclophosphamide within 1 week) prior to study drug unless recovered from toxicities | Immunotherapy within 4 weeks prior to study drug unless recovered from toxicities | Tumor treating fields within 1 week prior to study drug | Less than 12 weeks from radiation therapy unless progression outside field, two progressive scans >= 4 weeks apart, or histopathologic confirmation | Failure to complete standard-of-care treatments including surgery and radiation (age-adjusted dosing) | If MGMT promoter methylated or unknown, lack of at least one prior chemotherapy regimen | Neoplastic lesions in brainstem, cerebellum, or spinal cord | Active multifocal disease, extensive subependymal disease, tumor crossing midline, or leptomeningeal disease | Dexamethasone > 4 mg/day within 2 weeks prior to first lerapolturev infusion | Worsening steroid myopathy | Prior unrelated malignancy requiring current active treatment (except cervical carcinoma in situ and adequately treated basal cell or squamous cell skin cancer) | Active autoimmune disease requiring systemic immunomodulatory treatment within the past 3 months | Known hypersensitivity to lomustine, dacarbazine, or components of lomustine","Maximal safe resection of recurrent tumor prior to study treatment; Completion of standard-of-care radiation therapy (age-adjusted dosing) prior to enrollment; If MGMT promoter methylated or unknown, at least one prior chemotherapy regimen required; Washout: chemotherapy or bevacizumab > 4 weeks (nitrosourea > 6 weeks; metronomic daily etoposide or cyclophosphamide > 1 week) before study drug; Washout: immunotherapy > 4 weeks before study drug; Washout: tumor treating fields > 1 week before study drug; Radiation therapy >= 12 weeks before study drug unless specified progression criteria met; Prior poliovirus vaccination series and IPV booster 1–6 weeks before lerapolturev",ALL,A,"Disease and setting match (recurrent GBM), age fits, and prior standard surgery plus chemoradiation align with trial requirements; ECOG 1 is compatible with the performance status threshold. No explicit exclusion conflicts are evident, and IDH-wildtype is acceptable.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,A,"No hard exclusions identified. Stage/setting (recurrent GBM) matches and prior-exposure/line (post surgery and chemoradiation/temozolomide) matches, satisfying ≥2 core anchors. Age/sex within limits. Location (supratentorial) and poliovirus immunity are unknown but not mismatches per rubric. Thus A is appropriate.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT06379217,0.7249555587768555,Metastatic Castration-Resistant Prostate Cancer,"A Phase I, Open-label, Multi-center Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.",PHASE1,18 years to 100 years,Metastatic Neuroendocrine Prostate Cancer,"Metastatic prostate cancer with neuroendocrine differentiation by one of: small cell/neuroendocrine histology; neuroendocrine marker expression (chromogranin or synaptophysin) by IHC; progression of visceral metastases without PSA progression; serum chromogranin A > 5 x ULN or neuron-specific enolase > 2 x ULN (with PPI control); or prostate adenocarcinoma with molecular features of neuroendocrine differentiation (e.g., loss of 2 of PTEN, TP53, RB). | PSMA and/or SSTR2 and/or GRPR PET-positive with at least one measurable lesion per RECIST 1.1 and moderate target expression on at least one of the 3 PET scans. | Castrate testosterone level < 50 ng/dL (or < 1.7 nmol/L) for participants with adenocarcinoma component, or stable testosterone level for pure neuroendocrine carcinoma. | Recovered to <= Grade 2 from clinically significant toxicities related to prior therapy. | Adequate bone marrow and organ function. | ECOG performance status <= 2.","Prior treatment within 6 months with bone-seeking radionuclides: strontium-89, samarium-153, rhenium-186, rhenium-188, or radium-223, or hemi-body irradiation. | Previous PSMA-, SSTR2-, or GRPR-targeted radioligand therapy. | Concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, or investigational therapy. | CNS metastases that are neurologically unstable, symptomatic, or requiring corticosteroids to maintain neurologic integrity. | Symptomatic spinal cord compression or clinical/radiologic signs of impending cord compression. | Clinically significant ECG abnormalities indicating increased safety risk.",(none),MALE,A,"Metastatic prostate cancer setting, age, and male sex fit; prior abiraterone/enzalutamide are allowed, and PSMA PET avidity aligns with the PET-target requirement. Neuroendocrine differentiation is required but not documented (unknown rather than conflicting), and no explicit exclusions are evident.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),INCORRECT,C,"No hard exclusions. Stage (metastatic) and prior-exposure compatibility match, but the trial requires neuroendocrine differentiation, which is unknown for the patient. A requires required biomarkers/subtype to be satisfied; here it is not documented, so A is not permissible. With key required subtype unknown and no soft mismatches, the correct grade is C (relevant/uncertain), not A.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT06660654,0.8386564254760742,Recurrent Clear Cell Ovarian Carcinoma,"REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants With Advanced/Metastatic Solid Tumors",PHASE2,18 years,Endometrial Cancer; Cervical Cancer; Clear Cell Ovarian Carcinoma; Endometrioid Ovarian Cancer (low grade); Serous Ovarian Cancer (low grade); Mucinous Ovarian Cancer; Urothelial Carcinoma; Clear Cell Renal Cell Carcinoma,"Age >= 18 years | At least 1 lesion not previously irradiated | Lesion amenable to biopsy and willingness to provide a pre-treatment biopsy | Measurable disease per RECIST 1.1 | Radiographic progression on or after the most recent line of systemic therapy | ECOG performance status 0–1 | Endometrial cancer: Pathologically or cytologically documented endometrial carcinoma (any histology) or carcinosarcoma, irrespective of MSI/MMR status | Endometrial cancer: Disease progression after 1–3 prior lines including platinum-based chemotherapy and an anti-PD-1–containing regimen (combined or sequential) in the advanced/metastatic setting | Cervical cancer: Pathologically or cytologically documented recurrent or persistent squamous, adenosquamous, or adenocarcinoma of the cervix | Cervical cancer: Disease progression after >=1 prior line of systemic therapy in the advanced or metastatic setting | Non-HGS ovarian cancer: Pathologically or cytologically documented unresectable or metastatic clear cell, low-grade endometrioid, low-grade serous, or mucinous ovarian cancer previously treated with >=1 prior line | Urothelial cancer: Pathologically or cytologically documented unresectable or metastatic urothelial carcinoma of bladder, renal pelvis, ureter, or urethra; histologic variants allowed if predominantly urothelial | Urothelial cancer: Relapsed/progressed after >=1 prior line (maximum 3) that contained anti-PD-(L)1 therapy in the perioperative or metastatic setting | ccRCC: Pathologically or cytologically documented unresectable or metastatic clear cell renal cell carcinoma | ccRCC: Previously treated with <=3 prior systemic regimens for advanced/metastatic RCC, including both a PD-(L)1 checkpoint inhibitor and a VEGF-TKI in sequence or combination","Clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis | Cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event within 6 months | Uncontrolled or significant cardiovascular disease | History of noninfectious ILD/pneumonitis requiring steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis on screening imaging | Clinically severe pulmonary compromise | Chronic steroid treatment >10 mg/day (with protocol-specified exceptions) | History of other active malignancy within 3 years, except those with negligible risk and treated with expected curative outcome | Unresolved toxicities from prior anticancer therapy (except alopecia) not resolved to <= Grade 1 or baseline per NCI-CTCAE v5.0 | Prior exposure to CDH6-targeted agents or to an ADC with an exatecan derivative topoisomerase I inhibitor (e.g., trastuzumab deruxtecan, datopotamab deruxtecan) | Ongoing uncontrolled systemic bacterial, fungal, or viral infection | Active or uncontrolled HIV, HBV, or HCV infection",Progression on or after the most recent line of systemic therapy; Endometrial cancer: 1–3 prior lines including platinum-based chemotherapy and an anti-PD-1–containing regimen; Cervical cancer: >=1 prior line of systemic therapy in advanced/metastatic setting; Non-HGS ovarian cancer: >=1 prior line of therapy; Urothelial cancer: >=1 prior line (max 3) including anti-PD-(L)1 therapy; ccRCC: <=3 prior systemic regimens including both a PD-(L)1 inhibitor and a VEGF-TKI,ALL,A,"Tumor type matches the trial’s non-HGS clear cell ovarian carcinoma cohort, and the patient has recurrent/advanced disease after ≥1 prior platinum-based line. Age and sex fit, and no explicit exclusion is evident from the available data.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,"Disease matches the non-HGS clear cell ovarian cohort. Patient has recurrent/advanced disease after ≥1 prior systemic line, meeting stage/setting and line/prior anchors; age/sex fit; no explicit exclusions identified. Unknowns (measurable disease, ECOG, biopsy) are neutral per rubric. Thus A is appropriate.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT06764771,0.8073819875717163,Recurrent Clear Cell Ovarian Carcinoma,A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors,PHASE1,18 years,Clear-Cell Renal Cell Carcinoma; Clear-Cell Ovarian Cancer; Non-Small Cell Lung Cancer; Colorectal Cancer; Pancreatic Ductal Adenocarcinoma,"Age >= 18 years | Histologically confirmed locally advanced unresectable or metastatic solid tumor | Part 1A tumor types: clear-cell renal cell carcinoma, clear-cell ovarian cancer, non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma | Parts 2A, 1D, 2D: clear-cell renal cell carcinoma | Part 1B: solid tumors with KRAS G12C mutation | Part 2B: non-small cell lung cancer with KRAS G12C mutation | Parts 1C, 2C: colorectal cancer with KRAS G12C mutation | ECOG 0–1 | Measurable disease per RECIST v1.1","Untreated central nervous system metastases | Leptomeningeal metastasis | Impaired cardiac function or clinically significant cardiac disease | For adagrasib combination cohorts (Parts 1B, 1C, 2B, 2C): history of pneumonitis or interstitial lung disease | For adagrasib combination cohorts (Parts 1B, 1C, 2B, 2C): history of severe cutaneous adverse reactions including Stevens-Johnson syndrome or toxic epidermal necrolysis",(none),ALL,A,"Disease matches (clear-cell ovarian cancer), and the patient has recurrent disease with malignant pleural effusion consistent with an advanced/metastatic setting; prior adjuvant carboplatin/paclitaxel/bevacizumab is allowed and no exclusions are triggered.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,A,"No hard exclusions. Disease matches (clear-cell ovarian). Stage/setting compatible given recurrent disease with cytology-positive pleural effusion (advanced/metastatic), and prior adjuvant therapy is allowed with no disallowed exposures. At least two anchors match (stage/setting and line/prior), with no soft conflicts; unknowns like RECIST measurability/ECOG are neutral. Grade A is appropriate.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT06784193,0.8638753294944763,Metastatic Castration-Resistant Prostate Cancer,"A Phase 1 First-in-Human, Open-Label, Multicenter Study of OP-3136 in Adult Participants With Advanced or Metastatic Solid Tumors",PHASE1,18 years,Breast Cancer (ER+ HER2-); Prostate Cancer (castration-resistant metastatic); Non-Small Cell Lung Cancer (metastatic),Advanced or metastatic ER+ HER2- breast cancer (per cohort definitions) | Metastatic castration-resistant prostate cancer | Advanced or metastatic non-small cell lung cancer (Part 1 only) | Part 1A monotherapy: Unresectable or metastatic tumor with no life-prolonging options or intolerant/refractory to available therapies,"Prior therapy with a KAT6A/B inhibitor | Symptomatic visceral disease at risk of short-term life-threatening complications | Known active or symptomatic CNS metastases, carcinomatous meningitis, leptomeningeal disease, or spinal cord compression requiring CNS-directed therapy | CNS disease not clinically and radiologically stable for >= 2 months prior to first dose | Requirement for or current steroid therapy for CNS metastases | History of cerebrovascular disease, including transient ischemic attack, within 6 months prior to first dose | Impaired cardiac function or clinically significant cardiac disease within 6 months prior to first dose",ER+ HER2- mBC Part 1B/Part 2B (combo with fulvestrant): Progressed on or after >=1 prior line including endocrine therapy and a CDK4/6 inhibitor in the advanced/metastatic setting; ER+ HER2- mBC Part 1B/Part 2B (combo with fulvestrant): No more than 2 prior lines of endocrine therapy in the advanced/metastatic setting (Part 2B); no more than 3 prior lines of endocrine therapy with >=1 line combined with a CDK4/6 inhibitor (Part 1B); ER+ HER2- mBC Part 1B: No more than 1 prior line of chemotherapy or an antibody-drug conjugate in the advanced/metastatic setting; ER+ HER2- mBC Part 2A monotherapy: Up to 3 prior lines of endocrine therapy (one with a CDK4/6 inhibitor) and up to 1 prior line of chemotherapy or an antibody-drug conjugate; mCRPC Part 2A monotherapy: Up to 4 prior lines of systemic therapy for prostate cancer; mCRPC Part 2A monotherapy: Prior treatment must include an androgen receptor pathway inhibitor,ALL,A,"Disease and stage match mCRPC, and prior enzalutamide/abiraterone meet the trial’s requirement for prior AR pathway inhibitor exposure within allowed prior lines. Age/sex fit, and no explicit exclusions are triggered (symptomatic high‑risk visceral disease not specified).",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,A,"No hard exclusions. Disease matches mCRPC; stage/setting matches metastatic CRPC. Prior-exposure/line criterion met (AR pathway inhibitors received and within allowed lines, with no evidence exceeding max). No required biomarker. Mets pattern exclusions not triggered (symptomatic visceral disease not specified). Thus ≥2 core anchors match with no soft conflicts → A.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06835283,0.6440473794937134,Dementia,Sequential Accelerated ITBS / Remote tDCS for Treatment of Neuropsychiatric Symptoms in Alzheimer's Disease: A Pilot Study,NA,65 years to 85 years,Alzheimer Disease; Alzheimer Disease-related Dementia,Age 60–85 years | Clinical diagnosis of mild to moderate Alzheimer disease or related dementia | Clinically significant neuropsychiatric symptoms with NPI-Q domain score >= 2 in at least one domain | MMSE score 15–23,"Contraindication to MRI | Contraindication to iTBS or tDCS (e.g., seizure disorder, severe cardiovascular disease, history of brain surgery, or cortical stroke near stimulation site) | Current alcohol or substance use disorder | Neuropsychiatric symptoms severe enough to preclude safe and effective intervention (e.g., agitation or aggression) | Unstable coexisting medical condition that may interfere with the protocol or increase risk",Psychotropic medications allowed if stable for >= 4 weeks,ALL,A,"Disease and severity align (moderate dementia within mild–moderate AD/related dementia), and key criteria match (age 68 and MMSE 19) with no conflicting exclusions or therapy restrictions. The required NPI-Q ≥2 neuropsychiatric symptom criterion is unknown and may affect eligibility but is not an explicit mismatch.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),INCORRECT,B,"No hard exclusions. Disease is compatible (AD or related dementia), and stage/severity matches (moderate; MMSE 19 within 15–23). Other core anchors are unknown/not applicable (no line/prior constraints; no required biomarker). Age/MMSE are not core anchors. Thus exactly 1 core anchor matches → Grade B, not A.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06918808,0.6366053819656372,Crohn's Disease,A Phase 2a Study of Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product (DB-3Q) in Patients With Perianal Fistulizing Crohn's Disease,PHASE2,18 years to 75 years,Perianal Fistula (Crohn's Disease),"Age 18-75 years | Crohn's Disease diagnosed for >= 6 months prior to Day 1 | Single and/or multi-tract perianal fistula(s) with 2 or fewer openings that are actively draining | Failed at least one medical therapy within the last year (e.g., antibiotics, immunomodulators, monoclonal antibodies, or small molecule inhibitors) | Previous failed surgical intervention (including seton placement >= 2 weeks prior to screening) or not a candidate for/willing to undergo surgical intervention | Medical therapy for Crohn's Disease stable for >= 2 months prior to Day 1","Pregnant or breastfeeding | Woman of childbearing potential without a documented negative urine or serum pregnancy test | Active perianal abscess or infection at screening or Day 1 | Clinically significant medical conditions within 6 months before Day 1 that could compromise safety | Confirmed HIV infection | Confirmed Hepatitis B infection | Confirmed Hepatitis C infection | History of cancer, including melanoma, within 1 year of screening (except localized non-melanoma skin cancers) | History of colorectal cancer within 2 years of screening | Use of investigational therapy or treatment within 30 days prior to Day 1 | Unwilling to use medically acceptable contraception during the study",Failed at least one prior medical therapy for Crohn's Disease within the last year; Previous failed surgical intervention for perianal fistula or not a candidate/willing; Current Crohn's Disease medical therapy stable for >= 2 months prior to Day 1; No investigational therapy within 30 days prior to Day 1,ALL,A,"Strong disease/setting match: perianal fistulizing Crohn’s with an active draining seton, and the patient’s age/sex fit. Prior failure of biologics aligns with the requirement for failed medical therapy; other specifics (number of openings, timing within 1 year, stable meds) are unspecified but no explicit exclusions are evident.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,A,"No hard exclusions. Disease and setting (perianal fistulizing Crohn’s with active drainage/seton) match. Prior failures align with the trial’s requirement for failed medical therapy; timing and other specifics (<=2 openings, med stability) are unknown but not conflicting. At least two core anchors (stage/setting and line/prior) match, so A is appropriate.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT00268385,0.7373702526092529,Recurrent Glioblastoma,A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination With Temozolomide in Patients With Malignant Gliomas,PHASE1,18 years,Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Mixed Glioma; Brain Neoplasm (recurrent),"Histologically proven intracranial malignant glioma (glioblastoma, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed oligoastrocytoma, or malignant astrocytoma NOS); prior low-grade glioma allowed if subsequently malignant | Life expectancy > 8 weeks | Karnofsky performance status >= 60 | WBC >= 3,000/µL | ANC >= 1,500/µL | Platelet count >= 100,000/µL | Hemoglobin >= 10 g/dL (transfusion permitted to meet threshold) | AST (SGOT) < 2 x ULN | Bilirubin < 2 x ULN | Creatinine < 1.5 mg/dL | Baseline MRI or CT within 14 days on stable steroid dose >= 5 days; same modality used for follow-up; if steroids increased before registration, new baseline imaging required | Interval >= 3 weeks from completion of radiation therapy to study entry | Women of childbearing potential: negative pregnancy test within 7 days prior to registration | Women of childbearing potential and men agree to use adequate contraception during study | Willing to participate in pharmacokinetic studies | Part I: Stable disease after radiation therapy or progression eligible (unless progressed on temozolomide); prior relapses allowed | Recovered from prior therapy toxicities with required washouts (see prior therapies) | Post-resection eligibility: recovered from surgery; imaging within 96 hours post-op or >= 4 weeks post-op (within 14 days of registration) on stable steroids >= 5 days | Prior brachytherapy or stereotactic radiosurgery requires confirmation of true progression (PET or thallium scan, MR spectroscopy, or surgical documentation) | Part II: Only patients with stable disease after radiation therapy; no recurrent disease | Part II: Only prior therapy allowed is radiation alone or radiation with concomitant temozolomide; patients stable on adjuvant temozolomide may participate",Progressed on temozolomide | Significant uncontrolled medical illness that would compromise therapy tolerance | History of other cancer within 3 years (except non-melanoma skin cancer or carcinoma in situ of the cervix) unless in complete remission and off therapy >= 3 years | Active infection | Pregnant | Breastfeeding (if treated with vorinostat; potential risks may also apply to temozolomide) | Any disease that would obscure toxicity assessment or dangerously alter drug metabolism | HIV positive receiving combination antiretroviral therapy | Receiving other investigational agents | Allergic reactions to vorinostat or compounds of similar chemical or biologic composition | Use of valproic acid within 2 weeks prior to enrollment,">= 3 weeks since completion of radiation therapy; >= 28 days since any investigational agent; >= 28 days since prior cytotoxic therapy (>= 23 days since last standard 5/28 temozolomide); >= 14 days since vincristine; >= 42 days since nitrosoureas; >= 21 days since procarbazine; >= 7 days since non-cytotoxic agents (e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid); Recent resection allowed if recovered from surgery and imaging criteria met; Prior interstitial brachytherapy or stereotactic radiosurgery allowed with confirmation of true progression; Part I: Prior relapses and prior temozolomide with stable disease allowed; progression on temozolomide not allowed; Part II: Only prior therapy permitted is radiation with or without concomitant temozolomide; adjuvant temozolomide allowed if stable; no other prior chemotherapies",ALL,B,"Disease and recurrent setting match, and age/sex are within trial parameters. Prior temozolomide is allowed in Part I unless the patient progressed on temozolomide, which is unknown here, so line/prior-exposure compatibility is uncertain.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,B,"No hard exclusions apply. Disease matches and the recurrent setting is allowed (Part I), giving one clear CORE ANCHOR match. Line/prior-exposure is uncertain due to the “no progression on temozolomide” requirement and unknown progression status. With exactly one anchor match and no soft conflicts, B is correct.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT00365157,0.81846022605896,Metastatic Urothelial Carcinoma,A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency,PHASE1/PHASE2,18 years,Urothelial Carcinoma (advanced/metastatic),"Locally advanced or metastatic urothelial cancer not amenable to surgical treatment | Histologically or cytologically confirmed urothelial tract carcinoma | Measurable disease (>= 20 mm by conventional imaging or >= 10 mm by spiral CT) | Up to two prior lines of chemotherapy for recurrent/advanced disease allowed | Received at least one platinum-based chemotherapy for recurrent/advanced disease | For a specified cohort, prior tubulin inhibitor therapy required (e.g., paclitaxel, docetaxel, or vinblastine) | Women with or without prior therapy eligible | Life expectancy > 6 months | ECOG performance status 0-2 or Karnofsky >= 60% | Absolute neutrophil count >= 1,000/µL | Platelets >= 100,000/µL | Hemoglobin >= 9 g/dL | Total bilirubin <= 1.5 x ULN | AST/ALT <= 2.5 x ULN | Renal function: creatinine <= 1.5 x ULN or creatinine clearance >= 60 mL/min, or moderate/severe renal dysfunction with creatinine clearance >= 20 mL/min","Concurrent treatment with other investigational agents | Unstable or untreated brain metastases | Uncontrolled intercurrent illness (including active infection, symptomatic congestive heart failure, unstable angina, clinically significant arrhythmia, or psychiatric illness/social conditions limiting compliance) | Pregnant or breastfeeding | HIV-positive on combination antiretroviral therapy | HIV-positive with CD4+ <= 500/mm3 | Prior therapy with eribulin | Symptomatic uremia, uncontrolled edema, or unstable serum electrolytes not stabilized prior to enrollment","Prior platinum-based chemotherapy for recurrent/advanced disease required; Up to two prior lines of chemotherapy for recurrent/advanced disease allowed; Prior tubulin inhibitor required for a specified cohort (e.g., paclitaxel, docetaxel, vinblastine)",ALL,B,"Disease and metastatic setting match, and age/sex fit; the allowance of up to two prior lines is compatible with being after second-line therapy. However, required prior platinum-based therapy for recurrent/advanced disease and measurable disease status are unknown, preventing confirmation of full eligibility.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),INCORRECT,A,"No hard exclusions. Stage/setting clearly matches (metastatic), and line-of-therapy is compatible (post-2L with trial allowing up to two prior lines). Unknown prior platinum and measurable disease should not downgrade per rubric (unknowns are neutral). Thus ≥2 core anchors match, yielding A. The grader’s B incorrectly penalized unknowns.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT00565851,0.7942113876342773,Recurrent Clear Cell Ovarian Carcinoma,"A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)",PHASE3,18 years,Ovarian Carcinoma (recurrent); Fallopian Tube Carcinoma (recurrent); Primary Peritoneal Carcinoma (recurrent),"Candidate for cytoreductive surgery when applicable per protocol/randomization plan | Histologic epithelial ovarian, primary peritoneal, or fallopian tube carcinoma, recurrent | Eligible epithelial histologies include serous, endometrioid, mucinous, clear cell, transitional cell, undifferentiated, malignant Brenner tumor, mixed epithelial, or adenocarcinoma NOS | Complete response to front-line platinum-taxane therapy (>=3 cycles) | Treatment-free interval without progression >=6 months after completion of front-line chemotherapy (platinum and taxane) | Maintenance biologic or hormonal therapy allowed if recurrence >6 months and >=4 weeks since last biologic infusion | Clinically evident recurrent disease | Measurable disease per RECIST with at least one lesion: >=20 mm by conventional imaging/MRI/CT or >=10 mm by spiral CT | ANC >=1500/µL | Platelets >=100000/µL | Creatinine <=1.5 x ULN | Total bilirubin <=1.5 x ULN | AST <=2.5 x ULN | Alkaline phosphatase <=2.5 x ULN | Urine protein-to-creatinine ratio <1.0 mg/dL (if receiving bevacizumab) | ECOG 0–2","More than one prior chemotherapy regimen (maintenance not counted as a separate regimen) | Concurrent immunotherapy or radiotherapy | Prior radiotherapy to any portion of the abdominal cavity or pelvis | Prior secondary cytoreductive surgery for recurrent disease | Requirement for parenteral hydration or nutrition with evidence of partial bowel obstruction or perforation | Prior chemotherapy for other abdominal or pelvic tumors (except ovarian, fallopian tube, primary peritoneal) | Synchronous or prior primary endometrial cancer unless all met: stage <= IB; no more than superficial myometrial invasion without vascular/lymphatic invasion; no poorly differentiated subtypes (papillary serous, clear cell, FIGO grade 3) | Uncontrolled infection | Severe uncontrolled comorbid medical conditions limiting compliance or increasing risk | Peripheral neuropathy >= grade 2 | History of hypersensitivity to carboplatin and/or paclitaxel unless successfully desensitized | Hypersensitivity to CHO cell products or other recombinant antibodies (applies to bevacizumab recipients) | Pregnant or breastfeeding; inadequate contraception | Other invasive malignancy within 5 years (except non-melanoma skin cancer) or prior cancer therapy contraindicating protocol therapy | Active bleeding or high-risk bleeding conditions/coagulopathy (applies to bevacizumab recipients) | CNS disease (including brain metastases), uncontrolled seizures, or stroke within 5 years (applies to bevacizumab recipients) | Significant cardiovascular disease, including conduction abnormalities (PR >0.24 s or 2nd/3rd-degree AV block), uncontrolled hypertension (systolic >150 mmHg or diastolic >90 mmHg), myocardial infarction/cardiac arrhythmia/unstable angina within 6 months, NYHA class >= II heart failure, serious arrhythmia requiring medication, peripheral vascular disease grade >= II, or cerebrovascular accident within 6 months (applies to bevacizumab recipients) | Major surgery, open biopsy, dental extractions/procedures resulting in open wound, or significant traumatic injury within 28 days before treatment; vascular access device placement or core biopsy within 7 days before treatment",Complete response to front-line platinum-taxane therapy (>=3 cycles) required; Treatment-free interval >=6 months from completion of front-line platinum and taxane chemotherapy; Front-line therapy may have included bevacizumab; Maintenance cytotoxic chemotherapy must be discontinued >=6 months before documentation of recurrence; Maintenance biological or hormonal therapy allowed if recurrence >6 months and >=4 weeks since last biologic infusion,FEMALE,B,"Disease and setting match (recurrent epithelial ovarian carcinoma with clear cell histology; female age 36), and prior front-line platinum-taxane ± bevacizumab is allowed. However, platinum-sensitive status (≥6-month interval and prior complete response) and other required eligibility details (measurable disease/ECOG/labs) are unknown, so only one core anchor is clearly satisfied.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),INCORRECT,A,"No hard exclusions. Disease matches (recurrent epithelial ovarian, clear cell allowed). Core anchors: (1) Stage/setting matches (recurrent). (2) Line/prior exposure aligns (post front-line platinum–taxane ± bevacizumab is required/allowed and patient had it). Platinum-sensitive interval and CR status are unknown and should be treated as neutral, not preventing counting the line/prior anchor as a match. With ≥2 anchors matched and no soft conflicts, the correct grade is A, not B.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT00692939,0.999911367893219,Crohn's Disease,Autologous Stem Cell Transplantation with CD34-Selected Peripheral Blood Stem Cells (PBSC) in Pediatric and Adult Patients with Severe Crohn's Disease,PHASE1/PHASE2,10 years to 60 years,Crohn's Disease,"Age 10–60 years | Severe, refractory Crohn's Disease appropriate for stem cell transplant therapy | Prior surgery with severe recurrent disease despite aggressive maintenance therapy | Diffuse small bowel and colonic disease refractory to aggressive medical treatment and not eligible for surgery without high risk of short bowel syndrome or other contraindications to surgery | Persistently high disease activity: HBI > 6 or CDAI > 250 or PCDAI > 45, or moderate disease (HBI <= 6, CDAI < 250, PCDAI 30–45) requiring daily corticosteroids and aggressive medical treatment to maintain status | Resistant complications unresponsive to medical management (e.g., multiple enteric fistulas, enterovesicular or enterovaginal fistulas, severe perianal disease, debilitating arthritis, severe skin lesions such as pyoderma, severe bony complications such as aseptic necrosis or pathologic fractures) | Severe complications from medical therapy (e.g., pancreatitis from 6-mercaptopurine, colitis from 5-ASA, severe hypersensitivity to TNF-alpha inhibitors, anti-integrin agents, or anti-IL12/23 agents) | Stoma present is allowed | No surgical therapeutic option due to risk of short bowel syndrome or patient refusal | Harvey Bradshaw Index > 5, or CDAI > 250, or PCDAI > 30 | Platelet count > 100,000/µL | Absolute neutrophil count > 1500/µL | Creatinine <= 2.0 mg/dL | No history of coronary artery disease; LVEF >= 40% or shortening fraction >= 26% | FEV1/FVC >= 60% predicted; DLCO >= 60% predicted | Negative pregnancy test for females of childbearing potential | Agreement to use effective contraception during treatment and for up to 24 months after PBSC transplant or while on any medication that may harm a pregnancy","No prior adequate dosing of 6-mercaptopurine, 5-ASA products, and metronidazole | Sustained corticosteroid-free response to anti-TNF-alpha, anti-integrin, or anti-IL12/23 therapy after a 4-month course | Toxic megacolon | Intestinal perforation | Conjugated bilirubin > 2.0 mg/dL | Pregnancy or nursing | HIV seropositive, HTLV seropositive, HBsAg positive, or HCV RNA positive by PCR | Active infection within two weeks of mobilization and high-dose chemotherapy | Other significant medical problems or abnormal findings that increase risk, interfere with compliance, or impact data quality in the investigator's opinion","Prior adequate dosing of 6-mercaptopurine, 5-ASA products, and metronidazole required; Prior surgery allowed",ALL,B,"Disease and severity match (CDAI > 250, fistulizing perianal disease) and age is within range; refractory to biologics is compatible with the trial’s refractory setting. However, prior adequate dosing of 6‑MP, 5‑ASA, and metronidazole—explicitly required—is not documented, so line/prior-therapy eligibility cannot be confirmed.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,B,"No hard exclusions. Disease matches. Stage/setting matches (severe, refractory Crohn’s with high CDAI and fistulizing perianal disease). Line/prior-exposure cannot be confirmed because required prior 6-MP/5-ASA/metronidazole exposure is unknown. Other anchors not applicable. Exactly one core anchor match → B per rubric. The grader’s reasoning aligns with this.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT01962415,0.6105722188949585,Crohn's Disease,"A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation",PHASE2,2 months to 55 years,Primary Immunodeficiency; Congenital Bone Marrow Failure Syndrome; Inherited Metabolic Disorder; Hereditary Anemia; Crohn's Disease; Inflammatory Bowel Disease; Juvenile Rheumatoid Arthritis; Systemic Juvenile Idiopathic Arthritis,"Availability of a suitable graft: 4/6–6/6 HLA matched related or unrelated UCB unit with total nucleated cells >= 3 x 10^7/kg (or double units each >= 2 x 10^7/kg) or 8/8 or 7/8 HLA allele-matched unrelated donor bone marrow or peripheral blood progenitor graft | Serum creatinine <= 2.0 mg/dL | Creatinine clearance >= 50 mL/min | ALT <= 4 x ULN | AST <= 4 x ULN | Cardiac function adequate: shortening fraction > 26% or ejection fraction > 40% or > 80% of normal for age | Pulmonary function: FEV1/FVC >= 50% predicted for age | Pulmonary function: DLCO (hemoglobin-corrected) >= 50% predicted (adults, if obtainable) | Resting pulse oximetry >= 92% on room air | HIV negative | Negative pregnancy test if pubertal and/or menstruating | Non-malignant disorder amenable to HSCT, including primary immunodeficiency syndromes (e.g., SCID with NK activity, Omenn, BLS, CID, CVID, Wiskott-Aldrich, leukocyte adhesion deficiency, CGD, X-linked hyper IgM, IPEX, Chediak-Higashi, ALPS, HLH, lymphocyte signaling defects) | Congenital bone marrow failure syndromes (e.g., dyskeratosis congenita, congenital amegakaryocytic thrombocytopenia, osteopetrosis) | Inherited metabolic disorders (e.g., mucopolysaccharidoses [Hurler, Hunter], leukodystrophies [Krabbe, metachromatic leukodystrophy, X-linked adrenoleukodystrophy, HDLS], alpha mannosidosis, Gaucher disease) | Hereditary anemias (e.g., thalassemia major, sickle cell disease with qualifying complications, Diamond-Blackfan anemia, other congenital transfusion-dependent anemias) | Inflammatory conditions (e.g., Crohn's disease/Inflammatory Bowel Disease)","Allogeneic hematopoietic stem cell transplant within the previous 6 months | Active malignancy or myelodysplastic syndrome | Severe acquired aplastic anemia | Uncontrolled bacterial, viral, or fungal infection with progression of clinical symptoms despite therapy | Pregnancy or nursing | Poorly controlled pulmonary hypertension | Any condition that precludes serial follow-up",(none),ALL,B,"Disease and age match without conflicting prior therapies, and Crohn’s/IBD is explicitly eligible. However, transplant candidacy (suitable graft/HSCT setting) and required organ function/HIV status are not provided, so key inclusion elements are unknown.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),INCORRECT,C,"No hard exclusions. Disease and age match, but age is not a CORE ANCHOR. Stage/setting (HSCT candidacy) is unknown; line/prior exposure requirements are not specified; no biomarker or mets pattern anchors apply. With 0 anchors matched and no soft mismatch, rubric dictates C, not B.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT02208362,0.78951495885849,Recurrent Glioblastoma,"Phase I Study of Cellular ImmunoTx Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Pts With Rec/Ref MaligGlioma",PHASE1,12 years to 75 years,Glioblastoma (recurrent/refractory); Malignant Glioma (recurrent/refractory); WHO Grade II Glioma (recurrent/refractory); WHO Grade III Glioma (recurrent/refractory),"Histologically confirmed grade III or IV glioma, or prior grade II glioma with radiographic progression consistent with grade III or IV after standard therapy | Radiographic progression/recurrence of measurable disease >12 weeks after completion of initial radiation therapy | Karnofsky performance status >=60% | Life expectancy >4 weeks | Tumor IL13RA2 expression by immunohistochemistry >=20% (>=1+) | Dexamethasone requirement <=2 mg TID at PBMC collection | Creatinine <1.6 mg/dL (for Rickham placement eligibility) | White blood cell count >2000/µL (for Rickham placement eligibility) | Absolute neutrophil count >1000/µL (for Rickham placement eligibility) | Platelets >=100000/µL (for Rickham placement eligibility) | INR <1.3 (for Rickham placement eligibility) | Total bilirubin <1.5 mg/dL (for Rickham placement eligibility) | ALT and AST <=2.5 x ULN (for Rickham placement eligibility) | Released cryopreserved T cell product available | No supplemental oxygen required to maintain O2 saturation >95% and no progressive chest radiographic abnormalities prior to infusion | No pressor support required and no symptomatic cardiac arrhythmias prior to infusion | Afebrile (<=38.5 C) with no positive blood cultures or signs of meningitis within 48 hours prior to infusion | Total bilirubin <=2 x ULN prior to infusion | Transaminases <=2 x ULN prior to infusion | Serum creatinine <=1.8 mg/dL prior to infusion | No uncontrolled seizure activity following surgery prior to first T cell dose | Platelets >=100000/µL prior to infusion (or transfuse to >=100000/µL) | Dexamethasone requirement <=2 mg TID during T cell therapy","Requires supplemental oxygen to keep saturation >95% with no expected resolution within 2 weeks | Requires pressor support and/or has symptomatic cardiac arrhythmias | Requires dialysis | Uncontrolled seizure activity and/or clinically evident progressive encephalopathy | Non-malignant intercurrent illness that is poorly controlled or severe enough to preclude participation | Any other active malignancy | Severe infection under treatment or recovering from major surgery until recovery is complete | Uncontrolled illness including ongoing or active infection | Known active hepatitis B infection | Known active hepatitis C infection | Signs or symptoms of active infection, positive blood cultures, or radiologic evidence of infection | Confirmed human immunodeficiency virus (HIV) infection within 4 weeks of screening",At least 12 weeks since completion of initial radiation therapy; At least 2 weeks since last chemotherapy or radiation before PBMC collection; At least 6 weeks since completion of nitrosourea-containing chemotherapy; At least 23 days since completion of temozolomide; At least 4 weeks since completion of other non-nitrosourea cytotoxic chemotherapy; At least 2 weeks since last targeted agent if recovered from toxicity (except bevacizumab); At least 4 weeks since last dose of bevacizumab,ALL,B,"Disease and setting match (recurrent glioblastoma), and age/sex fit the trial; prior standard chemoradiation is consistent. However, the required tumor IL13RA2 expression and specific timing/performance details (e.g., >12 weeks post-RT, intervals since temozolomide, KPS) are not provided, so full eligibility cannot be confirmed.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,B,"No hard exclusions. Stage/setting matches (recurrent GBM). Line/prior-exposure compatibility is uncertain due to required timing (>12 weeks post-RT, intervals since temozolomide) not provided. Required IL13RA2 biomarker is unknown, so A cannot be awarded. With exactly one clear anchor (stage/setting) and no soft mismatches, B is appropriate.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT02365597,0.8147107362747192,Metastatic Urothelial Carcinoma,"A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With FGFR Genomic Alterations",PHASE2,18 years,Urothelial Cancer (metastatic/unresectable),"Histologic metastatic or surgically unresectable urothelial cancer; minor variant histology allowed | Measurable disease per RECIST v1.1 | ECOG performance status 0–2 | Adequate bone marrow, liver, and renal function | Negative pregnancy test for women of childbearing potential | Disease progression per RECIST v1.1 after prior chemotherapy for metastatic or unresectable disease | Neoadjuvant or adjuvant chemotherapy with recurrence/progression within 12 months of last dose counts as metastatic setting | Prior anti-PD-1/PD-L1 therapy with progression also eligible","Systemic anticancer therapy (chemotherapy, targeted therapy) within 2 weeks before first dose (6 weeks for nitrosoureas or mitomycin C) | Immunotherapy within 4 weeks before first dose | Definitive radiotherapy within 2 weeks before first dose (localized palliative RT allowed; not to target lesions) | Persistent serum phosphate > ULN during screening despite medical management | History of or current uncontrolled cardiovascular disease | Pregnant or breastfeeding | Planning to conceive during study or within 3 months (female) or 5 months (male) after last dose | Not recovered from reversible toxicities of prior anticancer therapy (except nonclinically significant toxicities such as alopecia, skin discoloration, or Grade 1 neuropathy)",Prior chemotherapy for metastatic or unresectable urothelial cancer with progression required; Neoadjuvant or adjuvant chemotherapy with recurrence/progression within 12 months qualifies as prior chemotherapy in the metastatic setting; Prior anti-PD-1/PD-L1 therapy allowed,ALL,B,"Stage/setting matches (metastatic urothelial carcinoma) and age/sex fit, but the required FGFR genomic alteration and prior chemotherapy exposure are not documented. Without confirmation of FGFR alteration and prior chemo, eligibility remains uncertain.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,B,"No hard exclusions. Disease and stage/setting match (metastatic UC). Required FGFR alteration and prior chemotherapy status are unknown, so they are not mismatches but cannot be counted as matches. That leaves exactly one CORE ANCHOR match with no soft conflicts, consistent with grade B.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT02432963,0.7823978066444397,Metastatic Non-Small Cell Lung Cancer,A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab,PHASE1,18 years,Non-Small Cell Lung Carcinoma; Head and Neck Squamous Cell Carcinoma; Hepatocellular Carcinoma; Renal Cell Carcinoma; Melanoma; Bladder Carcinoma; Soft Tissue Sarcoma; Triple-Negative Breast Carcinoma; Colorectal Carcinoma; Pancreatic Carcinoma,"Advanced (unresectable) solid tumors from predefined histologies (NSCLC, head and neck squamous cell carcinoma, hepatocellular carcinoma, renal cell carcinoma, melanoma, bladder carcinoma, soft tissue sarcoma, triple-negative breast cancer, colorectal carcinoma displaying microsatellite instability, or pancreatic cancer) | Failed or intolerant to at least one line of standard therapy or refusal of standard treatment | ECOG performance status <= 2 (Karnofsky >= 60%) | Absolute neutrophil count >= 1500/µL | Platelets >= 100000/µL | Hemoglobin > 9 g/dL | Creatinine clearance >= 50 mL/min or serum creatinine <= 1.6 mg/dL | Total bilirubin <= 1.5 x ULN | AST <= 3 x ULN (<= 5 x ULN with liver metastasis) | ALT <= 3 x ULN (<= 5 x ULN with liver metastasis) | Confirmed TP53 involvement: TP53 overexpression by IHC (>= 10% tumor cells) or TP53 mutation by tumor mutational analysis","Concurrent investigational agents or radiation therapy | Pregnant or breastfeeding | Known brain metastasis | Radiotherapy within 4 weeks prior to study entry | Prior exposure to anti-PD-1 or anti-PD-L1 therapy | History of allergy to egg proteins | Unresolved adverse events from prior therapy > 4 weeks | Concurrent use of systemic corticosteroids (nasal, inhaled, adrenal replacement, and topical allowed) | History of immunodeficiency including organ grafts or HIV infection | Active autoimmune disease or condition requiring systemic corticosteroids (exceptions: vitiligo, type 1 diabetes mellitus) | History of severe immune-mediated adverse reactions with ipilimumab (grade 4 toxicity requiring > 10 mg/day prednisone or equivalent for > 12 weeks) | History of cardiac disease or abnormal screening ECG (excluding 1st degree bundle branch block, sinus bradycardia, sinus tachycardia, or non-specific T wave changes) or serum troponin >= grade 2 | Investigator-assessed inability to comply with safety monitoring","At least one prior line of standard therapy failed or intolerant, or refusal of standard treatment",ALL,B,"Disease (NSCLC) and metastatic/advanced setting match. However, required TP53 involvement is not provided and it’s unclear if the patient has failed at least one prior standard therapy, so key eligibility anchors are uncertain; no explicit exclusions are met.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,B,"No hard exclusions. Disease matches and stage/setting (metastatic/advanced) matches. Required TP53 biomarker is unknown (precludes A). Line-of-therapy requirement (failure of standard therapy) is unclear, so not a confirmed match; no soft mismatches identified. Thus exactly one core anchor match → B.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT02658279,0.9180697202682495,Recurrent Glioblastoma,"A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype",NA,18 years,Recurrent Malignant Glioma,"Histologically confirmed malignant glioma | WHO grade IV glioblastoma or variants | WHO grade III anaplastic astrocytoma or oligodendroglial tumor | WHO grade II glioma with contrast enhancement on MRI | Recurrent tumor after prior therapy including at least radiation therapy and one cytotoxic chemotherapy | Hypermutator phenotype defined as >=30 nonsynonymous somatic mutations by CLIA-certified NGS (or per PI approval, mutation in mismatch repair gene or other hypermutator-associated genes, or presence of microsatellite instability) | Age >= 18 years | >=12 weeks since prior radiation therapy unless histopathologic confirmation of recurrence or new enhancement outside radiation field | >=4 weeks since last investigational agent or any other treatment prior to first dose of pembrolizumab | Recovered to <= Grade 1 from adverse events of prior therapy | Karnofsky performance status >= 70 | Adequate organ function | Negative pregnancy test for females of childbearing potential | Agreement to use effective contraception","Requirement for escalating or chronic supraphysiologic corticosteroids (>10 mg/day prednisone equivalent) for disease control at registration | Prior treatment with anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti-PD-L2 agents | Hypersensitivity to pembrolizumab or its excipients | Immunodeficiency including HIV/AIDS | Active hepatitis B or active hepatitis C infection | Known history of active tuberculosis | Additional malignancy that is progressing or requires active treatment (except certain skin cancers or in situ cervical cancer) | Active autoimmune disease requiring systemic treatment in the past 2 years | History or evidence of active non-infectious pneumonitis | Active infection requiring systemic therapy | Pregnant or breastfeeding | Unable to undergo brain MRI | Live vaccine within 30 days before start of study therapy | Prior treatment with bevacizumab",Must have received prior radiation therapy; Must have received at least one prior cytotoxic chemotherapy; >=12 weeks since prior radiation therapy unless pathologic confirmation of recurrence or new enhancement outside radiation field; >=4 weeks since last investigational agent or any other treatment; Recovered to <= Grade 1 from prior therapy adverse events; Prior surgical resection for recurrence allowed,ALL,B,"Disease and setting match (recurrent glioblastoma within recurrent malignant glioma), and prior radiation plus temozolomide meets prior-therapy requirements. However, the trial requires a hypermutator phenotype, which is not reported for this patient, making eligibility uncertain.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),INCORRECT,A,"No hard exclusions. Disease and recurrent setting match, and prior radiation plus temozolomide satisfies line/prior requirements, giving ≥2 core anchor matches. The required hypermutator biomarker is unknown (not a soft mismatch), so per the decision procedure this should be graded A, not downgraded to B.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT02795052,1.0,Dementia,Neurologic Bone Marrow Derived Stem Cell Treatment Study,NA,18 years,Amyotrophic Lateral Sclerosis; Alzheimer Disease; CADASIL; Cerebral Hemorrhage; Cerebral Infarction; Cerebral Ischemia; Chronic Traumatic Encephalopathy; Cognitive Impairment; Dementia; Diabetic Neuropathy; Frontotemporal Dementia; Lewy Body Disease; Lewy Body Variant of Alzheimer Disease; Multiple System Atrophy; Neuropathy; Parkinson Disease; Progressive Supranuclear Palsy; Stroke; Traumatic Brain Injury,"Documented functional damage to the central or peripheral nervous system unlikely to improve with current standard of care | >= 6 months since disease onset | If on pharmacologic or surgical therapy, clinically stable and unlikely to have reversal of neurologic damage from that therapy | Investigator assessment that there is potential for improvement with BMSC and minimal risk from the procedure | Age > 18 years | Medically stable and able to be cleared by a primary care practitioner for the procedure",Not medically stable or at significant risk to health from undergoing the procedure | Pregnant at the time of treatment or planning pregnancy within 3 months post-treatment,Current pharmacologic or surgical therapy allowed if stable,ALL,B,"Disease matches (dementia), age is eligible, and prior therapy/line requirements are compatible. Stage/setting specifics and investigator/medical stability criteria are not specified, so only one core anchor clearly matches.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,B,"No hard exclusions. Disease matches. Line/prior-exposure is compatible (allowed if stable; patient has none). Stage/setting, biomarker, and mets pattern are not applicable/unknown. Exactly one core anchor match → B per rubric.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT03113487,0.7289217710494995,Recurrent Clear Cell Ovarian Carcinoma,"P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",PHASE2,18 years,"Ovarian Carcinoma (platinum-resistant, recurrent); Primary Peritoneal Carcinoma (platinum-resistant, recurrent); Fallopian Tube Carcinoma (platinum-resistant, recurrent)","Histologically or cytologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube cancer | Recurrent or progressive disease within 6 months after completion of platinum-based chemotherapy (platinum-resistant or refractory) | Measurable disease per RECIST 1.1 or detectable disease | CA-125 >= 2 x ULN if no measurable disease | Ascites and/or pleural effusion attributed to tumor if no measurable disease | Non-measurable solid and/or cystic abnormalities on imaging not meeting target lesion criteria if no measurable disease | TP53 mutation and/or p53 overexpression by IHC (>= 10% tumor cells) | ECOG <=2 | Life expectancy >= 3 months | Up to 4 prior chemotherapy regimens for recurrent disease allowed","Positive pregnancy test or pregnant/breastfeeding | Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, or other T-cell checkpoint agents (e.g., CTLA-4, OX-40, CD137) | Systemic anti-cancer therapy within 4 weeks before start | Radiotherapy within 3 weeks before start (1-week washout allowed for short palliative non-CNS RT) | Live vaccine within 30 days before first dose | Participation in another investigational agent or device study within 4 weeks before start | Immunodeficiency (including organ grafts or HIV) or systemic immunosuppression >10 mg prednisone equivalent within 7 days before start | Another malignancy requiring active treatment within the past 3 years (except certain in situ and non-melanoma skin cancers) | Active CNS metastases or carcinomatous meningitis (previously treated, stable brain metastases allowed off steroids >=14 days) | Severe hypersensitivity (>= grade 3) to pembrolizumab or excipients | Active autoimmune disease requiring systemic treatment in the past 2 years | History of non-infectious pneumonitis requiring steroids or current pneumonitis | Active infection requiring systemic therapy | Known HIV infection | Active hepatitis A, hepatitis B surface antigen positive, or active hepatitis C (HCV RNA detectable) | Active tuberculosis infection | Significant cardiac disease: myocardial infarction or arterial thromboembolic event within 6 months, severe/unstable angina, NYHA class III/IV heart failure, QTcB > 470 ms, uncontrolled hypertension (>150/100 mm Hg), abnormal EKG/echo/troponin (>= grade 2) | Li-Fraumeni syndrome (family history or confirmed) | Severe environmental allergies or allergy to egg proteins | Psychiatric or substance use disorders interfering with study requirements",Up to 4 prior chemotherapy regimens for recurrent disease allowed; Adjuvant chemotherapy and maintenance paclitaxel not counted toward regimen limit; Prior targeted agents or hormone therapy not counted as systemic chemotherapy regimens; No prior anti-PD-1/PD-L1/PD-L2 or other T-cell checkpoint therapy; No systemic anti-cancer therapy within 4 weeks before start (toxicities recovered to <= grade 1 except <= grade 2 neuropathy); No radiotherapy within 3 weeks before start (1-week washout allowed for short palliative non-CNS RT); No investigational agents or devices within 4 weeks before start; No live vaccines within 30 days before first dose; No non-oncology viral vaccines within 30 days before start,FEMALE,B,"Disease category and prior therapy exposure are compatible (female, age ≥18; epithelial ovarian cancer; no prior PD-1; adjuvant platinum allowed). However, the trial specifically requires platinum-resistant recurrence and TP53 mutation or p53 overexpression, both of which are unknown for this patient, making eligibility uncertain.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,B,"No hard exclusions. Disease matches; patient is PD-1–naïve and prior therapy exposure is compatible (one anchor). Stage/setting requires platinum-resistant recurrence, which is unknown, and required TP53/p53 biomarker is unknown. No soft mismatches identified. Thus exactly one core anchor match → B. Grader’s reasoning aligns with the rubric.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT03170960,0.8316410779953003,Metastatic Castration-Resistant Prostate Cancer,A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,PHASE1,18 years,Castration-Resistant Prostate Cancer; Colorectal Cancer; Differentiated Thyroid Cancer; Endometrial Cancer; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Head and Neck Cancer; Hepatocellular Carcinoma; Lower Esophageal Cancer; Non-Small Cell Lung Cancer; Ovarian Cancer; Renal Cell Carcinoma; Triple Negative Breast Cancer; Urothelial Carcinoma,"Histologically or cytologically and radiologically confirmed inoperable, locally advanced, metastatic, or recurrent solid tumor per cohort definitions | Measurable disease per RECIST 1.1 | Tumor tissue available (archival or recent biopsy) | Recovery to baseline or <= Grade 1 from prior treatment toxicities unless clinically nonsignificant/stable on supportive therapy | Age >= 18 years | ECOG performance status 0–1 | Adequate organ and marrow function | Use of effective contraception if of childbearing potential or sexually active | Negative pregnancy test for females of childbearing potential","Prior treatment with cabozantinib or immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, anti-PD-L1, anti-PD-L2) except in specified cohorts (5, 7, 9, 11, 17, 19, 20) | Known brain metastases or cranial epidural disease unless adequately treated and stable for >= 4 weeks prior to first dose | Concomitant anticoagulation with oral anticoagulants | Systemic steroid therapy >10 mg daily prednisone equivalent or other immunosuppressive therapy within 2 weeks prior to first dose | Receipt of a live attenuated vaccine within 30 days before first dose | Uncontrolled significant intercurrent or recent illness, including active or history of autoimmune disease or immune deficiency | Interstitial lung disease (idiopathic pulmonary fibrosis, organizing pneumonia) or pneumonitis | Active infection requiring systemic treatment | HIV infection or AIDS-related illness | Acute or chronic hepatitis B or C infection | Positive test for tuberculosis | Moderate to severe hepatic impairment (Child-Pugh B or C) | Pregnant or lactating | Allergy or hypersensitivity to components of study treatments | Another malignancy diagnosed within 2 years prior to first dose","Prior platinum-based chemotherapy for urothelial carcinoma (specific cohorts); Up to one prior VEGFR-targeting TKI allowed for non–clear cell RCC (Expansion Cohort 10); No prior systemic anticancer therapy required for selected cohorts (e.g., clear cell RCC, HCC, PD-L1 positive NSCLC); Progression after prior immune checkpoint inhibitor required for selected UC and NSCLC cohorts; Prior EGFR-targeting TKI with subsequent progression required for EGFR-mutant NSCLC cohort; Prior systemic chemotherapy containing fluoropyrimidine with oxaliplatin or irinotecan required for CRC cohort; At least one prior systemic therapy required for TNBC cohort; Platinum-resistant or refractory OC after up to two prior lines; At least one prior systemic therapy required for EC cohort; Prior enzalutamide and/or abiraterone for metastatic CRPC (specific cohort); Exactly one prior novel hormonal therapy for mCRPC cohorts; Prior docetaxel for mCRPC required in a specific cohort",ALL,B,"Disease and metastatic setting match an mCRPC cohort, and no hard exclusions are evident. Prior-therapy requirements for the mCRPC cohorts vary (some specify exactly one prior novel hormonal therapy), so eligibility with both enzalutamide and abiraterone is uncertain.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,B,No hard exclusions. Disease matches and metastatic setting aligns (1 core anchor). Line/prior-exposure is uncertain given trial text about mCRPC cohorts often requiring exactly one prior novel hormonal therapy while the patient had both enzalutamide and abiraterone; not a clear mismatch. Thus exactly one anchor match → B.,,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03375307,0.7561202645301819,Metastatic Urothelial Carcinoma,A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair Defects,PHASE2,18 years,Genitourinary Carcinoma (advanced/metastatic); Bladder Cancer (metastatic),Histologically confirmed non-prostate genitourinary (GU) cancer | Presence of cancer-associated genetic mutations per FoundationOne CDx per cohort definitions or TMB >= 10 mut/Mb | Measurable disease per RECIST 1.1 | Evidence of disease progression during or after at least one platinum-based chemotherapy regimen and/or an immune-checkpoint inhibitor | Age >= 18 years | ECOG performance status <= 1 (or Karnofsky >= 70%) | Able to tolerate oral medications; no gastrointestinal condition precluding absorption of olaparib | Negative pregnancy test for women of childbearing potential at screening and within 3 days prior to day 1 | Use of effective contraception during treatment and for required period after last dose | Provision of archival tumor sample or willingness to undergo mandatory screening biopsy (or liquid biopsy if tissue unavailable),"Prior treatment with olaparib or any PARP inhibitor | Myelodysplastic syndrome or acute myeloid leukemia, or baseline features suggestive of MDS/AML | Persistent toxicities >= CTCAE grade 2 from prior therapy (except alopecia or peripheral neuropathy) | Concurrent treatment with other investigational agents (per protocol during treatment phase) | Known brain metastases or spinal cord compression unless definitively treated and clinically stable for >= 28 days | Allergic reactions to compounds of similar chemical or biologic composition to olaparib | Current use of strong or moderate CYP3A inhibitors or inducers without adequate washout (>= 5 half-lives or 3 weeks, whichever is shorter) | Pregnancy or breastfeeding | Any chronic or concurrent acute liver disease | History of stroke, transient ischemic attack, or myocardial infarction within 6 months | Uncontrolled infection | Symptomatic congestive heart failure, unstable angina, or clinically significant cardiac arrhythmia | Unstable or untreated cardiac conditions or left ventricular ejection fraction < 50% | Uncontrolled diabetes mellitus | Psychiatric illness or social situation limiting compliance | Other severe medical or psychiatric condition or laboratory abnormality increasing risk or interfering with study | Immunocompromised state (e.g., HIV with detectable virus not on HAART) | Active hepatitis B or C infection | Other malignancy within 2 years except allowed low-risk cancers as specified | Systemic chemotherapy or radiotherapy (except palliative) within 2 weeks prior to study treatment | Major surgery within 2 weeks prior to starting study treatment without adequate recovery | Previous allogeneic bone marrow transplant or double umbilical cord blood transplantation","Progression during or after at least one platinum-based chemotherapy regimen required; Prior treatment with an immune-checkpoint inhibitor (atezolizumab, pembrolizumab, nivolumab, avelumab, or durvalumab) allowed and may qualify; Washout from chemotherapy >= 2 weeks before study treatment; Washout from monoclonal antibody therapy >= 4 weeks before study treatment",ALL,B,"Disease and metastatic setting match the trial. However, required biomarker status (DNA-repair mutation or TMB ≥10) and confirmation of prior platinum/ICI exposure are unknown, preventing a higher confidence match.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,B,"No hard exclusions. Disease and metastatic setting match (1 anchor). Biomarker requirement (DNA repair defect or TMB ≥10) and required prior exposure to platinum and/or ICI are unknown, so no additional anchors can be counted. No soft mismatches identified. Grade B is appropriate per rubric.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT03389230,0.9556378126144409,Recurrent Glioblastoma,"Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a HER2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients With Recurrent/Refractory Malignant Glioma",PHASE1,18 years to 75 years,Glioblastoma; Malignant Glioma; Recurrent Glioma; Refractory Glioma; WHO Grade III Glioma,"Histologically confirmed grade III or IV glioma, or prior grade II glioma with radiographic progression consistent with grade III or IV malignant glioma | Karnofsky performance status >= 60% | Life expectancy > 4 weeks | HER2 positive tumor by immunohistochemistry (>= 20%, 1+) confirmed by City of Hope Clinical Pathology | Appropriate venous access | Dexamethasone <= 2 mg TID on the day of PBMC collection | At least 2 weeks since last targeted agent, chemotherapy, or radiation before PBMC collection (PI discretion for locally delivered CSF investigational agents) | Creatinine < 1.6 mg/dL | White blood cell count > 2,000/µL or absolute neutrophil count > 1,000/µL | Platelets >= 100,000/µL | INR < 1.3 | Total bilirubin < 1.5 mg/dL | ALT and AST <= 2 x ULN | Released cryopreserved CAR T cell product available | No supplemental oxygen required to keep saturation > 95% and no progressive chest X-ray abnormalities | No history of CHF NYHA class III–IV, cardiomyopathy, myocarditis, or MI within 6 months; if risk factors present, EKG and echocardiogram within 42 days prior to registration | If new cardiac symptoms or cardiotoxic exposures: cardiac consultation, CPK, and troponin deem fit for study | Afebrile (<= 38.5 C), negative blood cultures within 48 hours prior to infusion, and no signs of meningitis | Serum creatinine < 1.8 mg/dL at infusion eligibility | Serum total bilirubin and transaminases <= 2 x ULN at infusion eligibility | Platelets > 100,000/µL (if 75,000–99,999/µL, may proceed after transfusion with post-transfusion >= 100,000/µL) | Dexamethasone <= 2 mg TID during CAR T cell therapy | Washouts before CAR T infusion: >= 6 weeks since nitrosourea; >= 23 days since temozolomide; >= 4 weeks since other non-nitrosourea cytotoxic chemotherapy; >= 2 weeks since last targeted agent (>= 4 weeks for bevacizumab)","Requires supplemental oxygen to maintain saturation > 95% and not expected to resolve within 2 weeks | History of CHF NYHA class III–IV within 6 months, cardiomyopathy, myocarditis, or MI; or significant cardiotoxic exposures without appropriate cardiac evaluation | Requires dialysis | Uncontrolled seizure activity and/or clinically evident progressive encephalopathy | Other active malignancies | Severe infection under treatment or recovering from major surgery until recovery is complete | Uncontrolled illness including ongoing or active infection | Known active hepatitis B or hepatitis C infection | Confirmed HIV positivity within 4 weeks of enrollment | Inability to understand the study or its risks/benefits (unless a legal guardian consents)","At least 2 weeks since last targeted therapy, chemotherapy, or radiation before PBMC collection; At least 6 weeks since nitrosourea chemotherapy before CAR T infusion; At least 23 days since temozolomide before CAR T infusion; At least 4 weeks since other non-nitrosourea cytotoxic chemotherapy before CAR T infusion; At least 2 weeks since last targeted agent before CAR T infusion (at least 4 weeks for bevacizumab)",ALL,B,"Recurrent glioblastoma matches the trial’s disease and setting. However, HER2-positivity (required) is unknown, and other specifics like KPS and treatment washout timing are not provided, making eligibility uncertain.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,B,"No hard exclusions. Disease and recurrent setting match (1 core anchor). Required HER2 biomarker is unknown (not a soft mismatch), and other anchors (line/washout, performance status) are unspecified. Exactly one anchor match with no soft conflicts → B. The grader’s reasoning aligns with the rubric.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03390504,0.7830958962440491,Metastatic Urothelial Carcinoma,A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations,PHASE3,18 years,Urothelial Cancer,"Histologic transitional cell carcinoma of the urothelium (minor variant histology <50% allowed) | Metastatic or surgically unresectable urothelial cancer | Documented disease progression requiring a change in treatment prior to randomization | Cohort 1: Prior treatment with an anti–PD-(L)1 agent; no more than 2 prior lines of systemic therapy | Cohort 2: No prior treatment with an anti–PD-(L)1 agent; only 1 prior line of systemic therapy | Neoadjuvant or adjuvant chemotherapy with progression within 12 months counts as systemic therapy in the metastatic setting | Meets molecular eligibility by FGFR clinical trial assay | ECOG performance status 0–2 | Adequate bone marrow, liver, and renal function","Treatment with another investigational agent or participation in another therapeutic clinical study within 30 days prior to randomization | Active malignancy requiring treatment change in the last 24 months (exceptions: urothelial cancer, completely cured skin cancer, localized prostate cancer with Gleason 6 treated or under surveillance, or Gleason 3+4 treated >6 months with very low risk of recurrence) | Symptomatic central nervous system metastases | Prior treatment with an FGFR inhibitor | Known hypersensitivity or intolerance to erdafitinib or its excipients | Current central serous retinopathy or retinal pigment epithelial detachment of any grade | History of uncontrolled cardiovascular disease | Impaired wound healing capacity (e.g., skin/decubitus ulcers, chronic leg ulcers, known gastric ulcers, or unhealed incisions)",Cohort 1 requires prior anti–PD-(L)1 therapy; Cohort 1 allows up to 2 prior lines of systemic therapy; Cohort 2 prohibits prior anti–PD-(L)1 therapy; Cohort 2 allows only 1 prior line of systemic therapy; Neoadjuvant/adjuvant chemotherapy within 12 months of last dose counts as prior systemic therapy,ALL,B,"Disease and stage match (metastatic urothelial cancer; age/sex eligible). However, the trial requires an FGFR gene aberration and cohort-specific prior PD-1 exposure; both FGFR status and PD-1 history are unknown (patient is after 2L, which could fit Cohort 1), so eligibility cannot be confirmed.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,B,"No hard exclusions. Stage/setting matches (metastatic). Line/prior is uncertain due to unknown PD-1 exposure, though 2 prior lines could fit Cohort 1. Required FGFR biomarker is unknown. With exactly one confirmed anchor (stage) and no soft conflicts, B is appropriate.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03474107,0.791737973690033,Metastatic Urothelial Carcinoma,"An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)",PHASE3,18 years,Urothelial Carcinoma (locally advanced or metastatic),"Histologically or cytologically confirmed urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra (including squamous differentiation or mixed types). | Radiographic progression or relapse during or after PD-1/PD-L1 checkpoint inhibitor for locally advanced or metastatic disease (progression after discontinuation due to toxicity allowed). | Received a platinum-containing regimen (cisplatin or carboplatin) in metastatic/locally advanced, neoadjuvant, or adjuvant setting; if adjuvant/neoadjuvant, progression within 12 months of completion. | Radiologically documented metastatic or locally advanced disease at baseline not amenable to curative resection. | ECOG 0–1. | ANC >= 1500/µL. | Platelet count >= 100000/µL. | Hemoglobin >= 9 g/dL. | Total bilirubin <= 1.5 x ULN (<= 3 x ULN with Gilbert's disease). | ALT <= 2.5 x ULN. | AST <= 2.5 x ULN. | Creatinine clearance >= 30 mL/min.","Preexisting sensory or motor neuropathy grade >= 2. | Active central nervous system metastases (allowed if treated and clinically stable >= 6 weeks, no new or enlarged lesions, no leptomeningeal disease, and on <= 20 mg/day prednisone equivalent if steroids required). | Ongoing clinically significant toxicity grade >= 2 from prior therapy (except alopecia; <= grade 2 hypothyroidism or panhypopituitarism on replacement allowed). | Ongoing immunotherapy-related colitis, uveitis, or pneumonitis, or requirement for high-dose steroids > 20 mg/day prednisone equivalent. | Prior treatment with enfortumab vedotin or other MMAE-based antibody-drug conjugates. | Prior chemotherapy for urothelial cancer including all available control-arm agents (docetaxel and paclitaxel ± vinflunine depending on region). | More than 1 prior chemotherapy regimen for locally advanced or metastatic urothelial cancer (including adjuvant or neoadjuvant if recurrence within 12 months). | History of another malignancy within 3 years (exceptions include nonmelanoma skin cancer, certain localized prostate cancer, and carcinoma in situ completely resected). | Active systemic infection requiring antimicrobial therapy. | Active hepatitis B or active hepatitis C infection. | Known HIV infection. | Cerebrovascular event (stroke or TIA), unstable angina, myocardial infarction, or NYHA class III–IV heart failure within 6 months. | Radiotherapy or major surgery within 4 weeks before first dose. | Chemotherapy, biologics, investigational agents, or immunotherapy not completed >= 2 weeks before first dose. | Hypersensitivity to enfortumab vedotin or to biopharmaceuticals produced in CHO cells. | Hypersensitivity to docetaxel (including polysorbate 80), paclitaxel (including macrogolglycerol ricinoleate 35), or vinflunine (including other vinca alkaloids). | Active keratitis or corneal ulceration. | Other underlying medical condition that would impair ability to receive or tolerate treatment and follow-up. | Uncontrolled diabetes mellitus within 3 months (HbA1c >= 8% or HbA1c 7% to < 8% with polyuria or polydipsia).","Prior PD-1/PD-L1 checkpoint inhibitor required for locally advanced or metastatic disease.; Prior platinum-containing regimen (cisplatin or carboplatin) required in metastatic/locally advanced, neoadjuvant, or adjuvant setting.; No more than 1 prior chemotherapy regimen for locally advanced or metastatic urothelial cancer.; Washout: radiotherapy or major surgery completed >= 4 weeks before first dose.; Washout: chemotherapy, biologics, investigational agents, or immunotherapy completed >= 2 weeks before first dose.",ALL,B,"Disease and metastatic setting match, and age/sex are eligible. However, prior platinum and PD-1/PD-L1 exposure (and having ≤1 prior chemotherapy for metastatic disease) are required but not confirmed, making line-of-therapy compatibility uncertain.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,B,"No hard exclusions. Disease and metastatic setting match (1 core anchor). Prior PD-1 and platinum exposure and allowed number of prior chemo regimens are unknown, so line/prior anchor is not confirmed and not a soft mismatch. With exactly one anchor match and no soft conflicts, B is appropriate.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03547973,0.958637535572052,Metastatic Urothelial Carcinoma,A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer,PHASE2,18 years,Metastatic Urothelial Cancer,"Age >= 18 years | ECOG performance status 0–1 | Adequate renal and hepatic function | Adequate hematologic parameters without transfusional support | Life expectancy >= 3 months | Cohorts 4 and 6: Measurable disease by RECIST 1.1 | Cohorts 1, 2, 3, 5: Creatinine clearance >= 30 mL/min | Cohort 4: No prior platinum-based chemotherapy in the metastatic or unresectable locally advanced setting | Cohort 4: Creatinine clearance >= 50 mL/min; if receiving cisplatin 70 mg/m2 Day 1 q21d, creatinine clearance >= 60 mL/min; if creatinine clearance 50–59 mL/min, receive split-dose cisplatin | Cohorts 4, 5, 6, 7: Archival tumor tissue (muscle-invasive or metastatic urothelial carcinoma) or biopsy of metastatic urothelial carcinoma | Cohort 5: Completed 4–6 cycles of gemcitabine + cisplatin with CR/PR/SD and treatment-free interval of 4–10 weeks | Cohort 6: Cisplatin-ineligible; no prior therapy for metastatic or unresectable locally advanced disease; CPI-naive or >12 months from completion of adjuvant therapy | Cohort 7: No prior systemic therapy for locally advanced or metastatic urothelial cancer (recurrence >12 months after curative therapy allowed) | Cohort 7: Measurable disease by RECIST 1.1","Pregnant or lactating | Active second malignancy | Known active hepatitis B or hepatitis C | Known active central nervous system metastases and/or carcinomatous meningitis | Other concurrent medical or psychiatric conditions that would preclude study participation | Prior anti-cancer monoclonal antibody within 4 weeks before Day 1 or unresolved > Grade 1 toxicities from prior therapy | Cohorts 3–6: Active autoimmune disease requiring systemic treatment in past 2 years | Cohorts 3–6: Receipt of a live vaccine within 30 days prior to first dose | Cohorts 3–6: History or evidence of interstitial lung disease or non-infectious pneumonitis | Cohort 3: Prior anti-PD-1/PD-L1 therapy | Cohort 4: Refractory to platinum in neoadjuvant/adjuvant setting (relapse <= 12 months after completion) | Cohorts 4, 5, 6: If prior checkpoint inhibitor, treatment-free interval must be >12 months between last dose and date of recurrence | Cohort 7: Prior anticancer therapy within 12 months before C1D1 or prior radiation within 2 weeks before C1D1 | Cohort 7: History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced or idiopathic pneumonitis, or active pneumonitis on screening CT | Cohort 7: Child-Pugh class B or C hepatic impairment | Cohort 7: Uncontrolled diabetes | Cohort 7: Active keratitis or corneal ulcerations | Cohort 7: Ongoing sensory or motor neuropathy Grade >= 2",Cohort 1: Prior platinum-containing therapy and prior anti-PD-1/PD-L1 therapy with progression/recurrence; Cohort 2: Platinum-ineligible for first-line metastatic disease and progression after first-line anti-PD-1/PD-L1 therapy; no prior platinum for recurrent/metastatic/advanced disease; Cohort 3: Prior platinum-containing therapy with progression/recurrence; Cohort 4: No prior platinum-based chemotherapy in the metastatic or unresectable locally advanced setting; Cohort 5: Completed 4–6 cycles of gemcitabine + cisplatin without progressive disease; Cohort 6: No prior therapy for metastatic or unresectable locally advanced disease; CPI-naive or >12 months since completion of adjuvant therapy; Cohort 7: No prior systemic therapy for locally advanced or metastatic disease (curative-intent therapy allowed if recurrence >12 months),ALL,B,"Disease and metastatic setting match, and age/sex fit. However, cohort eligibility hinges on specific prior therapies (e.g., prior platinum and PD-1/PD-L1 for Cohort 1), which are not provided, so line-of-therapy/prior-exposure compatibility is uncertain.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,B,No hard exclusions. Disease and metastatic setting match (1 core anchor). Line/prior-exposure compatibility is unknown due to missing prior therapy details; no soft conflicts identified. Therefore B per rubric.,,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT04003649,0.712714672088623,Recurrent Glioblastoma,A Phase 1 Study to Evaluate IL13Rα2-Targeted Chimeric Antigen Receptor (CAR) T Cells Combined With Checkpoint Inhibition for Patients With Resectable Recurrent Glioblastoma,PHASE1,18 years,Glioblastoma (recurrent); Glioblastoma (refractory),"Age >= 18 years | ECOG <= 2 | Karnofsky >= 60% | Life expectancy >= 4 weeks | Histologically confirmed WHO grade IV glioblastoma or prior grade II/III glioma with progression consistent with grade IV glioblastoma after standard therapy | Relapsed/refractory measurable disease after standard therapy | >= 12 weeks after completion of front-line radiation therapy | IL13Ralpha2-positive tumor by IHC (H-score > 50) | WBC > 2000/µL or ANC >= 1000/µL (within 14 days prior to leukapheresis) | Platelets >= 75000/µL | Fasting blood glucose within ULN | Total bilirubin <= 1.5 x ULN | AST <= 2.5 x ULN | ALT <= 2.5 x ULN | Serum creatinine <= 1.6 mg/dL | Oxygen saturation >= 95% on room air | Seronegative for HIV Ag/Ab combo | Hepatitis C antibody negative or, if positive, HCV RNA negative | Hepatitis B surface antigen negative | Hepatitis A virus IgM antibody negative | Women of childbearing potential: negative pregnancy test | Agreement to use effective contraception during study and for at least 5 months after last nivolumab dose and/or 3 months after last CAR T cell cycle","Prior CTLA-4, PD-1, or PD-L1 inhibitor therapy | Steroid-dependent requiring > 6 mg dexamethasone per day at enrollment | Unresolved toxicities from prior therapy | History of or active autoimmune disease | Uncontrolled seizure activity or clinically evident progressive encephalopathy | History of allergic reactions to compounds similar to study agents | Active diarrhea | Clinically significant uncontrolled illness | Active infection requiring antibiotics | Known HIV, hepatitis B, or hepatitis C infection | Other active malignancy | Pregnant or breastfeeding | Any condition that contraindicates participation due to safety concerns per investigator | Inability to comply with study procedures",Completed standard therapy for glioblastoma; Radiographic progression after standard therapy; At least 12 weeks since completion of front-line radiation therapy,ALL,B,"Disease and post-standard therapy setting match (recurrent GBM, PD-1–naïve), but the trial requires IL13Rα2-positive tumor and resectable recurrence (and ≥12 weeks since frontline RT), which are not documented, preventing a higher grade.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,B,"No hard exclusions. Disease matches. Line/prior-exposure fits (post-standard therapy, PD-1–naïve). Stage/setting resectability is unknown, and required IL13Rα2 biomarker is unknown, so only one core anchor clearly matches. That supports a B. Grader’s reasoning aligns with the rubric.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT04388852,0.9999765753746033,Metastatic Urothelial Carcinoma,"DS3201 With Ipilimumab in Patients With Metastatic Aggressive Variant Prostate (AVPC), Urothelial (UC), and Renal Cell (RCC) Carcinomas",PHASE1,18 years,Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma; Metastatic Urothelial Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma,"ECOG performance status 0-1 | Histologically or cytologically confirmed prostate carcinoma, urothelial carcinoma, or clear cell renal cell carcinoma; variant prostate histologies (small cell/neuroendocrine) permitted | Metastatic disease by CT/MRI and/or bone scan, or locally advanced not amenable to locoregional therapy | Prostate carcinoma: castration-resistant disease and maintain castrate testosterone (<= 50 ng/dL or <= 2.0 nM) throughout the study; small cell histology exempt from progression on prior ADT but must maintain castrate levels | Aggressive variant prostate carcinoma requires molecular signature: loss or mutation in at least 2 of TP53, RB1, PTEN by CLIA-certified testing | Renal cell carcinoma: progressive disease during or after at least one anti-angiogenic agent and one PD-1 or PD-L1 inhibitor | Urothelial carcinoma: progressive disease during or after at least one PD-1 or PD-L1 inhibitor and prior platinum chemotherapy or platinum-ineligible | AVPC patients may have received prior PD-1 or PD-L1 inhibitor but not required | Evidence of disease progression by RECIST; for AVPC, rising PSA per PCWG3 may qualify if AVPC molecular criteria met | Known brain metastases allowed if stable >= 4 weeks after local therapy, off steroids or on stable/decreasing dose <= 10 mg prednisone equivalent daily, and without confounding neurologic dysfunction | Recovery from prior surgery, radiotherapy, chemotherapy, or other anti-cancer therapy to baseline or <= grade 1 (other low-grade toxicities may be allowed if clinically insignificant) | Ability to swallow and retain oral medications | Disease site accessible for serial biopsies","Pregnant or lactating | Carcinomatous meningitis | Prior treatment with an EZH2 inhibitor | PD-1, PD-L1, PD-L2, or CTLA-4 inhibitor within 4 weeks prior to day 1 | Monoclonal antibody within 4 weeks prior to day 1 | Investigational drug within 2 weeks prior to day 1 | Chemotherapy within 2 weeks prior to day 1 | Radiation therapy or radionuclide therapy within 2 weeks prior to day 1 | Receipt of live virus vaccine within 30 days prior to day 1 | Untreated symptomatic spinal cord compression or brain metastases | History of immune-related adverse event leading to permanent discontinuation of prior immunotherapy | History of >= grade 3 immune-related adverse event within past 16 weeks, any grade 4 life-threatening irAE, or neurologic/ocular irAE of any grade with prior immunotherapy (endocrine AEs allowed if on stable replacement, no adrenal crisis, asymptomatic) | Active, known, or suspected autoimmune disease (exceptions: vitiligo, type 1 diabetes, residual hypothyroidism on replacement, psoriasis/eczema not requiring systemic treatment, or conditions not expected to recur) | Requires chronic systemic corticosteroids > 10 mg prednisone equivalents daily or other immunosuppressive medications (physiologic adrenal replacement > 10 mg allowed without active autoimmune disease; inhaled/intranasal/intra-articular/topical allowed) | History of interstitial lung disease, idiopathic pulmonary fibrosis, or active pneumonitis on screening CT | Clinically significant cardiovascular disease: MI or stroke within 6 months; unstable angina within 3 months; CHF NYHA class 3-4; clinically significant ventricular arrhythmias; uncontrolled hypertension (SBP >= 140 mmHg or DBP >= 90 mmHg); baseline ECG abnormalities including QTc > 470 msec, complete LBBB, ischemic ST-T changes, second- or third-degree AV block, or serious brady-/tachyarrhythmias | Active hepatitis B (positive HBsAg) or active hepatitis C (detectable HCV RNA) | Known HIV infection | Gastrointestinal disorder that negatively affects absorption (e.g., short bowel syndrome, severe diarrhea, TPN requirement) | Additional malignancy that is progressing, requires active treatment, or has >= 30% probability of recurrence within 24 months (exceptions: non-melanoma skin cancer after curative therapy, Ta urothelial carcinoma, stage 0 CLL) | Any other severe/uncontrolled medical condition that could compromise participation | Unwilling or unable to comply with the study protocol",Renal cell carcinoma: prior treatment with at least one anti-angiogenic agent; Renal cell carcinoma: prior treatment with a PD-1 or PD-L1 inhibitor; Urothelial carcinoma: prior treatment with a PD-1 or PD-L1 inhibitor; Urothelial carcinoma: prior platinum-based chemotherapy or platinum-ineligible; Prostate cancer: maintain castrate testosterone during study; Washout: PD-1/PD-L1/PD-L2 or CTLA-4 inhibitors within 4 weeks prior to day 1 not allowed; Washout: monoclonal antibody within 4 weeks prior to day 1 not allowed; Washout: investigational drug within 2 weeks prior to day 1 not allowed; Washout: chemotherapy within 2 weeks prior to day 1 not allowed; Washout: radiation or radionuclide therapy within 2 weeks prior to day 1 not allowed,ALL,B,"Disease and metastatic setting match, and age/sex fit. However, the trial requires prior PD-1/PD-L1 therapy and prior platinum chemotherapy or platinum-ineligible status for urothelial carcinoma, which are not specified for the patient, so prior-exposure compatibility is uncertain.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,B,"No hard exclusions apply. Disease and metastatic setting match (1 core anchor). Prior-exposure requirements (PD-1 and platinum/platinum-ineligible) are unknown, not a mismatch. Other anchors are not applicable/unknown. Exactly one anchor match with no soft conflicts → Grade B. Grader’s reasoning aligns with the rubric.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04388852,0.8158129453659058,Metastatic Castration-Resistant Prostate Cancer,"DS3201 With Ipilimumab in Patients With Metastatic Aggressive Variant Prostate (AVPC), Urothelial (UC), and Renal Cell (RCC) Carcinomas",PHASE1,18 years,Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma; Metastatic Urothelial Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma,"ECOG performance status 0-1 | Histologically or cytologically confirmed prostate carcinoma, urothelial carcinoma, or clear cell renal cell carcinoma; variant prostate histologies (small cell/neuroendocrine) permitted | Metastatic disease by CT/MRI and/or bone scan, or locally advanced not amenable to locoregional therapy | Prostate carcinoma: castration-resistant disease and maintain castrate testosterone (<= 50 ng/dL or <= 2.0 nM) throughout the study; small cell histology exempt from progression on prior ADT but must maintain castrate levels | Aggressive variant prostate carcinoma requires molecular signature: loss or mutation in at least 2 of TP53, RB1, PTEN by CLIA-certified testing | Renal cell carcinoma: progressive disease during or after at least one anti-angiogenic agent and one PD-1 or PD-L1 inhibitor | Urothelial carcinoma: progressive disease during or after at least one PD-1 or PD-L1 inhibitor and prior platinum chemotherapy or platinum-ineligible | AVPC patients may have received prior PD-1 or PD-L1 inhibitor but not required | Evidence of disease progression by RECIST; for AVPC, rising PSA per PCWG3 may qualify if AVPC molecular criteria met | Known brain metastases allowed if stable >= 4 weeks after local therapy, off steroids or on stable/decreasing dose <= 10 mg prednisone equivalent daily, and without confounding neurologic dysfunction | Recovery from prior surgery, radiotherapy, chemotherapy, or other anti-cancer therapy to baseline or <= grade 1 (other low-grade toxicities may be allowed if clinically insignificant) | Ability to swallow and retain oral medications | Disease site accessible for serial biopsies","Pregnant or lactating | Carcinomatous meningitis | Prior treatment with an EZH2 inhibitor | PD-1, PD-L1, PD-L2, or CTLA-4 inhibitor within 4 weeks prior to day 1 | Monoclonal antibody within 4 weeks prior to day 1 | Investigational drug within 2 weeks prior to day 1 | Chemotherapy within 2 weeks prior to day 1 | Radiation therapy or radionuclide therapy within 2 weeks prior to day 1 | Receipt of live virus vaccine within 30 days prior to day 1 | Untreated symptomatic spinal cord compression or brain metastases | History of immune-related adverse event leading to permanent discontinuation of prior immunotherapy | History of >= grade 3 immune-related adverse event within past 16 weeks, any grade 4 life-threatening irAE, or neurologic/ocular irAE of any grade with prior immunotherapy (endocrine AEs allowed if on stable replacement, no adrenal crisis, asymptomatic) | Active, known, or suspected autoimmune disease (exceptions: vitiligo, type 1 diabetes, residual hypothyroidism on replacement, psoriasis/eczema not requiring systemic treatment, or conditions not expected to recur) | Requires chronic systemic corticosteroids > 10 mg prednisone equivalents daily or other immunosuppressive medications (physiologic adrenal replacement > 10 mg allowed without active autoimmune disease; inhaled/intranasal/intra-articular/topical allowed) | History of interstitial lung disease, idiopathic pulmonary fibrosis, or active pneumonitis on screening CT | Clinically significant cardiovascular disease: MI or stroke within 6 months; unstable angina within 3 months; CHF NYHA class 3-4; clinically significant ventricular arrhythmias; uncontrolled hypertension (SBP >= 140 mmHg or DBP >= 90 mmHg); baseline ECG abnormalities including QTc > 470 msec, complete LBBB, ischemic ST-T changes, second- or third-degree AV block, or serious brady-/tachyarrhythmias | Active hepatitis B (positive HBsAg) or active hepatitis C (detectable HCV RNA) | Known HIV infection | Gastrointestinal disorder that negatively affects absorption (e.g., short bowel syndrome, severe diarrhea, TPN requirement) | Additional malignancy that is progressing, requires active treatment, or has >= 30% probability of recurrence within 24 months (exceptions: non-melanoma skin cancer after curative therapy, Ta urothelial carcinoma, stage 0 CLL) | Any other severe/uncontrolled medical condition that could compromise participation | Unwilling or unable to comply with the study protocol",Renal cell carcinoma: prior treatment with at least one anti-angiogenic agent; Renal cell carcinoma: prior treatment with a PD-1 or PD-L1 inhibitor; Urothelial carcinoma: prior treatment with a PD-1 or PD-L1 inhibitor; Urothelial carcinoma: prior platinum-based chemotherapy or platinum-ineligible; Prostate cancer: maintain castrate testosterone during study; Washout: PD-1/PD-L1/PD-L2 or CTLA-4 inhibitors within 4 weeks prior to day 1 not allowed; Washout: monoclonal antibody within 4 weeks prior to day 1 not allowed; Washout: investigational drug within 2 weeks prior to day 1 not allowed; Washout: chemotherapy within 2 weeks prior to day 1 not allowed; Washout: radiation or radionuclide therapy within 2 weeks prior to day 1 not allowed,ALL,B,"Disease and stage/setting match (metastatic castration-resistant prostate cancer). However, the trial’s prostate cohort appears to require AVPC molecular criteria (loss/mutation in ≥2 of TP53/RB1/PTEN), which are not documented for the patient, so key eligibility remains uncertain; no explicit exclusions identified.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),INCORRECT,A,"No hard exclusions. Disease matches (CRPC cohort exists). Stage/setting matches (metastatic) and prior exposure/line are compatible (AR-targeted therapies allowed; no disallowed exposures). AVPC molecular signature is only required for the AVPC subset, not universally; its absence/unknown should not penalize. With ≥2 core anchors (stage and line) matched and no soft conflicts, rubric dictates A, not B.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04913337,0.7970306873321533,Metastatic Non-Small Cell Lung Cancer,A Phase 1/2 Dose Escalation/Expansion Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies,PHASE1/PHASE2,18 years,Breast Cancer; Cervical Cancer; Cholangiocarcinoma; Colorectal Cancer; Endocervical Cancer; Esophageal Cancer; Gastric Cancer; Glioblastoma; Melanoma; Mesothelioma; Non Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Ductal Adenocarcinoma; Renal Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck,"Histologically or cytologically confirmed locally advanced or metastatic solid tumor malignancy. | Progressed on or was intolerant to all available therapies known to confer clinical benefit appropriate for the tumor type, or refused standard-of-care treatments perceived to have marginal clinical benefit. | Adequate bone marrow, kidney, and liver function. | Performance status 0 or 1. | Acute effects of prior therapy resolved to baseline or CTCAE Grade 1 (except AEs not constituting a safety risk by investigator judgment).",Prior treatment targeting ILT2 and/or ILT4 or targeting HLA-G.,Received and progressed on or were intolerant to prior standard therapies known to confer clinical benefit for their tumor type.; Refusal of standard-of-care treatments perceived to have marginal clinical benefit is allowed.; Acute toxicities from prior therapy resolved to baseline or <= Grade 1 before enrollment.,ALL,B,"Disease and stage match (metastatic NSCLC), and age/ECOG fit; no exclusion for prior anti-ILT/HLA-G therapy applies. However, eligibility requires progression on or intolerance to all standard therapies for NSCLC, which is unclear since only prior osimertinib is documented, making line-of-therapy status uncertain.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,B,"No hard exclusions. Disease and metastatic setting match. Line/prior-therapy requirement (progressed on all available SOC) is unknown, not a clear mismatch. With exactly one core anchor match and no soft conflicts, B is appropriate per rubric.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT04953104,0.8375803232192993,Metastatic Urothelial Carcinoma,A Phase II Clinical Trial to Investigate ARID1A and/or KDM6A Mutation and CXCL13 Expression in the Pre-treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Urothelial Cancer,PHASE2,18 years,Urothelial Carcinoma (metastatic or unresectable),"Tumor harboring ARID1A and/or KDM6A mutation. | Histologic or cytologic evidence of metastatic or surgically unresectable urothelial carcinoma of bladder, urethra, ureter, or renal pelvis; minor variants < 50% allowed. | Progression or recurrence after at least 1 platinum-containing chemotherapy regimen for metastatic or unresectable disease, or ineligible/refused frontline chemotherapy. | Measurable disease by CT or MRI per RECIST 1.1. | Evaluable tumor tissue (archival or new biopsy) available for biomarker analysis. | ECOG performance status 0–1. | Prior palliative radiotherapy completed >= 2 weeks before study drug; progression in previously radiated field allowed. | Adequate hematologic, hepatic, renal function per protocol laboratory thresholds. | Participation in protocol PA13-0291 with consent for biopsy and peripheral blood collection. | Females of childbearing potential: agree to contraception during treatment and for 5 months after last dose; negative pregnancy test within 24 hours prior to start. | Males sexually active with FCBP: agree to contraception during treatment; refrain from sperm donation.","Prior treatment with anti-PD-1, anti-PD-L1, anti-CTLA-4, or other agents targeting T-cell co-stimulation or immune checkpoints. | Active brain or leptomeningeal metastases unless treated and stable >= 4 weeks and off immunosuppressive corticosteroids (> 10 mg/day prednisone equivalents) for >= 2 weeks. | Serious or uncontrolled medical disorder that may increase risk or interfere with study treatment or interpretation. | Active malignancy within 3 years except for locally curable cancers (e.g., basal or squamous cell skin cancer, carcinoma in situ) or prostate cancer without PSA progression. | Active, known, or suspected autoimmune disease except allowed conditions (e.g., vitiligo, type I diabetes, residual hypothyroidism on replacement, psoriasis not requiring systemic therapy). | Systemic corticosteroids > 10 mg/day prednisone equivalents or other immunosuppressive medications within 14 days prior to study drug (except inhaled/topical or adrenal replacement). | Unresolved toxicities from prior therapy > Grade 1 (CTCAE v5) except alopecia, fatigue, and neuropathy (neuropathy must be <= Grade 2). | Chemotherapy, radiation therapy, biologics for cancer, or investigational therapy within 14 days or 5 half-lives (whichever is shorter) before first dose. | Positive test for HBV surface antigen or for HCV RNA/antibody indicating acute or chronic infection. | Known HIV infection or AIDS.","Progression or recurrence after at least 1 prior platinum-containing chemotherapy regimen for metastatic or unresectable urothelial carcinoma, or ineligible/refused frontline chemotherapy.; Prior palliative radiotherapy allowed if completed >= 2 weeks before study drug.; Washout required: no chemotherapy, radiation, biologics, or investigational therapy within 14 days or 5 half-lives before first dose (whichever is shorter).",ALL,B,"Disease and metastatic setting match, and age/sex are eligible. However, required ARID1A/KDM6A mutation status, prior platinum exposure, and absence of prior checkpoint inhibitor therapy are not documented, so only one core anchor is confirmed.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,B,"No hard exclusions apply. Disease and metastatic setting match (1 core anchor). Prior platinum, checkpoint-naivety, and required ARID1A/KDM6A mutation are unknown, so other anchors are not confirmed and no soft mismatch is identified. Therefore B is appropriate.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04969315,0.8258353471755981,Metastatic Castration-Resistant Prostate Cancer,"Phase I/II First-in-Human Study of TT-10 (PORT-6), an Adenosine 2A Receptor Antagonist, and PORT-7, an Adenosine 2B Receptor Antagonist, as Single Agents and in Combination in Participants With Advanced Selected Solid Tumors",PHASE1/PHASE2,18 years,Castrate-Resistant Prostate Cancer; Colorectal Cancer; Endometrial Cancer; Head and Neck Squamous Cell Carcinoma; Non-Small Cell Lung Cancer; Ovarian Cancer; Renal Cell Carcinoma,"Histologically or cytologically confirmed advanced solid tumors per cohort definitions | RCC: locally advanced or metastatic with >=2 prior systemic regimens including VEGF-targeted therapy and checkpoint inhibitor therapy | CRPC: metastatic disease with prior second-generation hormonal agent and a taxane-based chemotherapy | SCCHN: advanced/metastatic, incurable by surgery or radiotherapy, progressed during/after platinum-based chemotherapy and/or checkpoint inhibitor therapy | NSCLC: metastatic, intolerant or resistant to standard therapy or no standard therapy available | CRC: metastatic, intolerant or resistant to standard therapy or no standard therapy available | Endometrial Cancer: metastatic, intolerant or resistant to standard therapy or no standard therapy available | Ovarian Cancer: metastatic, intolerant or resistant to standard therapy or no standard therapy available | ECOG 0–1 | Measurable disease per RECIST 1.1; CRPC may enroll with non-measurable disease if screening PSA >= 2.0 ng/mL with sponsor approval | Adequate hematologic, hepatic, and renal function | Consent to baseline biopsy or provision of recent archival tissue as specified | Able to swallow capsules","Major surgery within 4 weeks prior to screening | Active CNS metastases; treated/stable off corticosteroids allowed; leptomeningeal metastases excluded | Prior radiotherapy within 2 weeks of start; 1-week washout permitted for palliative radiotherapy (<= 2 weeks) to non-CNS disease | Prior anti-cancer therapy within 4 weeks (2 weeks for short-acting TKIs); unresolved treatment-related toxicities > Grade 1 | HIV infection | HBsAg positive unless on antiviral therapy >= 4 weeks with undetectable HBV viral load; must remain on therapy per guidelines | History of HCV infection unless curatively treated with undetectable viral load at screening | Requires immunosuppressive therapy including systemic steroids >= 10 mg prednisone equivalent daily or other immunosuppressants/biologics | Requires strong inhibitors or inducers of CYP3A4, CYP2C9, or CYP2C19 | Requires drugs that modify gastric pH (PPIs or H2 blockers); antacids allowed with dose separation | Ongoing systemic bacterial, fungal, or viral infection | Live vaccine within 6 weeks of first dose (mRNA COVID-19 vaccines permitted) | Baseline QTcF > 470 ms (average of triplicate) | Prior surgery or gastrointestinal dysfunction that may affect drug absorption (e.g., gastric bypass, gastrectomy) | Pregnant or breastfeeding | Concurrent active malignancy other than non-melanoma skin cancer, carcinoma in situ of the cervix, or prostate intraepithelial neoplasia | Past medical history of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonitis requiring steroids; or clinically active interstitial lung disease | History of peptic ulcer or gastrointestinal bleed within 6 months | History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring treatment within 6 months | Unstable or severe uncontrolled medical condition that increases study risk",RCC: prior >= 2 systemic regimens including VEGF-targeted therapy and checkpoint inhibitor therapy; CRPC: prior second-generation hormonal therapy and taxane-based chemotherapy; SCCHN: prior platinum-based chemotherapy and/or checkpoint inhibitor with progression; NSCLC/CRC/Endometrial/Ovarian Cancer: intolerant or resistant to standard therapy or no standard therapy available; Washout from prior anti-cancer therapy >= 4 weeks (>= 2 weeks for short-acting TKIs) before start; Washout from radiotherapy >= 2 weeks (>= 1 week for short palliative courses <= 2 weeks),ALL,B,"Disease and metastatic setting match the CRPC cohort, and sex/age fit. However, the trial requires prior taxane-based chemotherapy for CRPC, which is not documented for this patient, making line-of-therapy eligibility uncertain (other criteria like ECOG, labs, and concomitant meds are also unspecified).",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),INCORRECT,A,"No hard exclusions. Disease matches CRPC; stage/setting matches (metastatic). Metastatic pattern constraint is satisfied (no CNS mets where active CNS is excluded). Line/prior exposure (taxane) is unknown, not a soft mismatch. Thus ≥2 core anchors match with no soft conflicts → A. The grader’s B undercounts anchors.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT05355701,0.8058992028236389,Metastatic Non-Small Cell Lung Cancer,"A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS",PHASE1,16 years,Glioma; Melanoma; Non-Small-Cell Lung Cancer; Thyroid Cancer,"Advanced or metastatic solid tumor, including primary brain tumor | Qualifying BRAF alteration: V600 or non-V600 Class II/Class III in tumor tissue and/or ctDNA | Disease progression during or after last prior treatment with no satisfactory alternative options (Parts 1 and 2) | Tumor-specific cohorts (melanoma, colorectal cancer) must have received prior approved therapies",Brain metastasis >4 cm | Ongoing systemic anti-cancer therapy or small molecule therapeutics at start of study treatment | History or current evidence of retinal vein occlusion (for participants who may receive binimetinib) | Concurrent neuromuscular disorder associated with elevated creatine kinase (for participants who may receive binimetinib),Progression on or after prior therapy required (Parts 1–2); Prior approved therapies required for melanoma and colorectal cancer cohorts,ALL,B,"Disease and stage match (metastatic NSCLC; age/sex eligible). However, the trial requires a qualifying BRAF alteration and progression after prior therapy, which are not documented for this patient, so only one core anchor clearly matches.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),INCORRECT,D,"Disease and stage match, but the trial requires a qualifying BRAF alteration. The patient’s known EGFR exon 19 driver implies a likely biomarker mismatch (implied biomarker miss per rubric), which constitutes a soft mismatch on a core anchor → D. Progression after prior therapy is also unknown. The grader treated biomarker as merely unknown and gave B, but per rubric this should be D.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT05394675,0.7714447379112244,Metastatic Non-Small Cell Lung Cancer,"A Phase 1, First-in-Human Study of DS-9606a in Patients With Tumor Types Known to Express Claudin-6 (CLDN6)",PHASE1,18 years,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Germ Cell Tumor; Endometrial Cancer; Pancreatic Adenocarcinoma; Non-Squamous Non-Small Cell Lung Cancer; Gastric Cancer,"Age >= 18 years | ECOG performance status 0–1 | Archived tumor tissue available (mandatory in Part A); germ cell tumor patients without archived samples may be allowed with approval | Left ventricular ejection fraction >= 50% | Adequate bone marrow and organ function | Life expectancy >= 3 months | Adequate treatment washout prior to study start | Dose Escalation: Histologically or cytologically confirmed locally advanced or metastatic solid tumors including ovarian cancer (including fallopian tube and primary peritoneal), germ cell tumors, uterine/endometrial cancers, pancreatic adenocarcinoma, non-squamous non-small cell lung cancer, or gastric cancer | Dose Escalation: Disease progression after standard therapies for metastatic disease known to confer benefit, or intolerant to or refuse standard treatment | Dose Expansion: Histologically or cytologically confirmed locally advanced or metastatic ovarian cancer | Dose Expansion: Provide archived tumor sample if available or mandatory pre-treatment and on-treatment tumor biopsies if not clinically contraindicated","History or presence of central nervous system metastases unless treated >= 4 weeks prior, with no CNS progression and no chronic corticosteroids within 2 weeks before treatment | Other invasive malignancy within 2 years, except certain non-invasive or curatively treated localized malignancies with low risk of recurrence | Myocardial infarction or unstable angina within 6 months before study treatment | Symptomatic congestive heart failure (NYHA class II–IV) or serious cardiac arrhythmia requiring treatment | QTcF > 470 ms | History of interstitial lung disease/pneumonitis requiring corticosteroids, current ILD/pneumonitis, or suspected ILD/pneumonitis on screening imaging | Uncontrolled infection requiring ongoing or long-term therapy | Known active hepatitis or uncontrolled hepatitis B or C infection",Progressed after standard therapies for metastatic disease or intolerant/refuse standard treatment; Treatment washout period required,ALL,B,"Disease and metastatic setting match an eligible NSCLC cohort, and age/ECOG meet general criteria. However, non-squamous histology and progression after standard therapy are not documented, leaving line/prior-exposure and subtype anchors uncertain.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,B,"No hard exclusions. Stage/setting matches (metastatic allowed). Line/prior progression requirement and non-squamous histology are unknown, not mismatches. CNS mets constraint cannot be confirmed from provided data. With exactly one confirmed core anchor and no soft conflicts, B is appropriate.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05843578,0.7004152536392212,Crohn's Disease,"A Phase 2a, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AGMB-129 in Patients With Fibrostenotic Crohn's Disease",PHASE2,18 years,Crohn's Disease (fibrostenotic),"Diagnosis of ileal or ileocolonic Crohn's disease established >=3 months prior to screening | At least one terminal ileum stricture confirmed by MRE meeting criteria: localized luminal narrowing <=50% vs adjacent bowel, bowel wall thickening >=25%, and either prestenotic dilation >=3 cm or nonpassable with adult colonoscope | Tolerable obstructive symptoms with screening S-PRO severity score >=2 and not expected to require hospitalization, dilation, surgery, or additional therapy during the study | Stable background therapy for Crohn's disease and agree to maintain during the study","History or current diagnosis of ulcerative colitis, indeterminate colitis, ischemic colitis, NSAID-induced colitis, idiopathic colitis, radiation colitis, microscopic colitis, colonic mucosal dysplasia, or untreated bile acid malabsorption | Crohn's disease-related complications (e.g., extensive small bowel resection, ileorectal anastomosis, proctocolectomy, short bowel syndrome, ostomy or stoma, ileoanal pouch, inactive fistulae in or adjacent to an ileal stricture, anal/perianal stricture, active intra-abdominal or perianal abscess not appropriately treated, abscess related to the stricture, toxic megacolon, very severe inflammation, or deep ulceration in the colon or terminal ileum) | Ileitis not associated with Crohn's disease (e.g., infectious, spondyloarthropathy-associated, ischemic) | Endoscopic balloon dilation or surgical treatment of the same small bowel stricture within 6 months prior to screening | Receiving cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil within 8 weeks of screening | Janus kinase inhibitor therapy within 4 weeks of screening | Requiring continued treatment with systemic medications that are sensitive CYP3A4/5 substrates with a narrow therapeutic index or strong inhibitors of aldehyde oxidase or xanthine oxidase | Current or history of vasculitis, valvulopathy, large vessel disorder, or major abnormalities on cardiac echocardiography with Doppler","Stable background therapy for Crohn's disease required and maintained during the study; No cyclosporine, tacrolimus, sirolimus, or mycophenolate within 8 weeks before screening; No Janus kinase inhibitor therapy within 4 weeks before screening",ALL,B,"Crohn's disease diagnosis and prior exposure to infliximab/ustekinumab are compatible with the trial’s allowed background/prior therapies. However, the study specifically requires a fibrostenotic ileal/ileocolonic stricture with obstructive symptoms per MRE criteria, which is not documented in the patient’s profile.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,B,"No hard exclusions. Disease matches. Required fibrostenotic ileal stricture and obstructive symptoms are unknown, not a mismatch. Prior therapy/exposure is compatible, yielding exactly one CORE ANCHOR match. Thus B is appropriate; the grader’s reasoning highlights the key missing subtype requirement.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT06311578,0.816875696182251,Metastatic Non-Small Cell Lung Cancer,"Phase 1 Study of Intratumoral Administration of JNJ-87704916, an Oncolytic Virus, as Monotherapy and in Combination for Advanced Solid Tumors",PHASE1,18 years,Solid Tumor (advanced/metastatic); Non-Small Cell Lung Cancer (metastatic or locally advanced),Advanced or metastatic solid tumor with no available standard of care therapy (Part 1) | Histologically or cytologically confirmed metastatic or locally advanced non-small cell lung cancer (Part 2) | At least 1 injectable tumor | ECOG performance status 0–1 | Negative pregnancy test if of childbearing potential | Thyroid function laboratory values within normal range,"Active central nervous system involvement (primary CNS tumors, metastases, or leptomeningeal disease) with limited exceptions | Prior history of, or active, significant herpetic infections (e.g., herpetic keratitis or encephalitis) or active herpetic infections requiring ongoing systemic antiviral therapy | Active infection requiring systemic anti-infective therapy within 7 days prior to first dose or chronic use of anti-infective agents | History of solid organ or hematologic stem cell transplantation | Known HIV infection or other immunodeficiency syndrome | History of Grade >=3 toxicity with prior immunotherapy or requirement of anti-TNF or anti-IL-6 agents to manage prior immunotherapy adverse events | History of allergy to protein-based therapies or significant drug allergy (e.g., anaphylaxis, hepatotoxicity, immune-mediated thrombocytopenia or anemia)",Exhausted all available standard of care therapy (Part 1),ALL,B,"Disease and stage/setting match (metastatic NSCLC; ECOG 0 within allowed 0–1). Line-of-therapy/prior-exposure requirements for the NSCLC cohort are not specified and the required presence of an injectable lesion is unknown, so eligibility is uncertain but there are no explicit conflicts.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,B,"No hard exclusions. Disease and metastatic setting match. Line/prior-exposure for the NSCLC cohort is unspecified; injectable lesion requirement is unknown and not a core anchor. Other anchors (biomarker requirement, CNS mets constraints) are not specified or unknown. Exactly one core anchor matches, so B is appropriate.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT06483334,0.7763499021530151,Metastatic Urothelial Carcinoma,"A Phase 1/2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab, as Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04C",PHASE1/PHASE2,18 years,Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma,Histologically documented locally advanced or metastatic urothelial carcinoma | Archival or newly obtained tumor tissue adequate for biomarker evaluation (prefer newly obtained if feasible) | Adverse events from prior anticancer therapy recovered to <= Grade 1 or baseline (endocrine AEs allowed if adequately treated) | Part 1: Prior platinum-based chemotherapy for la/mUC | Part 1: <= 2 prior lines of therapy for la/mUC (platinum-based chemotherapy followed by avelumab maintenance counts as 2 lines) | Part 2: No prior systemic therapy for la/mUC,"Additional malignancy that is progressing or required active treatment within the past 3 years | Active central nervous system metastases or carcinomatous meningitis | Peripheral neuropathy Grade >= 2 | History of severe dry eye syndrome, severe Meibomian gland disease, blepharitis, or corneal disease that prevents/delays corneal healing | Active inflammatory bowel disease requiring immunosuppressive medication or prior history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, chronic diarrhea) | Uncontrolled significant cardiovascular or cerebrovascular disease, or serious cardiovascular/cerebrovascular events within 6 months | Active keratitis or corneal ulcerations (superficial punctate keratitis allowed if adequately treated) | History of uncontrolled diabetes | Received an investigational agent or used an investigational device within 4 weeks prior to study intervention | Received a live or live-attenuated vaccine within 30 days prior to first dose | Part 2: Diagnosis of immunodeficiency or receiving chronic systemic steroids or other immunosuppressive therapy within 7 days before first dose (inhaled/topical steroids permitted; physiologic replacement allowed for adrenal insufficiency) | Part 2: Active autoimmune disease requiring systemic treatment in past 2 years except replacement therapy | Human immunodeficiency virus infection with history of Kaposi's sarcoma and/or Multicentric Castleman's Disease | Active hepatitis B or hepatitis C virus infection | History of noninfectious pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease | Active infection requiring systemic therapy | Part 2: History of allogeneic tissue/solid organ transplant | Not adequately recovered from major surgery or ongoing surgical complications",Part 1: Prior platinum-based chemotherapy required for la/mUC; Part 1: <= 2 prior lines of therapy for la/mUC; Part 2: No prior systemic therapy for la/mUC,ALL,B,"Disease and metastatic setting match, and the post–second-line status fits Part 1 (≤2 prior lines). However, required prior platinum-based chemotherapy is unknown, and other exclusion factors (e.g., comorbidities, tissue availability) are not provided.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,B,"No hard exclusions. Disease and metastatic setting match (1 anchor). Line/prior exposure is uncertain because prior platinum is required and unknown, so not a clear match. Other anchors are not applicable/unknown. Exactly one anchor match → B per rubric.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT06570798,0.7005309462547302,Rheumatoid Arthritis,"A Phase 2a, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases",PHASE2,18 years to 75 years,Systemic Lupus Erythematosus (lupus nephritis); Rheumatoid Arthritis (refractory),"Subprotocols A/B: Systemic lupus erythematosus meeting 2019 EULAR/ACR classification criteria | Subprotocols A/B: Positive autoantibody at screening or documented history: ANA >= 1:80 or anti-dsDNA positive or anti-Smith positive | Subprotocols A/B: Active, biopsy-proven proliferative lupus nephritis class III or IV with/without class V features (2018 ISN/RPS) | Subprotocol A: Inadequate response, loss of response, or intolerance to >= 1 KDIGO-recommended therapy; UPCR >= 1.0 mg/mg | Subprotocol B: Inadequate response, loss of response, or intolerance to >= 2 KDIGO-recommended therapies; UPCR >= 1.0 mg/mg | Subprotocols A/B: If on background meds, stable doses prior to Day 1: prednisone <= 20 mg/day for 5 days; hydroxychloroquine <= 400 mg/day (or chloroquine/quinacrine) for 4 weeks; mycophenolate mofetil <= 3 g/day or mycophenolic acid <= 2160 mg/day for 2 weeks; azathioprine <= 2 mg/kg/day for 2 weeks | Subprotocol C: Rheumatoid arthritis meeting 2010 ACR/EULAR classification criteria | Subprotocol C: Active disease: DAS28-CRP > 3.2, >= 6 tender joints, and >= 6 swollen joints at screening | Subprotocol C: Refractory disease: prior treatment with >= 1 csDMARD and (>= 2 bDMARDs of different MOA OR >= 1 bDMARD and >= 1 tsDMARD) | Subprotocol C: Inadequate response despite >= 12 weeks of treatment with a csDMARD, bDMARD, or tsDMARD, or intolerance to these therapies","Subprotocols A/B: eGFR < 30 mL/min (MDRD) | Subprotocols A/B: Significant likely irreversible SLE-related organ damage (e.g., ESRD) | Subprotocols A/B: Acute, severe lupus flare during screening requiring immediate treatment | Subprotocols A/B: Prior kidney transplant or planned transplant during study treatment period | Subprotocols A/B: Other renal diseases that could interfere with lupus nephritis assessment (e.g., diabetic nephropathy) | Subprotocols A/B: Renal biopsy showing pure class V lupus nephritis | Subprotocol C: Other inflammatory joint disease history/current (non-RA) or significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis, Felty's syndrome) | Subprotocol C: ACR Functional Class IV",Lupus nephritis: prior inadequate response/loss of response/intolerance to >= 1 (Subprotocol A) or >= 2 (Subprotocol B) KDIGO-recommended therapies; Rheumatoid arthritis: prior >= 1 csDMARD and >= 2 bDMARDs of different MOA OR >= 1 bDMARD and >= 1 tsDMARD; Rheumatoid arthritis: prior exposure >= 12 weeks to csDMARD/bDMARD/tsDMARD or documented intolerance; Allowed background medications if stable: prednisone <= 20 mg/day; hydroxychloroquine <= 400 mg/day (or chloroquine/quinacrine); mycophenolate mofetil <= 3 g/day or mycophenolic acid <= 2160 mg/day; azathioprine <= 2 mg/kg/day,ALL,B,"Disease matches the RA cohort and the patient meets line/prior therapy requirements (csDMARD plus ≥2 bDMARDs of different MOA). Active disease is indicated (DAS28 5.5), but specific RA classification confirmation and joint count criteria at screening are not provided, so those remain unknown.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),INCORRECT,A,"No hard exclusions. Disease matches RA cohort. Two CORE ANCHORS match: (1) Line/prior exposure meets refractory definition (csDMARD + ≥2 bDMARDs with different MOA), and (2) Stage/setting matches active RA (DAS28 5.5 indicates active disease). No soft conflicts. Thus ≥2 anchors → A. The grader was overly conservative, treating stage/setting as unknown due to missing joint counts, which isn’t required at the anchor level.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT06860594,0.822833240032196,Recurrent Glioblastoma,A Phase I Trial Combining Triapine With Radiation Therapy for Recurrent Glioblastoma or Astrocytoma,PHASE1,18 years,(none),,,(none),ALL,B,"The trial title specifies recurrent glioblastoma, matching the patient’s disease and setting, and the patient meets age and gender criteria. Other core anchors (prior-therapy requirements, biomarkers, specific constraints) are not specified, so only the stage/setting anchor clearly matches.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,B,"No hard exclusions. Disease and recurrent setting match via the official title. Other core anchors (line/prior exposure, biomarkers, mets pattern) are not specified, yielding exactly one anchor match and no soft conflicts. Grade B is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT06915012,0.6914706230163574,Rheumatoid Arthritis,A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Impact of Biophoton Therapy on Chronic Severe Arthritis Pain,NA,18 years to 80 years,Arthritis,Age 18-80 years | Chronic severe arthritis pain for >=3 months | Current VAS pain rating >=5/10,"Untreated psychiatric disturbances that would affect participation | Ventilator dependence | Implantable electronic devices (e.g., pacemaker, deep brain stimulator) | Severe comorbid conditions that could interfere with study activities (e.g., severe chronic pulmonary disease, uncontrolled seizures, acute or chronic infectious illness, severe diabetes, kidney failure, end-of-life prognosis) | Active infectious disease (e.g., COVID-19) | Pregnancy",(none),ALL,B,"The trial targets arthritis and allows prior therapies, and the patient's age/sex fit the eligibility window. However, required pain severity/duration (VAS ≥5/10 for ≥3 months) and key exclusions (e.g., pregnancy, implantable devices) are not documented, so eligibility on those criteria is uncertain.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),INCORRECT,C,"No hard exclusions. Disease category (arthritis) reasonably includes RA. However, there is insufficient information to confirm any CORE ANCHOR match: stage/setting (chronic severe pain criteria) is unknown for the patient, and line/prior exposure isn’t explicitly addressed by the trial (no stated allowance/restriction), so it should be treated as neutral, not a match. With 0 confirmed anchors and no soft conflicts, the correct grade is C, not B.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT07087860,0.8714519143104553,Metastatic Urothelial Carcinoma,Randomized Phase II Rescuing Cancer Immunotherapy With Plasma Exchange in Bladder Cancer 1 (ReCIPE-B1),PHASE2,18 years,Bladder Urothelial Carcinoma (metastatic); Upper Tract Urothelial Carcinoma (metastatic),"Age >= 18 years | Histologically proven urothelial carcinoma of the bladder or upper urinary tract | Disease progressed despite prior enfortumab vedotin and pembrolizumab treatment (primary or secondary progression allowed) | Measurable disease per RECIST v1.1 | ECOG performance status 0-2 | Hemoglobin > 7.0 g/dL (within 30 days) | Platelet count >= 75,000/µL (within 30 days) | ALT <= 3.5 x ULN (within 30 days) | AST <= 3.5 x ULN (within 30 days) | Total bilirubin <= 3 x ULN (within 30 days) | Direct bilirubin <= 3 x ULN (within 30 days) | Estimated GFR >= 15 mL/min (within 30 days)","Pregnant | Breastfeeding | Persons of childbearing potential or able to father a child unwilling to use adequate contraception | Histologic variants/divergent differentiation including any neuroendocrine, micropapillary, or signet ring cell features | Active malignancy other than the study disease within 24 months (with specified exceptions) | Significant cardiovascular disease within 6 months (e.g., NYHA class >= III CHF, unstable angina, cardiac arrhythmia, myocardial infarction, ventricular fibrillation, Torsades de Pointes, cerebrovascular accident, transient ischemic attack) | Psychiatric illness or substance abuse that would limit compliance | Any condition that, in the investigator's opinion, would not be in the participant's best interest or could confound assessments",Prior enfortumab vedotin and pembrolizumab with documented progression,ALL,B,"Disease and metastatic setting match and age/sex are within trial bounds. However, the trial requires progression after enfortumab vedotin and pembrolizumab, and the patient’s prior therapies are unspecified, so line/prior-exposure compatibility is uncertain.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,B,"No hard exclusions. Disease and metastatic setting match. Prior exposure to enfortumab vedotin and pembrolizumab is required but unknown, so line/prior anchor is unknown rather than a mismatch. Exactly one core anchor matches, so B is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT00611585,1.0,Rheumatoid Arthritis,"Birmingham Hip Resurfacing System (BHR) Post Approval Study: A Prospective, Multi-Centered Study of the Birmingham Hip Resurfacing System",NA,21 years to 75 years,Osteoarthritis; Traumatic Arthritis; Avascular Necrosis; Hip Dysplasia; Rheumatoid Arthritis,Age >= 21 years | Skeletally mature | Requires primary hip resurfacing due to osteoarthritis | Requires primary hip resurfacing due to traumatic arthritis | Requires primary hip resurfacing due to avascular necrosis | Requires primary hip resurfacing due to hip dysplasia | Requires primary hip resurfacing due to rheumatoid arthritis,"Active infection or sepsis | Vascular insufficiency severe enough to compromise implant stability or postoperative recovery | Muscular atrophy severe enough to compromise implant stability or postoperative recovery | Neuromuscular disease severe enough to compromise implant stability or postoperative recovery | Female of child-bearing age | Bone stock inadequate to support the device | Moderate to severe renal insufficiency | Known or suspected metal hypersensitivity | Immunosuppressed state (e.g., AIDS) or receiving high doses of corticosteroids | Psychological or neurological conditions precluding participation | Severely overweight",(none),ALL,C,"Disease (rheumatoid arthritis) and age fit the trial, but the study specifically requires patients who need primary hip resurfacing due to RA, which is not stated for this patient. No relevant line-of-therapy or biomarker requirements are specified.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,C,"No hard exclusions are triggered. Disease (RA) matches and age fits, but the trial requires need for primary hip resurfacing due to RA, which is not stated—stage/setting is unknown. No line/prior, biomarker, or mets pattern anchors apply. With 0 core anchors matched and no soft conflict, C is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT01961986,0.685097336769104,Rheumatoid Arthritis,"Rotator Cuff Sparing Total Arthroplasty - A Prospective, Randomized Clinical Trial",NA,21 years,Inflammatory Arthritis; Osteoarthritis,Indicated for shoulder joint replacement | Age >= 21 years | Expected survival >= 2 years beyond surgery,Prior arthroplasty in the affected shoulder | Significant deformity of the proximal humerus requiring a custom implant or consideration of osteotomy of the shaft and/or tuberosity | Significant medial erosion of the glenoid with the lateral edge of the humeral head medial to the lateral rim of the acromion | Significant injury to the brachial plexus | Pregnant or lactating,(none),ALL,C,"Rheumatoid arthritis falls under inflammatory arthritis and the patient meets age/sex criteria with no explicit exclusions. However, candidacy for shoulder joint replacement—a key setting requirement—is unknown and line/prior-therapy requirements are not specified, so no core anchors can be confirmed.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,C,"No hard exclusions. RA fits under inflammatory arthritis. Stage/setting (indicated for shoulder arthroplasty) is unknown, and line/prior requirements are not specified. With 0 confirmed core anchors and no soft conflicts, C is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT02038140,0.6365199685096741,Rheumatoid Arthritis,Prospective Post Market Clinical Follow-Up (PMCF) Study of the Zimmer® Trabecular Metal™ Total Ankle,NA,18 years,Degenerative Arthritis; Post-traumatic Arthritis; Rheumatoid Arthritis,"Age > 18 years | Skeletally mature | Eligible for primary or revision total ankle arthroplasty for degenerative arthritis, rheumatoid arthritis, or post-traumatic arthritis","Ankle arthrodesis with malleolar exeresis compromising the affected limb | Severe neurological disease affecting the limb | Severe vascular disease affecting the limb | Loss of musculature or neuromuscular compromise affecting the limb | Severe instability, maltracking, or misalignment of the tibia and talus uncorrectable by surgery | Local or systemic infection that may affect the prosthetic joint | Previous history of infection in the affected joint | Pregnant | Insufficient bone stock or bone quality to fix components (e.g., osteoporosis, Charcot disease) | Known sensitivity or allergic reaction to implanted materials",(none),ALL,C,"Disease matches (rheumatoid arthritis) and age/sex fit, but the trial requires candidates eligible for total ankle arthroplasty; the patient’s ankle involvement and surgical eligibility are not specified. No explicit exclusion conflicts are identified.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,C,"No hard exclusions. Disease matches RA. Stage/setting (eligibility for total ankle arthroplasty) is unknown, as is line/prior exposure relevance; no biomarker or mets constraints apply. With 0 clear CORE ANCHOR matches and no soft mismatch, C is appropriate. The grader’s reasoning correctly highlighted the surgical eligibility uncertainty.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT02171104,0.42895352840423584,PMM2-CDG,"MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG",PHASE2,up to 55 years,Acyl-CoA Oxidase Deficiency; Adrenoleukodystrophy (cerebral); Alpha-mannosidosis; Alpha-methylacyl-CoA Racemase Deficiency; Aspartylglucosaminuria; D-Bifunctional Enzyme Deficiency; Fucosidosis; Globoid Cell Leukodystrophy; Glycoprotein Metabolic Disorders; Hereditary Leukoencephalopathy With Axonal Spheroids; Hunter Syndrome; Hurler Syndrome; Infantile Refsum Disease; Inherited Metabolic Disorders; Maroteaux Lamy Syndrome; Metachromatic Leukodystrophy; Mitochondrial Neurogastrointestinal Encephalopathy; Mucopolysaccharidosis Disorders; Multifunctional Enzyme Deficiency; Neonatal Adrenoleukodystrophy; Niemann-Pick B; Niemann-Pick C Subtype 2; Peroxisomal Disorders; Recessive Leukodystrophies; Severe Osteopetrosis; Sly Syndrome; Sphingolipidoses; Sphingomyelin Deficiency; Zellweger Syndrome,"Age 0–55 years | Adequate graft available | Adequate organ function | MPS IH (Hurler syndrome) | MPS II (Hunter syndrome) with no or minimal symptomatic neurologic disease but expected neurologic phenotype | MPS VI (Maroteaux-Lamy syndrome) | MPS VII (Sly syndrome) | Alpha-mannosidosis | Fucosidosis | Aspartylglucosaminuria | Globoid cell leukodystrophy | Metachromatic leukodystrophy | Niemann-Pick disease type B (sphingomyelin deficiency) | Niemann-Pick C subtype 2 | Adrenoleukodystrophy (cerebral involvement) | Zellweger syndrome | Neonatal adrenoleukodystrophy | Infantile Refsum disease | Acyl-CoA oxidase deficiency | D-bifunctional enzyme deficiency | Multifunctional enzyme deficiency | Alpha-methylacyl-CoA racemase deficiency (AMACRD) | Mitochondrial neurogastrointestinal encephalopathy (MNGIE) | Severe osteopetrosis | Hereditary leukoencephalopathy with axonal spheroids (CSF1R mutation) | Other life-threatening lysosomal, peroxisomal or similar inherited disorders with white matter disease or neurologic manifestations where transplantation is rational (e.g., Wolman disease, GM1 gangliosidosis, I-cell disease, Tay-Sachs disease, Sandhoff disease) | Voluntary written consent","Pregnancy | Prior myeloablative chemotherapy within 4 months of start of conditioning | Uncontrolled bacterial, fungal, or viral infection including HIV | Active Aspergillus or other mold infection within 30 days",(none),ALL,C,"PMM2-CDG fits the trial’s broad disease category (glycoprotein metabolic disorder), the patient is age-eligible, and no exclusions are evident. However, stage/setting and line-of-therapy requirements are not specified and no biomarker is required, leaving core anchors largely unknown.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,C,"No hard exclusions apply; the trial’s disease scope includes glycoprotein metabolic disorders, age/sex are eligible, and no explicit exclusions are triggered. Core anchors (stage/setting, line/prior, biomarker requirement, mets pattern) are largely not specified/irrelevant, with no soft mismatches identified. Thus C is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT02255383,0.6466730833053589,Rheumatoid Arthritis,Persona The Personalized Knee System TKA Outcomes Study: Prospective Multicenter Study of the Persona Knee System,NA,18 years to 75 years,Osteoarthritis; Rheumatoid Arthritis; Traumatic Arthritis; Polyarthritis; Avascular Necrosis of the Femoral Condyle,"Age 18-75 years | Severe knee pain/disability due to rheumatoid arthritis | Severe knee pain/disability due to osteoarthritis | Severe knee pain/disability due to traumatic arthritis | Severe knee pain/disability due to polyarthritis | Severe knee pain/disability due to collagen disorders | Severe knee pain/disability due to avascular necrosis of the femoral condyle | Post-traumatic loss of joint configuration (e.g., patellofemoral erosion/dysfunction or prior patellectomy) | Moderate valgus deformity | Moderate varus deformity | Moderate flexion deformity | Salvage of previously failed surgical attempts not including prior partial or total knee arthroplasty of the ipsilateral knee | Candidate for Persona fixed bearing knee components implanted per product labeling","Previous infection in the affected joint or other local/systemic infection that may affect the prosthetic joint | Insufficient bone stock on femoral or tibial surfaces | Skeletal immaturity | Neuropathic arthropathy | Osteoporosis compromising the affected limb | Loss of musculature or neuromuscular disease compromising the affected limb | Stable, painless arthrodesis in a satisfactory functional position | Severe instability due to absence of collateral ligament integrity | Rheumatoid arthritis with a skin ulcer or recurrent skin breakdown | Known or suspected sensitivity or allergy to implant materials | Pregnant | Prior partial or total knee arthroplasty of the ipsilateral knee",(none),ALL,C,"Disease and age match, but it's unknown whether the patient has severe knee-specific RA symptoms or is a candidate for total knee arthroplasty per the device study’s inclusion criteria. No explicit exclusions are identified from the available data.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,C,"No hard exclusions: disease (RA), age, and sex fit; no explicit conflicting exclusions. Core anchors: stage/setting (surgical TKA candidacy) unknown; line/prior exposure not specified; required knee-specific severity unknown; mets pattern N/A. With 0 clear anchor matches and no soft mismatch, grade C is appropriate. The grader’s reasoning aligns with the rubric.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT02356653,0.5412865877151489,Ornithine Transcarbamylase Deficiency,Expanded Access Protocol Using CD3+/CD19+ Depleted Unrelated Donor or Related Donor Peripheral Stem Cells,EARLY_PHASE1,up to 30 years,Bone Marrow Failure Syndrome; Immunodeficiency; Immunodysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome; Inborn Error of Metabolism; Leukemia; Lymphoma; Myelodysplastic Syndrome; Hemoglobinopathy; Metabolic Storage Disease,"Lacks a fully HLA-matched sibling and is a candidate for allogeneic HSCT not suitable for current institutional CliniMACs protocols | Metabolic storage disease correctable by HSCT | Bone marrow failure syndrome | Immunodeficiency or immune dysregulation syndromes (including HLH) | Hemoglobinopathy correctable and requiring HSCT | Other non-malignant blood, metabolic, or immune disorders for which HSCT is recommended | Acute leukemia | Chronic leukemia | Lymphoma | Myelodysplastic syndrome | Identified living donor (related or unrelated) meeting institutional and regulatory eligibility criteria | Unrelated donor meeting NMDP matching criteria at HLA-A, -B, -C, -DRB1, and -DQB1 (10/10, 9/10, or 8/10 if the mismatch is at DQB1) | Related donor suitable for mobilization and infectious disease screening per SOP (HIV, HepB, HepC PCR negative) | Unrelated donor identified through NMDP, willing and able to undergo mobilization and apheresis | Adequate hematologic and organ function per institutional SOP | Negative pregnancy test for participants of childbearing potential","Uncontrolled bacterial, viral, or fungal infection | Availability of a fully HLA-matched sibling donor | Donor unable to donate peripheral stem cells | Pregnant",(none),ALL,C,"The diagnosis (inborn error of metabolism) aligns with the trial’s broad disease categories and the patient is under the max age, but key requirements—being an HSCT candidate and donor/HLA criteria—are unknown. No hard exclusions are triggered, making the match uncertain.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,C,"No hard exclusions. Disease matches broad trial category (inborn error of metabolism). Stage/setting (HSCT candidate) and donor/HLA requirements are unknown; no clear soft mismatch identified. With 0 confirmed core anchor matches and no conflicts, C is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT02469662,0.755436360836029,Rheumatoid Arthritis,Retrospective and Prospective Clinical Outcomes Study of the Zimmer® Nexel™ Total Elbow,NA,18 years,Acute Comminuted Elbow Articular Fracture; Rheumatoid Arthritis (advanced); Joint Ankylosis; Bilateral Joint Ankylosis (non-septic); Elbow Instability (bone loss); Degenerative Arthritis; Elbow Joint Destruction; Joint Instability; Loss of Joint Motion; Post-traumatic Arthritis; Post-traumatic Lesion,Age >= 18 years | Candidate for primary or revision total elbow arthroplasty | Elbow joint destruction compromising daily living | Post-traumatic lesions contributing to elbow instability | Bone loss contributing to elbow instability | Ankylosed joints including bilateral ankylosis from non-septic causes | Advanced rheumatoid arthritis with incapacitating pain | Post-traumatic arthritis with incapacitating pain | Degenerative arthritis with incapacitating pain | Instability or loss of motion when joint or soft tissue damage precludes reliable osteosynthesis | Acute comminuted articular fracture of elbow joint surfaces (including 13-C3 distal humerus fractures),"Active or repeated local infection at the surgical site | Current major infection distant from the operative site | History of prior sepsis | Paralysis or dysfunctional neuropathy at the elbow joint | Significant ipsilateral hand dysfunction | Excessive scarring near the surgical site preventing adequate soft tissue coverage | Daily activities that place significant stress on an implanted device (heavy labor, torsional stress, competitive sports) | Known alcohol or drug abuse | Known pregnancy",(none),ALL,C,"Disease matches (rheumatoid arthritis) and age/sex fit, but the trial targets candidates for total elbow arthroplasty/advanced RA with incapacitating elbow involvement, which is not specified for this patient; line/prior therapy requirements are not defined. No explicit exclusions are identified.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,C,"No hard exclusions. Disease (RA) matches. Stage/setting (candidate for total elbow arthroplasty/advanced elbow involvement) is not specified for the patient, so not a clear mismatch—just unknown. Other anchors (line/prior, biomarker, mets) are N/A/unknown. With 0 clear anchor matches and no soft conflicts, C is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT03283878,0.6045668125152588,Rheumatoid Arthritis,"Perioperative Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty: A Prospective, Randomized, Open-label, Controlled Multi-center Trial",PHASE4,18 years,Knee Osteoarthritis; Inflammatory Arthritis; Avascular Necrosis; Posttraumatic Arthritis,"Age >= 18 years | No open wounds on operative leg | Elective total knee arthroplasty for posttraumatic arthritis, osteoarthritis, avascular necrosis, or inflammatory arthritis | No active infection in the operative leg or joint",Age <= 18 years | Pregnancy | Psychiatric disorder that precludes safe participation | Emergent or urgent total knee arthroplasty for traumatic injury | Active infection in the operative leg or joint | Severe dementia | Suspicion of illicit drug abuse | ASA score 5–6 | Use of topical antibiotic powder or antibiotic beads in the surgical wound | Intra-operative antibiotic re-dosing outside protocol or without excessive blood loss (<1500 mL) | History of prior native septic knee arthritis,(none),ALL,C,"Rheumatoid arthritis fits the trial’s inflammatory arthritis cohort, and age/sex meet criteria. However, it is unknown whether she is undergoing elective total knee arthroplasty and meets perioperative requirements (e.g., no active leg infection), so key stage/setting criteria are not confirmed.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,C,"No hard exclusions. Disease fits under inflammatory arthritis; age/sex OK. Stage/setting (undergoing elective TKA) is unknown, and other anchors are N/A/unknown. With 0 confirmed core anchors and no soft mismatch, C is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT03726554,0.5769773125648499,Rheumatoid Arthritis,Comprehensive Reverse Shoulder: Porous Augmented Glenoid Baseplate and Mini Humeral Tray Post-Market Clinical Follow-up Study,NA,18 years,Shoulder Arthropathy; Rotator Cuff Deficiency; Shoulder Osteoarthritis; Post-Traumatic Arthritis; Rheumatoid Arthritis,Age >= 18 years | Anatomically and structurally suited to receive the implants | Functional deltoid | Grossly deficient rotator cuff with severe arthropathy | Previously failed shoulder joint replacement with a grossly deficient rotator cuff,Osteoporosis | Metabolic disorder that may impair bone formation | Osteomalacia | Distant foci of infection that may spread to the implant site | Rapid joint destruction | Marked bone loss | Bone resorption on radiograph,(none),ALL,C,"Disease (rheumatoid arthritis) matches and age/sex fit. However, this is a surgical device study requiring severe shoulder rotator cuff arthropathy/deficiency or failed shoulder replacement, and the patient’s shoulder status and surgical setting are not documented.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,C,"No hard exclusions: disease (RA) is listed; age/sex fit; exclusions not triggered. Core anchors: stage/setting (surgical shoulder pathology) unknown; line/prior exposure not applicable/unknown; required subtype (rotator cuff deficiency/severe shoulder arthropathy) unknown; mets pattern not relevant. With 0 anchors matched and no soft mismatch, C is appropriate. The grader’s reasoning aligns with this.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT03944447,0.5730265974998474,Crohn's Disease,Outcomes Mandate National Integration With Cannabis as Medicine,PHASE2,7 years,Amyotrophic Lateral Sclerosis; Anxiety; Autism; Bipolar Disorder; COVID-19; Cancer; Chronic Pain; Chronic Pain Due to Injury; Chronic Pain Due to Trauma; Chronic Pain Syndrome; Chronic Traumatic Encephalopathy; Crohn Disease; Depression; Epilepsy; Fibromyalgia; Glaucoma; HIV/AIDS; Hepatitis C; Inflammatory Bowel Diseases; Insomnia; Multiple Sclerosis; Opioid-use Disorder; Parkinson Disease; Post Traumatic Stress Disorder; SARS-CoV Infection; Seizures; Sickle Cell Disease; Tourette Syndrome; Traumatic Brain Injury; Ulcerative Colitis,Clinical diagnosis of a qualifying condition for medical marijuana | Age >= 18 years or with parental/legal guardian consent per state law,Pregnancy | Breastfeeding | Active suicidality | Psychosis that could be exacerbated by cannabis,(none),ALL,C,"Disease matches (Crohn’s) with age/sex eligible and no conflicting exclusions. However, the trial doesn’t specify stage/setting or prior-therapy requirements, so no core anchors can be confirmed.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,C,"No hard exclusions apply. Disease matches (Crohn’s). Core anchors (stage/setting, line/prior, biomarkers, mets pattern) are unspecified/not applicable, yielding 0 confirmed matches and no soft mismatches. Grade C is appropriate per rubric.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT04684602,0.5959930419921875,Dementia,"Evaluation of the Safety, Tolerability and Efficacy of Regenerative Therapy for the Treatment of Various Chronic and Acute Conditions",PHASE1/PHASE2,18 years,Autoimmune Disease; Cardiovascular Disorder; Diabetes Complication; Integumentary Disease; Musculoskeletal Disorder; Neurodegenerative Disorder; Neurologic Disorder; Pulmonary Disorder; Sexual Dysfunction; Urologic Disorder; Viral Illness,Age >= 18 years,Active or recent malignancy within 2 years | Pregnancy or breastfeeding,(none),ALL,C,"The trial targets neurodegenerative disorders, which encompasses dementia, and the patient meets broad age and gender criteria with no explicit exclusions noted. However, stage/setting and line-of-therapy requirements are not specified, leaving core anchors largely unknown.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,C,"No hard exclusions apply. Disease broadly matches under neurodegenerative disorders. Stage/setting and line/prior are unspecified, and no biomarker or mets constraints are required, leaving 0 anchors matched without soft conflicts. Grade C is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT04704544,0.7276947498321533,Rheumatoid Arthritis,Effectiveness of Tele-rheumatology for Delivering High Quality Rheumatology Care During the COVID-19 Crisis,NA,18 years,Rheumatic Disease,"Diagnosis of rheumatic disease (e.g., rheumatoid arthritis, systemic lupus erythematosus)","Unstable rheumatic disease requiring in-person visits (e.g., recent diagnosis of severe lupus nephritis) | Expected need for in-office procedures (e.g., joint injection) | Lack of access to a phone",(none),ALL,C,"Rheumatoid arthritis is included and the patient meets age/sex with no specified prior-therapy restrictions. However, core anchors like stage/setting and line/prior exposure are not defined for this trial, so no specific anchor can be confirmed as a match, and there are no clear soft conflicts.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,C,"No hard exclusions: RA fits rheumatic disease; age/sex OK; exclusions not triggered by known data. Core anchors are largely undefined: stage/setting for telemedicine not specified for patient; line/prior exposure has no trial constraints. With 0 anchor matches and no soft conflicts, C is appropriate.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05224089,0.5924150943756104,Crohn's Disease,Bilateral Mid-Abdominal Transverse Abdominis Plane and Rectus Sheath Blocks Comparing The Use of Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy Procedures.,PHASE4,18 years,Bowel Disease,Elective laparoscopic colectomy planned | American Society of Anesthesiology (ASA) physical status I–IV,"Emergency laparoscopic colectomy | Distant metastatic cancer | Planned multi-organ resection in addition to colectomy | Contraindications to TAP or rectus sheath blocks (anatomical abnormality, prior surgery preventing bilateral blocks, or infection at injection site) | Current colostomy | Allergy to local anesthetics | Coagulopathy or on antithrombotic therapy contraindicating single-shot peripheral nerve block per ASRA guidelines | Weight < 40 kg | Chronic long-acting opioid therapy or continuous opioid > 50 MME/day for >= 30 days within 90 days preoperatively, or chronic pain syndrome with recent preoperative pain consultation | Current substance abuse or within 3 months, including excessive alcohol use as defined by protocol | Pregnant, nursing, or planning pregnancy during the study or within 1 month postoperatively | Refusal or inability to provide consent",(none),ALL,C,"Crohn’s disease falls under the trial’s broad 'bowel disease' scope and the patient meets age/sex allowances, but the trial requires an elective laparoscopic colectomy with perioperative nerve blocks, which is not specified for this patient. Line/prior therapy and biomarker requirements are not applicable, leaving core anchors largely unknown.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,C,"No hard exclusions apply (age/sex ok; no explicit exclusions triggered; required surgical setting not confirmed but not definitively lacking). Disease can be considered within the trial’s broad “Bowel Disease.” Core anchors: stage/setting is unknown (surgery not specified), others N/A, yielding 0 matches and no soft mismatch. Grade C is appropriate.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06111131,0.5416669249534607,Crohn's Disease,A Randomized Controlled Trial to Demonstrate the Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures for Diagnosis and Treatment in the Small Intestine,NA,18 years to 90 years,Small Bowel Disease,Meets safety criteria for single-balloon enteroscopy: ASA Class I–III | Age >= 18 years and <= 90 years | Video capsule endoscopy shows lesions in the middle third of the small bowel,History of gastric bypass or related procedures | History of foregut and/or midgut surgery | Pathology located in the proximal one-third of the small bowel | Pathology located in the distal one-third of the small bowel | Anticoagulant or antiplatelet therapy that cannot be stopped for the enteroscopy | Capsule endoscopy without clear visualization of pathology in the middle small bowel | Inability to tolerate the investigator's standard-of-care sedation method | Previous small bowel surgery or anastomosis causing extensive adhesions and/or altered anatomy | Allergy to medications or products used in the endoscopic procedure not preventable with pre-medication | Pregnancy | Life expectancy < 6 months,(none),ALL,C,"This device trial requires capsule evidence of mid–small-bowel lesions for single-balloon enteroscopy; the patient’s Crohn’s profile (perianal fistula, CDAI 350) does not confirm small-bowel involvement or capsule findings. Age and sex fit and there are no explicit exclusions noted, but key eligibility details are unknown, so match is uncertain.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,C,"No hard exclusions: age/sex fit; disease category plausibly overlaps (Crohn’s can be a small bowel disease), and required mid–small-bowel lesion on capsule is unknown, not a definitive mismatch. Core anchors: stage/setting and line/prior not applicable; required lesion criterion unknown; no soft conflicts identified. With 0 confirmed anchor matches and no soft mismatch, grade C is appropriate.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06112353,0.581324577331543,Crohn's Disease,"Sugammadex VS Neostigmine and Glycopyrrolate Reversal of Neuromuscular Relaxation For Time to Return of Bowel Function After Bowel Resection: Prospective, Randomized, Triple-blinded Clinical Trial For Quality Improvement",PHASE4,18 years,Intestinal Disease,Age >= 18 years | Undergoing laparoscopic bowel resection surgery | General anesthesia with nondepolarizing neuromuscular blockade using rocuronium or vecuronium | Requires inpatient admission,Allergy to rocuronium | Allergy to vecuronium | Allergy to sugammadex | Bowel resection requiring an ostomy | Severe valvulopathy | Systolic heart failure with reduced ejection fraction (HFrEF) | Coronary artery disease with positive stress test for ischemic regional wall motion abnormality | Autoimmune pulmonary disease | Severe pulmonary fibrosis | Severe pulmonary hypertension | COPD requiring home oxygen | Pulmonary cancer (primary or metastatic) | Creatinine clearance < 30 mL/min | Pregnancy | Incapable of providing informed consent or understanding the research project,(none),ALL,C,"Crohn's disease falls under the trial’s broad 'intestinal disease' scope, but the trial specifically requires patients undergoing laparoscopic bowel resection with specified anesthesia, which is unknown for this patient. No explicit exclusions apply based on the provided data.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,C,"No hard exclusions. Crohn’s fits under the trial’s broad “intestinal disease.” The key required setting (undergoing laparoscopic bowel resection with specified anesthesia) is unknown for the patient, and other anchors are not applicable. With 0 anchors confirmed and no soft mismatch, grade C is appropriate per the rubric.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT07138898,0.6021736860275269,Rheumatoid Arthritis,Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty,PHASE2,18 years,Rheumatoid Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Systemic Lupus Erythematosus; Juvenile Idiopathic Arthritis; Spondyloarthritis; Polymyalgia Rheumatica; Giant Cell Arteritis; Vasculitis; Granulomatosis With Polyangiitis; Dermatomyositis; Polymyositis; Inflammatory Bowel Disease-Associated Arthritis,"Age >= 18 years | Diagnosis of rheumatic disease (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, juvenile idiopathic arthritis, spondyloarthritis, polymyalgia rheumatica, giant cell arteritis, vasculitis, granulomatosis with polyangiitis, dermatomyositis, polymyositis, inflammatory bowel disease-associated arthritis) | On active immunosuppression for >= 3 months prior to scheduled surgery | Scheduled for elective total shoulder arthroplasty",Active infection | Active malignancy | Shoulder arthroplasty indication is fracture or tumor | Pregnancy or breastfeeding | Severe systemic lupus erythematosus with marked activity,On active immunosuppression for >= 3 months,ALL,C,"Disease (RA), age, and sex align, but key requirements—being on active immunosuppression for ≥3 months and being scheduled for elective total shoulder arthroplasty—are not provided, so core setting/prior-therapy anchors are unknown.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,C,"No hard exclusions. Disease matches. Key CORE ANCHORS (stage/setting: scheduled elective shoulder arthroplasty; line/prior: on active immunosuppression ≥3 months) are unknown from patient data, with no soft mismatches identified. Thus 0 anchors match → C.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02122185,0.8480544686317444,Recurrent Clear Cell Ovarian Carcinoma,"A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction With Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer",PHASE2,18 years,Ovarian Epithelial Cancer (Stage III–IV); Fallopian Tube Cancer (Stage III–IV); Primary Peritoneal Cancer (Stage III–IV); Ovarian Serous Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Clear Cell Carcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Undifferentiated Adenocarcinoma; Brenner Tumor,"Age >= 18 years | ECOG performance status <= 2 | Leukocytes >= 3,000/µL | Absolute neutrophil count >= 1,500/µL | Platelets >= 100,000/µL | Total bilirubin <= 1 x ULN (Gilbert syndrome allowed) | AST <= 2.0 x ULN | ALT <= 2.0 x ULN | Creatinine <= 1 x ULN or creatinine clearance >= 60 mL/min | Fasting blood glucose <= 126 mg/dL or nonfasting glucose <= 140 mg/dL | Histologically confirmed carcinoma consistent with ovarian, fallopian tube, or primary peritoneal carcinoma | Stage III or IV disease with gross macroscopic residual disease after primary debulking surgery | For planned neoadjuvant chemotherapy: cytology or biopsy showing adenocarcinoma and CA-125 > 250 or CA-125:CEA ratio > 25 or CA-125 <= 250 with no evidence of GI cancer; presumed stage III or IV based on carcinomatosis/effusions/ascites | Agreement to receive 6–8 cycles of an allowed standard chemotherapy regimen as specified | Women of child-bearing potential agree to use effective non-hormonal contraception during the study","Known diabetes mellitus or fasting glucose > 126 mg/dL or random glucose > 140 mg/dL | Current use of metformin, sulfonylureas, thiazolidinediones, or insulin | Use of other investigational agents | Comorbidities with expected survival < 2 years unrelated to ovarian cancer | Concurrent active invasive malignancy or prior malignancy with > 30% risk of recurrence within 2 years | Allergy to metformin or compounds of similar composition | NYHA class III or IV heart failure | History of any acidosis | Alcoholic liver disease | Habitual intake of >= 3 alcoholic beverages per day | Uncontrolled intercurrent illness (e.g., active major infection, unstable angina, symptomatic CHF, significant arrhythmia, psychiatric illness limiting compliance) | Pregnant or nursing | Mucinous adenocarcinoma or borderline tumors | Planned intraperitoneal chemotherapy | Neoadjuvant chemotherapy without planned interval debulking surgery (assuming adequate response) | Planned chemotherapy regimens not specified in the protocol | Participation in other interventional trials to reduce ovarian cancer recurrence or planned off-protocol maintenance therapy (e.g., paclitaxel or bevacizumab)",(none),FEMALE,D,"Disease and age/sex match, but the trial is for newly diagnosed stage III–IV patients starting first-line chemotherapy (with gross residual disease or planned interval debulking), whereas this patient has recurrent disease after prior debulking and adjuvant carboplatin/paclitaxel/bevacizumab; thus stage/setting and prior-therapy requirements are not met.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,D,"No hard exclusions apply. Disease, sex, and age match, but there is a clear soft mismatch on stage/setting (trial is for newly diagnosed first-line advanced disease) and line/prior exposure (patient is recurrent post adjuvant chemo ± bevacizumab). Per rubric, any clear soft mismatch on a core anchor → D.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT02266745,0.9999508261680603,Metastatic Castration-Resistant Prostate Cancer,"A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts",PHASE2,18 years,Metastatic Castration-Resistant Prostate Cancer,"Male >= 18 years of age | Histologically or cytologically confirmed adenocarcinoma of the prostate | Metastatic castration-resistant prostate cancer with documented metastatic lesions on bone scan or CT/MRI | Received at least three prior intended life-prolonging therapies for metastatic disease | ECOG 0-1 | Progressive disease by RECIST v1.1 or PCWG3 or by informative tumor markers | Adequate organ function | If known history of brain metastases, disease must be stable",Cytotoxic chemotherapy within 21 days prior to initiation of study drug | Immunomodulatory drug therapy within 14 days prior to initiation of study drug | Anti-neoplastic hormonal therapy within 14 days prior to initiation of study drug | Immunosuppressive therapy within 14 days prior to initiation of study drug | Corticosteroids within 14 days prior to initiation of study drug | Growth factor treatment within 14 days prior to initiation of study drug | Inadequate bone marrow reserve | Radiotherapy within 14 days prior to baseline | Radiotherapy to >25% of active bone marrow | Major surgery within 28 days prior to initiation of study drug,At least three prior intended life-prolonging therapies for metastatic disease; Washout: cytotoxic chemotherapy >= 21 days before study drug; Washout: immunomodulatory drugs >= 14 days before study drug; Washout: anti-neoplastic hormonal therapy >= 14 days before study drug; Washout: immunosuppressive therapy >= 14 days before study drug; Washout: corticosteroids >= 14 days before study drug; Washout: growth factors >= 14 days before study drug; Washout: radiotherapy >= 14 days before baseline; Washout: major surgery >= 28 days before study drug,MALE,D,"Stage and disease match (male, mCRPC with progression), but the trial requires at least three prior life-prolonging therapies for metastatic disease and only enzalutamide and abiraterone are documented. Other criteria (washouts, ECOG, imaging modality) are unknown.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,D,"No hard exclusions. Disease and stage match (mCRPC, male, age OK). Clear soft mismatch on line-of-therapy: trial requires ≥3 prior life-prolonging therapies; patient has only two documented (abiraterone and enzalutamide). Per rubric, a soft mismatch on a core anchor → D.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03036098,0.852511465549469,Metastatic Urothelial Carcinoma,"A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer",PHASE3,18 years,Urothelial Cancer (metastatic),"Histological or cytological evidence of metastatic or surgically inoperable transitional cell carcinoma of the urothelium (renal pelvis, ureter, bladder, or urethra) | No prior systemic chemotherapy for metastatic or surgically inoperable urothelial cancer | ECOG performance status 0 or 1","Disease suitable for local therapy with curative intent | Serious or uncontrolled medical disorder that may increase risk or interfere with study participation or interpretation | Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibodies, or other agents targeting T-cell co-stimulation or checkpoint pathways",(none),ALL,D,"While the disease and age/sex match, the trial is for previously untreated metastatic urothelial cancer with no prior systemic therapy, whereas the patient is after second-line therapy, creating a line-of-therapy mismatch.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,D,"No hard exclusions apply (disease/age/sex match; exclusion about prior PD-1 use is unknown). Clear soft mismatch on the line-of-therapy anchor: trial requires previously untreated metastatic disease, while patient is after second-line therapy. Stage matches. Thus D is appropriate per rubric.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT03517969,0.8671190142631531,Metastatic Castration-Resistant Prostate Cancer,"A Phase 2 Study of M6620 (VX-970, Berzosertib) in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate Cancer",PHASE2,18 years,Castration-Resistant Prostate Cancer (metastatic),"Histologically or cytologically confirmed prostate cancer with progressive disease (rising PSA or radiographic progression) | Metastatic disease on imaging and castrate testosterone < 50 ng/dL | Baseline PSA >= 2.0 ng/mL or measurable disease per RECIST 1.1 | Maintain castrate state (LHRH/GnRH therapy if no orchiectomy unless intolerant) | At least 2 prior treatments for castration-resistant prostate cancer | Prior progression or intolerance to at least one secondary hormonal therapy (e.g., abiraterone, enzalutamide, apalutamide, darolutamide, etc.) | Prior progression or intolerance to taxane-based chemotherapy | ECOG performance status <= 1 | Leukocytes >= 3,000/µL | Absolute neutrophil count >= 1,500/µL | Hemoglobin >= 9 g/dL | Platelets >= 150,000/µL | Total bilirubin <= 1.5 x ULN (except Gilbert syndrome) | AST <= 2.5 x ULN (<= 5 x ULN if liver metastases) | ALT <= 2.5 x ULN (<= 5 x ULN if liver metastases) | Creatinine clearance >= 40 mL/min | Prior treatment with mTOR inhibitors, TKIs, or biologic therapies allowed | Prior treatment with PARP inhibitors permitted | Lesion amenable to image-guided core biopsy for NGS prior to cycle 1 day 1 (may be waived per PI if required)","Chemotherapy or radiotherapy within 4 weeks prior to cycle 1 day 1 (6 weeks for nitrosoureas or mitomycin C) | Oral antineoplastic agents (including oral hormonal agents, PARP inhibitors, oral experimental agents) not discontinued >= 14 days prior to cycle 1 day 1 | Residual toxicities > grade 1 from prior therapy (except grade 2 anorexia, alopecia, neuropathy, or fatigue) | Concurrent treatment with other investigational agents | Known brain metastases or leptomeningeal disease | History of allergic reactions to compounds similar to berzosertib or carboplatin | Use of ototoxic or nephrotoxic medications that cannot be discontinued >= 7 days before first carboplatin dose and during study | Concomitant strong CYP3A4 inhibitors or inducers prohibited with berzosertib | Uncontrolled intercurrent illness (e.g., active infection, symptomatic CHF, unstable angina, significant arrhythmia, significant psychiatric illness) | Pregnant or nursing women | HIV-positive with detectable viral load and/or CD4 count <= 300/µL, or on interacting antiretroviral therapy | Prior platinum-containing regimen or prior ATR inhibitor for prostate cancer","Progression or intolerance to at least one secondary hormonal therapy required; Progression or intolerance to taxane-based chemotherapy required; Prior mTOR inhibitors, TKIs, or biologic therapies allowed; Prior PARP inhibitors permitted; Washout: chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to cycle 1 day 1 not allowed; Washout: oral antineoplastic agents discontinued >= 14 days prior to cycle 1 day 1",MALE,D,"The disease and metastatic CRPC setting match, but the trial requires prior progression/intolerance to taxane-based chemotherapy, which is not documented; the patient has only received abiraterone and enzalutamide.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,D,"No hard exclusions. Disease and metastatic CRPC setting match. The trial requires prior progression/intolerance to taxane-based chemotherapy, which the patient’s listed prior therapies do not include, creating a clear soft mismatch on the Line/prior anchor. Therefore D is appropriate.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03582475,0.7541158199310303,Metastatic Urothelial Carcinoma,Phase Ib Trial of Pembrolizumab (MK-3475) With Platinum-Based Chemotherapy in Small Cell/Neuroendocrine Cancers of Urothelium and Prostate,PHASE1,18 years,Small Cell Bladder Carcinoma; Small Cell Urethral Carcinoma; Small Cell Ureter Carcinoma; Small Cell Prostate Carcinoma; Prostate Neuroendocrine Neoplasm,"Histologically confirmed locally advanced or metastatic small cell cancer of the bladder, urethra, or upper urinary tract, or primary small cell/neuroendocrine prostate cancer | Measurable disease per RECIST 1.1 | Archival or newly obtained tumor tissue available (FFPE preferred) | ECOG performance status 0–1 | Adequate hematologic and organ function per protocol labs","Disease suitable for curative local therapy | Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, or other T-cell co-regulatory agents (e.g., CTLA-4, OX40, CD137) | Prior systemic anticancer therapy within 4 weeks before first dose or unresolved toxicities > grade 1 (except <= grade 2 neuropathy) | Major surgery without adequate recovery prior to study treatment | Radiotherapy within 2 weeks before start of study treatment (1-week washout allowed for palliative <= 2 weeks non-CNS radiation) | Live vaccine within 30 days before first dose | Participation in another investigational study or use of an investigational device within 4 weeks before first dose | Immunodeficiency or chronic systemic steroids > 10 mg prednisone equivalent daily or other immunosuppressive therapy within 7 days before first dose | Another active malignancy requiring treatment within the past 3 years (except certain skin cancers or carcinoma in situ) | Active CNS metastases or carcinomatous meningitis (previously treated stable brain metastases allowed without steroids) | Severe hypersensitivity to pembrolizumab | Active autoimmune disease requiring systemic treatment within the past 2 years | History of pneumonitis requiring steroids or current pneumonitis | Active infection requiring systemic therapy | Known HIV infection | Active hepatitis B or active hepatitis C infection | Active tuberculosis | Pregnant or breastfeeding","Cohort 1: No prior systemic chemotherapy for locally advanced/metastatic urothelial carcinoma; prior platinum-based chemotherapy allowed if recurrence > 12 months after completion; Cohort 2: No prior systemic chemotherapy for primary small cell prostate cancer; prior platinum-based chemotherapy allowed if recurrence > 12 months after completion; Cohort 2: Prior mCRPC treatments allowed, including up to 2 prior chemotherapy agents if > 6 months since last dose (docetaxel used twice counts as 1 therapy); Cohort 2: Ongoing androgen deprivation therapy with up to 2 second-generation hormonal agents (e.g., abiraterone, enzalutamide) permitted; Cohort 2: Ongoing bone-targeted therapy (denosumab or zoledronic acid) permitted; Cohort 2: Prior sipuleucel-T allowed if completed > 4 weeks before enrollment; Washout: No systemic anticancer therapy (including investigational agents) within 4 weeks before first dose; Washout: No radiotherapy within 2 weeks before start (1-week washout allowed for palliative <= 2 weeks non-CNS)",ALL,D,"The trial requires first-line therapy for metastatic small cell/neuroendocrine urothelial disease, but the patient is post–second-line, creating a line-of-therapy mismatch. Additionally, the required small cell/neuroendocrine histology is not specified for the patient, so eligibility on subtype is uncertain.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,D,"No hard exclusions apply (age/sex ok; subtype unknown so not an F). There is a clear soft mismatch on line-of-therapy because the trial’s urothelial cohorts require no prior systemic therapy for metastatic disease, while the patient is post–second-line. Stage (metastatic) is compatible, but the soft mismatch triggers D. The grader’s reasoning aligns with the rubric.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03737994,0.8366274833679199,Metastatic Non-Small Cell Lung Cancer,A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol,PHASE2,18 years,Non-Squamous Non-Small Cell Lung Cancer (metastatic),"Histologically or cytologically confirmed stage IV ALK-positive non-squamous NSCLC | ALK rearrangement demonstrated by FDA-approved assay (FISH or IHC) or by NGS | Willing and able to undergo a fresh biopsy or provide recent post-progression biopsy with sufficient tissue | Progressive disease per RECIST 1.1 after exactly one second-generation ALK inhibitor (ceritinib, alectinib, ensartinib, or brigatinib) | Prior crizotinib allowed; the second-generation ALK inhibitor must be the last treatment before enrollment | No prior chemotherapy except one prior cycle at initial metastatic diagnosis without progression; adjuvant/neoadjuvant chemotherapy allowed if last dose >12 months before enrollment | ANC >= 1500/µL within 28 days prior to Step 2 | Platelets >= 100000/µL within 28 days prior to Step 2 | Creatinine clearance >= 60 mL/min within 28 days prior to Step 2 | Total bilirubin <= 1.5 x ULN within 28 days prior to Step 2 (except Gilbert's syndrome) | AST <= 2.5 x ULN within 28 days prior to Step 2 (<= 5 x ULN with liver metastases) | ALT <= 2.5 x ULN within 28 days prior to Step 2 (<= 5 x ULN with liver metastases) | Asymptomatic treated or untreated brain metastases allowed; measurable extracranial target lesion required if brain metastases present; stable/decreasing steroids for >= 7 days | ECOG performance status 0-2 | Acute effects of prior therapy resolved to baseline or CTCAE <= 1 (except alopecia, hearing loss) | Able to take oral medications","Prior lorlatinib (third-generation ALK inhibitor) | Major surgery within 2 weeks before study entry | Palliative radiotherapy (< 10 fractions) within 48 hours before study entry | Stereotactic/small field brain irradiation within 1 week before study entry | Whole brain or other palliative radiotherapy within 2 weeks before study entry | Dose of next-generation ALK inhibitor (ceritinib, alectinib, ensartinib, lorlatinib) within 5 days before Step 2; brigatinib within 7 days before Step 2 | History of interstitial lung disease or interstitial fibrosis (including pneumonitis, obliterative bronchiolitis, pulmonary fibrosis) | Active inflammatory gastrointestinal disease or conditions affecting absorption (e.g., Crohn's disease, ulcerative colitis), chronic diarrhea, symptomatic diverticular disease | Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, NYHA class 3 heart failure, unstable angina, poorly controlled arrhythmia, recent MI within 6 months) | Active and clinically significant bacterial, fungal, or viral infection | Active or chronic pancreatitis | Other serious illness or organ dysfunction that could compromise safety or study drug evaluation | Planned receipt of other investigational agents during therapy | Active malignancy other than ALK-positive NSCLC within 2 years, except specified adequately treated cancers | No chemotherapy and/or immunotherapy allowed after Step 1 registration | Pregnant or breastfeeding","Progression after one second-generation ALK inhibitor required (ceritinib, alectinib, ensartinib, or brigatinib); Prior crizotinib allowed; No prior lorlatinib allowed; No prior chemotherapy except one cycle at initial metastatic diagnosis without progression; Prior adjuvant or neoadjuvant chemotherapy allowed if last dose > 12 months before enrollment; No chemotherapy or immunotherapy permitted after Step 1 registration",ALL,D,"Disease setting (metastatic NSCLC) matches, but the trial requires ALK-positive disease with progression after exactly one second-generation ALK inhibitor as the most recent therapy. The patient has EGFR exon 19-mutant NSCLC treated with osimertinib and no prior ALK inhibitor exposure documented, making them likely ineligible.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,D,"No hard exclusions apply (ALK status unknown, age/sex OK). Stage/setting matches. There is a clear soft mismatch on line/prior exposure: trial requires progression after a second-generation ALK inhibitor, while patient received osimertinib (EGFR TKI) with no ALK inhibitor. Per rubric, any anchor soft mismatch → D. Grader’s reasoning aligns.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT03926520,0.7645418643951416,Dementia,Effect and Safety of Electroconvulsive Therapy Plus Usual Care for the Acute Management of Severe Agitation in Dementia,NA,40 years,Alzheimer Dementia; Vascular Dementia; Frontotemporal Dementia; Dementia with Lewy Bodies,"Diagnosis of Alzheimer's dementia per NIA-AA criteria | Diagnosis of vascular dementia with MRI evidence of microvascular ischemic disease and no clinical/radiologic evidence of stroke | Diagnosis of frontotemporal dementia | Diagnosis of dementia with Lewy bodies | Mini-Mental State Examination (MMSE) <= 15 | Cohen-Mansfield Agitation Inventory (CMAI) threshold for severe agitation as specified | At least one failed pharmacological intervention to manage behavioral symptoms | Medically stable for safe ECT based on physical exam, urinalysis, and serum chemistries (and brain imaging when indicated) | Comprehension of English | Authorized legal representative able and willing to provide informed consent | Age >= 40 years","Current co-morbid delirium by Confusion Assessment Method (CAM) or clinical diagnosis | Vascular dementia due to stroke (abrupt onset, step-wise decline, MRI evidence of hemorrhagic/embolic stroke, or exam consistent with current/prior stroke) | Schizophrenia | Bipolar disorder | Schizoaffective disorder | Active substance use disorder within the past 6 months | Treatment with ECT, transcranial magnetic stimulation, or vagal nerve stimulation within the past 3 months",At least one failed pharmacological intervention for behavioral symptoms,ALL,D,"MMSE 19 exceeds the trial’s inclusion threshold (<=15), and the study requires severe agitation with at least one failed pharmacologic intervention for behavioral symptoms—neither is supported by the provided profile (no prior behavioral therapy, agitation not documented). Age and sex fit, and dementia subtype is unspecified but not an explicit exclusion.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,D,"No hard exclusions apply (age/sex ok; disease subtype unspecified so not an explicit mismatch; exclusions not triggered). There are clear soft mismatches on core anchors: required stage/severity (MMSE <=15 and severe agitation) not met (MMSE 19, agitation not documented) and required prior failed behavioral pharmacotherapy absent. Thus D per rubric.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04154956,0.8322389125823975,Metastatic Non-Small Cell Lung Cancer,"Randomized, Open-label, Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated, Metastatic Nonsquamous, Non-small-cell Lung Cancer Patients With CEACAM5-positive Tumors",PHASE3,18 years,Non-squamous Non-small Cell Lung Cancer (metastatic),Histologically or cytologically confirmed non-squamous non-small cell lung cancer with metastatic disease | Progression after platinum-based chemotherapy | Progression after an immune checkpoint inhibitor | CEACAM5 expression >=2+ in >=50% of tumor cells by IHC (central lab) | At least one measurable lesion per RECIST v1.1 | ECOG performance status 0-1,"Untreated brain metastases or history of leptomeningeal disease; if previously treated brain metastases, no documented non-progressive disease on imaging >=4 weeks after CNS therapy and >=2 weeks before first dose | Significant concomitant illnesses that would impair participation or interpretation | Invasive malignancy within 3 years other than cured local tumors (e.g., resected/ablated basal or squamous cell skin cancer or cervical carcinoma in situ) | Unresolved prior treatment-related toxicity >= grade 2 (except alopecia, vitiligo, or controlled thyroiditis) | Known AIDS-related illnesses or HIV requiring antiretroviral therapy, or unresolved viral hepatitis | History of and/or unresolved corneal disorders; contact lens use not permitted | Concurrent anticancer therapy | Prior treatment with docetaxel, maytansinoid ADCs (DM1 or DM4), or any CEACAM5-targeting drug | Contraindication to corticosteroid premedication | Poor bone marrow, liver, or kidney function | Hypersensitivity to study interventions or components (including EDTA, paclitaxel, polysorbate 80)",Progression after platinum-based chemotherapy; Progression after immune checkpoint inhibitor,ALL,D,"Stage and performance status match, but the trial requires prior progression after both platinum chemotherapy and an immune checkpoint inhibitor, whereas the patient has only received osimertinib. CEACAM5-positive status and nonsquamous histology are also required but not provided, further limiting eligibility.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,D,"No hard exclusions apply. Disease matches and stage/setting (metastatic, previously treated) matches, but there is a clear soft mismatch on line/prior-exposure since the trial requires progression after platinum chemo and an immune checkpoint inhibitor, while the patient only had osimertinib. Biomarker/histology (CEACAM5+, nonsquamous) are unknown, not hard exclusions. Grade D is appropriate.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04225117,0.7794124484062195,Metastatic Non-Small Cell Lung Cancer,"An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)",PHASE2,18 years,Breast Cancer (HR+/HER2-); Triple Negative Breast Cancer; Squamous Non-Small Cell Lung Cancer; Non-squamous Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma,"Adult per local regulations | Measurable disease by RECIST 1.1 | Archival tumor tissue available or agree to biopsy (unless unsafe) | ECOG performance status 0–1 | Baseline labs meet protocol thresholds | Evidence of progression on or after last regimen | Locally advanced or metastatic disease not amenable to curative treatment | Cohort 1 (HR+/HER2- breast cancer): Histologically/cytologically confirmed HR+/HER2- and not a candidate for further hormonal therapy (ER and/or PR >= 1% per ASCO/CAP) | Cohort 1: Prior taxane or anthracycline in neoadjuvant/adjuvant or advanced setting | Cohort 1: >=1 prior standard cytotoxic regimen in advanced setting and <=2 prior cytotoxic lines in advanced setting; progressed/relapsed or discontinued for toxicity; prior endocrine and/or CDK inhibitor therapy with progression/toxicity (CDK inhibitor not required) | Cohort 2 (TNBC): Histologically/cytologically confirmed TNBC (ER-/PR- <1%, HER2 0–1+ or 2+ and FISH negative) | Cohort 2: Prior taxane or anthracycline; >=1 prior standard cytotoxic regimen in advanced setting and <=2 prior cytotoxic lines; prior anti-PD-1/PD-L1 per guidelines with progression/toxicity or contraindicated | Cohort 3 (Squamous NSCLC): Histologically/cytologically confirmed squamous NSCLC; mixed histology allowed if no neuroendocrine component; actionable mutations allowed if treated and progressed/toxic | Cohort 3: Progressed/relapsed or discontinued due to toxicity after 1 platinum-based regimen for advanced disease; <=2 prior cytotoxic lines in advanced setting; prior anti-PD-1/PD-L1 per guidelines with progression/toxicity or contraindicated | Cohort 4 (Non-squamous NSCLC): Histologically/cytologically confirmed non-squamous NSCLC; mixed histology allowed if no neuroendocrine component; actionable mutations allowed if treated and progressed/toxic | Cohort 4: Progressed/relapsed or discontinued due to toxicity after 1 platinum-based regimen for advanced disease; <=2 prior cytotoxic lines in advanced setting; prior anti-PD-1/PD-L1 per guidelines with progression/toxicity or contraindicated | Cohort 5 (Head and neck cancer, 2L+): Histologically/cytologically confirmed head and neck cancer of oral cavity, oropharynx, hypopharynx, or larynx (non-nasopharyngeal) | Cohort 5: Progressed/relapsed or discontinued due to toxicity after 1 platinum-based regimen for advanced disease; <=2 prior cytotoxic lines; prior anti-PD-1/PD-L1 per guidelines with progression/toxicity or contraindicated | Cohorts 6–8 (Gastric/GEJ/esophageal): Histologically/cytologically confirmed gastric, GEJ, or esophageal cancer; progressed/relapsed or discontinued due to toxicity after 1 platinum-based regimen for advanced disease; <=2 prior cytotoxic lines; HER2+ must have received HER2-directed therapy; prior anti-PD-1/PD-L1 per guidelines with progression/toxicity or contraindicated | Cohort 9 (1L HNSCC): Histologically/cytologically confirmed HNSCC of oral cavity, oropharynx, hypopharynx, or larynx (non-nasopharyngeal) | Cohort 9: Recurrent or metastatic and incurable by local therapy | Cohort 9: PD-L1 CPS >= 1 by local or central IHC | Cohort 9: No prior systemic therapy for recurrent/metastatic disease (allowed if >6 months since completion of systemic therapy given for locally advanced disease); prior PD-1/PD-L1 in curative setting allowed if >=12 months since last dose | Cohort 9: ANC >= 1.5 x 10^9/L | Cohort 9: INR or PT and aPTT <= 1.5 x ULN (unless on therapeutic anticoagulation) | Cohort 9: For oropharynx tumors, HPV status by p16 testing available","Preexisting sensory or motor neuropathy >= Grade 2 | Active CNS metastases unless clinically stable >=6 weeks, on <=20 mg/day prednisone equivalent if needed, no new/enlarged lesions, and no leptomeningeal disease | Ongoing clinically significant toxicity >= Grade 2 from prior therapy (except alopecia) | Ongoing >= Grade 3 immunotherapy-related hypothyroidism or panhypopituitarism; history of immunotherapy-related colitis, uveitis, myocarditis or pneumonitis; or immunotherapy-related AEs requiring >20 mg/day prednisone equivalent | Uncontrolled diabetes within 3 months (HbA1c >= 8% or 7% to <8% with diabetes symptoms) | Prior treatment with enfortumab vedotin or other MMAE-based ADCs | Second malignancy within 3 years or residual disease from prior malignancy (exceptions apply) | Active systemic infection requiring treatment; active hepatitis B or C; known HIV infection | Recent significant cardiovascular event within 6 months (stroke/TIA, unstable angina, MI, or NYHA III–IV heart failure) | Major surgery within 4 weeks before first dose | Prior radiotherapy, chemotherapy, biologics, investigational agents, or immunotherapy not completed >= 2 weeks before first dose | Known hypersensitivity to enfortumab vedotin or CHO cell products/excipients | Active keratitis or corneal ulcerations (adequately treated superficial punctate keratitis allowed) | Any condition that makes the subject unsuitable for study participation | Cohort 9: Disease progression within 6 months of completing curative systemic therapy for locoregionally advanced HNSCC | Cohort 9: Prior allogeneic tissue/solid organ transplant | Cohort 9: Severe hypersensitivity (>= Grade 3) to pembrolizumab or its excipients | Cohort 9: History of non-infectious pneumonitis/ILD requiring steroids or current pneumonitis/ILD | Cohort 9: Idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced/idiopathic pneumonitis, or active pneumonitis on screening CT | Cohort 9: Life expectancy < 3 months or rapidly progressing disease per investigator | Cohort 9: Active autoimmune disease requiring systemic treatment in past 2 years (specified exceptions allowed) | Cohort 9: Active infection requiring systemic therapy | Cohort 9: Prior anti-PD-1/PD-L1 therapy in the recurrent/metastatic setting (if given as curative therapy, must be >= 1 year since last dose) | Cohort 9: Live vaccine within 30 days before start of therapy | Cohort 9: Active tuberculosis",Breast cancer (HR+/HER2- or TNBC): Prior taxane or anthracycline in neoadjuvant/adjuvant or advanced setting; Breast cancer HR+: >=1 prior cytotoxic regimen in advanced setting; <=2 prior cytotoxic lines; progression after endocrine therapy and/or CDK inhibitor (CDK inhibitor not required); TNBC: >=1 prior cytotoxic regimen in advanced setting; <=2 prior cytotoxic lines; prior anti-PD-1/PD-L1 with progression/toxicity or contraindicated; Squamous and non-squamous NSCLC: Progressed/relapsed or toxic after 1 platinum-based regimen for advanced disease; <=2 prior cytotoxic lines; prior anti-PD-1/PD-L1 with progression/toxicity or contraindicated; actionable mutations treated with targeted therapy if present; Head and neck cancer (2L+): Progressed/relapsed or toxic after 1 platinum-based regimen; <=2 prior cytotoxic lines; prior anti-PD-1/PD-L1 with progression/toxicity or contraindicated; Gastric/GEJ/esophageal: Progressed/relapsed or toxic after 1 platinum-based regimen; <=2 prior cytotoxic lines; HER2+ must have received HER2-directed therapy; prior anti-PD-1/PD-L1 with progression/toxicity or contraindicated; All cohorts: Prior anti-cancer therapies completed >= 2 weeks before first dose,ALL,D,"Disease and stage match (metastatic NSCLC, ECOG 0), and EGFR-mutant disease is allowed after targeted therapy, but the NSCLC cohorts require prior platinum-based chemotherapy and prior PD-1/PD-L1 therapy (or documented contraindication), which the patient lacks—making line-of-therapy a soft mismatch.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,D,"No hard exclusions. Disease and metastatic setting match, but the NSCLC cohorts require prior platinum-based chemo and prior PD-1/PD-L1 (or contraindication) with progression, which the patient lacks. This is a clear line-of-therapy soft mismatch → D. The grader’s reasoning aligns with the rubric.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT04754087,0.8256611824035645,Rheumatoid Arthritis,"Global, Multicenter, and Prospective Post-Market Clinical Follow-Up Study of the G7 Acetabular System With Vivacit-E and Longevity Highly Crosslinked Polyethylene (HXLPE) Liners & Instrumentation",NA,18 years,Hip Avascular Necrosis; Hip Degenerative Joint Disease; Hip Fracture; Hip Osteoarthritis; Hip Rheumatoid Arthritis,"Adult with full skeletal maturity | Indicated for noninflammatory degenerative joint disease (including osteoarthritis and avascular necrosis) | Rheumatoid arthritis of the hip | Correction of functional deformity of the hip | Treatment of non-union, femoral neck fracture, or trochanteric fractures of the proximal femur with head involvement unmanageable by other techniques | Revision procedure where other treatment or devices have failed","Osteoporosis that may limit ability to support total hip arthroplasty | Metabolic disorder that may impair bone formation | Osteomalacia | Infection, sepsis, osteomyelitis, or distant foci of infection that may spread to the implant site | Rapid joint destruction, marked bone loss, or bone resorption on imaging | Vascular insufficiency, muscular atrophy, or neuromuscular disease | Current alcohol or drug abuse | Neurologic disorder with inability or unwillingness to follow directions | Pregnancy",(none),ALL,D,"While the patient has rheumatoid arthritis, this device study enrolls adults specifically indicated for total hip arthroplasty (e.g., rheumatoid arthritis of the hip). The patient’s profile does not indicate hip involvement or a surgical indication, creating a stage/setting mismatch; age and sex fit and no explicit exclusions are evident.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),INCORRECT,C,"No hard exclusions apply (age/sex fit; no explicit exclusions; disease potentially relevant as RA with possible hip involvement). The trial’s setting requires hip involvement/THA indication, which is not contradicted but simply unknown from the patient data. Per rubric, unknowns are neutral, not a soft mismatch. With no clear anchor matches and no soft conflicts, the correct grade is C, not D.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05397639,0.588747501373291,Dementia,"A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Masupirdine (SUVN-502) for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type",PHASE3,50 years to 90 years,Alzheimer's Disease (agitation),Diagnosis of dementia of the Alzheimer's type per NIA-AA criteria. | Confirmed agitation per IPA Consensus Provisional Definition of Agitation in Cognitive Disorders. | MMSE score 8 to 24 (inclusive).,"Dementia predominantly of the non-Alzheimer's type (e.g., vascular dementia, Parkinson's disease, Lewy body disease, frontotemporal dementia). | Agitation not secondary to Alzheimer's disease (e.g., due to pain, other psychiatric disorder, delirium from metabolic disorder, systemic infection, or substance-induced).",(none),ALL,D,"The trial requires dementia of the Alzheimer's type; the patient’s amyloid PET and CSF amyloid are negative, suggesting a non-AD profile that likely conflicts with this requirement (the trial excludes non-AD dementias). Age (68) and MMSE (19) are within range, but agitation status is not provided.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,D,"No hard exclusions: age/sex within bounds; disease not definitively non-AD (cannot F on disease mismatch). Core anchors: Stage/setting (agitation) unknown; Line/prior N/A; Required subtype (AD) shows a soft mismatch given amyloid PET and CSF amyloid are negative, suggesting non-AD; mets N/A. Presence of a specific soft mismatch on a core anchor → D. Grader’s reasoning aligns with rubric.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05511363,0.5763745307922363,Dementia,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease",PHASE3,55 years to 90 years,Alzheimer's Disease (psychosis),"Age 55 to 90 years | Possible or probable Alzheimer's disease diagnosis | Brain MRI or CT to rule out other CNS disease (within past 5 years or during screening) | History of psychotic symptoms meeting IPA criteria for >=2 months prior to screening | CGI-S score >=4 (moderate) at screening and baseline | Moderate to severe delusions or hallucinations per NPI-C criteria at screening and baseline | MMSE score 8 to 22, inclusive, at screening | Stable dose of cholinesterase inhibitor and/or memantine for >=6 weeks prior to screening (if taking) | BMI 18 to 40 kg/m2 | Female not pregnant or breastfeeding; effective contraception required for WOCBP and partners as specified","Psychotic symptoms primarily due to a condition other than Alzheimer's disease | Major depressive episode with psychotic features within 12 months prior to screening | History of bipolar disorder, schizophrenia, or schizoaffective disorder | Significant or severe medical conditions that could jeopardize safety or study validity | eGFR <60 mL/min/1.73 m2 (significant or severe renal impairment) | History of ischemic stroke within 12 months prior to screening or any hemorrhagic stroke | History of cerebral amyloid angiopathy, epilepsy, CNS neoplasm, unstable thyroid function, or unexplained syncope | NYHA Class 2 congestive heart failure | Grade 2 or greater angina pectoris | Sustained ventricular tachycardia, ventricular fibrillation, or torsade de pointes | Implantable cardioverter defibrillator | Myocardial infarction within 6 months prior to screening | Personal or family history suggestive of long QT syndrome | HIV infection, cirrhosis, biliary duct abnormalities, hepatobiliary carcinoma, or active hepatic viral infections | High risk of urinary retention, gastric retention, or narrow-angle glaucoma | Males: history of bladder stones | Males: history of recurrent urinary tract infections | Males: PSA >10 ng/mL at screening | Males: IPSS score of 5 (almost always) on items 1, 3, 5, or 6 | Males: sum of IPSS items 1, 3, 5, and 6 >=9 | History of irritable bowel syndrome or serious constipation requiring treatment within last 6 months | Risk of suicidal behavior per clinical assessment and/or C-SSRS | Clinically significant abnormal physical exam, ECG, or clinical laboratory findings at screening | Urine toxicology positive for substances other than permitted cannabis or short-/medium-acting benzodiazepines unless approved by Medical Monitor | Recent use of MAO inhibitors, anticonvulsants (e.g., lamotrigine, divalproex), lithium, or tricyclic antidepressants; SSRIs/SNRIs allowed only if stable >=8 weeks; mirtazapine or trazodone as hypnotic allowed only if started >=8 weeks | Investigator/Sponsor judgment of unsuitability for the study | Positive COVID-19 test within 2 weeks before or at screening | Unable to taper/discontinue prohibited concomitant medications | Prior exposure to KarXT | Known hypersensitivity to trospium or prior significant adverse events due to trospium | Received an investigational drug within 3 months prior to screening or >2 clinical studies in past year",Stable cholinesterase inhibitor and/or memantine for >=6 weeks prior to screening permitted; SSRIs or SNRIs permitted if on a stable dose for >=8 weeks prior to screening; Mirtazapine or trazodone may be used as hypnotic if started >=8 weeks prior to screening; No investigational drug within 3 months prior to screening,ALL,D,"Age and MMSE fit, but the trial specifically requires psychosis associated with Alzheimer’s disease and a possible/probable AD diagnosis; the patient has dementia without documented psychotic symptoms and amyloid-negative biomarkers arguing against AD. This creates a likely eligibility mismatch, though not an explicit exclusion.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),INCORRECT,B,"No hard exclusions: age and sex fit, and there’s no explicit exclusion triggered. Disease is dementia (AD subset uncertain), so not a definitive disease mismatch per “do not infer.” Core anchors: Stage/severity matches (MMSE 19 within 8–22). Line/prior neutral. Required subtype (AD diagnosis and psychosis) is unknown, not confirmed mismatch. No specific soft conflict identified. Therefore exactly one anchor matches with no soft conflict → B. The grader’s D relies on inferred lack of psychosis/AD, which the rubric disallows.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT00309985,0.702932596206665,Metastatic Castration-Resistant Prostate Cancer,CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer,PHASE3,18 years,Prostate Cancer (metastatic hormone-sensitive),Histologically or cytologically confirmed prostate cancer | Metastatic disease | On androgen-deprivation therapy < 120 days | ECOG 0-2; PS 2 eligible only if decline in PS is due to metastatic prostate cancer,PSA progression from nadir between start of androgen-deprivation therapy and randomization | Prior malignancy within 5 years except basal or squamous cell skin cancer (other low-risk malignancies may be allowed per study chair) | Peripheral neuropathy > grade 1 | History of severe hypersensitivity to docetaxel or polysorbate 80 | Active angina | Symptomatic congestive heart failure | Myocardial infarction within the past 6 months | Prior chemotherapy in the adjuvant or neoadjuvant setting | Prior hormone therapy in the metastatic setting | Concurrent 5-alpha reductase inhibitors | Simultaneous enrollment on CALGB 90202,"Prior adjuvant or neoadjuvant hormonal therapy allowed if discontinued >= 12 months ago and total duration <= 24 months (last depot injection expired by 24 months); Prior palliative radiotherapy allowed if commenced within 30 days before starting androgen deprivation; Anti-androgen therapy allowed as single agent <= 7 days before medical castration to prevent flare; Concurrent antiandrogen therapy allowed, but not as sole hormonal therapy; At least 4 weeks since prior major surgery and recovered from toxicity; > 30 days (or 6 half-lives, whichever is longer) since prior participation in another clinical trial",MALE,F,"The trial is for metastatic hormone-sensitive prostate cancer and explicitly excludes prior hormone therapy in the metastatic setting. The patient has metastatic castration-resistant disease with prior enzalutamide and abiraterone, which is disqualifying.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,F,"Hard exclusion applies: the trial targets metastatic hormone-sensitive prostate cancer and explicitly excludes prior hormone therapy in the metastatic setting. The patient has mCRPC with prior enzalutamide and abiraterone, so F is correct.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT00499330,0.8164030909538269,Metastatic Non-Small Cell Lung Cancer,A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer,PHASE3,18 years,Non-Small Cell Lung Cancer,Peripheral lung nodule <= 2 cm on preoperative CT located in the outer third of the lung | Tumor location suitable for either lobar or sublobar resection | ECOG 0–2 | Age >= 18 years | Histologic confirmation of non-small cell lung cancer | Pathologic N0 status by intraoperative frozen section with required nodal stations negative,"Pure ground glass opacity lesion | Pathologically confirmed N1 or N2 disease | Prior malignancy within 3 years other than non-melanoma skin cancer, superficial bladder cancer, or cervical carcinoma in situ | Prior chemotherapy or radiation therapy for this malignancy | Evidence of locally advanced or metastatic disease",(none),ALL,F,"The trial explicitly excludes patients with evidence of locally advanced or metastatic disease; the patient has de novo metastatic NSCLC (bone and liver). The study also requires a small (≤2 cm) resectable N0 tumor, which conflicts with the patient's metastatic setting.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with evidence of locally advanced or metastatic disease, which the patient has. This is a hard exclusion per the rubric, so grade F is correct. The grader’s reasoning correctly identified this.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT00600496,0.5345115661621094,Crohn's Disease,"A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) When Given in Combination With Standard Doses of Selected Chemotherapies to Patients With Advanced Solid Tumors",PHASE1,18 years to 130 years,Breast Cancer; Colon Cancer; Kidney Cancer; Lung Cancer; Melanoma,Measurable and/or non-measurable advanced disease lacking curative options where the selected chemotherapy agents are standard of care | WHO performance status 0-1 | Able to swallow selumetinib (AZD6244) capsules,Prior treatment with a MEK inhibitor | Participation in a clinical study within 30 days | Not recovered from side effects of an investigational study drug | Brain metastases or spinal cord compression unless treated and stable for >=1 month off steroids,(none),ALL,F,"Disease mismatch: the trial enrolls patients with advanced solid tumors (breast, colon, kidney, lung cancers, or melanoma), whereas the patient has Crohn's disease. Therefore, the patient does not meet the trial’s disease cohort.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion since the trial targets advanced solid tumors (breast, colon, kidney, lung cancers, melanoma) and the patient has Crohn’s disease. The grader correctly assigned F for this reason.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT01050855,0.583087682723999,Ornithine Transcarbamylase Deficiency,Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders,PHASE2,6 months to 25 years,IPEX Syndrome; Sickle Cell Disease; Thalassemia Major; Bone Marrow Failure; Hemophagocytic Lymphohistiocytosis; Langerhans Cell Histiocytosis; Severe Combined Immunodeficiency; Adenosine Deaminase Deficiency; Common Variable Immunodeficiency; Wiskott-Aldrich Syndrome,Age >6 months to 25 years | Immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome | Sickle cell disease | Thalassemia major | Bone marrow failure | Hemophagocytic lymphohistiocytosis or other macrophage activation syndromes | Severe Langerhans cell histiocytosis | Severe combined immunodeficiency | Adenosine deaminase deficiency | Common variable immunodeficiency | Wiskott-Aldrich syndrome | Echocardiogram shortening fraction >27% | Serum creatinine <1.5 x ULN for age | Liver function tests <5 x ULN | No active infections,"Uncontrolled bacterial, fungal, or viral infections",(none),ALL,F,"Disease mismatch: the trial targets specific immunodeficiency/hematologic disorders and not OTC deficiency, and the patient is also below the minimum age of 6 months.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Correct F: the patient’s disease (OTC deficiency) is not among the trial’s listed disorders (disease mismatch hard exclusion), and the patient is below the trial’s minimum age of 6 months (age window hard exclusion).",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT01134614,0.7160961627960205,Recurrent Glioblastoma,A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma,PHASE2,18 years,Advanced Melanoma; Metastatic Melanoma; Recurrent Melanoma; Unresectable Melanoma; Cutaneous Melanoma (Stage III); Cutaneous Melanoma (Stage IV),Measurable disease per RECIST | <=1 prior systemic therapeutic regimen for unresectable stage III or IV melanoma (adjuvant therapies excluded from this count) | Histologic diagnosis of metastatic melanoma (FNA cytology alone for unknown primary not acceptable) | Not pregnant or breast-feeding | No HIV infection | No active hepatitis B infection | No active or chronic hepatitis C infection | ECOG performance status 0-1 | WBC >= 2000/µL | ANC >= 1500/µL | Platelets >= 100000/µL | Hemoglobin >= 8 g/dL | Creatinine <= 3.0 x ULN | AST <= 2.5 x ULN | ALT <= 2.5 x ULN | Bilirubin <= 3.0 x ULN (except Gilbert's syndrome),"History of central nervous system metastases | History of other malignancy within 2 years except adequately treated basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix | History of autoimmune disease (except treated, stable autoimmune thyroiditis) | Underlying medical or psychiatric condition that makes study drug hazardous or obscures adverse event interpretation (e.g., frequent diarrhea) | Receipt of non-oncology vaccine for prevention of infectious diseases within 28 days before or after any ipilimumab dose | Prior treatment with ipilimumab, CD137 agonists, or CTLA-4 inhibitors/agonists | Concurrent systemic steroids required (inhaled/topical steroids permitted) | Concurrent therapy with IL-2, interferon, or other non-study immunotherapy regimens | Concurrent cytotoxic chemotherapy | Concurrent immunosuppressive agents | Concurrent other investigational therapies","<=1 prior systemic regimen for unresectable stage III or IV melanoma (adjuvant therapies allowed); Discontinue immunotherapy, cytotoxic chemotherapy, immunosuppressive agents, investigational therapies, and chronic systemic corticosteroids >=4 weeks before randomization",ALL,F,"The trial is for advanced melanoma, whereas the patient has recurrent glioblastoma; this disease mismatch is a hard exclusion.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,F,"Disease mismatch: the trial exclusively targets melanoma, while the patient has recurrent glioblastoma. This is a hard exclusion per the rubric, so F is correct.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT01171898,0.8290226459503174,Metastatic Castration-Resistant Prostate Cancer,"An Open-Label, Phase 1/2, Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Patients With Progressive Advanced Castration-Resistant Prostate Cancer",PHASE1/PHASE2,18 years,Prostate Cancer (castration-resistant),Histologically or cytologically confirmed prostate cancer | Non-metastatic CRPC with PSA >= 8 ng/mL (within 3 months) | Non-metastatic CRPC with PSA doubling time <= 10 months | Progressive metastatic CRPC by PSA progression | Progressive metastatic CRPC by radiographic progression | Ongoing androgen deprivation therapy with a GnRH analog/inhibitor or orchiectomy | Serum testosterone <= 50 ng/dL | ECOG 0-1 | Life expectancy >= 3 months | Prior abiraterone therapy >= 6 months before progression (post-abiraterone cohort),"Distant metastases including CNS, vertebral, or meningeal involvement (for non-metastatic cohort) | Brain metastases or untreated spinal cord compression | Prior treatment with enzalutamide (MDV3100) | Prior treatment with abiraterone | Prior treatment with ketoconazole | Concurrent treatment with medications known to have seizure potential | Concurrent corticosteroids (must taper off as soon as possible if already on) | QTc > 450 msec | History of seizure or condition predisposing to seizure | Severe or uncontrolled systemic disease | HIV infection",Ongoing androgen deprivation therapy required; Prior abiraterone therapy >= 6 months required for post-abiraterone cohort,MALE,F,"The trial explicitly excludes patients with prior enzalutamide (MDV3100), and the patient has progressed on enzalutamide. This hard exclusion overrides other matching factors.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,F,"The trial explicitly excludes prior enzalutamide (MDV3100). The patient progressed on enzalutamide, triggering a hard exclusion per rubric. Therefore F is correct regardless of other matches.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT01522976,0.4421641230583191,PMM2-CDG,A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML),PHASE2,18 years,Myelodysplastic Syndrome; Myelodysplastic Syndrome With Excess Blasts; Myelodysplastic Syndrome With Excess Blasts-1; Chronic Myelomonocytic Leukemia; Chronic Myelomonocytic Leukemia-1; Chronic Myelomonocytic Leukemia-2,"Diagnosis of myelodysplastic syndrome (MDS) meeting FAB RAEB (5-20% marrow blasts) or WHO RAEB-1 (5-9% marrow blasts) or RAEB-2 (10-19% marrow blasts and/or 5-19% blood blasts) | Diagnosis of chronic myelomonocytic leukemia (CMML) meeting FAB criteria (10-19% marrow blasts and/or 5-19% blood blasts) or WHO CMML-1 (<10% marrow blasts and/or <5% blood blasts) or CMML-2 (10-19% marrow blasts and/or 5-19% blood blasts) | IPSS risk intermediate-2 (1.5-2.0 points) or high (>= 2.5 points); intermediate-1 (0.5-1.0 points) allowed only if >= 5% myeloblasts | Baseline disease assessment specimens obtained within 30 days prior to registration | Zubrod performance status 0-2 | Females of childbearing potential: negative pregnancy test within 10-14 days prior to registration; if assigned lenalidomide, second test within 24 hours prior to cycle 1 and adherence to dual contraception; men agree to condom use with FCBP | Pretreatment cytogenetics required within 30 days prior to registration per cooperative group specifications","Acute myeloid leukemia (AML) | Prior treatment with lenalidomide, azacitidine, vorinostat, or decitabine | Prior radiation therapy, chemotherapy, or other cytotoxic therapy for conditions other than MDS within 12 months | Prior allogeneic stem cell or bone marrow transplantation (autologous transplant permitted) | Use of histone deacetylase (HDAC) inhibitor agents for anticancer treatment | Use of valproic acid for epilepsy within 30 days prior to registration | Pre-existing neurotoxicity/neuropathy >= grade 2, or prior >= grade 3 allergic reaction/hypersensitivity or rash to thalidomide not resolved to < grade 2 | Serious medical condition, laboratory abnormality, or psychiatric illness that poses unacceptable risk or prevents informed consent | History of thromboembolic event or condition requiring current anticoagulation with warfarin or low molecular-weight heparin | Known or suspected hypersensitivity to mannitol | White blood cell count > 30,000/µL at registration | Active second malignancy within 3 years, except adequately treated basal/squamous cell skin cancer or in situ cervical cancer",Hematopoietic growth factors stopped >= 14 days before registration; Prior low-dose cytarabine for MDS allowed if discontinued >= 28 days before registration; Prior hydroxyurea for CMML allowed if discontinued >= 7 days before registration,ALL,F,"Hard exclusions: the trial targets MDS/CMML, not PMM2-CDG, and the patient is 8 years old while the trial requires age ≥18.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,Hard exclusions apply: the trial targets MDS/CMML (not PMM2-CDG) and the patient is 8 years old while the trial minimum age is 18. Either suffices for an F. The grader’s reasoning aligns with the rubric.,,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT01688492,0.8519825339317322,Metastatic Castration-Resistant Prostate Cancer,A Phase 2 Study Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer,PHASE1/PHASE2,18 years,"Prostate Cancer (castration-resistant, metastatic)","Chemotherapy- and immunotherapy-naive metastatic castration-resistant prostate cancer | Age >= 18 years | Histologically or cytologically confirmed adenocarcinoma of the prostate | Castrate serum testosterone <= 50 ng/dL | Ongoing androgen deprivation therapy with a GnRH analogue or prior bilateral orchiectomy | Metastatic disease on imaging; if lymph node-only metastasis, at least one node >= 2 cm in diameter | Progressive disease at study entry per PCWG2 by PSA and/or radiographic criteria | Karnofsky performance status >= 80% | Estimated life expectancy >= 6 months | Toxicities from prior therapy resolved to <= Grade 1 or baseline or deemed irreversible and stable | Able to swallow study drug and comply with study requirements","History of another malignancy within the previous 5 years other than nonmelanoma skin cancer | Absolute neutrophil count < 1500/µL | Platelet count < 75000/µL | Hemoglobin < 9 g/dL | Serum bilirubin >= 1.5 x ULN or, with Gilbert's disease, >= 3 mg/dL | AST or ALT >= 2.5 x ULN (<= 5 x ULN allowed with known liver metastases) | Creatinine > 2 mg/dL | Albumin < 3.0 g/dL | Potassium <= 3.5 mEq/L | Clinically significant cardiovascular disease (myocardial infarction within 6 months, uncontrolled angina within 3 months, NYHA class 3 or 4 heart failure, uncontrolled hypertension with SBP > 160 mmHg or DBP > 95 mmHg) | Major surgery or radiation therapy within 4 weeks of enrollment | Treatment with antiandrogens (bicalutamide, flutamide, nilutamide) within 4 weeks of enrollment | History of progression of prostate cancer while receiving ketoconazole | Prior use or participation in a trial of androgen synthesis inhibitors (e.g., abiraterone, TAK-700, TAK-683, TAK-448), chemotherapy, or immunologic agents (immune modulators, cytokines, vaccines, antibody-delivered chemotherapy) | Known allergy to any study compounds | Uncontrolled or significant medical condition that would make participation hazardous in the investigator's opinion | Autoimmune disease (e.g., inflammatory bowel disease, rheumatoid arthritis, systemic sclerosis, systemic lupus erythematosus, autoimmune vasculitis, motor neuropathy of autoimmune origin) | Known or suspected brain metastasis or untreated leptomeningeal disease | Active infection or other medical condition making prednisone use contraindicated | Active or symptomatic viral hepatitis or chronic liver disease | Disease limited to regional pelvic lymph nodes only | Use of hematopoietic growth factors within 7 days or blood transfusions within 28 days prior to screening labs",Chemotherapy-naive required; Immunotherapy-naive required; Ongoing androgen deprivation therapy required; Antiandrogens discontinued >= 4 weeks before enrollment; No major surgery or radiation therapy within 4 weeks before enrollment; No hematopoietic growth factors within 7 days and no blood transfusions within 28 days before screening labs,MALE,F,"The trial explicitly excludes patients with prior use of androgen synthesis inhibitors such as abiraterone, which this patient received for 3 years. This is a hard exclusion despite other matching factors.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,F,"The trial explicitly excludes prior use of androgen synthesis inhibitors (e.g., abiraterone). The patient received abiraterone for 3 years, triggering a hard exclusion per rubric → F. The grader’s reasoning correctly identified this.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT01708954,0.8649299144744873,Metastatic Non-Small Cell Lung Cancer,"A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib Plus Cabozantinib as 2nd or 3rd Line Therapy in Patients With EGFR Wild-Type NSCLC",PHASE2,18 years,Non-Small Cell Lung Cancer (metastatic),"Non-small cell lung carcinoma confirmed cytologically or histologically | Predominant non-squamous histology; small cell components excluded | Stage IV or recurrent disease by AJCC 7th edition | Measurable disease per RECIST v1.1 | Tumor tissue available for MET IHC testing | One to two prior lines of chemotherapy for advanced disease | Any prior chemotherapy completed per required washout | Discontinued investigational agents >= 4 weeks before registration | Recovered to baseline or CTCAE v4.0 <= grade 1 from prior therapy toxicities (except alopecia and non-clinically significant AEs) | Brain metastases status meeting protocol criteria (stable if present); baseline brain imaging per protocol | Radiation-related toxicities resolved to <= grade 1 | ECOG performance status 0-2 | Anticipated life expectancy > 3 months | Acceptable bone marrow, renal, and hepatic function within 2 weeks prior to registration | QTcF <= 500 ms within 28 days before registration | Able to swallow tablets | Step 2: Radiographic progressive disease after >= 2 courses on Arm A or Arm B | Step 2: Registered within 4 weeks of last dose from Step 1 | Step 2: ECOG performance status 0-2 | Step 2: Recovered to baseline (pre-Step 1) or CTCAE v4.0 <= grade 1 from prior therapy toxicities","Insufficient tumor pathology material (tumor block or 10 unstained slides) for required testing | Prior erlotinib or other EGFR tyrosine kinase inhibitor therapy | Prior VEGFR tyrosine kinase inhibitor therapy | Prior MET tyrosine kinase inhibitor therapy or MET monoclonal antibody | Radiation therapy to thoracic cavity, abdomen, or pelvis within 3 months; to bone or brain within 14 days; or to any other site within 28 days prior to registration | Clinically significant gastrointestinal bleeding within 6 months | Hemoptysis >= 2.5 mL within 3 months | Other signs of pulmonary hemorrhage within 3 months | Tumor invading the gastrointestinal tract or endotracheal/endobronchial tumor within 28 days prior to registration | Cavitating pulmonary lesion(s) within 28 days prior to registration | Tumor in contact with, invading, or encasing major blood vessels within 28 days prior to registration | History of major thrombotic events (deep vein thrombosis or pulmonary embolism) within 6 months | Therapeutic anticoagulation or antiplatelet therapy (except low-dose aspirin <= 81 mg/day and prophylactic LMWH) | Concomitant strong CYP3A4 inducers | Congestive heart failure NYHA class III or IV | Uncontrolled hypertension | History of congenital long QT syndrome | Unstable angina within 6 months | Clinically significant cardiac arrhythmias within 6 months | Stroke or transient ischemic attack or other ischemic event within 6 months | Myocardial infarction within 6 months | Gastrointestinal disorders with high risk of perforation or fistula | High risk of fistula including PEG tube placement within 3 months | Uncontrolled, significant intercurrent or recent illness | Prior malignancy within 2 years requiring systemic treatment or currently active | Pregnant or breastfeeding | HIV infection on antiretroviral therapy | Chronic active hepatitis B | Step 2: Intervening anticancer treatment or major surgery between Step 1 and Step 2 (except palliative bone radiation finished >= 2 weeks before Step 2 registration) | Step 2: Central nervous system progression | Step 2: Intercurrent illness or complication limiting ability to safely tolerate erlotinib plus cabozantinib",Required: 1-2 prior lines of chemotherapy for advanced NSCLC; Prior adjuvant chemotherapy allowed if > 12 months before first-line systemic therapy (otherwise counts as one line); Discontinue investigational agents >= 4 weeks before registration,ALL,F,"Explicit exclusion: the trial bars prior EGFR TKI therapy, and the patient received osimertinib. Additionally, the trial requires 1–2 prior lines of chemotherapy for advanced disease, which the patient lacks.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Hard exclusion applies: the trial excludes any prior EGFR TKI therapy, and the patient received osimertinib (an EGFR TKI). The noted lack of required prior chemotherapy would also be a mismatch, but the explicit exclusion alone warrants grade F.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT01809691,0.7116049528121948,Metastatic Castration-Resistant Prostate Cancer,A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer,PHASE3,18 years,Prostate Cancer (metastatic),"Clinical diagnosis of metastatic prostate cancer | Serum testosterone within normal limits | PSA >= 2 ng/mL | QTc <= 460 msec on ECG | LVEF within normal limits | Adequate hepatic function: bilirubin <= 2 x ULN; AST and ALT <= 3 x ULN (<= 5 x ULN if liver metastases present) | Creatinine clearance >= 40 mL/min | Leukocytes >= 3,000/µL, ANC >= 1,500/µL, hemoglobin >= 9 g/dL, platelets >= 100,000/µL | Zubrod performance status 0–2; 3 allowed if due to bone pain only | Age >= 18 years","Known brain metastases | More than 36 months of prior neoadjuvant and/or adjuvant hormonal therapy | 6 months or more since completion of androgen deprivation therapy | Prior or concurrent therapy with ketoconazole | Prior or concurrent therapy with aminoglutethimide | Prior or concurrent therapy with abiraterone acetate | Prior or concurrent therapy with enzalutamide | Prior chemotherapy for metastatic prostate cancer | Less than 2 years since completion of neoadjuvant or adjuvant chemotherapy | Concurrent use of experimental therapy | 30 days or more since prior medical castration for metastatic prostate cancer | Prior bilateral orchiectomy | Concurrent use of LHRH antagonists (e.g., degarelix) | NYHA class III/IV cardiac disease, thromboembolic event, unstable angina, myocardial infarction within 6 months, or serious uncontrolled arrhythmia | Uncontrolled hypertension > 160/90 mmHg despite therapy | Known HIV infection, active chronic hepatitis B or C, life-threatening illness unrelated to cancer, or serious medical/psychiatric illness interfering with participation | History of primary or secondary adrenal insufficiency | Hypersensitivity to TAK-700, TAK-700 metabolites, bicalutamide, or LHRH agonists | Gastrointestinal disease or procedure interfering with oral absorption or tolerance of TAK-700, including difficulty swallowing | Other prior malignancy except adequately treated basal/squamous cell skin cancer, adequately treated stage I/II cancer in complete remission, or any other cancer disease-free for 5 years",Prior neoadjuvant/adjuvant hormonal therapy allowed (<= 36 months total); Prior neoadjuvant/adjuvant chemotherapy allowed (>= 2 years since completion),MALE,F,"The trial explicitly excludes patients with prior abiraterone or enzalutamide, both of which this patient has received. Additionally, the study targets newly diagnosed metastatic hormone-sensitive disease, not castration-resistant.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,F,"Explicit hard exclusions apply: the trial excludes any prior abiraterone or enzalutamide, both of which the patient received. Thus F is correct; the noted stage/setting mismatch further supports ineligibility but is not needed once the hard exclusion is present.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT01892397,0.7136385440826416,Recurrent Glioblastoma,Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma,NA,18 years,Atypical Meningioma (recurrent); Anaplastic Meningioma (recurrent),"Histologically proven recurrent WHO grade II (atypical) or grade III (anaplastic) supratentorial meningioma | Radiographic evidence of progression by MRI (or CT if MRI contraindicated) within 14 days of registration | Stable or decreased dose of steroids for >=5 days prior to baseline imaging | Recovered from effects of recent resection; start treatment >=28 days after surgery | Measurable disease >=1 cm x 1 cm contrast-enhancing lesion | Prior radiotherapy for meningioma required; interval >4 weeks from completion with subsequent progression documented | Confirmation of true progression (not radiation necrosis) required after prior brachytherapy or stereotactic radiosurgery (via PET/MR-perfusion/MR-spectroscopy or surgery) | Age >=18 years | Karnofsky performance status >=60% | >=4 weeks from any radiation, stereotactic radiosurgery, conventional surgery, or chemotherapy | Life expectancy >=3 months | Neurofibromatosis patients eligible; other CNS tumors allowed if stable for >=6 months","History of other cancer unless in complete remission off therapy for >=3 years (except non-melanoma skin cancer or cervical carcinoma in situ) | Concomitant use of investigational drugs | Concurrent treatment on another therapeutic clinical trial | Pregnancy or breastfeeding | Implanted active medical device (e.g., pacemaker, defibrillator, deep brain stimulator, vagus nerve stimulator) or significant arrhythmia | Evidence of increased intracranial pressure (midline shift >5 mm, clinically significant papilledema, vomiting/nausea, or reduced consciousness) | Infratentorial meningioma without a concurrent growing supratentorial target lesion | Coagulopathy: PT or APTT >1.5 x ULN (if not on anticoagulation) | Thrombocytopenia: platelets <100 x 10^3/µL | Neutropenia: ANC <1 x 10^3/µL | Severe acute infection | Skull defect with missing bone | Ventricular shunt or catheter | Intracranial foreign body (e.g., bullet fragment)","Prior radiotherapy for meningioma required; No limit on number of prior surgeries, radiotherapy treatments, radiosurgery treatments, or chemotherapy; Washout >=4 weeks from any radiation treatment, stereotactic radiosurgery, conventional surgery, or chemotherapy before study entry; Start treatment >=28 days after surgery with recovery from surgical effects",ALL,F,"The trial is specifically for recurrent WHO grade II/III meningioma, while the patient has recurrent glioblastoma (IDH wildtype). This disease mismatch is a hard exclusion.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,F,"Disease mismatch: trial is for recurrent atypical/anaplastic meningioma, while patient has recurrent glioblastoma. This is a hard exclusion per rubric; F is correct.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT01946204,0.8112713098526001,Metastatic Castration-Resistant Prostate Cancer,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer",PHASE3,18 years,Prostate Cancer (non-metastatic castration-resistant),"Histologically or cytologically confirmed prostate adenocarcinoma without neuroendocrine or small cell features | High risk for metastasis defined as PSA doubling time <= 10 months during continuous ADT | Castration-resistant prostate cancer on continuous ADT with 3 PSA rises >= 1 week apart and last PSA > 2 ng/mL | Maintain castrate levels of testosterone within 4 weeks prior to randomization and throughout the study | Bone-sparing agents allowed if on stable doses for >= 4 weeks prior to randomization | Washout from first-generation anti-androgen (e.g., bicalutamide, flutamide, nilutamide) for >= 4 weeks with PSA progression after washout | >= 4 weeks since 5-alpha reductase inhibitors, estrogens, and any other anti-cancer therapy prior to randomization | >= 4 weeks since major surgery or radiation therapy prior to randomization | ECOG performance status 0 or 1 | Resolution of acute toxicities from prior therapy or surgery to Grade <= 1 or baseline before randomization | Adequate organ function per protocol-defined criteria | No growth factors or blood transfusions within 4 weeks before hematology labs for eligibility","Confirmed distant metastases, including CNS, vertebral, or meningeal involvement | Symptomatic local or regional disease requiring medical intervention | Prior treatment with second-generation anti-androgens | Prior treatment with CYP17 inhibitors | Prior treatment with radiopharmaceutical agents or any other investigational agent for non-metastatic castration-resistant prostate cancer | Prior chemotherapy for prostate cancer except if given in the adjuvant or neoadjuvant setting | History of seizure or condition predisposing to seizure | Concurrent therapy with protocol-defined excluded medications | Any prior malignancy within 5 years except adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or cancer in situ in complete remission | Severe or unstable angina within 6 months prior to randomization | Myocardial infarction within 6 months prior to randomization | Symptomatic congestive heart failure within 6 months prior to randomization | Arterial or venous thromboembolic events within 6 months prior to randomization | Clinically significant ventricular arrhythmias within 6 months prior to randomization | Uncontrolled hypertension | Gastrointestinal disorder affecting absorption | Active infection | Any other condition that would impair the patient's ability to comply with study procedures",Continuous ADT required; Washout from first-generation anti-androgens >= 4 weeks with PSA progression after washout; >= 4 weeks since 5-alpha reductase inhibitors or estrogens; >= 4 weeks since any other anti-cancer therapy; >= 4 weeks since major surgery; >= 4 weeks since radiation therapy; Bone-sparing agents allowed if stable for >= 4 weeks,MALE,F,"The trial is for non-metastatic (M0) CRPC and explicitly excludes patients with distant metastases, while the patient has metastatic CRPC with liver and bone involvement. It also excludes prior treatment with second-generation anti-androgens and CYP17 inhibitors, which the patient received (enzalutamide and abiraterone).",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,F,Explicit exclusion criteria disqualify the patient: the trial excludes distant metastases and prior second-generation anti-androgens/CYP17 inhibitors; the patient has metastatic disease and received enzalutamide and abiraterone. F is correct per hard exclusions.,,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT01962415,0.7642838358879089,Rheumatoid Arthritis,"A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation",PHASE2,2 months to 55 years,Primary Immunodeficiency; Congenital Bone Marrow Failure Syndrome; Inherited Metabolic Disorder; Hereditary Anemia; Crohn's Disease; Inflammatory Bowel Disease; Juvenile Rheumatoid Arthritis; Systemic Juvenile Idiopathic Arthritis,"Availability of a suitable graft: 4/6–6/6 HLA matched related or unrelated UCB unit with total nucleated cells >= 3 x 10^7/kg (or double units each >= 2 x 10^7/kg) or 8/8 or 7/8 HLA allele-matched unrelated donor bone marrow or peripheral blood progenitor graft | Serum creatinine <= 2.0 mg/dL | Creatinine clearance >= 50 mL/min | ALT <= 4 x ULN | AST <= 4 x ULN | Cardiac function adequate: shortening fraction > 26% or ejection fraction > 40% or > 80% of normal for age | Pulmonary function: FEV1/FVC >= 50% predicted for age | Pulmonary function: DLCO (hemoglobin-corrected) >= 50% predicted (adults, if obtainable) | Resting pulse oximetry >= 92% on room air | HIV negative | Negative pregnancy test if pubertal and/or menstruating | Non-malignant disorder amenable to HSCT, including primary immunodeficiency syndromes (e.g., SCID with NK activity, Omenn, BLS, CID, CVID, Wiskott-Aldrich, leukocyte adhesion deficiency, CGD, X-linked hyper IgM, IPEX, Chediak-Higashi, ALPS, HLH, lymphocyte signaling defects) | Congenital bone marrow failure syndromes (e.g., dyskeratosis congenita, congenital amegakaryocytic thrombocytopenia, osteopetrosis) | Inherited metabolic disorders (e.g., mucopolysaccharidoses [Hurler, Hunter], leukodystrophies [Krabbe, metachromatic leukodystrophy, X-linked adrenoleukodystrophy, HDLS], alpha mannosidosis, Gaucher disease) | Hereditary anemias (e.g., thalassemia major, sickle cell disease with qualifying complications, Diamond-Blackfan anemia, other congenital transfusion-dependent anemias) | Inflammatory conditions (e.g., Crohn's disease/Inflammatory Bowel Disease)","Allogeneic hematopoietic stem cell transplant within the previous 6 months | Active malignancy or myelodysplastic syndrome | Severe acquired aplastic anemia | Uncontrolled bacterial, viral, or fungal infection with progression of clinical symptoms despite therapy | Pregnancy or nursing | Poorly controlled pulmonary hypertension | Any condition that precludes serial follow-up",(none),ALL,F,"Disease mismatch: the trial targets non-malignant disorders including juvenile rheumatoid arthritis/systemic juvenile idiopathic arthritis, not adult rheumatoid arthritis. While the patient is within the age and sex parameters, their disease is not an eligible cohort.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Disease mismatch is a hard exclusion: the trial lists juvenile rheumatoid arthritis/systemic JIA and other non-malignant disorders, not adult rheumatoid arthritis. Age and sex fit, but per rubric disease mismatch → F. The grader’s reasoning aligns with this.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT02003924,0.8028826713562012,Metastatic Castration-Resistant Prostate Cancer,"PROSPER: A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER",PHASE3,18 years,Prostate Cancer (nonmetastatic castration-resistant),"Histologically or cytologically confirmed prostate adenocarcinoma without neuroendocrine, signet cell, or small cell features | Ongoing androgen deprivation therapy with GnRH agonist/antagonist or prior bilateral orchiectomy | Testosterone <= 50 ng/dL at screening | Progressive disease on androgen deprivation therapy at enrollment | PSA >= 2 ng/mL (central) | PSA doubling time <= 10 months | No prior or present evidence of metastatic disease | Asymptomatic prostate cancer | ECOG performance status 0–1 | Estimated life expectancy >= 12 months","Prior cytotoxic chemotherapy | Hormonal therapy or biologic therapy for prostate cancer (other than approved bone-targeting agents and GnRH therapy) within 4 weeks of randomization | Investigational agent within 4 weeks of randomization | Known or suspected brain metastasis or active leptomeningeal disease | History of another invasive cancer within 3 years of randomization | Absolute neutrophil count < 1000/µL | Platelet count < 100,000/µL | Hemoglobin < 10 g/dL | Total bilirubin >= 1.5 x ULN | Creatinine > 2 mg/dL | Albumin < 3.0 g/dL | History of seizure or condition predisposing to seizure | Clinically significant cardiovascular disease | Gastrointestinal disorder affecting absorption | Major surgery within 4 weeks of randomization | Hypersensitivity to enzalutamide or capsule components (including Labrasol, butylated hydroxyanisole, butylated hydroxytoluene) | Any concurrent disease, infection, or comorbidity that interferes with participation or data interpretation",Ongoing androgen deprivation therapy with GnRH agonist/antagonist or prior bilateral orchiectomy required; Washout >= 4 weeks since hormonal/biologic therapy for prostate cancer or any investigational agent,MALE,F,"This trial enrolls nonmetastatic castration-resistant prostate cancer and requires no evidence of metastases, whereas the patient has metastatic CRPC with liver and bone metastases. This disease/stage mismatch is a hard exclusion.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,F,"The trial is for nonmetastatic CRPC and explicitly requires no evidence of metastases, while the patient has metastatic CRPC with liver and bone mets. This is a hard disease/stage exclusion, so F is correct.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT02020070,0.8325384259223938,Metastatic Castration-Resistant Prostate Cancer,"A Phase 2 Study Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy",PHASE2,18 years,Prostate Cancer (metastatic castration sensitive),"Age >= 18 years | Histologically confirmed adenocarcinoma of the prostate | Newly diagnosed metastatic prostate cancer (Cohort A) | Castration-sensitive disease | <= 10 bony metastatic lesions allowed (biopsy-proven lesions without clear bone imaging permitted) | Distant metastatic lymph nodes allowed; regional pelvic lymph nodes count as metastasis if > 1.5 cm short axis | Medically fit for radical prostatectomy (Cohort A) | Karnofsky performance status 80-100 | WBC >= 2000/µL | ANC >= 1000/µL | Platelets >= 75000/µL | Creatinine <= 2.0 x ULN | AST <= 2.5 x ULN | ALT <= 2.5 x ULN | Bilirubin <= 1.5 x ULN (Gilbert's syndrome allowed if total bilirubin < 3.0 mg/dL) | Negative HIV, Hepatitis B, and Hepatitis C screening tests | No more than 5 months of prior androgen deprivation therapy; no prior primary local therapy (radiation or surgery) to the prostate (Cohort A) | Biochemical recurrence after radical prostatectomy with progressive disease defined by rising PSA (>= 50% increase to >= 1 ng/mL based on >= 3 determinations >= 1 week apart) or PSA doubling time <= 12 months (Cohort B) | Prior prostate radiotherapy allowed (Cohort B)","Other malignancy within 5 years (except adequately treated basal/squamous cell skin cancer or superficial bladder cancer) | Major surgery within 4 weeks of enrollment | Prior radiation therapy to the prostate (Cohort A); prior palliative radiation to metastatic sites allowed | > 5 months of prior hormonal therapy for prostate cancer | Use of megestrol acetate or anti-androgen within 2 weeks of enrollment | Use of 5-alpha reductase inhibitor within 2 weeks of enrollment | Prior ketoconazole, abiraterone, or enzalutamide for prostate cancer | Current or prior investigational therapies for prostate cancer | Prior chemotherapy administered with intent to treat prostate cancer | Concomitant therapy with any other experimental drug | Autoimmune disease (e.g., inflammatory bowel disease, rheumatoid arthritis, scleroderma, systemic lupus erythematosus, autoimmune vasculitis) | Motor neuropathy of autoimmune origin (e.g., Guillain-Barre syndrome, myasthenia gravis) | Medical or psychiatric condition that would make ipilimumab hazardous or obscure adverse event interpretation (e.g., frequent diarrhea) | Underlying heart conditions rendering patient ineligible for surgery (Cohort A) | Non-oncology vaccine therapy within 1 month before or after any dose of ipilimumab (inactivated vaccines allowed) | Prior treatment with ipilimumab, CTLA-4 inhibitor/agonist, or CD137 agonist | Concomitant or prior IL-2, interferon, or other non-study immunotherapy regimens | Immunosuppressive agents or chronic systemic corticosteroids within 6 weeks of study entry | Visceral metastatic disease (Cohort B) | > 3 cycles of intermittent androgen deprivation therapy (Cohort B) | History of acute diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, or abdominal carcinomatosis",<= 5 months of prior androgen deprivation therapy allowed (Cohort A); No prior primary local therapy to the prostate (radiation or surgery) required (Cohort A); Prior prostate radiotherapy allowed (Cohort B); <= 3 cycles of intermittent androgen deprivation therapy allowed (Cohort B); No washout required for GnRH analogs; 2-week washout required for megestrol acetate or anti-androgens; 2-week washout required for 5-alpha reductase inhibitors,MALE,F,"Disease/setting mismatch: the trial enrolls castration-sensitive or biochemically recurrent disease, while the patient has metastatic castration-resistant prostate cancer. The trial also explicitly excludes prior abiraterone or enzalutamide, both of which the patient received.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,F,Correct: the trial requires castration-sensitive disease and explicitly excludes prior abiraterone or enzalutamide; the patient is castration-resistant and has received both drugs. These are hard exclusions → F.,,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02101788,0.7824990749359131,Recurrent Clear Cell Ovarian Carcinoma,A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer,PHASE2/PHASE3,18 years,Ovarian Low-Grade Serous Carcinoma (recurrent); Primary Peritoneal Low-Grade Serous Carcinoma (recurrent),"Age >= 18 years | Recurrent low-grade serous ovarian or peritoneal carcinoma (including invasive micropapillary serous carcinoma or invasive grade I serous carcinomas) after initial diagnosis of low-grade serous disease | Recurrent low-grade serous carcinoma after initial diagnosis of serous borderline ovarian or peritoneal carcinoma | Prospective pathology confirmation of low-grade serous carcinoma prior to study entry | Measurable disease per RECIST 1.1 with required lesion size; imaging within 28 days prior to registration | At least 4 weeks since any major surgery | Progression/recurrence after at least one platinum-based chemotherapy regimen | Unlimited number of prior therapy regimens allowed | Hormonal therapy for malignancy discontinued >= 1 week prior to registration | Chemotherapy and radiation therapy discontinued >= 4 weeks prior to registration | Investigational agents discontinued >= 28 days prior to registration | Women of childbearing potential and men agree to use highly effective contraception during treatment and for 6 months after last dose; negative serum pregnancy test within 14 days prior to randomization; not breastfeeding | Ability to understand and sign informed consent | GOG performance status 0 or 1 | Able to swallow and retain oral medication; no clinically significant GI abnormalities that may alter absorption | All prior treatment-related toxicities <= grade 1 (except alopecia) at randomization | Left ventricular ejection fraction >= lower limit of normal by ECHO or MUGA | Serum creatinine <= 1.5 mg/dL or creatinine clearance >= 50 mL/min | Total bilirubin <= 1.5 x ULN | ALT <= 2.5 x ULN | AST <= 2.5 x ULN | Albumin >= 2.5 g/dL | PT and APTT <= 1.5 x ULN | Absolute neutrophil count >= 1500/µL | Platelet count >= 100000/µL | Hemoglobin >= 9.0 g/dL | If letrozole selected: patient must be postmenopausal (bilateral oophorectomy or >= 5 years after spontaneous menopause, or postmenopausal LH/FSH if within 5 years or hysterectomy without oophorectomy); discontinue HRT before letrozole","Chemotherapy or radiotherapy within 4 weeks prior to entry (6 weeks for nitrosoureas or mitomycin C) or unresolved toxicities from prior therapy > grade 1 | Use of other investigational drugs within 28 days (or five half-lives, whichever shorter; minimum 14 days) before first dose | Index lesion previously irradiated must have progressed post-radiation to be measurable | Prior therapy with MEK, KRAS, or BRAF inhibitors | Concurrent use of other anticancer agents or investigational agents | Concurrent use of herbal supplements (e.g., St. John's wort, kava, ephedra, ginkgo biloba, DHEA, yohimbe, saw palmetto, ginseng) | Known leptomeningeal or brain metastases or spinal cord compression | Bowel obstruction or GI conditions affecting absorption (malabsorption, inability to swallow, major gastric or bowel resection) | History of interstitial lung disease or pneumonitis | Previous or current malignancy at other sites, except curatively treated in-situ cervix or non-melanoma skin cancer, or cancers without relapse for 5 years | Active HBV or HCV infection (chronic or cleared HBV/HCV allowed); HIV-positive patients on antiretroviral therapy not eligible | Hypersensitivity to trametinib, related compounds, excipients, dimethyl sulfoxide (DMSO), or Cremophor EL (Cremophor exclusion relevant only if paclitaxel is the only available agent and patient randomized to control) | Cardiovascular risk: LVEF < LLN, QTcB >= 480 msec, clinically significant uncontrolled arrhythmias (except controlled AF > 30 days), ACS/MI/unstable angina, coronary angioplasty or stenting within 6 months, NYHA class >= II heart failure, refractory hypertension (SBP > 140 mmHg and/or DBP > 90 mmHg despite therapy), intracardiac defibrillator or permanent pacemaker, known cardiac metastases | History or risk of retinal vein occlusion | Serious/unstable medical or psychiatric disorder that could interfere with safety or compliance | Concomitant medications that prolong QT interval required | Pregnant or nursing",Progression after at least one platinum-based chemotherapy regimen required; Unlimited prior therapy regimens allowed; Hormonal therapy for malignancy discontinued >= 1 week before registration; Chemotherapy and radiation therapy discontinued >= 4 weeks before registration; Investigational agents discontinued >= 28 days before registration; At least 4 weeks since major surgery before registration,FEMALE,F,"Disease mismatch: the trial is restricted to recurrent low-grade serous ovarian/peritoneal carcinoma, while the patient has clear cell ovarian carcinoma.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,F,"Hard exclusion applies: trial targets recurrent low-grade serous ovarian/peritoneal carcinoma, while the patient has clear cell ovarian carcinoma. Disease mismatch → F per rubric. Grader’s reasoning aligns.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT02127398,0.54350745677948,Crohn's Disease,Fecal Microbiota Transplantation in Refractory Clostridium Difficile Colitis,PHASE2,18 years,Clostridium Difficile Colitis,Age >18 years | Three or more episodes of Clostridium difficile colitis within the previous 12 months,"Absolute neutrophil count < 500 cells/mm3 | Active infection at other sites requiring ongoing antibacterial therapy (antiviral or antifungal therapy acceptable) | Current or planned cytotoxic chemotherapy within 14 days of fecal transplantation date | Life expectancy < 180 days | Diagnosis of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) | Inability to swallow capsules | Indwelling nasogastric, orogastric, gastrostomy, or jejunostomy tube | History of partial or total gastrectomy | Short gut syndrome requiring total parenteral nutrition | Pregnancy | Documented intestinal parasite infection without documentation of appropriate treatment",(none),ALL,F,"Disease mismatch (trial targets recurrent Clostridium difficile colitis) and the protocol explicitly excludes inflammatory bowel disease, including Crohn's disease.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,Correct: The trial targets C. difficile colitis (disease mismatch) and explicitly excludes inflammatory bowel disease including Crohn’s disease. Either is a hard exclusion → F.,,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT02171104,0.5901163220405579,Ornithine Transcarbamylase Deficiency,"MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG",PHASE2,up to 55 years,Acyl-CoA Oxidase Deficiency; Adrenoleukodystrophy (cerebral); Alpha-mannosidosis; Alpha-methylacyl-CoA Racemase Deficiency; Aspartylglucosaminuria; D-Bifunctional Enzyme Deficiency; Fucosidosis; Globoid Cell Leukodystrophy; Glycoprotein Metabolic Disorders; Hereditary Leukoencephalopathy With Axonal Spheroids; Hunter Syndrome; Hurler Syndrome; Infantile Refsum Disease; Inherited Metabolic Disorders; Maroteaux Lamy Syndrome; Metachromatic Leukodystrophy; Mitochondrial Neurogastrointestinal Encephalopathy; Mucopolysaccharidosis Disorders; Multifunctional Enzyme Deficiency; Neonatal Adrenoleukodystrophy; Niemann-Pick B; Niemann-Pick C Subtype 2; Peroxisomal Disorders; Recessive Leukodystrophies; Severe Osteopetrosis; Sly Syndrome; Sphingolipidoses; Sphingomyelin Deficiency; Zellweger Syndrome,"Age 0–55 years | Adequate graft available | Adequate organ function | MPS IH (Hurler syndrome) | MPS II (Hunter syndrome) with no or minimal symptomatic neurologic disease but expected neurologic phenotype | MPS VI (Maroteaux-Lamy syndrome) | MPS VII (Sly syndrome) | Alpha-mannosidosis | Fucosidosis | Aspartylglucosaminuria | Globoid cell leukodystrophy | Metachromatic leukodystrophy | Niemann-Pick disease type B (sphingomyelin deficiency) | Niemann-Pick C subtype 2 | Adrenoleukodystrophy (cerebral involvement) | Zellweger syndrome | Neonatal adrenoleukodystrophy | Infantile Refsum disease | Acyl-CoA oxidase deficiency | D-bifunctional enzyme deficiency | Multifunctional enzyme deficiency | Alpha-methylacyl-CoA racemase deficiency (AMACRD) | Mitochondrial neurogastrointestinal encephalopathy (MNGIE) | Severe osteopetrosis | Hereditary leukoencephalopathy with axonal spheroids (CSF1R mutation) | Other life-threatening lysosomal, peroxisomal or similar inherited disorders with white matter disease or neurologic manifestations where transplantation is rational (e.g., Wolman disease, GM1 gangliosidosis, I-cell disease, Tay-Sachs disease, Sandhoff disease) | Voluntary written consent","Pregnancy | Prior myeloablative chemotherapy within 4 months of start of conditioning | Uncontrolled bacterial, fungal, or viral infection including HIV | Active Aspergillus or other mold infection within 30 days",(none),ALL,F,"Ornithine transcarbamylase deficiency is not among the eligible disorders and does not fit the trial’s lysosomal/peroxisomal or similar neurologic white matter disease catch-all. Despite appropriate age/sex, this is a disease mismatch hard exclusion.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,OTC deficiency is not among the listed eligible disorders and does not fit the trial’s lysosomal/peroxisomal/white matter disease catch-all; thus disease mismatch is a hard exclusion. Age/sex do not rescue eligibility. Grade F is appropriate.,,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02257528,0.7345178127288818,Recurrent Clear Cell Ovarian Carcinoma,"A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer",PHASE2,18 years,Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Recurrent Cervical Carcinoma; Cervical Cancer (stage IV),"Histologically confirmed squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix that is persistent, recurrent, or metastatic with documented progression and not amenable to curative therapy. | Measurable disease per RECIST 1.1. | At least one target lesion per RECIST 1.1; lesions in previously irradiated fields are non-target unless progression is documented or biopsy confirms persistence >=90 days after radiation. | Recovery from adverse effects of prior surgery, radiotherapy, or chemotherapy. | Exactly one prior systemic chemotherapy regimen for persistent, recurrent, or metastatic cervical carcinoma. | Performance status 0 or 1. | ANC >= 1,500/µL. | Platelets >= 100,000/µL. | Creatinine <= 1.5 x ULN or creatinine clearance >= 40 mL/min. | Bilirubin <= 1.5 x ULN. | AST <= 3 x ULN. | ALT <= 3 x ULN.","Prior therapy with nivolumab, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, or other agents targeting T-cell co-stimulation or immune checkpoint pathways. | History of severe hypersensitivity reaction to any monoclonal antibody. | Prior invasive malignancy (except non-melanoma skin cancer) unless disease-free for >=3 years. | Uncontrolled intercurrent illness including active infection, symptomatic congestive heart failure, unstable angina, significant arrhythmia, or psychiatric/social conditions limiting compliance. | Pregnant or breastfeeding. | Known brain or leptomeningeal metastases unless treated with no MRI evidence of progression for >=4 weeks and no requirement for systemic corticosteroids >10 mg/day prednisone equivalents for >=2 weeks. | Known HIV infection or AIDS. | Positive hepatitis B surface antigen or positive hepatitis C RNA indicating acute or chronic infection. | Active autoimmune disease or history of autoimmune disease that might recur, affect vital organ function, or require immunosuppressive treatment (exceptions include vitiligo, type I diabetes, residual hypothyroidism on replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur). | Systemic corticosteroids >10 mg/day prednisone equivalents or other immunosuppressive medications within 14 days prior to study drug (topical, inhaled, ocular, intra-articular, intranasal, and physiologic replacement doses allowed). | Active or recent gastrointestinal conditions including diverticulitis, intra-abdominal abscess, abdominal/pelvic fistula, gastrointestinal perforation, gastrointestinal obstruction, or requirement for parenteral hydration/nutrition.","Exactly one prior systemic chemotherapy regimen for persistent/recurrent/metastatic cervical cancer is required.; Chemotherapy, biologic/targeted agents, and immunologic agents must be discontinued >=3 weeks before registration.; Investigational agents must be discontinued >=30 days before registration.; Prior radiation therapy must be completed >=4 weeks before registration.; Major surgery must be completed >=4 weeks before registration.",FEMALE,F,"Disease mismatch: the trial enrolls cervical cancer only, while the patient has recurrent clear cell ovarian carcinoma. This fails a hard exclusion.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,F,"Correct: The trial targets cervical cancer only, while the patient has recurrent clear cell ovarian carcinoma. This is a hard disease mismatch, triggering an F per the rubric.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT02291523,0.6159580945968628,Crohn's Disease,The Effect of Therapeutic Fecal Transplant on the Gut Microbiome in Children With Ulcerative Colitis,PHASE1,7 years to 21 years,Ulcerative Colitis,Age 7-21 years with diagnosed ulcerative colitis | Mild to moderate disease per PUCAI score 10-64 | Clinical need for colonoscopy,"Known resistance to steroid therapy, immunomodulators, and biologics | Current steroid dose >0.5 mg/kg/day (maximum 20 mg) | Recent dose change within 4 weeks of biologics, 5-ASA, steroids, or immunomodulators | Allergy or intolerance to mesalamine or 5-ASA products | Evidence of infectious colitis | Concurrent infections requiring antimicrobial therapy | Received probiotic preparations within 4 weeks prior to randomization | Pregnancy or breastfeeding | Significant renal dysfunction | Significant liver dysfunction | Congenital or acquired immunodeficiency | Immunosuppressed due to conditions other than ulcerative colitis (e.g., neoplastic disease or organ transplantation) | Received or receiving chemotherapy | Diagnosed with HIV | Unable to give informed consent/assent","Stable dosing of biologics, 5-ASA, steroids, or immunomodulators for >= 4 weeks prior to randomization; No probiotic preparations within 4 weeks prior to randomization",ALL,F,"Hard exclusions apply: the trial targets ulcerative colitis in participants aged 7–21, while the patient has Crohn's disease and is 32 years old.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,Hard exclusions apply: disease mismatch (Crohn’s vs ulcerative colitis) and age outside the 7–21 window. The grader correctly identified these and assigned F.,,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT02616484,0.5332478284835815,Ornithine Transcarbamylase Deficiency,Phase 3 Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:,PHASE3,6 months to 17 years,Pyruvate Dehydrogenase Complex Deficiency,Age 6 months through 17 years | Characteristic clinical or metabolic features of pyruvate dehydrogenase complex deficiency | Known pathogenic mutation in a gene specifically associated with PDCD,"Genetic mitochondrial disease other than those included under PDCD | Primary disorders of amino acid metabolism | Primary disorders of fatty acid oxidation | Secondary lactic acidosis due to impaired oxygenation or circulation (e.g., cardiomyopathy or congenital heart defect) | Renal insufficiency (requires chronic dialysis or serum creatinine >= 1.2 mg/dL; creatinine clearance < 60 mL/min) | Primary hepatic disease unrelated to PDCD | Pregnancy or breastfeeding",(none),ALL,F,"Disease mismatch: the trial targets pyruvate dehydrogenase complex deficiency, not OTC deficiency. The patient is also younger than the 6-month minimum and has a primary amino acid metabolism disorder explicitly excluded.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Correct: The trial targets PDCD, not OTC deficiency (hard disease mismatch), and the patient is under the 6-month minimum age (hard exclusion). Either alone warrants F. The added note about primary amino acid metabolism is plausible but unnecessary; the F grade is still correct.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT02621424,0.7123395800590515,Dementia,Repetitive Transcranial Magnetic Stimulation for Dementia,NA,55 years to 99 years,Alzheimer's Disease; Mild Cognitive Impairment,"Age >= 55 years | Diagnosed with mild cognitive impairment or dementia likely due to Alzheimer's disease | Ability to obtain motor threshold during screening | If on prescription cognition medication, dose stable for >= 4 weeks prior to randomization","Prior exposure to repetitive transcranial magnetic stimulation or electroconvulsive therapy | Unable to safely withdraw from medications that substantially increase seizure risk >= 2 weeks before treatment | Cardiac pacemaker or cochlear implant | Implanted deep brain stimulation device or metal in the brain | Current substance abuse (excluding caffeine or nicotine) | Active current suicidal intent or plan | Current or prior seizure disorder | Traumatic brain injury within the last 2 months | Participation in another concurrent interventional clinical trial | Known current psychosis | Current or prior mass lesion, cerebral infarct, or other active CNS disease increasing seizure risk | Not fluent in English or severe hearing impairment impairing comprehension",Cognition medications allowed if dose stable for >= 4 weeks prior to randomization; Washout of medications that increase seizure risk for >= 2 weeks before treatment,ALL,F,"The trial requires mild cognitive impairment or dementia likely due to Alzheimer’s disease, whereas the patient has unspecified dementia with amyloid PET and CSF amyloid negative findings, which is inconsistent with AD. Age and sex fit, but the required disease subtype is not met.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"Hard exclusion applies: the trial requires MCI or dementia likely due to Alzheimer’s disease, while the patient has unspecified dementia with amyloid PET and CSF amyloid negative results, indicating they definitively lack the required AD subtype. Age and sex fit, but disease/subtype requirement is not met. F is appropriate.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02627443,0.7143391966819763,Recurrent Clear Cell Ovarian Carcinoma,"Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer",PHASE1,18 years,High Grade Serous Ovarian Carcinoma; Endometrioid Ovarian Carcinoma; Primary Peritoneal Carcinoma; Fallopian Tube Carcinoma,"Histologically confirmed high grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube malignancy that is metastatic and not curable | Measurable disease by RECIST: >= 20 mm by conventional imaging or >= 10 mm by spiral CT/MRI/clinical calipers | Expansion cohort: archival tumor tissue available and willingness for baseline and on-treatment biopsies | Platinum-sensitive disease in first or second recurrence (recurrence > 6 months after last platinum therapy) | No more than two prior platinum-based regimens | ECOG performance status <=2 (Karnofsky >=60%) | Life expectancy > 6 months | Leukocytes >= 3,000/µL | Absolute neutrophil count >= 1,500/µL | Platelets >= 100,000/µL | Total bilirubin within normal limits | AST/ALT <= 2 x ULN | Creatinine within normal limits or creatinine clearance >= 50 mL/min | Negative serum pregnancy test for females of childbearing potential","Platinum-resistant disease or beyond second platinum-sensitive recurrence | Chemotherapy or radiotherapy within 4 weeks prior to enrollment or unresolved > grade 1 toxicities (except alopecia; peripheral neuropathy <= grade 1 allowed) | Prior exposure to gemcitabine | Concurrent treatment with other investigational agents | Known brain metastases | History of allergic reactions to compounds similar to berzosertib, carboplatin, or gemcitabine | Concomitant use of strong CYP3A4 inhibitors or inducers | Uncontrolled intercurrent illness (e.g., active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, significant psychiatric illness) | Pregnant or breastfeeding | Li-Fraumeni syndrome | Addition of bevacizumab to study treatment not allowed",Platinum-sensitive recurrence (first or second) required; No more than two prior platinum-based regimens; Prior PARP inhibitor allowed; Prior bevacizumab allowed; Washout >= 4 weeks since chemotherapy or radiotherapy,FEMALE,F,"The trial requires high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer, but the patient has clear cell ovarian carcinoma, which is not an eligible histology.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,F,"Disease mismatch: trial limits to high-grade serous or endometrioid ovarian (plus peritoneal/fallopian tube) while patient has clear cell ovarian carcinoma. This is a hard exclusion per the rubric, so F is correct.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT02659241,0.7140681743621826,Recurrent Clear Cell Ovarian Carcinoma,A Pilot Study of Wee1 Inhibition Induction Prior to Tumor Reductive Surgery in Ovarian Cancer,EARLY_PHASE1,18 years,Ovarian High Grade Serous Carcinoma; Fallopian Tube High Grade Serous Carcinoma; Primary Peritoneal High Grade Serous Carcinoma,"Presumed advanced-stage high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma | Medically able to undergo primary cytoreductive surgery 13-28 days after starting study drug | No prior therapy for high-grade serous ovarian, fallopian tube, or primary peritoneal carcinoma | Able to swallow and tolerate oral medications; no GI illness precluding absorption | Absolute neutrophil count >= 1,500/µL | Hemoglobin >= 9 g/dL | Platelets >= 100,000/µL | Total bilirubin <= 1.5 x ULN | AST <= 2.5 x ULN | ALT <= 2.5 x ULN | Creatinine clearance > 50 mL/min | Creatinine < 1.5 x ULN | ECOG performance status 0-1","Prior treatment for ovarian, fallopian tube, or primary peritoneal cancer | Current receipt of other investigational agents or additional anti-cancer agents | Active CNS disease other than neurologically stable, treated brain metastases | Other active cancers (exceptions: certain stage I, in-situ, or prior non-melanoma skin cancers) | Major surgery within 28 days or minor surgery within 7 days before starting treatment | Significant symptom burden including large volume ascites, pain requiring narcotics, or dyspnea on exertion | Myocardial infarction within 6 months, symptomatic CHF (NYHA > class II), unstable angina, or unstable arrhythmia | QTc > 470 msec or congenital long QT syndrome | Use of moderate to strong CYP3A4 inhibitors/inducers or sensitive/narrow therapeutic index CYP3A4 substrates that cannot be discontinued (including aprepitant/fosaprepitant) | Herbal preparations prohibited (e.g., St. John's wort, kava, ephedra, ginkgo, DHEA, yohimbe, saw palmetto, ginseng) and avoidance of grapefruit/exotic citrus during study | Known hypersensitivity to study treatment components | Pregnant or breast-feeding | Severe or uncontrolled systemic diseases (e.g., severe hepatic impairment, interstitial lung disease, uncontrolled chronic renal disease), serious active infection, uncontrolled hypertension (>= 140/90), active bleeding diathesis, or active infection including hepatitis B, hepatitis C, or HIV | Investigator deems patient unsuitable or unlikely to comply | Statin use (e.g., atorvastatin) prohibited due to BCRP inhibition","No prior therapy for high-grade serous ovarian, fallopian tube, or primary peritoneal carcinoma",FEMALE,F,"Disease mismatch: the trial is restricted to untreated high-grade serous ovarian/fallopian tube/primary peritoneal carcinoma, whereas the patient has recurrent clear cell ovarian carcinoma. Additionally, the study excludes any prior treatment, but the patient has received surgery and adjuvant carboplatin/paclitaxel/bevacizumab.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,F,"Hard exclusion applies: disease mismatch (trial limited to high-grade serous ovarian/fallopian/peritoneal carcinoma; patient has clear cell ovarian carcinoma). Additionally, explicit exclusion for prior treatment applies. F is correct per rubric.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT02690558,0.7811245918273926,Metastatic Urothelial Carcinoma,Phase II Single Arm Study of Gemcitabine and Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer,PHASE2,18 years,Urothelial Bladder Cancer,"Age >= 18 years | ECOG performance status 0–1 | Histologically confirmed urothelial carcinoma of the bladder (mixed histology allowed if component of urothelial carcinoma; excludes pure small cell, pure adenocarcinoma, pure squamous) | Clinical stage T2–T4a N0/X M0 urothelial carcinoma | Medically appropriate candidate for radical cystectomy and planning to receive cystectomy | No prior systemic cytotoxic chemotherapy for urothelial carcinoma (prior intravesical chemotherapy permitted) | Adequate organ function per protocol laboratory criteria | Life expectancy > 3 months","Participation in another investigational study or use of an investigational device within 4 weeks prior to first dose | Immunodeficiency or systemic steroid/immunosuppressive therapy within 7 days prior to first dose (except allowed prophylactic antiemetic steroids, inhaled/topical steroids) | Active tuberculosis | Hypersensitivity to pembrolizumab or its excipients | Prior monoclonal antibody therapy within 4 weeks prior to Day 1 or not recovered to <= Grade 1 from prior adverse events | Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to Day 1 or not recovered to <= Grade 1 from prior adverse events | Additional malignancy that is progressing or requires active treatment (except certain skin cancers or in situ cervical cancer after curative therapy) | Active autoimmune disease requiring systemic treatment within the past 2 years | Interstitial lung disease or active, non-infectious pneumonitis | Active infection requiring systemic therapy | Pregnant or breastfeeding, or planning conception/fathering during study and for 120 days after last dose | Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibodies | Prior radiation therapy to the bladder for urothelial carcinoma | Known HIV infection | Active hepatitis B or hepatitis C infection | Clinically relevant hearing impairment > Grade 2 | Live vaccine within 30 days prior to first dose","No prior systemic cytotoxic chemotherapy for urothelial carcinoma; No prior checkpoint inhibitor therapy (anti-PD-1/PD-L1/PD-L2, anti-CD137, anti-CTLA-4); Washout >= 4 weeks from prior monoclonal antibody therapy; Washout >= 2 weeks from prior chemotherapy, targeted therapy, or radiation therapy; No prior radiation therapy to the bladder for urothelial carcinoma; No investigational agents/devices within 4 weeks prior to first dose",ALL,F,"The trial requires non-metastatic (T2–T4a N0/X M0) muscle-invasive bladder cancer eligible for neoadjuvant therapy prior to cystectomy, while the patient has metastatic disease after second-line therapy. This is a definitive stage/setting mismatch to a required criterion.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"The trial requires non-metastatic (T2–T4a N0/X M0) neoadjuvant setting prior to cystectomy. The patient has metastatic disease (M1). This is a required stage/setting mismatch, which is a hard exclusion per the rubric, so F is correct.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT02812420,0.8373793363571167,Metastatic Urothelial Carcinoma,"A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Neoadjuvant Chemotherapy",EARLY_PHASE1,18 years,Bladder Urothelial Carcinoma; Infiltrating Bladder Urothelial Carcinoma (micropapillary variant); Infiltrating Bladder Urothelial Carcinoma (plasmacytoid variant); Infiltrating Bladder Urothelial Carcinoma (sarcomatoid variant); Renal Pelvis Urothelial Carcinoma; Infiltrating Renal Pelvis Urothelial Carcinoma (sarcomatoid variant); Ureter Urothelial Carcinoma; Urethral Urothelial Carcinoma,"Transurethral resection of bladder tissue (TURBT) performed at MD Anderson Cancer Center | Histologic proof of urothelial cancer (bladder, renal pelvis, ureter, or urethra); upper tract urothelial carcinoma included | Muscle-invasive disease (e.g., cT2-3aN0M0) or tumor not completely removed at TURBT, or requiring cystectomy/applicable surgery | High-risk features not candidates for traditional neoadjuvant chemotherapy: micropapillary, sarcomatoid, or plasmacytoid features | High-risk feature: 3-dimensional mass on exam under anesthesia | High-risk feature: lymphovascular invasion | High-risk feature: hydronephrosis (unless deemed not due to tumor) | High-risk feature: high-grade tumors of the ureter or renal pelvis with radiographic mass on CT or MRI | High-risk feature: direct invasion of prostatic stroma or vaginal wall (cT4a) | Candidates for but refusing conventional chemotherapy may be eligible | No prior exposure to immunotherapy such as anti-CTLA-4, anti-PD-1, or anti-PD-L1 antibodies (vaccines excluded) | ECOG performance status 0–1 | Adequate organ and marrow function without transfusions or growth factor support within 28 days prior to first dose | Hemoglobin >= 9 g/dL | Absolute neutrophil count >= 1,000/µL | Platelet count >= 100,000/µL | Total bilirubin <= 1.5 x ULN (Gilbert's syndrome allowed up to 3.0 mg/dL) | Cisplatin ineligible due to renal dysfunction, hearing impairment, comorbidities, or refusal; examples include GFR < 60 mL/min, CHF NYHA class III or higher, peripheral neuropathy grade >= 2, ECOG PS >= 2, impaired hearing, or patient refusal | Contraception required for females of childbearing potential through 180 days after final dose | Contraception required for nonsterilized males through 90 days after final dose","Concurrent enrollment in another clinical trial (unless in follow-up or observational) | Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer | Investigational anticancer therapy within 28 days prior to first dose | Major surgical procedure within 28 days prior to first dose or not recovered from prior surgery | Unresolved toxicities from prior anticancer therapy > grade 1 (except alopecia and specified labs); irreversible toxicities not expected to be exacerbated may be allowed | Known or suspected autoimmune disease including inflammatory bowel disease, rheumatoid arthritis, systemic sclerosis, systemic lupus erythematosus, or autoimmune vasculitis | Systemic corticosteroids > 10 mg prednisone equivalents daily or other immunosuppressive medications within 14 days prior to first dose (inhaled/adrenal replacement allowed) | History of primary immunodeficiency | Prior organ allograft | Active hepatitis B or hepatitis C infection | Known HIV infection or AIDS | Receipt of live attenuated vaccine within 28 days prior to first dose (and not during study or for 180 days after last dose) | Pregnant or lactating | Uncontrolled intercurrent illness including active infection, current pneumonitis, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, interstitial lung disease, or significant psychiatric/social conditions limiting compliance | Other invasive malignancy within 2 years except certain in situ or non-melanoma skin cancers surgically cured | Evidence of metastatic urothelial carcinoma | Known allergy or hypersensitivity to study drug formulations | Currently on dialysis",>=28 days since prior investigational anticancer therapy,ALL,F,"The trial explicitly excludes patients with metastatic urothelial carcinoma, and this patient has metastatic disease after second-line therapy. The study targets a pre-surgical, non-metastatic setting.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with metastatic urothelial carcinoma, and the patient has metastatic disease. This is a hard exclusion per rubric, so grade F is correct. Other factors (stage/setting, prior immunotherapy) are irrelevant once the hard exclusion applies.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT02818920,0.7922804355621338,Metastatic Non-Small Cell Lung Cancer,"Pembrolizumab Prior to Surgery for Stage 1B, 2 or 3A Non-small Cell Lung Cancer (NSCLC): A Phase II Study",PHASE2,18 years,Non-small Cell Lung Cancer,"Histologically or cytologically confirmed non-small cell lung cancer | Clinical stage IB (>= 3 cm), stage IIA/IIB, or stage IIIA (N0-2) amenable to surgical resection | Primary tumor >= 3 cm | Deemed a surgical candidate | ECOG performance status 0–1 | No active invasive malignancy in the past 2 years other than non-melanoma skin cancer; in-situ cancers allowed | Age >= 18 years | Negative pregnancy test for females of childbearing potential within 48 hours prior to initial study procedures | Measurable disease per RECIST 1.1 | Post-operative predicted FEV1 > 40% predicted | Post-operative predicted DLCO > 40% predicted | Adequate organ function","Treatment within the last 30 days with an investigational drug or use of an investigational device within 4 weeks of first dose | Known history of active tuberculosis | Hypersensitivity to pembrolizumab or any of its excipients | Concurrent administration of any other anti-tumor therapy | Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent | Known active hepatitis B or active hepatitis C infection | Active infection requiring antibiotics, antifungal, or antiviral therapy | History of or evidence of active, non-infectious pneumonitis | Known history of HIV infection | Active autoimmune disease requiring systemic treatment in the past 2 years | Autoimmune motor neuropathy (e.g., Guillain-Barre syndrome, myasthenia gravis) | Systemic steroid therapy or other immunosuppressive therapy within 7 days prior to first dose | Known additional invasive malignancy that is progressing or requires active treatment (exceptions for certain skin cancers and in situ cervical cancer) | Pregnant or breastfeeding, or planning to conceive/father children during treatment and for 120 days after last dose | Major surgery (other than definitive lung cancer surgery) within 2 weeks prior to study | Receipt of non-oncology vaccine within 30 days before or after any dose of pembrolizumab (inactivated injectable influenza vaccines allowed; live attenuated intranasal vaccines not allowed) | History of myocardial infarction within 6 months, uncontrolled arrhythmia, symptomatic angina, active ischemia, or uncontrolled heart failure | History of interstitial lung disease | Inability to comply with study procedures | Prisoners or subjects involuntarily detained",(none),ALL,F,"The trial requires resectable stage IB–IIIA NSCLC for neoadjuvant therapy, whereas the patient has de novo metastatic (stage IV) disease. This is a required stage/setting mismatch.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Trial requires resectable stage IB–IIIA NSCLC (neoadjuvant setting), while the patient has de novo metastatic (stage IV) disease. Per rubric, a required stage/setting mismatch is a hard exclusion → F. The grader’s reasoning correctly identifies this.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT02928991,0.5115711688995361,Ornithine Transcarbamylase Deficiency,Fludarabine-Based Conditioning for Matched Related Donor Bone Marrow Transplantation in Patients With Bone Marrow Failure Syndromes,EARLY_PHASE1,up to 22 years,Aplastic Anemia; Fanconi Anemia; Dyskeratosis Congenita; Severe Congenital Neutropenia; Diamond-Blackfan Anemia; Congenital Dyserythropoietic Anemia; Sideroblastic Anemia; Congenital Amegakaryocytic Thrombocytopenia; Shwachman-Diamond Syndrome,"Age 0-22 years at enrollment | Severe or very severe acquired aplastic anemia with bone marrow cellularity <25% plus at least 2 of: ANC <500/µL, platelets <20,000/µL, absolute reticulocytes <40,000/µL | Negative evaluation for inherited bone marrow failure conditions and for dysplasia or cytogenetic abnormalities associated with myelodysplastic syndromes | Paroxysmal nocturnal hemoglobinuria clones permitted if aplastic anemia severity criteria are met | Clinically diagnosed and/or genetically proven inherited bone marrow failure syndrome with chronic red blood cell or platelet transfusion dependence and/or ANC <500/µL | Inherited bone marrow failure disorders may include: Fanconi Anemia, Dyskeratosis Congenita, Severe Congenital Neutropenia, Diamond-Blackfan Anemia, Congenital Dyserythropoietic Anemia, Sideroblastic Anemia, Congenital Amegakaryocytic Thrombocytopenia, Shwachman-Diamond Syndrome | Karnofsky/Lansky >60% | Fully HLA-matched (10/10) related donor available | No active untreated infection | Negative pregnancy test (females of childbearing potential) | Serum creatinine <1.5 x ULN | Transaminases (AST/ALT) <5 x ULN | Bilirubin <2.5 x ULN | Cardiac shortening fraction >27%","Uncontrolled bacterial, viral, or fungal infection | No eligible fully HLA-matched related donor | Pregnancy | Clinical diagnosis of myelodysplastic syndrome | Paroxysmal nocturnal hemoglobinuria without underlying bone marrow aplasia",(none),ALL,F,"Disease mismatch: the trial targets inherited/acquired bone marrow failure syndromes (e.g., aplastic anemia, Fanconi anemia) and does not include ornithine transcarbamylase deficiency.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion. The trial targets bone marrow failure syndromes (e.g., aplastic anemia, Fanconi anemia) and does not include ornithine transcarbamylase deficiency, so F is appropriate.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT03047746,0.5065252780914307,Ornithine Transcarbamylase Deficiency,Unrelated And Partially Matched Related Donor Peripheral Blood Stem Cell Transplantation (PSCT) With TCR αβ + T Cell And B Cell Depletion For Patients With Acquired And Inherited Bone Marrow Failure,NA,up to 25 years,Acquired Aplastic Anemia; Paroxysmal Nocturnal Hemoglobinuria; Fanconi Anemia; Dyskeratosis Congenita; Shwachman-Diamond Syndrome; Severe Congenital Neutropenia; Diamond-Blackfan Anemia; Congenital Dyserythropoietic Anemia; Congenital Sideroblastic Anemia; Congenital Amegakaryocytic Thrombocytopenia,"Acquired severe or very severe aplastic anemia: bone marrow cellularity <25% or hypocellular for age with reductions in any two lineages (myeloid, erythroid, megakaryocyte) | Acquired severe or very severe aplastic anemia: at least two of ANC <500/µL (severe) or <200/µL (very severe), platelets <30,000/µL or transfusion dependence, absolute reticulocyte count <40,000/µL | Acquired severe or very severe aplastic anemia: negative evaluation for inherited bone marrow failure conditions | Paroxysmal nocturnal hemoglobinuria: PNH clone >10% by absent CD55 or CD59 on flow cytometry with clinical or laboratory evidence of hemolysis | Fanconi anemia: bone marrow cellularity <25% with cytopenias and positive chromosomal breakage testing (MMC or DEB sensitivity) | Dyskeratosis congenita/telomere disorder: bone marrow cellularity <25% with cytopenias and lymphocyte telomere length <1%ile for age (CLIA-certified) | Shwachman-Diamond syndrome: SBDS mutation and/or classic clinical features with trilineage bone marrow failure (cellularity <25%) | Severe congenital neutropenia: baseline ANC <500/µL prior to G-CSF therapy | Severe congenital neutropenia: requires chronic G-CSF >3 doses/week to maintain ANC >1000/µL | Severe congenital neutropenia: pathogenic mutation in a known SCN gene and/or marrow myeloid maturation arrest with exclusion of autoimmune causes | Severe congenital neutropenia: history of severe infection related to neutropenia or toxicity due to chronic G-CSF (e.g., osteopenia, splenomegaly, cytogenetic abnormalities) if no infection history | Isolated disorders of erythropoiesis (Diamond-Blackfan anemia, congenital dyserythropoietic anemia, congenital sideroblastic anemia): chronic RBC transfusion dependence at least every 8 weeks | Isolated disorders of erythropoiesis: bone marrow showing selective erythroid hypoplasia or dyserythropoiesis | Diamond-Blackfan anemia: failed at least one therapeutic trial of corticosteroids | Congenital thrombocytopenia syndromes (e.g., congenital amegakaryocytic thrombocytopenia): platelet transfusion dependence at least every 8 weeks | Congenital thrombocytopenia syndromes: MPL gene sequencing required | Renal function: serum creatinine <1.5 x ULN for age | Hepatic function: bilirubin <2.5 mg/dL (unless due to Gilbert syndrome or known hemolytic anemia) | Hepatic function: transaminases <= 5 x ULN | Cardiac function: shortening fraction >= 27% | Pulmonary function: DLCO >= 50% predicted or no baseline oxygen requirement in younger patients unable to perform PFTs | No active, untreated infections; bacterial infections on appropriate therapy with response | Fungal infections: received >= 2 weeks of appropriate antifungal therapy and asymptomatic | Viral infections: symptoms resolved and viremia (e.g., CMV, EBV) cleared prior to therapy | Lansky or Karnofsky performance status >= 60","Does not meet disease, organ function, or infectious disease criteria | Myelodysplastic syndrome by marrow dysplasia with classic cytogenetic lesion (e.g., monosomy 7, trisomy 8) with or without excess blasts | No suitable closely HLA-matched unrelated or haploidentical related donor available | Suitable fully matched related donor available | Pregnant females",Aplastic anemia: prior immunosuppressive therapy allowed if refractory or relapsed and at least 12 weeks after initiation; Diamond-Blackfan anemia: failed at least one corticosteroid trial,ALL,F,"Disease mismatch: the trial targets bone marrow failure syndromes (e.g., aplastic anemia, PNH, Fanconi anemia) and does not include ornithine transcarbamylase deficiency.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,Disease mismatch is a hard exclusion. The trial targets bone marrow failure syndromes and does not include OTC deficiency; thus F is appropriate regardless of other factors.,,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT03067181,0.7121695280075073,Recurrent Clear Cell Ovarian Carcinoma,A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors,PHASE3,Not specified,Germ Cell Tumor; Malignant Germ Cell Tumor; Extracranial Germ Cell Tumor; Malignant Ovarian Teratoma; Ovarian Embryonal Carcinoma; Ovarian Yolk Sac Tumor; Ovarian Choriocarcinoma; Testicular Seminoma; Testicular Embryonal Carcinoma; Testicular Yolk Sac Tumor; Testicular Choriocarcinoma; Extragonadal Embryonal Carcinoma; Testicular Mixed Choriocarcinoma and Embryonal Carcinoma; Testicular Mixed Choriocarcinoma and Teratoma; Testicular Mixed Choriocarcinoma and Yolk Sac Tumor,"Low risk stratum: no age limit | Standard risk 1: age < 11 years at enrollment | Standard risk 2: age >= 11 and < 25 years at enrollment | Low risk arms: newly diagnosed stage I germ cell tumor | Standard risk arms: newly diagnosed malignant germ cell tumor (stage II or higher) | Histologic confirmation of primary extracranial germ cell tumor required unless markedly elevated tumor markers (AFP >= 500 ng/mL or HCG >= 500 IU/L) with imaging consistent with GCT and biopsy not feasible/urgent therapy needed | Low risk ovarian immature teratoma: ovarian site; any stage/grade; pure or mixed immature/mature teratoma; may contain microscopic foci of yolk sac tumor (< 3 mm); AFP <= 1,000 ng/mL; beta-HCG normal; all ages | Low risk stage I non-seminoma MGCT: ovarian, testicular, or extragonadal; must contain yolk sac tumor, embryonal carcinoma, or choriocarcinoma (pure or mixed); all ages | Low risk stage I seminoma MGCT: testicular; histology only seminoma (may contain immature/mature teratoma); all ages | Standard risk 1: ovarian, testicular, or extragonadal; COG stage II–IV or FIGO IC–IV; must contain yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age < 11 years | Standard risk 2 ovarian: COG stage II, III, III-X or FIGO IC–III; must contain yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age >= 11 and < 25 years | Standard risk 2 testicular: COG stage II–IV, AJCC II–III, IGCCC good risk; must contain yolk sac tumor, embryonal carcinoma, or choriocarcinoma; post-op AFP < 1,000 ng/mL, beta-HCG < 5,000 IU/mL, LDH < 3 x ULN; age >= 11 and < 25 years | ECOG performance status 0–3 (Karnofsky for > 16 years; Lansky for <= 16 years) | Organ function requirements apply only to chemotherapy recipients (SR1 and SR2) | Adequate renal function: creatinine clearance or GFR >= 70 mL/min/1.73 m^2 within 7 days prior to enrollment or age/sex-specific serum creatinine threshold | Total bilirubin <= 2 x ULN (unless due to Gilbert's disease, malignant liver involvement, or vanishing bile duct syndrome) | AST and ALT < 3 x ULN (unless due to Gilbert's disease, malignant liver involvement, or vanishing bile duct syndrome) | Absolute neutrophil count >= 750/µL and platelets >= 75,000/µL within 7 days prior to enrollment | Standard risk arms: medically fit for protocol treatment with no contraindications to chemotherapy | AYA-HEARS substudy: age >= 11 and < 25 years; fluent in English; prior cisplatin- or carboplatin-based chemotherapy for any malignancy; followed for care at specified participating institutions","Stage I testicular cancer with prior primary retroperitoneal lymph node dissection | Pure ovarian or extragonadal dysgerminoma/seminoma | Pure mature teratoma | Pure immature teratoma with AFP >= 1000 ng/mL | Poor-risk germ cell tumor (age >= 11 years with COG stage IV ovarian, COG stage II–IV extragonadal, or IGCCC intermediate/poor-risk testicular) | Primary central nervous system germ cell tumor | Germ cell tumor with somatic malignant transformation | Spermatocytic seminoma | Prior systemic therapy for the current cancer diagnosis | Prior radiation therapy (except CNS irradiation for brain metastases in SR1 patients) | Significant pre-existing respiratory disease contraindicating bleomycin (ineligible for standard risk chemotherapy arms) | Pregnancy (for patients receiving chemotherapy) | Lactation with intent to breastfeed (for patients receiving chemotherapy) | Sexually active patients of reproductive potential not agreeing to effective contraception during study participation (for patients receiving chemotherapy)",No prior systemic therapy for current cancer diagnosis; No prior radiation therapy (except CNS irradiation for brain metastases in SR1 patients); Prior cisplatin- or carboplatin-based chemotherapy for another malignancy required for AYA-HEARS substudy eligibility,ALL,F,"Disease mismatch: the trial is for germ cell tumors (e.g., ovarian yolk sac, embryonal carcinoma, choriocarcinoma, teratoma), while the patient has clear cell ovarian carcinoma (epithelial). Additionally, the trial generally targets pediatric/AYA populations and often requires newly diagnosed disease without prior systemic therapy.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,F,"Hard exclusion applies: disease mismatch. The trial targets germ cell tumors (including ovarian germ cell subtypes), while the patient has epithelial clear cell ovarian carcinoma. This triggers an immediate F per rubric. The grader’s added notes on age/prior therapy are ancillary but do not affect the hard exclusion decision.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT03120624,0.759219765663147,Recurrent Clear Cell Ovarian Carcinoma,"Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer",PHASE1,18 years,Endometrial Carcinoma (recurrent); Endometrial Adenocarcinoma (recurrent); Endometrial Clear Cell Adenocarcinoma (recurrent); Endometrial Endometrioid Adenocarcinoma (recurrent); Endometrial Serous Adenocarcinoma (recurrent); Endometrial Undifferentiated Carcinoma (recurrent); Endometrial Mixed Cell Adenocarcinoma (recurrent); Uterine Carcinosarcoma (recurrent); Uterine Corpus Cancer (stage IV),"Stage IVA–IVB or recurrent endometrial carcinoma | Eligible histologies: endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, carcinosarcoma, adenocarcinoma NOS | Group A only: largest tumor diameter <= 5 cm (no maximum for Group B) | Life expectancy >= 12 weeks | ECOG performance status 0–2 | Prior chemotherapy, targeted therapy, external beam radiation, and/or hormonal therapy allowed if last treatment >= 4 weeks before registration | Vaginal brachytherapy may have been given at any time prior to registration","Availability of and patient acceptance of curative therapy | Active infection requiring treatment within 5 days prior to registration | Active or latent tuberculosis or hepatitis | Known untreated or symptomatic brain metastases | Chemotherapy < 4 weeks prior to registration | Targeted biologic therapy < 4 weeks prior to registration | Immunotherapy < 4 weeks prior to registration | Any prior viral or gene therapy | External beam radiotherapy < 4 weeks prior to registration | NYHA class III or IV heart failure, symptomatic coronary artery disease, or uncontrolled arrhythmias (atrial fibrillation or SVT) | Active CNS disorder, seizure disorder, known CNS disease, or neurologic symptoms | HIV infection, other immunodeficiency, or immunosuppression | History of hepatitis B or C or chronic hepatitis | Concurrent chemotherapy, immunotherapy, radiotherapy, or other investigational therapy | Treatment with systemic corticosteroids (excluding topical or inhaled) | Household contact with infants <= 15 months old or with known immunodeficiency | Pregnancy, nursing, or unwillingness to use effective contraception | Any condition deemed by the investigator to negatively impact treatment safety | Ongoing immunotherapy-related adverse events > grade 1 | Receipt of a live virus vaccine within 2 months prior to registration",Any number of prior chemotherapy regimens allowed; Any number of prior targeted therapies allowed; Prior external beam radiation therapy allowed; Prior hormonal therapy allowed; Last systemic treatment must be >= 4 weeks before registration; Vaginal brachytherapy may have been given at any time,FEMALE,F,"Disease mismatch: the trial enrolls recurrent/metastatic endometrial/uterine corpus cancers (including endometrial clear cell), while the patient has recurrent clear cell ovarian carcinoma, which is not included.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,F,"Correct: The trial is for endometrial/uterine corpus cancers, not ovarian cancer. Disease mismatch triggers a hard exclusion per rubric, so F is appropriate.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT03162432,0.9730192422866821,Crohn's Disease,High Dose Interval Vitamin D Supplementation in Patients With IBD Receiving Remicade,PHASE3,7 years to 25 years,Crohn Disease; Ulcerative Colitis,Existing diagnosis of inflammatory bowel disease | Age 0–25 years | Serum 25-OH vitamin D level 15–29 ng/mL within the last 8 weeks with no changes in vitamin D supplementation in the interim,"Pregnant | History of underlying kidney disease | History of granulomatous disease | Inability to take oral vitamin D | History of hypercalcemia | History of hypercalciuria | Currently taking an anti-epileptic medication | History of pre-existing liver disease (excluding primary sclerosing cholangitis, non-alcoholic fatty liver disease, or steatohepatitis)",(none),ALL,F,"The patient is 32 years old, which is outside the trial's 7–25-year age range, a hard exclusion. Other criteria (e.g., vitamin D level) are unknown, but the age mismatch alone makes the patient ineligible.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Age window conflict is a hard exclusion: patient is 32 while trial allows ages 7–25. Disease matches and other criteria are unknown, but the age mismatch alone triggers F per rubric. The grader’s reasoning aligns with the rubric.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT03406611,0.5333319902420044,Ornithine Transcarbamylase Deficiency,"A Double Blind, Randomized, Placebo-controlled, Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effects on Clinical Outcomes of Pegtibatinase (TVT-058), Administered Subcutaneously in Patients with Cystathionine Beta-Synthase Deficient Homocystinuria (COMPOSE)",PHASE1/PHASE2,12 years to 65 years,Homocystinuria,Genetic confirmation of cystathionine beta-synthase deficient homocystinuria | Plasma total homocysteine >= 50 micromoles/L with prior documented total homocysteine >= 80 micromoles/L,"Previous exposure to pegtibatinase or prior participation in a pegtibatinase trial | Use of injectable polyethylene glycol (PEG)–containing drugs within 3 months prior to screening and during study participation | Known hypersensitivity to PEG-containing products or any components of pegtibatinase | Positive test for HIV antibody, hepatitis B surface antigen, or hepatitis C antibody | History of organ transplantation | Chronic immunosuppressive therapy | Substance abuse | Pregnant or breastfeeding or planning pregnancy/breastfeeding during the study | Concurrent disease or condition that would interfere with study participation or safety in the opinion of the investigator | Planned major surgery during the study period | High risk of poor treatment compliance or not completing the study in the investigator's opinion",No investigational product or investigational medical device within 30 days prior to screening,ALL,F,"The trial targets CBS-deficient homocystinuria and requires genetic confirmation of CBS deficiency, whereas the patient has OTC deficiency; additionally, the patient is 3 months old, below the trial’s 12–65 year age range.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Multiple hard exclusions: disease mismatch (trial targets CBS-deficient homocystinuria; patient has OTC deficiency), required biomarker/subtype mismatch (CBS confirmation required, patient has OTC), and age outside window (3 months vs 12–65 years). Grade F is correct.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT03482479,0.615860641002655,Rheumatoid Arthritis,Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis,PHASE2,18 years,Giant Cell Arteritis; Takayasu Arteritis; Polyarteritis Nodosa; Granulomatosis With Polyangiitis; Microscopic Polyangiitis; Eosinophilic Granulomatosis With Polyangiitis,"Diagnosis of giant cell arteritis, Takayasu arteritis, polyarteritis nodosa, granulomatosis with polyangiitis, microscopic polyangiitis, or eosinophilic granulomatosis with polyangiitis per specified criteria | PROMIS Global Physical Health normalized score <= 40 at baseline | Vasculitis in remission or very low disease activity (Physician Global Assessment 0–1) for >= 12 weeks | Stable immunosuppressive therapy (including prednisone) related to vasculitis for >= 12 weeks | No change in medications in the past 12 weeks made with the expectation of improving pain, fatigue, or mood | No plan to change medication or non-pharmacologic treatment regimen likely to affect pain, fatigue, mood, or vasculitis activity during the next 12 weeks | Age >= 18 years","Change in any medication related to control of vasculitis, pain, fatigue, or mood within the past 12 weeks | Use of another investigational agent within 30 days of enrollment | Current use of any opioid agonist including tramadol or buprenorphine/naloxone | Change in vasculitis activity in the past 12 weeks (change in Physician Global Assessment > 1) | Baseline PROMIS Global Physical Health normalized score > 40 | New major medical problem or surgery in the past 12 weeks | Pregnancy or breastfeeding | Schizophrenia or bipolar disorder | Poorly controlled depression or anxiety (PHQ-9 >= 20) | Liver cirrhosis | Significant kidney disease (GFR < 30 mL/min)",Stable immunosuppressive therapy (including prednisone) allowed if stable for >= 12 weeks; >= 30-day washout from other investigational agents,ALL,F,"Disease mismatch: the trial enrolls specific vasculitides (e.g., GCA, GPA, MPA), not rheumatoid arthritis. The patient’s RA diagnosis makes them ineligible regardless of other factors.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"The trial targets specific vasculitides, not rheumatoid arthritis. This is a hard disease mismatch per the rubric, triggering an immediate F. The grader’s reasoning correctly identifies this.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT03520491,0.8203475475311279,Metastatic Urothelial Carcinoma,A Pilot Study to Evaluate the Safety of Neoadjuvant Nivolumab Alone or in Combination With Ipilimumab for Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (CA209-9DJ),PHASE2,18 years,"Bladder Cancer (urothelial, muscle-invasive); Upper Tract Urothelial Carcinoma","Histologically confirmed urothelial carcinoma of the bladder; variant histology allowed if predominantly urothelial. | Muscle-invasive bladder cancer (Cohorts 1–3): cT2–T4a cN0 cM0 by cystoscopy and imaging; cT4a with prostatic stromal invasion eligible without cystoscopic muscle invasion. | Upper tract urothelial carcinoma (Cohort U): High-grade urothelial carcinoma of ureter or renal pelvis with T2–T4a N0/x M0 and positive selective urinary cytology; hydronephrosis associated with tumor considered invasive; variant histology allowed if predominantly urothelial. | Cisplatin-ineligible: Creatinine clearance >= 30 mL/min and < 60 mL/min, or grade >= 2 hearing loss, or grade >= 2 peripheral neuropathy. | Availability of tumor block or 30 unstained slides from diagnosis of muscle-invasive disease (fewer allowed per PI discretion). | Karnofsky performance status >= 70%. | Medically appropriate candidate for radical cystectomy. | Age >= 18 years. | Baseline laboratory values meet protocol thresholds.","Prior systemic chemotherapy for urothelial cancer. | Prior immune checkpoint inhibitor therapy for non–muscle-invasive bladder cancer. | Prior bladder-directed radiotherapy (Cohorts 1–3). | Active autoimmune disease excluding permitted conditions (e.g., type 1 diabetes, residual hypothyroidism on replacement, certain skin disorders not requiring systemic therapy, asymptomatic autoantibodies, or conditions not expected to recur). | Systemic corticosteroids > 10 mg/day prednisone equivalent or other immunosuppressive medications within 14 days of first dose (except inhaled/topical/adrenal replacement). | Unstable angina. | NYHA class II or greater congestive heart failure. | Myocardial infarction within 6 months. | Stroke within 6 months. | Bleeding diathesis or coagulopathy (therapeutic anticoagulation allowed if on stable dose). | Major surgical procedure within 28 days prior to study (TURBT permitted). | Serious, non-healing wound, ulcer, or bone fracture. | Another active malignancy within 2 years, except definitively treated early-stage cancers with negligible risk of recurrence. | Prior therapy targeting T-cell co-stimulation/checkpoint pathways (e.g., anti–PD-1, anti–PD-L1, anti–PD-L2, anti–CTLA-4, anti–CD137); prior IL-2 permitted. | Intravesical BCG within 6 weeks of treatment. | Positive hepatitis B surface antigen or positive hepatitis C RNA/antibody indicating infection. | Known HIV infection or AIDS. | History of severe hypersensitivity to monoclonal antibodies or study drug components. | Pregnant or breastfeeding. | Women of childbearing potential not using acceptable contraception during treatment and for at least 23 weeks after last dose. | Male subjects unwilling to use contraception during treatment and for at least 31 weeks after last dose.",Intravesical BCG allowed with washout >= 6 weeks,ALL,F,"This trial requires non-metastatic (cM0) muscle-invasive urothelial carcinoma in the neoadjuvant setting with candidates for radical cystectomy, while the patient has metastatic urothelial carcinoma after second-line therapy. This required stage/setting mismatch is a hard exclusion.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"The trial requires non-metastatic (cM0) neoadjuvant setting candidates for radical cystectomy. The patient has metastatic disease after second-line therapy, a required stage/setting mismatch, which is a hard exclusion per the rubric. The F grade is appropriate.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT03531645,0.7126820087432861,Recurrent Clear Cell Ovarian Carcinoma,A Pilot Phase II Study of Neoadjuvant Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma,PHASE2,18 years,Low-Grade Serous Ovarian Carcinoma; Primary Peritoneal Carcinoma; Fallopian Tube Carcinoma,"Stage III or IV low-grade serous ovarian, primary peritoneal, or fallopian tube carcinoma deemed unlikely to be optimally cytoreduced and recommended for neoadjuvant therapy | Histologic diagnosis confirmed by surgical or core biopsy | Measurable disease by RECIST v1.1 | Women aged >= 18 years | ECOG performance status 0–1 | Resolution of acute toxic effects of prior therapy or surgery to CTCAE v4.03 grade <= 1 | Pre/perimenopausal women amenable to treatment with goserelin","Pregnant or breastfeeding | Serious preexisting medical conditions precluding participation (e.g., interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, history of major gastric or small bowel resection, Crohn's disease, ulcerative colitis, or baseline grade >= 2 diarrhea) | Current use of potent CYP3A4 inhibitors or inducers | Current use of drugs known to prolong the QT interval | Another malignancy within 3 years except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix | Previous chemotherapy or hormonal therapy for ovarian cancer | Known hepatitis B, hepatitis C, or HIV infection | Inability or unwillingness to swallow pills | Active infection requiring IV antibiotics or other uncontrolled intercurrent illness requiring hospitalization | History of syncope of cardiovascular etiology, ventricular arrhythmia, or sudden cardiac arrest | Prior hematopoietic stem cell or bone marrow transplantation | Coagulation abnormalities or anticoagulant therapy precluding intramuscular injections | Hypersensitivity to fulvestrant or abemaciclib or their excipients | Pre/perimenopausal women with hypersensitivity to GnRH agonists",Resolution of prior therapy or surgical toxicities to CTCAE v4.03 grade <=1,FEMALE,F,"Disease mismatch: the trial is for low-grade serous ovarian/fallopian tube/primary peritoneal carcinoma, while the patient has clear cell ovarian carcinoma. Additionally, the trial excludes any prior chemotherapy for ovarian cancer, and the patient received adjuvant carboplatin/paclitaxel/bevacizumab.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,F,"Correct: Hard exclusion due to disease mismatch (trial limited to low-grade serous; patient has clear cell). Additionally, explicit exclusion of prior chemotherapy applies since patient received adjuvant carboplatin/paclitaxel/bevacizumab.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT03531736,0.4508515000343323,PMM2-CDG,Allogeneic Hematopoietic Stem Cell Transplantation of α/β T-Lymphocyte Depleted Graft Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia,PHASE1,18 years,Acute Myeloid Leukemia; Myelodysplastic Syndrome; Myeloproliferative Neoplasm; MDS/MPN Overlap Syndrome; Chronic Myelomonocytic Leukemia; Chronic Myeloid Leukemia; Severe Aplastic Anemia; Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma; Multiple Myeloma,"Age >= 18 years | Bone marrow blasts <= 5% prior to conditioning | Acute Myeloid Leukemia in first complete remission with intermediate or high-risk features (non-good-risk cytogenetics) | Therapy-related Acute Myeloid Leukemia with history of prior antineoplastic therapy | Acute Myeloid Leukemia with normal karyotype and high-risk mutations (FLT3, RUNX1, TP53, ASXL1 or other high risk) | Acute Myeloid Leukemia in >= 2nd remission | Myelodysplastic Syndrome with IPSS INT-2 or high risk | Myelodysplastic Syndrome of any risk with life-threatening cytopenia | Myelodysplastic Syndrome with high-risk cytogenetic/genomic features (e.g., chromosome 7 or 3 abnormalities, TP53 mutation, complex or monosomal karyotype) | Myeloproliferative Neoplasm with high-risk features per protocol | MDS/MPN overlap syndrome with high-risk features per protocol | Chronic Myelomonocytic Leukemia | Chronic Myeloid Leukemia failed or intolerant to BCR-ABL tyrosine kinase inhibitors | Chronic Myeloid Leukemia with BCR-ABL mutation predicting poor TKI response (e.g., T351l) | Severe Aplastic Anemia | Chronic Lymphocytic Leukemia with high-risk disease per EBMT consensus criteria | Non-Hodgkin Lymphoma responding to therapy prior to enrollment | Non-Hodgkin Lymphoma with relapse after prior autologous transplant or ineligible for autologous transplant | Multiple Myeloma relapsed after autologous stem cell transplantation with at least partial response after additional chemotherapy | Multiple Myeloma with high-risk cytogenetics at diagnosis (complex karyotype, del17p, t(4;14), t(14;16) by FISH and/or del13 by karyotype) and at least partial response after autologous transplant | Karnofsky performance status >= 70% | Cardiac function: asymptomatic or, if symptomatic, LVEF >= 40% and improves with exercise | Hepatic function: ALT < 5 x ULN | Hepatic function: total bilirubin < 2 x ULN (unless congenital benign hyperbilirubinemia) | Renal function: creatinine clearance > 30 mL/min | Pulmonary function: DLCO > 50% predicted (hemoglobin-corrected)","Prior allogeneic hematopoietic stem cell transplantation | Prior total body irradiation >= 400 cGy | Bone marrow fibrosis with reticulin stain > 1/3 | Active and uncontrolled infection at time of transplantation | HIV infection | Seropositivity for HTLV-1 | Inadequate performance status or organ function | Pregnancy or breastfeeding | Unable to give informed consent or comply with protocol, supportive care, follow-up, or research tests",Therapy-related AML with prior antineoplastic therapy; CML: failed or intolerant to BCR-ABL tyrosine kinase inhibitors; Non-Hodgkin Lymphoma: responding to therapy prior to enrollment; Non-Hodgkin Lymphoma: relapsed after prior autologous transplant or ineligible for autologous transplant; Multiple Myeloma: prior autologous stem cell transplantation; Multiple Myeloma: at least partial response after additional chemotherapy,ALL,F,"Disease mismatch: the trial targets adult patients with specific hematologic malignancies or severe aplastic anemia, not PMM2-CDG. Additionally, the minimum age is 18, while the patient is 8, creating an age window conflict.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,Correct: There is a clear disease mismatch (PMM2-CDG not among trial diseases) and an age window conflict (patient 8 < trial min 18). Either hard exclusion yields F. The grader’s reasoning aligns with the rubric.,,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT03536767,0.5018824338912964,Ornithine Transcarbamylase Deficiency,An Open-Label Extension and Safety Monitoring Study of Patients with Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201,PHASE2,18 years to 90 years,Transthyretin Amyloid Cardiomyopathy,Completed participation in study AG10-201,"Hemodynamic instability that would pose too great a risk | Abnormalities in clinical laboratory tests that would pose too great a risk | Clinically significant ongoing medical condition or laboratory abnormality that could adversely affect safety | Known hypersensitivity to AG10, its metabolites, or excipients | Likely to undergo heart transplantation or mechanical circulatory device placement within the next year | Current treatment with diflunisal, tafamidis, green tea, doxycycline, ursodiol/TUDCA, patisiran, inotersen, or any other investigational ATTR agent within 14 days or 5 half-lives prior to dosing | Pregnant or breastfeeding","Completed prior study AG10-201; Washout >=14 days or 5 half-lives from prior diflunisal, tafamidis, green tea, doxycycline, ursodiol/TUDCA, patisiran, inotersen, or other investigational ATTR agent",ALL,F,"Disease mismatch (trial is for transthyretin amyloid cardiomyopathy, patient has OTC deficiency) and the patient is 3 months old, below the trial’s minimum age of 18.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,Disease mismatch (OTC deficiency vs ATTR-CM) and age below trial minimum (3 months vs ≥18) are both hard exclusions. F is correct per rubric.,,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT03542383,0.597878098487854,Dementia,Treatment of Memory Disorders in Gulf War Illness With High Definition Transcranial Direct Cortical Stimulation,NA,45 years to 78 years,Gulf War Illness; Memory Disorder,Right-handed,History of dementia | Moderate to severe traumatic brain injury | Brain tumor | Present or past drug abuse | Stroke | Cerebrovascular abnormalities in the brain | Parkinson's disease | Huntington's disease | Multiple sclerosis | Amphetamines use | Levodopa use | Carbamazepine use | Sulpiride use | Pergolide use | Lorazepam use | Rivastigmine use | Dextromethorphan use | D-cycloserine use | Flunarizine use | Ropinirole use | Citalopram use | Cardiac pacemaker | Implanted medication pump | Severe heart disease | Metal objects in or near the head that cannot be safely removed,(none),ALL,F,"The trial explicitly excludes participants with a history of dementia, and the patient has moderate-stage dementia. Therefore the patient is ineligible despite age and sex being within allowed ranges.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"The trial explicitly excludes participants with a history of dementia, and the patient has moderate-stage dementia. This is a hard exclusion per rubric, so grade F is correct regardless of other factors.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT03613116,0.5806409120559692,Dementia,Phase II RCT of High-dose Vitamin D Supplements in Older Adults,PHASE2,65 years to 90 years,Mild Cognitive Impairment; Alzheimer Disease (mild); Vitamin D Deficiency,"Age 65-90 years | Serum 25-hydroxyvitamin D < 20 ng/mL at screening | Fluent in English or Spanish | Willingness to be randomized to high-dose vs standard-dose vitamin D | Education-adjusted Montreal Cognitive Assessment (MOCA) score 12-30 at baseline | Consensus clinical diagnosis of No Cognitive Impairment, Mild Cognitive Impairment, or mild Alzheimer disease dementia | No Cognitive Impairment subgroup: MOCA >= 23 if education > 12 years or MOCA > 20 if education < 12 years | No Cognitive Impairment subgroup: CDR global usually 0; CDR may be 0.5 if Petersen MCI criteria not met and CDR-Sum of Boxes < 1.0 | Mild Cognitive Impairment subgroup: Amnestic MCI (single- or multiple-domain) with standardized memory scores > 1.5 SDs below average | Mild Cognitive Impairment subgroup: Global CDR = 0.5 | Mild Cognitive Impairment subgroup: MOCA > 20 if education > 12 years or MOCA > 17 if education < 12 years | Mild Alzheimer disease dementia subgroup: Probable or possible Alzheimer disease | Mild Alzheimer disease dementia subgroup: Global CDR = 1 | Mild Alzheimer disease dementia subgroup: MOCA > 15 if education > 12 years or MOCA > 12 if education < 12 years | Stable doses (> 6 weeks) of Alzheimer disease therapies (e.g., donepezil, memantine) permitted with no planned dose changes during the trial","Inadequate vision, hearing, or literacy to complete psychometric testing | Albumin < 3.3 g/dL | Alanine aminotransferase > 2 x ULN | Bilirubin > 2 x ULN | Aspartate aminotransferase > 3 x ULN | Serum creatinine > 1.7 mg/dL | Glomerular filtration rate < 40 mL/min/1.73 m2 | Hypercalcemia | Current serious or unstable medical illness that could interfere with safe participation or life expectancy < 4 years | History of recurrent renal stones | Unable to undergo MRI scanning | History of osteoporosis with screening 25-hydroxyvitamin D < 12 ng/mL | History of chronic psychiatric illness (e.g., schizophrenia, bipolar disorder) | Major depression within the last 2 years or current GDS > 6 | Recent suicide attempt or suicidal ideation | Serious infectious disease affecting the brain within 5 years | Head trauma within 5 years with > 10 minutes loss of consciousness or persistent cognitive deficit | Chronic alcohol or drug abuse/dependence within the past 5 years | Primary or recurrent malignant disease within the last 5 years (except resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or non-metastatic prostate cancer with normal PSA post-treatment) | Poor venous access precluding multiple blood draws | Regular use of benzodiazepines | Regular use of antipsychotics | Regular use of narcotics | Regular use of cholinesterase inhibitors (non-stable dosing) | Regular use of memantine (non-stable dosing) | Regular use of anti-epileptic drugs | Planned changes in doses of CNS-active medications during the trial | Plans to change dosage of any vitamin supplement during the study (unless to treat a documented deficiency) | Current participation in a clinical trial involving experimental Alzheimer disease therapies | Pregnancy or planning pregnancy during the trial | Inability to swallow oral capsules | History of multiple strokes | More than two incidental infarcts on structural MRI",Stable acetylcholinesterase inhibitor therapy >= 6 weeks allowed; Stable memantine therapy >= 6 weeks allowed; Stable SSRI or SNRI antidepressant doses allowed,ALL,F,"Disease mismatch: the trial enrolls No Impairment, MCI, or mild Alzheimer’s disease dementia, whereas the patient has moderate-stage dementia, which is not an included cohort. The required vitamin D deficiency and mild AD diagnosis are also not established.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"F is appropriate due to disease/cohort mismatch: the trial accepts only no impairment, MCI, or mild Alzheimer’s dementia, while the patient has moderate-stage dementia and no confirmed AD diagnosis. That is a hard exclusion under the rubric. The mention of vitamin D deficiency being unknown is not needed for F, but does not change the correct outcome.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT03613532,0.4264906644821167,PMM2-CDG,"A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination With a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients With High Risk AML, MDS, and MDS/MPN Overlap Syndromes",PHASE1,18 years,Acute Myeloid Leukemia; Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; MDS/MPN-Unclassifiable,"Age >= 18 years | High-risk Myelodysplastic Syndrome as defined (e.g., IPSS Int-2 or higher; TP53 mutation; RAS pathway mutation [NRAS, KRAS, PTPN11, CBL, NF1, RIT1, FLT3, KIT]; therapy-related MDS) | High-risk Acute Myeloid Leukemia as defined (e.g., ELN adverse risk features including TP53, RUNX1, ASXL1 mutations; KMT2A rearrangement; BCR-ABL1; inv(3)/t(3;3) [GATA2, MECOM(EVI1)]; t(6;9) [DEK-NUP214]; -5/del(5q); -7; -17/abn(17p); complex or monosomal karyotype; wild-type NPM1 with FLT3-ITD high; secondary AML; or ‘secondary-type’ AML gene mutations) | High-risk CMML or MDS/MPN-unclassifiable defined by trisomy 8, chromosome 7 abnormalities, complex karyotype, or ASXL1 mutation | AML with measurable residual disease by flow cytometry >= 0.1% despite morphologic remission (per PI review) eligible | Candidate for reduced-intensity conditioning allo-HCT with peripheral blood stem cell source | Matched related or 8/8 matched unrelated donor available | ECOG performance status <=2 | Total bilirubin <= 2 x ULN (Gilbert syndrome exception allowed) | AST <= 3 x ULN | ALT <= 3 x ULN | Creatinine clearance >= 30 mL/min (Cockcroft-Gault) | Part 2/3: No DLT from venetoclax addition prior to maintenance | Part 2/3: No morphologic relapse (blasts <5%) on marrow after day +28 prior to maintenance | Part 2/3: ANC >= 1.0 K/uL without growth factor and platelets >= 50 K/uL without transfusion within 7 days of starting maintenance | Part 2/3: Total bilirubin <= 2 x ULN (unless Gilbert’s) | Part 2/3: AST and ALT <= 3 x ULN | Part 2/3: Creatinine clearance >= 30 mL/min | Part 2/3: Absence of overall grade II–IV acute GVHD or after its resolution; prednisone <= 0.5 mg/kg/day allowed | Part 4: Left ventricular ejection fraction >= 45% within 3 months prior to first dose | No concurrent illnesses preventing oral therapy or interfering with safety assessment","Chemotherapy, radiotherapy, or investigational therapy within 14 days prior to first study dose (exceptions: hydroxyurea and/or dexamethasone) | Ongoing venetoclax within 3 days prior to first study dose | Use of BCR-ABL, IDH, or FLT3 inhibitors within 5 days prior to first study dose | MDS or MDS/MPN with >10% morphologic blasts on bone marrow biopsy | AML with >5% morphologic blasts on bone marrow biopsy | Candidates recommended for myeloablative conditioning regimen | Prior allogeneic stem cell transplantation | Symptomatic or untreated known CNS involvement of disease | Active heart disease (NYHA class 3–4) or unstable angina, stroke, or myocardial infarction within 6 months before first dose | Consumption of grapefruit, Seville oranges, or starfruit within 3 days prior to treatment or use of strong/moderate CYP inducers within 7 days before first dose | Malabsorption syndrome or significant condition precluding enteral administration | Other severe acute/chronic medical or psychiatric condition or lab abnormality increasing study risk or interfering with interpretation | Active hepatitis B infection (unless on effective therapy with undetectable HBV DNA and no liver complications) | Active hepatitis C infection (unless successfully treated or antibody positive with undetectable HCV RNA) | Known active HIV infection (due to potential drug-drug interactions with HAART) | Pregnant or breastfeeding or intending pregnancy during study or within 3 months after final dose | Live attenuated vaccine within 4 weeks prior to initiation or anticipated during study | Uncontrolled infection at time of first dose (antimicrobials allowed if hemodynamically stable) | Part 2/3/4: Recommended to receive FLT3 inhibitor or any other antileukemic maintenance post allo-HCT","No minimum or limit on prior therapy for advanced myeloid malignancy; Prior exposure to venetoclax allowed; Washout >=14 days from chemotherapy, radiotherapy, or investigational therapy (except hydroxyurea and/or dexamethasone) before first dose; BCR-ABL, IDH, and FLT3 inhibitors may continue until 5 days prior to first dose; If on venetoclax pre-transplant, require 3-day washout before first study dose",ALL,F,"Disease mismatch: the trial is for high-risk AML/MDS/CMML/MDS/MPN, not PMM2-CDG. Age mismatch: the trial requires ≥18 years, while the patient is 8 years old.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,"Hard exclusions apply: disease mismatch (trial is for AML/MDS/CMML/MDS/MPN, not PMM2-CDG) and age window conflict (trial ≥18 vs patient 8). F is correct per rubric.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT03635892,0.5362201929092407,Ornithine Transcarbamylase Deficiency,A Phase 2 Open-Label Study of Nivolumab Combined With Cabozantinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (CA209-9KU),PHASE2,18 years,"Renal Cell Carcinoma (non-clear cell, metastatic)",Histologically confirmed unresectable advanced or metastatic non-clear cell RCC | 0–1 prior systemic therapies allowed | Measurable disease per RECIST 1.1 | Age >= 18 years | Karnofsky >= 70% | Toxicities from prior therapy <= Grade 1 | Adequate hematologic and organ function | Creatinine clearance >= 30 mL/min | Urine protein/creatinine ratio <= 1 mg/mg | Serum albumin >= 2.8 g/dL,"Prior PD-1, PD-L1, CTLA-4, or high-dose IL-2 | Prior cabozantinib for non-clear cell RCC | Small molecule kinase inhibitor within 2 weeks | Anticancer antibodies, cytotoxic therapy, or investigational agents within 4 weeks | Active brain, spinal cord, or leptomeningeal metastases | Systemic corticosteroids > 10 mg prednisone equivalents or immunosuppressants within 14 days | Uncontrolled pleural, pericardial effusion, or ascites | Uncontrolled hypercalcemia | Another malignancy within 2 years (exceptions apply) | Pregnant or breastfeeding | HIV infection | Active or chronic hepatitis B or C | Significant cardiovascular disease or EF < 50% | Uncontrolled hypertension > 150/100 mmHg | Recent stroke or TIA within 6 months | Significant vascular disease within 6 months | Bleeding diathesis or significant coagulopathy | GI obstruction or abdominal free air | Recent abdominal fistula, perforation, or intraabdominal abscess | Serious non-healing wounds or fractures | Moderate to severe hepatic impairment (Child-Pugh B or C) | QTcF > 500 ms | Inability to swallow tablets or capsules | Allergy to study drug components | Clinically significant recent bleeding | Cavitating pulmonary lesions or endobronchial disease | Tumor invading major vessels or GI tract | Recent radiation within protocol-defined windows | Concomitant warfarin or prohibited anticoagulants",0 or 1 prior systemic therapies allowed; Washout: small molecule kinase inhibitors >= 2 weeks; Washout: antibodies/cytotoxic/investigational agents >= 4 weeks,ALL,F,"Disease mismatch: the trial targets advanced/metastatic non-clear cell renal cell carcinoma, not OTC deficiency. Additionally, the patient is 3 months old, below the minimum age of 18 years.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,Hard exclusions apply: disease mismatch (OTC deficiency vs non-clear cell RCC) and age below minimum (3 months vs ≥18 years). Either mandates F. The grader correctly identified these and assigned F.,,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT03639701,0.41768473386764526,PMM2-CDG,Deoxythymidine and Deoxycytidine Treatment for Thymidine Kinase 2 (TK2) Deficiency,PHASE1/PHASE2,Not specified,Thymidine Kinase 2 Deficiency; Mitochondrial DNA Depletion Syndrome 2 (myopathic),Genetically confirmed TK2 deficiency | Symptomatic due to TK2 deficiency | Single-gene disease; absence of polygenic disease | Hematocrit within normal range for age,Clinical history of bleeding or abnormal PT/PTT | Hepatic insufficiency with LFTs > 2 x ULN | Renal insufficiency requiring dialysis | Concurrent inborn error of metabolism (other than TK2 deficiency) | Severe end-organ hypoperfusion secondary to cardiac failure resulting in lactic acidosis,(none),ALL,F,"Disease mismatch: the trial is for TK2 deficiency and requires genetically confirmed TK2 mutations, while the patient has PMM2-CDG with PMM2 biallelic variants. This fails the trial’s required disease/biomarker criteria.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,"There is a clear hard exclusion: disease mismatch. The trial requires TK2 deficiency with genetically confirmed TK2 mutations, while the patient has PMM2-CDG with PMM2 variants. Per rubric, disease mismatch (and required biomarker mismatch) triggers an F. The grader’s reasoning and grade are correct.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT03639701,0.48333805799484253,Ornithine Transcarbamylase Deficiency,Deoxythymidine and Deoxycytidine Treatment for Thymidine Kinase 2 (TK2) Deficiency,PHASE1/PHASE2,Not specified,Thymidine Kinase 2 Deficiency; Mitochondrial DNA Depletion Syndrome 2 (myopathic),Genetically confirmed TK2 deficiency | Symptomatic due to TK2 deficiency | Single-gene disease; absence of polygenic disease | Hematocrit within normal range for age,Clinical history of bleeding or abnormal PT/PTT | Hepatic insufficiency with LFTs > 2 x ULN | Renal insufficiency requiring dialysis | Concurrent inborn error of metabolism (other than TK2 deficiency) | Severe end-organ hypoperfusion secondary to cardiac failure resulting in lactic acidosis,(none),ALL,F,"Disease mismatch: the trial targets TK2 deficiency and requires genetically confirmed TK2 mutations, while the patient has ornithine transcarbamylase (OTC) deficiency with an OTC mutation.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Disease mismatch: the trial targets TK2 deficiency and requires genetically confirmed TK2, while the patient has OTC deficiency. This is a hard exclusion per rubric, so F is correct.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT03661645,0.5917590260505676,Rheumatoid Arthritis,Post-operative Methylprednisolone Taper Course for Orthopedic Surgery,PHASE4,18 years to 95 years,Upper Extremity Fracture; Hip Osteoarthritis; Knee Osteoarthritis; Carpal Tunnel Syndrome; Upper Extremity Tendon Injury; Upper Extremity Arthritis,"Undergoing surgery for an upper extremity fracture | Undergoing total shoulder arthroplasty or reverse shoulder arthroplasty | Undergoing surgery for upper extremity arthritis | Undergoing release for upper extremity compressive neuropathies (e.g., carpal tunnel) | Undergoing procedures for upper extremity tendon pathologies (e.g., tendon repair) | Undergoing total hip arthroplasty for osteoarthritis of the hip | Undergoing total knee arthroplasty for osteoarthritis of the knee | Age 18 to 95 years",Concurrent significant injuries to other bones or organs | Local infection | Minors or vulnerable subjects | Allergy to glucocorticoids | Daily use of glucocorticoids | Chronic opioid use prior to injury | Severe heart disease (NYHA 2) | Renal failure | Liver dysfunction | Active peptic ulcer disease | Diabetic neuropathy | Rheumatoid arthritis | Neurological diseases potentially influencing pain perception | Psychiatric diseases potentially influencing pain perception | Pregnancy | Pre-existing immunosuppression | Non-compliance risk per investigator judgment,(none),ALL,F,"Disease mismatch: the trial targets orthopedic surgical conditions (e.g., fractures, osteoarthritis) and does not include rheumatoid arthritis. Additionally, rheumatoid arthritis is explicitly listed as an exclusion.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,Correct: The trial does not target rheumatoid arthritis (disease mismatch hard exclusion) and explicitly lists rheumatoid arthritis as an exclusion. Either condition triggers an F. The grader’s reasoning and grade align with the rubric.,,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT03671148,0.7093204259872437,Rheumatoid Arthritis,"A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE 2)",PHASE3,18 years,Psoriatic Arthritis,Clinical diagnosis of psoriatic arthritis with symptom onset >= 6 months before screening | Meets CASPAR criteria for psoriatic arthritis at screening | Active disease: >= 5 tender joints (68-joint count) and >= 5 swollen joints (66-joint count) at screening and baseline | Diagnosis of active plaque psoriasis with >= 1 plaque of >= 2 cm diameter or nail changes consistent with psoriasis at screening | Inadequate response or intolerance to biologic therapy(ies) or conventional synthetic DMARD therapy(ies),Investigator deems participant unsuitable for the study | Known hypersensitivity to risankizumab,Prior biologic therapy with inadequate response or intolerance; Prior conventional synthetic DMARD therapy with inadequate response or intolerance,ALL,F,"Hard exclusion: The trial targets psoriatic arthritis and requires CASPAR-defined PsA, while the patient has rheumatoid arthritis. Other factors are moot given the disease mismatch.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Disease mismatch is a hard exclusion: trial is for psoriatic arthritis (requires CASPAR and active psoriasis), while the patient has rheumatoid arthritis. The grader correctly assigned F based on this hard exclusion.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT03719859,0.6041219830513,Rheumatoid Arthritis,Multicenter Randomized Trial of Home vs. Physical Therapist-Directed Rehabilitation for Reverse Total Shoulder Arthroplasty,NA,Not specified,Rotator Cuff Tear Arthropathy; Shoulder Arthritis,Reverse total shoulder arthroplasty for cuff tear arthropathy | Reverse total shoulder arthroplasty for massive irreparable rotator cuff tear with pseudoparalysis | Reverse total shoulder arthroplasty for primary osteoarthritis,Non-reverse total shoulder arthroplasty | Reverse total shoulder arthroplasty for fracture | Tendon transfers as part of reverse total shoulder arthroplasty | Revision reverse total shoulder arthroplasty | Cognitive deficits limiting ability to follow directions,Reverse total shoulder arthroplasty,ALL,F,"Disease mismatch: the trial targets patients undergoing reverse total shoulder arthroplasty for rotator cuff tear arthropathy or shoulder osteoarthritis, not rheumatoid arthritis. The patient is not specified to be in the required surgical cohort.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Disease mismatch is a hard exclusion. The trial targets reverse total shoulder arthroplasty cohorts (rotator cuff tear arthropathy/primary OA), not rheumatoid arthritis. The grader correctly assigned F based on this hard exclusion.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT03725007,0.5699001550674438,Rheumatoid Arthritis,"An Open-Label Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis",PHASE1,2 years to 17 years,Juvenile Idiopathic Arthritis (polyarticular course),"Total body weight >=10 kg at screening | Diagnosis of polyarticular-course JIA (RF-positive or RF-negative polyarticular JIA, extended oligoarticular JIA, or systemic JIA with active arthritis and without active systemic features) with history of arthritis affecting >=5 joints within first 6 months of disease (for extended oligoarticular JIA: <=4 joints within first 6 months and >4 joints thereafter) | >=5 active joints at screening (swollen joints not due to deformity, or limitation of movement with pain on motion and/or tenderness; limitation of movement present in at least 3 active joints) | If receiving methotrexate, on MTX for >=12 weeks before and including Day 1 with stable dose <=20 mg/m2 for >=8 weeks before and including Day 1, with folic acid or folinic acid supplementation per standard of care | If on oral glucocorticosteroids, stable dose for >=1 week before and including Day 1 (<=10 mg/day or 0.2 mg/kg/day, whichever is lower)",Diagnosis of enthesitis-related arthritis or juvenile psoriatic arthritis | Prior exposure to a JAK inhibitor,Stable methotrexate for >=12 weeks with stable dose <=20 mg/m2 for >=8 weeks; Folic acid or folinic acid supplementation with methotrexate; Stable oral glucocorticoids (<=10 mg/day or 0.2 mg/kg/day) for >=1 week,ALL,F,"Hard exclusions: The trial is for pediatric polyarticular-course JIA (ages 2–17), while the patient has rheumatoid arthritis and is 55 years old. This is both a disease mismatch and an age window conflict.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Correct: The patient has adult rheumatoid arthritis and is 55 years old, while the trial targets pediatric polyarticular-course JIA with an age range of 2–17. Both disease mismatch and age window conflict are hard exclusions, warranting an F.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT03772977,0.7082419395446777,Dementia,The Brain Health Champion Study: Promoting Non-pharmacological Interventions in Cognitive Disorders and Those at Risk,NA,60 years to 79 years,Mild Cognitive Impairment; Mild Dementia; Subjective Cognitive Decline,"Age 60–79 years | Neurology participants: Diagnosis of Subjective Cognitive Disorder; Mild Cognitive Impairment due to Alzheimer disease, cerebrovascular disease, or mixed AD/CVD; or mild dementia due to AD, CVD, or mixed AD/CVD. | Primary care participants: CAIDE dementia risk score >= 6, or CAIDE = 5 plus a first-degree relative with ADRD, or type 2 diabetes or prediabetes (A1C >= 5.7).",Enrolled in another health behavior or non-pharmacologic intervention for a neurocognitive disorder. | Unable or unwilling to carry out regular physical exercise multiple times weekly. | Not recommended to participate by their Internist/Primary Care Provider due to health-related concerns.,(none),ALL,F,"The trial enrolls only SCD, MCI, or mild dementia, while the patient has moderate-stage dementia (MMSE 19), which does not meet the required stage. Although age and sex fit, this stage mismatch is a hard exclusion.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"Trial explicitly requires SCD, MCI, or mild dementia; patient has moderate-stage dementia. That is a required stage/setting the patient definitively lacks, which is a hard exclusion per rubric. Age and sex match do not overcome this. Grade F is correct.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT03836300,0.42293858528137207,PMM2-CDG,Piloting an Early Intervention Program for Infants With Rare Neurogenetic Disorders,NA,up to 99 years,Angelman Syndrome; Chromosome 22q11.2 Deletion Syndrome; Down Syndrome; Duchenne Muscular Dystrophy; Dup15Q Syndrome; Fragile X Syndrome; Klinefelter Syndrome; Phelan-McDermid Syndrome; Prader-Willi Syndrome; Rett Syndrome; Smith Magenis Syndrome; Tuberous Sclerosis; Turner Syndrome; Williams Syndrome,"Age <= 15 months at enrollment | Genetic diagnosis established not solely due to parental concerns (e.g., via prenatal/newborn screening or cascade testing)",Blindness | Severe hearing impairment,(none),ALL,F,"Disease mismatch: the trial targets specific neurogenetic syndromes (e.g., Angelman, Rett) and does not include PMM2-CDG. Additionally, the trial requires infants ≤15 months, while the patient is 8 years old.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,"Disease mismatch is a hard exclusion because PMM2-CDG is not among the trial’s listed diseases; thus F is correct. The grader also noted the infant age requirement (≤15 months) versus patient age (8 years), which further supports ineligibility, though the disease mismatch alone suffices.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT03887455,0.5751073360443115,Dementia,"A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease",PHASE3,50 years to 90 years,Alzheimer's Disease (early),"MCI due to Alzheimer's disease meeting NIA-AA core clinical criteria (intermediate likelihood) | Global CDR = 0.5 and CDR Memory Box >= 0.5 at Screening and Baseline (for MCI cohort) | Probable Alzheimer's disease dementia (mild) meeting NIA-AA core clinical criteria | Global CDR 0.5–1.0 and CDR Memory Box >= 0.5 at Screening and Baseline (for mild AD dementia cohort) | Objective episodic memory impairment: WMS-IV Logical Memory II at least 1 SD below age-adjusted mean | Positive biomarker for brain amyloid pathology | Age >= 50 and <= 90 years | MMSE score >= 22 and <= 30 at Screening and Baseline | BMI > 17 and < 35 at Screening | If on acetylcholinesterase inhibitor or memantine, must be on a stable dose for >= 12 weeks prior to Baseline","Any neurological condition contributing to cognitive impairment beyond Alzheimer's disease | History of transient ischemic attack, stroke, or seizures within 12 months of Screening | Psychiatric diagnosis or symptoms that could interfere with study procedures (e.g., hallucinations, major depression, delusions) | Geriatric Depression Scale score >= 8 at Screening | Contraindications to MRI scanning (e.g., pacemaker/defibrillator, ferromagnetic implants not approved for MRI) | Clinically significant brain MRI lesions suggesting non-AD dementia | More than 4 microhemorrhages (<= 10 mm), a single macrohemorrhage > 10 mm, superficial siderosis, vasogenic edema on MRI | Evidence on MRI of cerebral contusion, encephalomalacia, aneurysm, vascular malformation, infective lesion, multiple lacunar infarcts, major territorial stroke, severe small vessel disease, severe white matter disease, space-occupying lesion, or brain tumor (except meningioma or arachnoid cyst < 1 cm) | Immunological disease not adequately controlled or requiring treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives), systemic immunosuppressants, or plasmapheresis during the study | Bleeding disorder not adequately controlled, including platelet count < 50,000/µL or INR > 1.5 if not on anticoagulant treatment | Other significant uncontrolled medical conditions (cardiac, respiratory, gastrointestinal, renal) that could affect safety or assessments | Participation in a clinical study with any therapeutic monoclonal antibody, antibody-derived protein, immunoglobulin therapy, or vaccine within 6 months before Screening unless randomized to placebo | Participation in a clinical study with any anti-amyloid therapy (including monoclonal antibodies or BACE inhibitors) unless only placebo was received | Any known prior exposure to lecanemab | Participation in a clinical study with any new chemical entity for Alzheimer's disease within 6 months prior to Screening unless in a placebo arm | Hypersensitivity to lecanemab (BAN2401) or any monoclonal antibody treatment | Malignant neoplasms not stably and adequately controlled (except basal/squamous cell carcinoma in situ of skin or localized prostate cancer) | Severe visual or hearing impairment preventing accurate psychometric testing",Stable dose of acetylcholinesterase inhibitor and/or memantine for >= 12 weeks prior to Baseline (treatment-naive also allowed); For autoinjector substudy: at least 6 months prior exposure to lecanemab 10 mg/kg IV biweekly or lecanemab Dose 1 subcutaneous weekly; For subcutaneous Dose 3 autoinjector substudy: prior lecanemab (IV and/or SC) and completion of Extension Week 79 or later,ALL,F,"The trial requires early Alzheimer's disease with a positive amyloid biomarker and MMSE 22–30; the patient is amyloid PET/CSF negative with MMSE 19 and moderate-stage dementia, failing required eligibility.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"The trial requires a positive amyloid biomarker; the patient is definitively amyloid-negative (PET and CSF), which is a hard exclusion. MMSE 19 and moderate-stage (vs early AD) further support ineligibility but are not needed for the F. The grader correctly applied the rubric.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT03902951,0.7591832280158997,Metastatic Castration-Resistant Prostate Cancer,"A Single-Arm, Open-Label, Phase II Study of Systemic and Tumor Directed Therapy for Recurrent Oligometastatic M1 Prostate Cancer",PHASE2,18 years,Metastatic Prostate Adenocarcinoma; Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation; Recurrent Prostate Carcinoma; Prostate Cancer (Stage IVB),"Histologically confirmed prostate adenocarcinoma after radical prostatectomy (adenocarcinoma with neuroendocrine differentiation allowed; primary small cell not allowed) | 1–5 visible metastases by PSMA PET-CT | At least one metastasis M1a–M1b | No visceral metastases | Any number of pelvic nodal metastases allowed if largest < 2 cm | Metastases amenable to SBRT | Biopsy of one metastasis attempted unless unsafe | Fit to undergo SBRT to all visible sites and ADT | Total testosterone > 150 ng/dL prior to ADT | ECOG 0–1 | Hemoglobin >= 9.0 g/dL (independent of transfusion/growth factors within 3 months) | Platelet count >= 100,000/µL (independent of transfusion/growth factors within 3 months) | Serum albumin >= 3.0 g/dL | Glomerular filtration rate >= 45 mL/min | Serum potassium >= 3.5 mmol/L | Total bilirubin <= 1.5 x ULN (Gilbert syndrome exception allowed if direct bilirubin <= 1.5 x ULN) | AST or ALT <= 2.5 x ULN | Medications that lower seizure threshold discontinued or substituted >= 4 weeks prior to study entry","Evidence of spinal cord compression (radiologic or clinical) | Prior pelvic malignancy | Prior pelvic radiation aside from salvage prostate radiation | Concurrent malignancy aside from superficial skin cancers or superficial bladder tumors | Inability to undergo radiotherapy or ADT | Primary small cell carcinoma of the prostate | Inflammatory bowel disease or active collagen vascular disease | History of seizure or condition predisposing to seizure | Prior stroke within 1 year prior to randomization | Brain arteriovenous malformation, Schwannoma, meningioma, or other benign CNS/meningeal disease which may require surgery or radiotherapy | Severe or unstable angina within 6 months prior to randomization | Myocardial infarction within 6 months prior to randomization | Symptomatic congestive heart failure within 6 months prior to randomization | Arterial or venous thromboembolic events within 6 months prior to randomization | Clinically significant ventricular arrhythmias within 6 months prior to randomization | Uncontrolled hypertension | Gastrointestinal disorder affecting absorption | Active infection including HIV or viral hepatitis | Chronic corticosteroid requirement > 10 mg prednisone/prednisolone once daily | Concomitant strong CYP3A4 inducers | Treatment with CYP2D6 substrates with a narrow therapeutic index (unless an alternative or dose reduction is used) | Baseline moderate or severe hepatic impairment (Child-Pugh Class B or C) | Presence of visceral metastases (M1c)",Discontinue or substitute medications that lower the seizure threshold >= 4 weeks before study entry,MALE,F,"The trial explicitly excludes patients with visceral metastases (M1c), and the patient has PSMA PET–avid liver metastases. This is a definitive exclusion.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with visceral metastases (M1c). The patient has liver metastases, a visceral site, so this is a hard exclusion. The grader correctly applied the rubric and assigned F for this explicit exclusion.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03915951,0.8452445864677429,Metastatic Non-Small Cell Lung Cancer,"A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer",PHASE2,18 years,Non-small Cell Lung Cancer (metastatic),"Histologically confirmed non-small cell lung cancer, Stage IV | BRAF V600 mutation in tumor (V600E; V600K/D allowed) | Treatment-naive or one prior line of systemic therapy for advanced/metastatic disease | Measurable disease per RECIST v1.1 | ECOG performance status 0–1 | Adequate bone marrow, hepatic, and renal function","EGFR mutation, ALK fusion, or ROS1 rearrangement | More than one prior line of systemic therapy in the advanced/metastatic setting | Prior treatment with any BRAF inhibitor | Prior treatment with any MEK inhibitor | Impaired cardiovascular function or clinically significant cardiovascular disease | Thromboembolic or cerebrovascular events within 12 weeks prior to first dose | History or current evidence of retinal vein occlusion or risk factors for RVO | History of retinal degenerative disease | Concurrent neuromuscular disorder associated with elevated CK | Symptomatic brain metastases, leptomeningeal disease, or other active CNS metastases",Treatment-naive allowed; One prior line with platinum-based chemotherapy allowed; One prior line with PD-1/PD-L1 inhibitor allowed,ALL,F,"The trial requires a BRAF V600 mutation and explicitly excludes patients with EGFR mutations; the patient has an EGFR exon 19 deletion, which is a hard exclusion.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"The trial explicitly excludes EGFR mutations and requires BRAF V600; the patient has an EGFR exon 19 mutation and lacks BRAF V600. This is a hard exclusion, so F is correct.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT03924414,0.6197726130485535,Dementia,TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease,PHASE4,60 years,Parkinson Disease; Progressive Supranuclear Palsy; Multiple System Atrophy; Corticobasal Degeneration; Vascular Parkinsonism; Dementia With Lewy Bodies,"Age >= 60 years | Diagnosis of Parkinson's disease or neurodegenerative parkinsonism (e.g., progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, vascular parkinsonism, dementia with Lewy bodies) confirmed by neurologist assessment or telemedicine screening | Willing and able to continue follow-up for >= 2 years | Able to provide informed consent","History of hip fracture | Any bisphosphonate use within the last 12 months | Use of other osteoporosis treatments (e.g., SERMs, denosumab) within the last 6 months | Tooth extraction or invasive dental procedure within the past 30 days or planned in the next 12 months | Non-ambulatory (unable to walk without assistance of another person) | Undergoing kidney dialysis | Diagnosis of multiple myeloma or Paget's disease",(none),ALL,F,"Disease mismatch: the trial requires Parkinson’s disease or related parkinsonism (including dementia with Lewy bodies), while the patient has unspecified dementia without a PD/parkinsonism or DLB diagnosis. Age and sex fit but disease criteria are not met.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion: the trial requires Parkinson’s disease/parkinsonism (incl. DLB), while the patient has unspecified dementia with no PD/parkinsonism/DLB specified. Thus F is correct.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT03934840,0.8058024644851685,Metastatic Castration-Resistant Prostate Cancer,"A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer",PHASE2,18 years,"Prostate Cancer (metastatic, castration-sensitive)",Histologically confirmed prostate cancer | High-volume metastatic disease (visceral metastases or >=3 bone lesions) | Androgen deprivation therapy for <=3 months by day 1 of study chemotherapy; prior courses of ADT with radiation allowed | Testosterone <=50 ng/dL; continue primary ADT with an LHRH analogue if no orchiectomy | ECOG Performance Status 0–1 | Age >= 18 years,"Prior chemotherapy, PARP inhibitor, or immunotherapy for prostate cancer | Prior abiraterone or enzalutamide unless therapy was <2 weeks | Radiation therapy within 14 days prior to first dose | Major surgery within 28 days prior to first dose | Other systemic therapies for prostate cancer within 28 days or 5 half-lives (whichever is shorter) prior to day 1 of chemotherapy, except anti-androgens like bicalutamide | PSA <2.0 ng/mL at diagnosis | Peripheral neuropathy > Grade 1 | Active second malignancy that could interfere with participation | Central nervous system involvement unless >=4 weeks from prior therapy, clinically stable, and only if symptomatic screening is indicated | Severe psychiatric illness or social situation limiting compliance | History of non-compliance to medical regimens or inability to grant consent","Androgen deprivation therapy <= 3 months before day 1; prior ADT courses with radiation allowed; Must continue androgen deprivation therapy with LHRH analogue or have undergone orchiectomy; Radiation therapy washout >=14 days before first dose; Major surgery washout >=28 days before first dose; Other systemic prostate cancer therapies require washout of >=28 days or 5 half-lives (whichever is shorter), except bicalutamide; Prior abiraterone or enzalutamide allowed only if <2 weeks exposure",MALE,F,"The trial is for metastatic castration-sensitive prostate cancer and excludes prior abiraterone or enzalutamide use >2 weeks, whereas the patient has metastatic castration-resistant disease with long prior exposure to both. This is a hard disease-setting mismatch and an explicit exclusion.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,F,Hard exclusions apply: (1) Disease-setting mismatch (trial is for metastatic castration-sensitive; patient has metastatic castration-resistant). (2) Explicit exclusion: prior abiraterone/enzalutamide only allowed if <2 weeks; patient had long prior exposure to both. Therefore F is correct.,,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03976323,0.7815374135971069,Metastatic Non-Small Cell Lung Cancer,A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC),PHASE3,18 years,"Non-Small Cell Lung Cancer (nonsquamous, metastatic)",Histologically or cytologically confirmed nonsquamous non-small cell lung cancer | Stage IV nonsquamous non-small cell lung cancer | EGFR/ALK/ROS1-directed therapy not indicated | Measurable disease per RECIST 1.1 | Archival or newly obtained tumor tissue available; adequate sample confirmation by central lab | Life expectancy >= 3 months | ECOG performance status 0 or 1 | No prior systemic treatment for advanced/metastatic NSCLC | Adequate organ function,"Predominantly squamous cell histology NSCLC | Active additional malignancy requiring treatment or progressed within past 3 years | Known active CNS metastases and/or carcinomatous meningitis | Severe hypersensitivity (>= Grade 3) to pembrolizumab or its excipients | Known hypersensitivity to cisplatin, carboplatin, pemetrexed, or olaparib components/excipients | Active autoimmune disease requiring systemic treatment within past 2 years | Diagnosis of immunodeficiency or chronic systemic steroid therapy | Known history of HIV infection | Known history of hepatitis B infection | Known active hepatitis C virus infection | Interstitial lung disease or history of pneumonitis requiring systemic steroids | Prior therapy with olaparib or any PARP inhibitor | Prior therapy with PD-L1, anti PD-L2, CTLA-4, OX-40, CD137, or other stimulatory/co-inhibitory T-cell agents | Myelodysplastic syndrome or acute myeloid leukemia or features suggestive of MDS/AML | History of a second malignancy unless curatively treated with no evidence of disease for 2 years | Completed palliative radiotherapy within 7 days of first study dose or not recovered from radiation-related toxicities or requiring corticosteroids",No prior systemic therapy for advanced/metastatic NSCLC; No prior PARP inhibitor; No prior anti–PD-(L)1/PD-L2/CTLA-4 or other T-cell targeting agents; Palliative radiotherapy washout >= 7 days,ALL,F,"The trial requires no prior systemic therapy for advanced/metastatic NSCLC and that EGFR-directed therapy not be indicated; the patient has received osimertinib and has an EGFR exon 19 deletion, violating these criteria.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Correct. The trial requires EGFR/ALK/ROS1-directed therapy not be indicated; the patient has EGFR exon 19 deletion (required biomarker mismatch → hard exclusion). Additionally, the trial is first-line only and the patient has prior osimertinib, reinforcing ineligibility.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT03976362,0.7991423606872559,Metastatic Non-Small Cell Lung Cancer,A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC),PHASE3,18 years,Squamous Non-Small Cell Lung Cancer (metastatic),Histologically or cytologically confirmed squamous non-small cell lung cancer | Stage IV disease | Measurable disease per RECIST 1.1 | No prior systemic therapy for advanced/metastatic NSCLC | Archival or newly obtained tumor tissue available for central adequacy confirmation | ECOG performance status 0–1 | Life expectancy >= 3 months | Adequate organ function,"Non-squamous histology NSCLC | Additional malignancy requiring active treatment within past 3 years | Known active central nervous system metastases or carcinomatous meningitis | Hypersensitivity to carboplatin, paclitaxel, nab-paclitaxel, or olaparib | Severe hypersensitivity (>= Grade 3) to pembrolizumab or its excipients | Active autoimmune disease requiring systemic treatment within past 2 years | Immunodeficiency or chronic systemic steroid therapy | Known HIV infection | Known hepatitis B infection | Known active hepatitis C virus infection | Interstitial lung disease or history of pneumonitis requiring systemic steroids | Prior therapy with olaparib or any PARP inhibitor | Prior therapy with PD-1/PD-L1/PD-L2 or CTLA-4/OX-40/CD137 agents | Myelodysplastic syndrome or acute myeloid leukemia, or features suggestive of MDS/AML",No prior systemic therapy for advanced/metastatic NSCLC,ALL,F,"The trial requires no prior systemic therapy for advanced/metastatic NSCLC (first-line only), but the patient has received osimertinib in the metastatic setting. Additionally, the trial requires squamous histology, which is not confirmed for this patient.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Correct. The trial requires first-line treatment (no prior systemic therapy for advanced/metastatic NSCLC), but the patient has received osimertinib in the metastatic setting—this is a hard exclusion (required setting not met). Histology is unknown and should not trigger F by itself, but the prior-therapy requirement alone justifies F.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT04038619,0.5940563678741455,Crohn's Disease,Fecal Microbiota Transplantation (FMT) for Immune-Checkpoint Inhibitor Induced-Diarrhea/Colitis in Genitourinary Cancer Patients,PHASE1,18 years,Breast Cancer; Cervical Cancer; Colitis; Diarrhea; Lung Cancer; Malignant Genitourinary System Neoplasm; Melanoma; Ovarian Cancer; Uterine Cancer,"Diagnosis of malignancy in genitourinary, melanoma, non-melanoma skin, lung, head and neck, sarcoma/lymphoma, gastrointestinal (luminal GI, hepatobiliary, pancreas), gynecologic (ovarian, uterine, cervical), or breast cancer | Treatment with any immune checkpoint inhibitor (ICPI) agent(s) | New onset of >= grade 2 ICPI-induced diarrhea and/or colitis within 45 days prior to FMT, without involvement of non-GI toxicity | Prior steroid use allowed if last dose > 30 days before FMT or treatment duration < 7 days beyond one week prior to FMT | Prior immunosuppressant (e.g., infliximab, vedolizumab) use allowed if last dose >= 3 months prior when used for conditions other than ICI-induced GI toxicities | No active concomitant GI infection at initiation of protocol therapy as confirmed by stool tests or treating physician assessment | Cleared for enrollment by Infectious Diseases consultant or treating physician if positive infection workup or screening tests prior to therapy | Life expectancy > 6 months","Age < 18 years | Persistent GI infection with positive stool test(s) despite completing 5 days of antibiotics before protocol therapy | History of inflammatory bowel disease or radiation enteritis/colitis with active disease at treatment initiation | Pregnant or breastfeeding | Positive urine or serum pregnancy test or refusal to test unless clearly peri- or post-menopausal or objective evidence of no pregnancy within 30 days prior to treatment | Immunosuppressive treatment at onset of ICPI-induced diarrhea/colitis | Medical conditions high risk for colonoscopy (e.g., severe heart failure, brain hemorrhage, septic shock) | Concurrent non-GI toxicity at time of study treatment | Donors at risk for monkeypox infection or exposure","Prior treatment with any ICPI agent(s) required; Prior corticosteroids permitted with washout/restrictions as specified; Prior immunosuppressants (e.g., infliximab, vedolizumab) permitted if last dose >= 3 months and used for non-ICI GI indications",ALL,F,"The trial is for cancer patients with immune checkpoint inhibitor–induced diarrhea/colitis; the patient has Crohn's disease without malignancy or ICI exposure, and active inflammatory bowel disease is explicitly excluded.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,Hard exclusions apply: explicit exclusion of active inflammatory bowel disease (patient has active Crohn’s) and required prior ICPI exposure/malignancy not met. Disease mismatch also present. Grader correctly assigned F and cited key reasons.,,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT04095364,0.716698169708252,Recurrent Clear Cell Ovarian Carcinoma,"A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum",PHASE3,18 years,Ovarian Low Grade Serous Carcinoma; Fallopian Tube Low Grade Serous Carcinoma; Primary Peritoneal Low Grade Serous Carcinoma,"Newly diagnosed stage II–IV low-grade serous ovarian cancer (ovarian, fallopian tube, or primary peritoneal) | Prior history of serous borderline tumor allowed | p53 immunohistochemistry nonaberrant (consistent with TP53 wildtype) | Age >= 18 years | Attempt at maximal upfront cytoreductive surgery (optimal or suboptimal residual allowed) | Bilateral salpingo-oophorectomy performed | ECOG performance status 0–2 | Able to take oral medications | ANC >= 1500/µL | Platelets >= 100000/µL | Creatinine <= 1.5 x ULN | Bilirubin <= 1.5 x ULN | AST <= 3 x ULN | ALT <= 3 x ULN | Prior or concurrent malignancy allowed if not interfering with safety or efficacy assessment | HIV-infected patients on effective antiretroviral therapy with undetectable viral load within 6 months are eligible",Prior neoadjuvant or adjuvant chemotherapy for this disease | Prior radiotherapy for this disease | Previous hormonal therapy for this disease | Hypersensitivity to letrozole or intolerance/hypersensitivity to carboplatin/paclitaxel | Myocardial infarction or unstable angina within 6 months | New York Heart Association class II or greater congestive heart failure | Known central nervous system metastases | Active or uncontrolled systemic infection (except uncomplicated urinary tract infection) | Baseline neuropathy grade >= 2 | Aberrant p53 expression on IHC (consistent with TP53 mutation/high-grade serous ovarian cancer),(none),FEMALE,F,"The trial is for newly diagnosed low-grade serous ovarian/peritoneal carcinoma (TP53 wildtype), whereas the patient has recurrent clear cell ovarian carcinoma—a disease/histology mismatch. Additionally, the trial excludes patients with prior adjuvant chemotherapy for this disease, which the patient received (carboplatin/paclitaxel).",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,F,Hard exclusion applies: disease/histology mismatch (trial is for low-grade serous ovarian/peritoneal carcinoma; patient has clear cell ovarian carcinoma). This alone mandates F. The grader’s added note about prior adjuvant chemotherapy also conflicts with trial exclusions but is secondary. Grade F is correct.,,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT04103476,0.6005065441131592,Dementia,Atherosclerosis Intervention With Novel Tissue Selective Estrogen Complex Therapy,PHASE2,45 years to 59 years,Atherosclerosis; Cognitive Decline,Women 45-59 years old | <6 years postmenopausal | Serum estradiol <30 pg/mL | Cessation of regular menses >6 months,"Hysterectomy | Clinical signs, symptoms, or personal history of cardiovascular disease | Diabetes mellitus or fasting serum glucose >126 mg/dL | Life-threatening illness with prognosis <5 years | Cirrhosis or liver disease | History of deep vein thrombosis or pulmonary embolism | History of breast cancer | Current use of postmenopausal hormone replacement therapy within 1 month of randomization | Uncontrolled hypertension (>180/>110 mmHg) | Plasma triglycerides >500 mg/dL | Serum creatinine >2.0 mg/dL",Discontinue postmenopausal hormone replacement therapy >=1 month before randomization,FEMALE,F,"The trial enrolls only females aged 45–59 years (<6 years postmenopausal), whereas the patient is a 68-year-old male; both sex and age are hard exclusions.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"Sex restriction (female only) and age window (45–59) both exclude a 68-year-old male. These are hard exclusions per rubric, so F is correct.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT04159103,0.4920262098312378,Ornithine Transcarbamylase Deficiency,"A Global, Phase 1/2, Open-Label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants With Propionic Acidemia",PHASE1/PHASE2,Not specified,Propionic Acidemia,"Age criteria for Part 1 (>=8 years if among first 2 participants; otherwise >=1 year) | Confirmed diagnosis of propionic acidemia by molecular genetic testing (PCCA and/or PCCB mutations) | Part 2: At least one documented metabolic decompensation event in the 12 months prior to consent | Participants <1 year: Identified by newborn screening or suspected PA with an affected sibling; enrollment requires confirmed genetic diagnosis | Participants <1 year (NICU only): Gestational age >=37 weeks at birth without other conditions/comorbidities that may interfere with study | Participants <1 year: Body weight >=3 kg at Screening | Participants <1 year: At least one PA-related event prior to Screening (clinical signs of metabolic deterioration, meeting MDE definition, or laboratory abnormalities such as metabolic acidosis with elevated anion gap, acute hyperammonemia, neutropenia, or thrombocytopenia)","Clinically significant laboratory abnormalities that could interfere with or limit participation, per investigator or sponsor | Estimated glomerular filtration rate <30 mL/min/1.73 m^2 for participants of all ages receiving chronic dialysis | History of organ transplantation or planned organ transplantation during study participation | Corrected QT interval (Bazett) >480 ms | Grade 3 or 4 heart failure (Modified Ross for Children or NYHA) | Pregnant or breastfeeding | Other clinically significant conditions that could interfere with safety, interpretation of results, or participation, per investigator",(none),ALL,F,"Hard disease mismatch: the trial enrolls patients with propionic acidemia requiring PCCA/PCCB mutations, while the patient has ornithine transcarbamylase (OTC) deficiency with an OTC mutation.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"The trial targets propionic acidemia (PCCA/PCCB mutations), while the patient has ornithine transcarbamylase deficiency with an OTC mutation. This is a clear disease mismatch, a hard exclusion per the rubric, so grade F is correct.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04205812,0.8323574066162109,Metastatic Non-Small Cell Lung Cancer,"A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)",PHASE3,18 years,Squamous Non-Small Cell Lung Cancer (metastatic); Nonsquamous Non-Small Cell Lung Cancer (metastatic),Histologically or cytologically confirmed non-small cell lung cancer (squamous or nonsquamous) that is Stage IV (AJCC v8) | No prior systemic treatment for advanced/metastatic non-small cell lung cancer | Measurable disease per RECIST v1.1 | ECOG performance status 0–1 | Life expectancy >= 3 months | Adequate organ function per protocol-specified laboratory values,"Clinically significant cardiac disease within 6 months | Major surgery within 3 weeks before first dose | Thoracic radiation therapy > 30 Gy within 6 months | Peripheral neuropathy >= Grade 2 (for participants who may receive cisplatin, paclitaxel, or nab-paclitaxel) | Untreated central nervous system metastases or carcinomatous meningitis | History of interstitial lung disease or noninfectious pneumonitis that required systemic steroids | Active infection requiring systemic therapy or active tuberculosis | Superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers | Contraindications to study chemotherapy agents | Active autoimmune disease requiring systemic treatment in the past 2 years | Receiving systemic antibiotics or steroid therapy <= 7 days prior to first dose | Receipt of a live vaccine within 30 days before the first dose (and until 90 days after last dose of study drug) | Known active hepatitis B virus or hepatitis C virus infection",No prior systemic therapy for advanced/metastatic non-small cell lung cancer,ALL,F,"The trial requires no prior systemic therapy for advanced/metastatic NSCLC, but the patient has previously received osimertinib for metastatic disease, which is an explicit exclusion.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,Trial explicitly requires no prior systemic therapy for advanced/metastatic NSCLC; the patient received osimertinib for metastatic disease. This is a hard exclusion → F per rubric.,,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT04238143,0.5696934461593628,Rheumatoid Arthritis,Adipose-Derived Biocellular Regenerative Therapy in Treatment of Osteoarthritis (OA) and Associated Connective Tissue Degeneration and Pain,NA,18 years to 90 years,Osteoarthritis; Knee Osteoarthritis; Shoulder Osteoarthritis; Ankle/Foot Osteoarthritis; Hip Osteoarthritis; Osteoarthritis (multiple joints),"Documented osteoarthritic inflammatory and/or degenerative changes in the knee, hip, shoulder, Achilles tendon, sacroiliac joint, wrist/hand, foot/ankle, or plantar fasciitis | No systemic disorders that would preclude safely undergoing the procedures | Adequate perivascular and extracellular matrix donor tissues available",Systemic or psychological impairment that would preclude tolerance and understanding of procedures and follow-up | Active cancer or receiving chemotherapy or radiation therapy | Pregnancy | Active infections increasing risk for treatment | High-dose steroid use or receipt of corticosteroids within 6 months before treatment | Medication or opiate addiction or active treatment for drug rehabilitation | History of severe traumatic brain injuries | Investigator judges medical issues would prevent completing study requirements,(none),ALL,F,"The trial targets osteoarthritis (various joints), while the patient has rheumatoid arthritis, which is not included in the trial’s disease cohorts. This is a disease mismatch hard exclusion.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Disease mismatch hard exclusion applies: patient has rheumatoid arthritis, trial targets osteoarthritis cohorts only. The grader correctly assigned F based on this hard exclusion; other anchors need not be assessed.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT04240821,0.48869168758392334,Ornithine Transcarbamylase Deficiency,Open-Label Extension Study of Theophylline for Treatment of Pseudohypoparathyroidism,PHASE2,2 years to 99 years,Pseudohypoparathyroidism; Pseudohypoparathyroidism Type 1a; Albright Hereditary Osteodystrophy,"Successful completion of the randomized clinical trial ""Phase 2 Study of Theophylline Treatment of Pseudohypoparathyroidism IND 133103 (11/1/2016)""",History of a seizure disorder unrelated to hypocalcemia | History of a cardiac arrhythmia (not including bradycardia) | Hepatic insufficiency including cirrhosis or acute hepatitis | AST or ALT > 3 x ULN | Congestive heart failure | Current cigarette use | Alcohol abuse | Pregnancy or intention to become pregnant during the next year | Active peptic ulcer disease | Current use of medications known to affect theophylline levels | History of hypersensitivity to theophylline or other medication components | Unable to comply with study procedures in the opinion of the investigator,(none),ALL,F,"Disease mismatch: the trial targets pseudohypoparathyroidism, not ornithine transcarbamylase deficiency. Additionally, the patient is 3 months old, below the trial's minimum age of 2 years.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,Correct: Hard exclusions apply. Disease mismatch (OTC deficiency vs pseudohypoparathyroidism) and patient age (3 months) below trial minimum (2 years) both independently trigger an F. Grader’s reasoning aligns with the rubric.,,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04253964,0.8170062899589539,Metastatic Non-Small Cell Lung Cancer,Phase II Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-Small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy,PHASE2,18 years,Non-Small Cell Lung Cancer (metastatic or unresectable),Histologic or cytologic diagnosis of non-small cell lung cancer that is metastatic or unresectable with no curative options | No prior systemic treatment (chemotherapy or immunotherapy) for non-curative intent | Age >= 18 years | ECOG performance status 0-2 | Life expectancy > 3 months | Adequate organ and marrow function | Absolute neutrophil count >= 1000/µL | Platelets >= 100000/µL | Women of child-bearing potential and men agree to use adequate contraception during study treatment,"Presence of a targetable activating alteration for which first-line targeted therapy is indicated (e.g., EGFR activating mutation, ALK rearrangement, ROS1 rearrangement, BRAF mutation) | Active autoimmune disease requiring systemic treatment within the past 2 years | History of non-infectious pneumonitis that required systemic corticosteroids | Uncontrolled intercurrent illness (e.g., active infection, symptomatic congestive heart failure, unstable angina, clinically significant arrhythmia, or significant psychiatric illness) | Pregnancy or breastfeeding",No prior systemic therapy for advanced/metastatic disease; Prior curative-intent therapy allowed,ALL,F,The trial excludes patients with targetable EGFR activating mutations and requires no prior systemic therapy for metastatic disease; this patient has an EGFR exon 19 deletion and has received osimertinib.,Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with targetable EGFR activating mutations; the patient has an EGFR exon 19 deletion, triggering a hard exclusion. Additionally, the trial requires no prior systemic therapy for advanced disease, while the patient received osimertinib. F is correct.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04267887,0.8355609178543091,Metastatic Castration-Resistant Prostate Cancer,Advanced ChemoHormonal Therapy for Treatment Naïve Metastatic Prostate Cancer: Apalutamide and Abiraterone Acetate With Prednisone and Androgen Deprivation Therapy After Treatment With Docetaxel and Androgen Deprivation Therapy,PHASE2,18 years,Prostate Cancer (metastatic castration-sensitive),"Histologically or cytologically confirmed prostate cancer or strong clinical suspicion with metastatic pattern and PSA > 50 ng/mL | High-risk disease: either (a) at least 2 of visceral metastases, >=3 bone lesions, Gleason 8–10; or (b) >=4 bone lesions with >=1 outside vertebral column or pelvis and/or visceral metastases | Prior neoadjuvant or adjuvant ADT allowed if >= 24 months elapsed before restarting ADT for metastatic castration-sensitive disease | ADT-sensitive disease with no PSA progression or new metastatic deposits since starting ADT | Completed up to 6 cycles of docetaxel for metastatic castration-sensitive disease with <= 16 weeks since day 21 of the final cycle | Life expectancy > 18 months | ECOG performance status <= 2 | Hemoglobin > 9.0 g/dL | Leukocytes > 3,000/µL | Absolute neutrophil count > 1,500/µL | Platelets >= 100,000/µL | Total bilirubin <= 1.5 x ULN | AST/ALT < 2.5 x ULN | Albumin > 3 g/dL | eGFR > 30 mL/min | Potassium >= 3.5 mmol/L | Medications known to lower the seizure threshold discontinued or substituted >= 4 weeks prior to day 1","Unwilling to stop saw palmetto, PC-SPECs, or other herbal agents known to affect PSA | Receipt of other investigational agents within 30 days prior to day 1 | Prior exposure to apalutamide, enzalutamide, abiraterone, darolutamide, or any other second-generation antiandrogen therapy | History of allergic reactions to compounds similar to apalutamide or study agents | Another active malignancy other than non-melanoma skin cancer (unless metastatic) or superficial bladder cancer | Seizure or condition predisposing to seizure (e.g., prior stroke within 1 year, brain AVM, schwannoma, meningioma, or other benign CNS/meningeal disease requiring treatment) | Severe or unstable angina, recent myocardial infarction, symptomatic congestive heart failure or LVEF < 50%, thromboembolic events, or clinically significant ventricular arrhythmias within 6 months prior to day 1 | Uncontrolled hypertension | Gastrointestinal disorder affecting absorption | Active infection (e.g., HIV or viral hepatitis) | Chronic medical condition requiring > 10 mg prednisone/prednisolone daily | Baseline moderate or severe hepatic impairment (Child-Pugh Class B or C) | Inability to stop prohibited medications: atypical antipsychotics, bupropion, lithium, meperidine/pethidine, phenothiazine antipsychotics, tricyclic antidepressants, tramadol",Up to 6 cycles of docetaxel for metastatic castration-sensitive disease completed; <= 16 weeks since day 21 of final cycle; Prior neoadjuvant or adjuvant ADT allowed if >= 24 months elapsed before restarting ADT for metastatic castration-sensitive disease; Ongoing ADT with castration-sensitive disease and no PSA progression or new metastases since starting ADT,MALE,F,"Trial targets metastatic castration-sensitive prostate cancer and requires ADT-sensitive disease, but the patient has metastatic castration-resistant disease. It also explicitly excludes prior enzalutamide or abiraterone exposure, both of which the patient received.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,F,Hard exclusions apply: disease mismatch (mCRPC patient vs mCSPC trial) and explicit exclusion of prior enzalutamide/abiraterone exposure. The grader correctly identified these and assigned F.,,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT04314544,0.626903235912323,Rheumatoid Arthritis,"A Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)",PHASE3,18 years,Psoriatic Arthritis (active),Age >= 18 years | Rheumatoid factor negative | Anti-CCP antibody negative | Prior exposure to anti-TNF agent(s) for psoriasis or psoriatic arthritis,"Planned surgical intervention for a pretreatment condition between baseline and Week 24 | Active infection requiring systemic anti-infectives within 28 days before first dose | Serious infection requiring hospitalization or IV anti-infectives within 8 weeks before first dose | Recurrent or chronic infections (e.g., chronic pyelonephritis, chronic osteomyelitis, bronchiectasis) | History of hepatitis B infection | History of hepatitis C infection | History of HIV infection | Myocardial infarction, unstable angina, or ischemic stroke within 6 months before first dose | Active malignancy, including cutaneous basal or squamous cell carcinoma or melanoma | History of malignancy within 5 years except treated and cured cutaneous basal or squamous cell carcinoma, in situ cervical carcinoma, or in situ ductal breast carcinoma | History of alcohol or drug abuse within the previous 2 years | Unwilling or unable to use adequate contraception as specified | Donation or loss of >= 400 mL of blood within 8 weeks before dosing",Prior anti-TNF therapy for psoriasis or psoriatic arthritis,ALL,F,"Disease mismatch: the trial targets active psoriatic arthritis, while the patient has rheumatoid arthritis.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Disease mismatch is a hard exclusion: the trial is for psoriatic arthritis, while the patient has rheumatoid arthritis. The grader correctly assigned F based on this.",,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT04315233,0.7752779722213745,Recurrent Clear Cell Ovarian Carcinoma,A Phase I/Ib Trial of the CDK4/6 Antagonist Ribociclib And The HDAC Inhibitor Belinostat In Patients With Metastatic Triple Negative Breast Cancer And Recurrent Ovarian Cancer With Response Prediction By Genomics (CHARGE),PHASE1,18 years,"Triple-Negative Breast Cancer (metastatic); Ovarian Carcinoma (serous, recurrent)","Dose escalation: Pathologically confirmed metastatic or unresectable triple-negative breast cancer with measurable disease by RECIST 1.1, ER and PR <= 1% by IHC, HER2 negative, not amenable to curative therapy. | Dose escalation: Pathologically confirmed recurrent, unresectable serous ovarian carcinoma. | Dose expansion: Pathologically confirmed metastatic or unresectable triple-negative breast cancer with measurable disease by RECIST 1.1, ER and PR <= 1% by IHC, HER2 negative, not amenable to curative therapy. | Age >= 18. | ECOG performance status <= 2. | Able to swallow pills. | Adequate organ function per protocol thresholds. | At least one safely accessible metastatic site for biopsy and willingness to undergo up to 3 biopsies. | Negative pregnancy test for women of childbearing potential. | Agrees to use effective contraception for at least 6 months after last dose. | Able to provide informed consent.","Prior treatment with CDK4/6 inhibitors or HDAC inhibitors for cancer. | Major surgery, radiotherapy, anticancer therapy, or investigational agents within 4 weeks or <= 5 half-lives (whichever is shorter). | Active or progressive brain metastases or leptomeningeal disease unless CNS-specific treatment not required during first cycle per treating physician. | Requirement for valproic acid within 5 days before first belinostat dose or during study. | Active infection requiring systemic therapy. | Allergy or hypersensitivity to belinostat, ribociclib, or their binders. | Uncontrolled arrhythmia, congestive heart failure, or angina; MI, symptomatic pericarditis, or cardiac surgery within 6 months. | Left ventricular ejection fraction < 50%. | Clinically significant cardiac arrhythmias, complete left bundle branch block, or high-grade AV block. | Congenital long QT syndrome. | Baseline QTcF > 450 msec with heart rate 50–90 BPM required on qualifying ECG. | Concurrent use of UGT1A1 inhibitors within 7 days prior to day 1. | Concurrent herbal supplements unless approved; must discontinue >= 7 days prior to day 1. | Concurrent medications with known risk of Torsades de Pointes that cannot be discontinued or switched >= 7 days prior to start. | Unresolved diarrhea >= Grade 2 (CTCAE v5.0). | Use within 7 days prior to start of strong/moderate CYP3A4/5 inducers or inhibitors, certain narrow-therapeutic-index CYP3A4/5 substrates, or grapefruit/pomelo/star-fruit/Seville orange. | Current treatment with warfarin or other coumarin anticoagulants (other anticoagulants allowed). | Impaired GI function that may alter drug absorption (e.g., uncontrolled IBD, uncontrolled vomiting, major stomach or small bowel resection). | Pregnant or breastfeeding. | Women or men of childbearing potential not using highly effective contraception during treatment and for 6 months after. | Known HIV infection with detectable viral load within 6 months (controlled on ART with undetectable load eligible). | Known chronic HBV or HCV infection with detectable viral load (suppressed/undetectable viral load eligible). | Another malignancy (other than breast or ovarian in dose escalation) anticipated to need systemic treatment within 1 year.","Washout >= 4 weeks (or >= 5 half-lives) from major surgery, radiotherapy, anticancer therapy, or investigational agents before day 1.",ALL,F,"The ovarian cohort requires recurrent unresectable serous ovarian carcinoma, while the patient has clear cell ovarian carcinoma, a non-included subtype. This is a disease/subtype mismatch and a hard exclusion.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,F,"Trial ovarian cohort explicitly requires serous histology; patient has clear cell ovarian carcinoma. This is a required subtype mismatch, which is a hard exclusion per rubric, so F is appropriate.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04363164,0.8036922812461853,Metastatic Castration-Resistant Prostate Cancer,A Randomized Phase II Study Comparing Sequential High Dose Testosterone and Enzalutamide to Enzalutamide Alone in Asymptomatic Men With Castration Resistant Metastatic Prostate Cancer,PHASE2,18 years to 90 years,"Prostate Adenocarcinoma (metastatic, castration-resistant)","ECOG performance status <=2 | Age >=18 years | Histologically confirmed prostate adenocarcinoma | On continuous androgen deprivation therapy (surgical castration or LHRH agonist/antagonist) | Castrate serum testosterone <50 ng/dL | Metastatic disease documented by CT or bone scan | Disease progression on abiraterone acetate plus ADT (PSA and/or radiographic per RECIST 1.1 or PCWG3) | Screening PSA >= 1.0 ng/mL | Biopsy required if soft tissue lesion amenable (pre-treatment and on-treatment) | No prior enzalutamide, apalutamide, darolutamide, or investigational AR-targeted therapy | Prior testosterone allowed | Prior docetaxel for hormone-sensitive disease allowed (<=6 doses) | Prior sipuleucel-T and radium-223 allowed if >4 weeks from last dose | Abiraterone discontinued >=2 weeks before starting therapy | Attempt to wean off prednisone; continue lowest achievable dose if unable to fully wean | Bilirubin < 2.5 x ULN | AST < 2.5 x ULN | ALT < 2.5 x ULN | Serum creatinine < 2.5 x ULN | Absolute neutrophil count >= 1500 /µL | Platelet count >= 100000 /µL | Hemoglobin >= 8 g/dL | At least 4 weeks since prior radiation or chemotherapy","Pain due to metastatic prostate cancer requiring treatment intervention with pain medication | ECOG performance status >=3 | Prior enzalutamide therapy | Prior chemotherapy with docetaxel or cabazitaxel for castration-resistant prostate cancer | Requires urinary self-catheterization for voiding due to obstruction from prostate cancer or BPH (indwelling Foley or suprapubic catheter allowed) | Disease sites/extent that increase risk from testosterone therapy (e.g., femoral metastases with fracture risk, severe/extensive spinal metastases with cord compression risk, extensive liver metastases) | Serious or unstable medical, psychiatric, or other condition that could interfere with safety or consent | Active uncontrolled infection, including known HIV/AIDS, hepatitis B, or hepatitis C | Any condition or mental impairment compromising consent, safety, or compliance | Current anticoagulation with warfarin, rivaroxaban, or apixaban (unless transitioned to enoxaparin prior to treatment) | History of thromboembolic event within 12 months not on systemic anticoagulation | Hematocrit >51% | Untreated severe obstructive sleep apnea | Uncontrolled or poorly controlled heart failure | Allergy to sesame seed oil or cottonseed oil | Major surgery within 3 weeks before screening or not fully recovered from prior surgery","Continuous androgen deprivation therapy required; Progression on abiraterone acetate plus ADT required; No prior enzalutamide, apalutamide, darolutamide, or investigational AR-targeted therapy; Prior testosterone allowed; Prior docetaxel for hormone-sensitive disease allowed (<=6 doses); Prior sipuleucel-T allowed (>4 weeks washout); Prior radium-223 allowed (>4 weeks washout); Abiraterone washout >=2 weeks before starting study therapy; At least 4 weeks since prior radiation or chemotherapy; Attempt to taper prednisone to lowest feasible dose before starting therapy",MALE,F,"The trial explicitly excludes patients with any prior enzalutamide therapy, and this patient has progressed on enzalutamide. Additionally, the trial requires progression on abiraterone + ADT, which is not confirmed for this patient.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,F,"Correct: The trial explicitly excludes any prior enzalutamide, and the patient has progressed on enzalutamide. That is a hard exclusion → F. The note about abiraterone progression being unconfirmed is not needed for the F but does not affect the outcome.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT04411654,0.4312690496444702,PMM2-CDG,"An Open-label, Phase 1/2 Study to Evaluate the Safety and Efficacy of Single-dose LY3884961 in Infants With Type 2 Gaucher Disease",PHASE1/PHASE2,0 months to 24 months,Gaucher Disease Type 2,Bi-allelic GBA1 mutations consistent with Gaucher Disease Type 2 confirmed by central laboratory | Clinical diagnosis of Gaucher Disease Type 2,"Significant CNS disease other than Gaucher Disease Type 2 | Achieved independent gait | Severe peripheral symptoms of Gaucher Disease posing unacceptable risk or interfering with study conduct | Concomitant disease, condition, or treatment posing unacceptable risk or interfering with study conduct | Use of any substrate reduction therapy for Gaucher Disease treatment | Use of prohibited medications, herbal, or over-the-counter agents | Any prior gene or cell therapy | Use of systemic immunosuppressant or corticosteroid therapy other than protocol-specified immunosuppression | Participation in another investigational drug or device study within the past 3 months | Brain MRI/MRA showing clinically significant abnormality that contraindicates intracisternal injection | Clinically significant laboratory test result abnormalities at screening | Contraindications or intolerance to MRI, MRA, CT, or contrast agents | Contraindications to general anesthesia or sedation",No investigational drug or device within 3 months,ALL,F,"Disease mismatch: the trial is for Gaucher Disease Type 2 with required bi-allelic GBA1 mutations, while the patient has PMM2-CDG with PMM2 variants. Additionally, the trial enrolls infants ≤24 months, and the patient is 8 years old.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,"Clear hard exclusions: disease mismatch (Gaucher type 2 vs PMM2-CDG) and required biomarker mismatch (GBA1 vs PMM2). Additionally, age 8 years exceeds trial’s ≤24 months cap. F is appropriate per rubric.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT04436640,0.6091967821121216,Rheumatoid Arthritis,"A Multicenter, Open-Label Extension Study to Asses the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Study Participants With Active Axial Spondyloarthritis, Ankylosing Spondylitis, and Nonradiographic Axial Spondyloarthritis",PHASE3,18 years,Axial Spondyloarthritis; Ankylosing Spondylitis; Nonradiographic Axial Spondyloarthritis,Completed feeder study AS0010 (NCT03928704) or AS0011 (NCT03928743),Plans for pregnancy during the study or within 20 weeks after final dose (self or partner). | Meets withdrawal criteria in AS0010 or AS0011. | Ongoing serious adverse event or history of serious infections in feeder study (medical monitor approval required). | Positive or indeterminate interferon gamma release assay unless appropriately evaluated and treated.,(none),ALL,F,"Disease mismatch: the trial targets axial spondyloarthritis/ankylosing spondylitis, while the patient has rheumatoid arthritis. Additionally, it requires completion of specific feeder studies.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Correct: Hard exclusion due to disease mismatch (RA vs axial spondyloarthritis/AS/nr-axSpA). Age/sex do not conflict. The mention of feeder-study completion is not needed (and is unknown), but the disease mismatch alone warrants F.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT04510051,0.7210513353347778,Recurrent Glioblastoma,"Phase I Study of Cellular Immunotherapy Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Children With Recurrent/Refractory Malignant Brain Tumors",PHASE1,4 years to 25 years,Malignant Brain Neoplasm (recurrent/refractory),"Karnofsky Performance Status >= 60% (except loss of mobility due to disease involvement) | Life expectancy > 4 weeks | Histologically confirmed malignant brain neoplasm progressed after prior conventional therapy | Radiographic progression/recurrence > 12 weeks after completion of initial conventional therapy (including initial radiation therapy) | IL13Ralpha2-positive tumor expression by IHC (H-score >= 50) confirmed by institutional pathology | Programmable shunt present if applicable and able to tolerate being switched off for >= 2 consecutive days | Platelets >= 50,000/µL | Total bilirubin <= 2 x ULN (unless Gilbert's disease) | AST <= 2 x ULN | ALT <= 2 x ULN | Creatinine clearance >= 75 mL/min/1.73m^2 | Seronegative for HIV Ag/Ab combo, negative for active HBV (HBsAg negative), and HCV as per RNA testing if antibody positive | Women of childbearing potential: negative pregnancy test | Females and males of childbearing potential agree to effective contraception or abstinence during study and for 6 months after last dose | Dexamethasone dose <= 0.1 mg/kg/day on day of PBMC collection | Adequate venous access for PBMC collection | At least 2 weeks since last dose of prior targeted agents, chemotherapy, or radiation before PBMC collection | Serum creatinine < 1.6 mg/dL (for CNS catheter placement eligibility) | WBC >= 2,000/µL (for CNS catheter placement eligibility) | ANC >= 1,000/µL (for CNS catheter placement eligibility) | Platelets > 50,000/µL (for CNS catheter placement eligibility) | INR <= 1.3 (for CNS catheter placement eligibility) | Bilirubin < 1.5 mg/dL (for CNS catheter placement eligibility) | ALT and AST < 2 x ULN (for CNS catheter placement eligibility) | Second-line radiation therapy completed >= 4 weeks prior to surgical resection/biopsy/catheter placement | No supplemental oxygen required to keep saturation > 95% and no progressive chest radiographic abnormalities (for lymphodepletion/infusion eligibility) | No pressor support required and no symptomatic cardiac arrhythmias (for lymphodepletion/infusion eligibility) | Afebrile (<= 38.5 C) with no positive blood cultures and no indications of meningitis within 48 hours prior to infusion | Hepatic: total bilirubin or transaminases <= 2 x ULN (for lymphodepletion/infusion eligibility) | Renal: serum creatinine < 1.8 mg/dL (for lymphodepletion/infusion eligibility) | No uncontrolled seizure activity (for lymphodepletion/infusion eligibility) | For each CAR T infusion: platelet count >= 50,000/µL (transfusion permitted to achieve >= 50,000/µL) | For each CAR T infusion: dexamethasone <= 0.1 mg/kg/day","Requires supplemental oxygen to keep saturation > 95% and not expected to resolve within 2 weeks | Requires pressor support and/or has symptomatic cardiac arrhythmias | Requires dialysis | Uncontrolled seizure activity and/or clinically evident progressive encephalopathy | Poorly controlled non-malignant intercurrent illness or illness severity deemed unsafe by investigators | Any other active malignancy | Being treated for severe infection or recovering from major surgery until recovery is complete | Uncontrolled illness including ongoing or active infection; known active hepatitis B or C infection; signs or symptoms of active infection, positive blood cultures, or radiologic evidence of infections | Confirmed HIV positivity within 4 weeks of enrollment | Pregnant or breastfeeding","Progressed after prior conventional therapy; At least 2 weeks since last targeted agent, chemotherapy, or radiation before PBMC collection; At least 6 weeks since completion of nitrosourea-containing chemotherapy before study treatment; At least 23 days since completion of temozolomide before study treatment; At least 4 weeks since completion of other non-nitrosourea cytotoxic chemotherapy before study treatment; If most recent treatment was a targeted agent only and toxicities resolved, at least 2 weeks since last dose before study treatment; At least 4 weeks since last bevacizumab dose before starting study treatment; Second-line radiation therapy completed at least 4 weeks prior to surgery/biopsy/catheter placement",ALL,F,"The patient is 40 years old, which is outside the trial's age range of 4–25 years, constituting a hard exclusion.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,F,"Age is a hard exclusion: the trial allows ages 4–25, while the patient is 40. This alone mandates an F per the rubric. Other factors need not be considered.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT04532047,0.4194123148918152,PMM2-CDG,PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders),PHASE1,18 years to 50 years,"Gaucher Disease, Type 2; Gaucher Disease, Type 3; Mucopolysaccharidosis I; Mucopolysaccharidosis II; Mucopolysaccharidosis IVA; Mucopolysaccharidosis VI; Mucopolysaccharidosis VII; Pompe Disease (infantile-onset); Wolman Disease","Fetus at 18 0/7 to 34 6/7 weeks gestation | Confirmed in utero diagnosis of one of the 8 lysosomal storage disorders by genetic or enzymatic testing on prenatal samples (e.g., CVS, amniocentesis, cordocentesis, cell-free fetal DNA) | Pregnant woman age 18 to 50 years carrying the affected fetus | Ability to provide written informed consent",Fetal severe structural anomaly | Fetal additional pathogenic genetic variant unrelated to the LSD with significant risk of morbidity or mortality | Maternal inability to complete the procedure due to body habitus or placental location | Maternal significant cardiopulmonary disease | Maternal mirror syndrome | Maternal end-organ failure | Maternal altered mental status | Placental abruption | Active preterm labor | Preterm premature rupture of membranes | Maternal therapeutic anticoagulation within 24 hours prior to or following the intervention,(none),FEMALE,F,"Disease mismatch: PMM2-CDG is not among the trial’s lysosomal storage disorders. Additionally, the trial enrolls pregnant women (18–50 years) with affected fetuses, whereas the patient is an 8-year-old child.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,"Correct: The trial targets different diseases and requires a pregnant woman (18–50 years), while the patient is an 8-year-old with PMM2-CDG. Disease mismatch and age window conflict are hard exclusions → F.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT04592237,0.7733079195022583,Metastatic Urothelial Carcinoma,Randomized Phase II Study of Platinum-Taxane-Cetrelimab Induction Followed by Niraparib Plus or Minus Cetrelimab Maintenance in Men With Aggressive Variant Prostate Cancers,PHASE2,18 years,Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Small Cell Carcinoma; Stage IV Prostate Cancer,"Histologically or cytologically confirmed prostate carcinoma | Metastatic disease documented on imaging (bone scan, CT and/or MRI) | Meets at least one aggressive variant prostate carcinoma (AVPC) criterion | Histologically proven small cell (neuroendocrine) prostate carcinoma (AVPC criterion) | Exclusive visceral metastases (AVPC criterion) | Predominantly lytic bone metastases by x-ray or CT (AVPC criterion) | Bulky (>= 5 cm) lymphadenopathy or high-grade tumor mass in prostate/pelvis (AVPC criterion) | Low PSA (<= 10 ng/mL) at initial presentation or at symptomatic progression in the castrate-setting plus high-volume (>= 20) bone metastases (AVPC criterion) | Elevated LDH (>= 2 x ULN) or elevated CEA (>= 2 x ULN) without other etiologies (AVPC criterion) | Short interval (<= 180 days) to castration-resistant progression after initiation of hormonal therapy (AVPC criterion) | Loss or mutation in at least 2 of TP53, RB1, and PTEN by CLIA-certified testing, IHC and/or DNA sequencing (AVPC criterion) | Castration-resistant progression per RECIST without PSA rising to >= 1.0 ng/mL per PCWG3 (AVPC criterion) | Documented progressive disease by PSA progression (3 measurements >= 7 days apart with last >= 1.0 ng/mL), or new/increasing measurable disease (RECIST), or >= 2 new bone lesions (PCWG3), or increasing symptoms attributed to progression | Surgically or medically castrated with baseline testosterone <= 50 ng/dL | ECOG performance status <= 2 | Hemoglobin >= 10.0 g/dL (>= 8 g/dL if due to marrow infiltration) | Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1.0 x 10^9/L if due to marrow infiltration) | White blood cells (WBC) > 3 x 10^9/L (> 2 x 10^9/L if due to marrow infiltration) | Platelet count >= 100 x 10^9/L (>= 50 x 10^9/L if due to marrow infiltration) | Total bilirubin <= 1.5 x ULN (except Gilbert syndrome) | AST and ALT <= 2.5 x ULN (<= 5 x ULN with liver metastases) | Calculated creatinine clearance (Cockcroft-Gault) >= 30 mL/min | No features suggestive of MDS/AML on peripheral blood smear | Able to swallow study drugs whole (tablet/capsule)","Any prior treatment for CRPC with carboplatin, cisplatin, cabazitaxel, a PARP inhibitor, or an anti-PD-1/PD-L1 inhibitor | More than one prior line of chemotherapy | Unresolved toxicity from prior therapy > CTCAE grade 2 (except allowed ongoing LHRH therapy, bisphosphonates, or RANK ligand inhibitors) | Any unresolved CTCAE grade >= 2 toxicity from previous anti-cancer therapy (irreversible toxicities not expected to be exacerbated may be allowed) | History or current diagnosis of myelodysplastic syndrome or acute myeloid leukemia | Active uncontrolled infection | Active or symptomatic viral hepatitis or chronic liver disease | History of pneumonitis or extensive bilateral non-malignant lung disease | Another malignancy with >= 30% probability of recurrence within 24 months (except adequately treated non-melanoma skin cancer, curatively treated in-situ cervical cancer, or Ta urothelial carcinoma) | Serious underlying medical or psychiatric condition that would make study drug hazardous or confound adverse event interpretation (e.g., uncontrolled ventricular arrhythmia, recent myocardial infarction, superior vena cava syndrome, uncontrolled seizures, history of allogeneic transplant, primary immunodeficiency) | Unable to swallow oral medication or gastrointestinal disorders likely to interfere with absorption | Symptomatic uncontrolled brain metastases or spinal cord compression | Known hypersensitivity to niraparib, carboplatin, cabazitaxel, or anti-PD-1/PD-L1 inhibitors | Current or prior use of systemic immunosuppressive medication within 28 days before first cetrelimab dose (with specified corticosteroid exceptions) | Active or prior documented autoimmune or inflammatory disorders requiring systemic therapy (with specified exceptions such as vitiligo, alopecia, controlled hypothyroidism, certain inactive diseases, or celiac disease controlled by diet) | Receipt of live attenuated vaccine within 30 days prior to cetrelimab | Compulsory detention for treatment of psychiatric or physical illness",(none),MALE,F,"Disease mismatch: this trial enrolls men with metastatic/aggressive variant prostate cancer, while the patient has metastatic urothelial carcinoma.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"The trial targets prostate cancers only, while the patient has metastatic urothelial carcinoma. This is a disease mismatch, a hard exclusion per the rubric, so grade F is correct.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04592237,0.7712825536727905,Metastatic Non-Small Cell Lung Cancer,Randomized Phase II Study of Platinum-Taxane-Cetrelimab Induction Followed by Niraparib Plus or Minus Cetrelimab Maintenance in Men With Aggressive Variant Prostate Cancers,PHASE2,18 years,Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Small Cell Carcinoma; Stage IV Prostate Cancer,"Histologically or cytologically confirmed prostate carcinoma | Metastatic disease documented on imaging (bone scan, CT and/or MRI) | Meets at least one aggressive variant prostate carcinoma (AVPC) criterion | Histologically proven small cell (neuroendocrine) prostate carcinoma (AVPC criterion) | Exclusive visceral metastases (AVPC criterion) | Predominantly lytic bone metastases by x-ray or CT (AVPC criterion) | Bulky (>= 5 cm) lymphadenopathy or high-grade tumor mass in prostate/pelvis (AVPC criterion) | Low PSA (<= 10 ng/mL) at initial presentation or at symptomatic progression in the castrate-setting plus high-volume (>= 20) bone metastases (AVPC criterion) | Elevated LDH (>= 2 x ULN) or elevated CEA (>= 2 x ULN) without other etiologies (AVPC criterion) | Short interval (<= 180 days) to castration-resistant progression after initiation of hormonal therapy (AVPC criterion) | Loss or mutation in at least 2 of TP53, RB1, and PTEN by CLIA-certified testing, IHC and/or DNA sequencing (AVPC criterion) | Castration-resistant progression per RECIST without PSA rising to >= 1.0 ng/mL per PCWG3 (AVPC criterion) | Documented progressive disease by PSA progression (3 measurements >= 7 days apart with last >= 1.0 ng/mL), or new/increasing measurable disease (RECIST), or >= 2 new bone lesions (PCWG3), or increasing symptoms attributed to progression | Surgically or medically castrated with baseline testosterone <= 50 ng/dL | ECOG performance status <= 2 | Hemoglobin >= 10.0 g/dL (>= 8 g/dL if due to marrow infiltration) | Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1.0 x 10^9/L if due to marrow infiltration) | White blood cells (WBC) > 3 x 10^9/L (> 2 x 10^9/L if due to marrow infiltration) | Platelet count >= 100 x 10^9/L (>= 50 x 10^9/L if due to marrow infiltration) | Total bilirubin <= 1.5 x ULN (except Gilbert syndrome) | AST and ALT <= 2.5 x ULN (<= 5 x ULN with liver metastases) | Calculated creatinine clearance (Cockcroft-Gault) >= 30 mL/min | No features suggestive of MDS/AML on peripheral blood smear | Able to swallow study drugs whole (tablet/capsule)","Any prior treatment for CRPC with carboplatin, cisplatin, cabazitaxel, a PARP inhibitor, or an anti-PD-1/PD-L1 inhibitor | More than one prior line of chemotherapy | Unresolved toxicity from prior therapy > CTCAE grade 2 (except allowed ongoing LHRH therapy, bisphosphonates, or RANK ligand inhibitors) | Any unresolved CTCAE grade >= 2 toxicity from previous anti-cancer therapy (irreversible toxicities not expected to be exacerbated may be allowed) | History or current diagnosis of myelodysplastic syndrome or acute myeloid leukemia | Active uncontrolled infection | Active or symptomatic viral hepatitis or chronic liver disease | History of pneumonitis or extensive bilateral non-malignant lung disease | Another malignancy with >= 30% probability of recurrence within 24 months (except adequately treated non-melanoma skin cancer, curatively treated in-situ cervical cancer, or Ta urothelial carcinoma) | Serious underlying medical or psychiatric condition that would make study drug hazardous or confound adverse event interpretation (e.g., uncontrolled ventricular arrhythmia, recent myocardial infarction, superior vena cava syndrome, uncontrolled seizures, history of allogeneic transplant, primary immunodeficiency) | Unable to swallow oral medication or gastrointestinal disorders likely to interfere with absorption | Symptomatic uncontrolled brain metastases or spinal cord compression | Known hypersensitivity to niraparib, carboplatin, cabazitaxel, or anti-PD-1/PD-L1 inhibitors | Current or prior use of systemic immunosuppressive medication within 28 days before first cetrelimab dose (with specified corticosteroid exceptions) | Active or prior documented autoimmune or inflammatory disorders requiring systemic therapy (with specified exceptions such as vitiligo, alopecia, controlled hypothyroidism, certain inactive diseases, or celiac disease controlled by diet) | Receipt of live attenuated vaccine within 30 days prior to cetrelimab | Compulsory detention for treatment of psychiatric or physical illness",(none),MALE,F,"Disease mismatch: the trial targets aggressive variant/castration-resistant prostate cancers, while the patient has metastatic non-small cell lung cancer (EGFR exon 19 deletion).",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Correctly applied hard exclusion: the trial targets prostate cancer, while the patient has metastatic NSCLC. Disease mismatch mandates an F per rubric.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04619797,0.8011409044265747,Metastatic Non-Small Cell Lung Cancer,"A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients With Previously Untreated Advanced Non-Squamous Non-Small-Cell Lung Cancer",PHASE2/PHASE3,18 years,Non-Squamous Non-Small Cell Lung Cancer (metastatic or unresectable),ECOG performance status 0–1 | Histologically or cytologically documented locally advanced unresectable or metastatic non-squamous NSCLC not eligible for curative surgery and/or definitive chemoradiotherapy | No prior systemic treatment for metastatic non-squamous NSCLC | Known tumor PD-L1 status | Measurable disease per RECIST v1.1 | Life expectancy >= 12 weeks | Adequate hematologic and end-organ function | Negative HIV test at screening | Serology negative for active hepatitis B virus or active hepatitis C virus at screening,"EGFR sensitizing mutations or ALK fusion oncogene | Pulmonary lymphoepithelioma-like carcinoma subtype of NSCLC | Symptomatic, untreated, or actively progressing CNS metastases | Active or history of autoimmune disease or immune deficiency | History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis | History of malignancy other than NSCLC within 5 years prior to randomization, except malignancies with negligible risk of metastasis or death | Severe infection within 4 weeks prior to initiation of study treatment or any active infection that could impact patient safety | Treatment with investigational therapy within 28 days prior to initiation of study treatment | Prior treatment with CD137 agonists or immune checkpoint blockade therapies including anti-CTLA-4, anti-TIGIT, anti-PD-1, or anti-PD-L1 antibodies | Treatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives (whichever is longer) prior to initiation of study treatment | Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment or anticipated need for systemic immunosuppressive medication during study treatment | Known allergy or hypersensitivity or other contraindication to any component of the chemotherapy regimen | Pregnant or breastfeeding | Known targetable ROS1 or BRAF V600E genomic aberration",No prior systemic treatment for metastatic non-squamous NSCLC; Investigational therapy washout >= 28 days,ALL,F,The trial explicitly excludes patients with EGFR-sensitizing mutations and requires no prior systemic therapy for metastatic NSCLC; the patient has an EGFR exon 19 deletion and has received osimertinib.,Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Hard exclusion applies: the trial excludes EGFR-sensitizing mutations, and the patient has an EGFR exon 19 deletion. The prior systemic therapy (osimertinib) would also conflict with the trial’s “no prior systemic treatment for metastatic NSCLC” requirement. Thus F is correct.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04623775,0.811528205871582,Metastatic Non-Small Cell Lung Cancer,A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC),PHASE2,18 years,Non-Small Cell Lung Cancer (metastatic or recurrent),Histologically confirmed non-small cell lung cancer (squamous or non-squamous) that is stage IVA/IVB or recurrent after multimodal therapy for locally advanced disease. | ECOG performance status <=1 at screening and prior to randomization. | Measurable disease by CT or MRI per RECIST 1.1. | No prior systemic anti-cancer treatment given as primary therapy for advanced or metastatic disease (including EGFR or ALK inhibitors).,"EGFR, ALK, ROS1, or BRAF V600E mutations that are sensitive to available targeted therapy. | Untreated central nervous system metastases. | Leptomeningeal metastases. | Concurrent malignancy requiring treatment or prior malignancy active within 2 years before randomization. | Prior treatment with PD-1, PD-L1, PD-L2, CTLA-4, or other T-cell co-stimulation/checkpoint pathway-targeting agents.",No prior systemic therapy for advanced or metastatic disease.,ALL,F,"The trial explicitly excludes EGFR-mutant NSCLC sensitive to targeted therapy, and the patient has an EGFR exon 19 deletion. It also requires no prior systemic therapy for metastatic disease (including EGFR inhibitors), but the patient previously received osimertinib.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,Explicit exclusions apply: trial excludes EGFR mutation sensitive to targeted therapy and requires no prior systemic therapy for advanced disease. Patient has EGFR exon 19 deletion and prior osimertinib. Hard exclusion → F. Grader applied rubric correctly.,,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT04636190,0.6017745733261108,Rheumatoid Arthritis,"A Retrospectively Enrolled and Prospectively Followed, Post-market, Multi-center Evaluation of the Clinical Outcomes of the Triathlon All-Polyethylene Tibia",NA,18 years,Knee Arthritis,Implanted with Triathlon All-Polyethylene Tibia with compatible Stryker femoral and patellar components; no pending revision or removal | Age >= 18 years at time of device implantation | Non-pregnant,"Active or suspected latent infection in or around the affected knee at time of implantation | Distant foci of infection that could cause hematogenous spread to the implant site at time of implantation | Skeletally immature at time of device implantation | Mental or neuromuscular disorder creating unacceptable risk of prosthesis instability, fixation failure, or postoperative complications | Bone stock compromised by disease, infection, or prior implantation that cannot provide adequate support and/or fixation | Severe knee instability secondary to absent collateral ligament integrity and function | Immunologically suppressed or receiving steroids in excess of normal physiological requirements at the time of surgery (e.g., > 30 days)",(none),ALL,F,"Disease mismatch: the trial targets patients with knee arthritis who have received a specific knee implant, while the patient has rheumatoid arthritis and no indication of qualifying implant. This fails the trial’s disease/cohort requirements.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Correct: The trial targets knee arthritis patients with a specific knee implant cohort, while the patient’s condition is rheumatoid arthritis. Per rubric, this is a disease mismatch → hard exclusion → F. The implant requirement is also unmet/unknown but not needed to justify F since disease mismatch suffices.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT04685590,0.5880361795425415,Dementia,Phase II Clinical Trial to Evaluate the Safety and Feasibility of Senolytic Therapy in Alzheimer's Disease,PHASE2,60 years,Alzheimer Disease (early stage); Mild Cognitive Impairment (amnestic),Age >= 60 years | Amnestic mild cognitive impairment or early Alzheimer's disease | Elevated cerebrospinal fluid (CSF) tau protein | Tau PET positive | Total cholesterol < 240 mg/dL | HbA1c <= 7% | PT/PTT/INR within normal limits,"Body mass index > 40 kg/m2 | Average QTcF at screening >= 450 msec in males or >= 460 msec in females | MRI contraindications (e.g., claustrophobia, ferromagnetic implants, cardiac pacemaker) | Pregnancy or possible pregnancy | Significant neurologic disease other than prodromal or early Alzheimer's disease (e.g., Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or significant head trauma with persistent deficits or structural brain abnormalities) | Current or history of alcohol or substance abuse or dependence within the past 2 years | Current suicidality or suicidal ideation | Uncontrolled diabetes (HbA1c > 7% or current use of insulin or sulfonylureas) | Poorly controlled blood pressure: systolic > 160 mmHg or diastolic > 90 mmHg | eGFR < 10 mL/min/1.73 m2 | Myocardial infarction, angina, stroke, or transient ischemic attack within the past 6 months | Chronic heart failure | Significant liver disease with total bilirubin > 2 x ULN | Inability to tolerate oral medication | Use of medications that are sensitive substrates or have a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6, or strong inhibitors or inducers of CYP3A4 | Current use of drugs that induce cellular senescence (alkylating agents, anthracyclines, platinums, other chemotherapy) | Therapeutic-dose anticoagulation (e.g., warfarin, heparin, low molecular weight heparin, factor Xa inhibitors) unless can be held for 2 days prior to lumbar puncture with prescriber approval | Use of H2 antagonists or proton pump inhibitors unable or unwilling to hold for at least 2 days prior to and during each 2-day dosing course | Co-enrollment in another ADRD study with a potentially disease-modifying intervention or study drug affecting senescent cells (eligible after washout >= 6 months from last dose to screening) | Use of anti-amyloid therapies (e.g., aducanumab, lecanemab) | Any condition that, in the Investigator's judgment, would put the subject at risk or preclude successful completion of the trial","Stable dose (>= 3 months) of FDA-approved Alzheimer's disease medications (e.g., donepezil, rivastigmine, galantamine) permitted; Prior disease-modifying ADRD investigational therapy allowed with washout >= 6 months before screening",ALL,F,"Disease mismatch: the trial enrolls amnestic MCI or early Alzheimer’s disease, whereas the patient has moderate-stage dementia without a confirmed Alzheimer’s diagnosis (amyloid PET/CSF negative). The trial also requires tau PET positivity and early-stage disease, which are not met.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"Correct F: The patient has moderate-stage dementia without a specified Alzheimer’s diagnosis, while the trial only enrolls amnestic MCI or early Alzheimer’s disease. That is a disease mismatch hard exclusion. Age/sex are fine; tau PET status is unknown and shouldn’t drive F, but the disease/stage mismatch already triggers F.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04704505,0.8370788097381592,Metastatic Castration-Resistant Prostate Cancer,Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (BAT-RAD Study),PHASE2,18 years,Prostate Adenocarcinoma (metastatic castration-resistant),"Histologically confirmed prostate adenocarcinoma; if mixed histology, >50% adenocarcinoma. | Bone metastases on Technetium-99m bone scan within 2 months of screening. | Castrate-resistant prostate cancer with testosterone <= 50 ng/dL and evidence of progression by PSA or new lesions. | PSA progression defined by two rising values >= 2 ng/mL at least 7 days apart or new lesions on imaging. | Serum PSA >= 2.0 ng/mL. | On bone health agents (zoledronic acid or denosumab) for >= 4 weeks before enrollment and continued during study. | ECOG performance status <= 1. | Asymptomatic or minimally symptomatic disease (no opioids). | Prior treatment with <= 1 novel AR-targeted drug permitted (abiraterone, enzalutamide, darolutamide, apalutamide). | Prior first-generation antiandrogens (bicalutamide, nilutamide) permitted. | Prior chemotherapy for hormone-sensitive prostate cancer allowed if given >= 12 months prior to entry. | Adequate bone marrow, renal, and liver function (ANC > 1,000/µL; Platelets > 100,000/µL; Hemoglobin >= 9 g/dL; AST/ALT <= 1 x ULN; Total bilirubin <= 1 x ULN). | No other malignancy within 5 years except adequately treated basal or squamous cell skin cancer. | Availability of tumor tissue for genomic analysis (archival or new biopsy).","Known visceral metastasis (lung, liver, brain). | Spinal cord compression, imminent long bone fracture, or conditions likely to require radiation or steroids for pain during active phase. | Previous treatment with chemotherapy for mCRPC, or any chemotherapy within 12 months prior to registration (adjuvant or hormone-sensitive chemo allowed if completed > 6 months before registration). | Radiation therapy (external beam or brachytherapy) within 28 days prior to registration. | Systemic bone-seeking radiopharmaceuticals (strontium-89, samarium-153, rhenium-186, rhenium-188) within the previous 24 weeks. | Use of strong opioid analgesics for cancer-related pain (e.g., oxycodone, morphine, methadone); weak opioids like codeine or tramadol permitted. | Investigational drug use within 4 weeks of treatment. | Intact prostate with urinary obstructive symptoms (including symptomatic BPH). | Current warfarin anticoagulation (other anticoagulants such as rivaroxaban, dabigatran, apixaban permitted). | Symptomatic nodal disease (scrotal, penile, or leg edema). | Serious uncontrolled medical disorder or active infection posing poor medical risk (e.g., uncontrolled diabetes, heart failure, COPD, IBD, Paget's disease, ventricular arrhythmia, recent MI within 12 months, thromboembolic events, or psychiatric disorder interfering with consent). | Disease extent or sites posing risk from testosterone therapy (e.g., femoral metastases with fracture risk, severe extensive spinal metastases with cord compression risk); low-volume visceral metastasis permitted at investigator discretion if bone disease predominant.","Bone health agents (zoledronic acid or denosumab) required for >= 4 weeks prior to enrollment and continued during study.; <= 1 prior novel AR-targeted therapy allowed (abiraterone, enzalutamide, darolutamide, apalutamide).; Prior first-generation antiandrogens permitted (bicalutamide, nilutamide).; Prior chemotherapy for hormone-sensitive prostate cancer allowed if completed >= 12 months before entry.",MALE,F,"The trial excludes patients with known visceral metastases (lung, liver, brain), and the patient has liver metastases. In addition, the study allows ≤1 prior novel AR-targeted therapy, whereas the patient has received both abiraterone and enzalutamide.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),INCORRECT,D,"F is not justified as a hard exclusion. Although the trial lists visceral metastases as excluded, it also permits low-volume visceral disease at investigator discretion; volume predominance is unknown, so this is not a definitive hard exclusion. However, the patient has received two novel AR-targeted therapies while the trial permits ≤1, which is a clear line/prior soft mismatch. Disease and stage match. Therefore grade should be D, not F.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT04704544,0.5260495543479919,Crohn's Disease,Effectiveness of Tele-rheumatology for Delivering High Quality Rheumatology Care During the COVID-19 Crisis,NA,18 years,Rheumatic Disease,"Diagnosis of rheumatic disease (e.g., rheumatoid arthritis, systemic lupus erythematosus)","Unstable rheumatic disease requiring in-person visits (e.g., recent diagnosis of severe lupus nephritis) | Expected need for in-office procedures (e.g., joint injection) | Lack of access to a phone",(none),ALL,F,"Disease mismatch: the trial targets rheumatic diseases, while the patient has Crohn's disease. The inclusion explicitly requires a rheumatic disease diagnosis, so the patient is ineligible.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion. The trial requires a rheumatic disease diagnosis, while the patient has Crohn’s disease with no rheumatic diagnosis provided. The grader correctly assigned F based on the rubric.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT04706013,0.5607209205627441,Ornithine Transcarbamylase Deficiency,Study of Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency,PHASE3,Not specified,Pyridox(am)ine 5'-Phosphate Oxidase Deficiency,Confirmed PNPO deficiency by genetic analysis | Seizures typically controlled on oral pyridoxal phosphate with multiple daily doses | On pyridoxal phosphate therapy for >=30 days prior to enrollment | Previous failed treatment on pyridoxine allowed; off pyridoxine for >=24 hours,Any condition or abnormality that may compromise patient safety or ability to comply with study procedures | Known or suspected allergy to pyridoxal phosphate or related drugs | Participation in an interventional clinical research study within 4 weeks prior to screening or prior enrollment in this study,On pyridoxal phosphate therapy for >=30 days before enrollment; Prior pyridoxine allowed with washout >=24 hours,ALL,F,"Disease mismatch: the trial targets PNPO deficiency and requires genetic confirmation of PNPO deficiency, while the patient has OTC deficiency. This constitutes a hard exclusion.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Disease mismatch: trial targets PNPO deficiency with required genetic confirmation, while patient has OTC deficiency. This is a hard exclusion per rubric; F is correct.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT04713475,0.4419645667076111,PMM2-CDG,"Phase 1/2 Open-Label, Multicenter Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of PBGM01 Delivered Into the Cisterna Magna of Pediatric Type 1 (Early Onset) and Type 2a (Late Onset) Infantile GM1 Gangliosidosis",PHASE1/PHASE2,1 months to 24 months,"GM1 Gangliosidosis, Type I; GM1 Gangliosidosis, Type 2",Documented GM1 gangliosidosis with 2 pathogenic GLB1 mutations and beta-galactosidase enzyme deficiency | Type 1 (early onset infantile): age >= 1 month and < 12 months at enrollment; symptom onset < 6 months; specified minimum developmental milestones remaining | Type 2a (late onset infantile): age >= 6 months and <= 24 months at enrollment; symptom onset between 6 and 18 months; specified minimum developmental milestones remaining including ability to sit independently per WHO-MGRS (sit unsupported with head erect for >= 10 seconds),"Clinically significant neurocognitive deficit not attributable to GM1 gangliosidosis or that may confound study results | Acute illness requiring hospitalization within 30 days prior to enrollment | History of ventilation-assisted respiratory support or need for tracheostomy; chronic invasive or noninvasive mechanical ventilation | Intractable seizures or uncontrolled epilepsy, including status epilepticus or seizures requiring hospitalization within 30 days prior to dosing | Contraindication to intra-cisterna magna administration, fluoroscopic imaging, or anesthesia, or conditions increasing ICM procedure risk (e.g., mass effect/increased intracranial pressure, posterior fossa/foramen magnum space-occupying lesion, aberrant vascular or venous anatomy, Chiari malformation) | Contraindication to MRI or lumbar puncture | Prior gene therapy | Use of miglustat within 48 hours prior to dosing; miglustat prohibited during study | Use of enzyme replacement therapy or other investigational therapy within 5 half-lives prior to dosing; enzyme replacement prohibited during study | Receipt of a vaccine within 14 days prior to dosing or scheduled vaccine within 30 days after dosing | eGFR < 30 mL/min based on creatinine | Coagulopathy: INR > 1.5 or aPTT > 40 seconds | Platelet count < 100,000/µL | AST > 3 x ULN or ALT > 3 x ULN | Total bilirubin > 1.5 x ULN | Cardiomyopathy (screening troponin above ULN) | Peripheral neuropathy | Medical conditions or abnormal labs/vital signs increasing risk from ICM injection, anesthesia, fluoroscopy, LP, and/or MRI (e.g., temperature > 38°C, oxygen saturation < 95% on room air or baseline oxygen requirement, abnormal heart or respiratory rate for age, abnormal blood pressure for age, evidence of infection) | Any condition that would put the subject at undue risk during the procedure or interfere with evaluation of PBGM01 or interpretation of safety or results",Discontinue miglustat >= 48 hours before dosing; prohibited during study; No enzyme replacement therapy or other investigational therapy within 5 half-lives before dosing; enzyme replacement prohibited during study; No vaccines within 14 days before dosing and none scheduled within 30 days after dosing,ALL,F,"Disease mismatch: the trial targets GM1 gangliosidosis with GLB1 mutations, while the patient has PMM2-CDG with PMM2 variants. Age mismatch: trial age is 1–24 months, and the patient is 8 years old.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,Correct: There is a hard disease mismatch (trial is for GM1 gangliosidosis with GLB1 mutations; patient has PMM2-CDG) and an age hard exclusion (trial 1–24 months vs patient 8 years). Any one hard exclusion → F.,,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT04722887,0.5114943981170654,Ornithine Transcarbamylase Deficiency,"A Multi-Center, Single-Dose and Repeat-Dose Over Eight Weeks, Sequential Cohort Study to Evaluate Safety and Tolerability as Well as Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% Administered Subcutaneously in Subjects With Alpha1-Antitrypsin Deficiency",PHASE1/PHASE2,18 years to 80 years,Alpha-1 Antitrypsin Deficiency,"Congenital alpha-1 antitrypsin deficiency with allelic combination ZZ, SZ, Z(null), (null)(null), S(null), or at-risk alleles (per Medical Monitor). | Pre-augmentation serum alpha-1 antitrypsin level <11 μM (80 mg/dL by radial immunodiffusion or 50 mg/dL by nephelometry). | May be naive to augmentation or previously/currently on alpha1-PI augmentation therapy; if currently treated, must discontinue for >=25 days before Week 1 and remain off other alpha1-PI during the study. | Post-bronchodilator FEV1 >=30% and <80% predicted and FEV1/FVC <70% (GOLD stage II or III).","Moderate or severe COPD exacerbation within 4 weeks before Week 1. | History of lung or liver transplant. | Any lung surgery within the past 2 years (excluding lung biopsy). | Severe concomitant disease (e.g., congestive heart failure, clinically significant pulmonary fibrosis, malignant disease except non-melanoma skin cancer, history of acute hypersensitivity pneumonitis reaction, or current chronic hypersensitivity pneumonitis). | Pregnant or breastfeeding, or if of child-bearing potential, unwilling to use highly effective contraception during the study. | Smoked within the past 6 months or positive urine cotinine at screening due to smoking. | Participation in another investigational product study within 1 month prior to Week 1. | History of anaphylaxis or severe systemic reaction to plasma-derived alpha1-PI or other blood products. | Use of systemic steroids above a stable dose equivalent to >5 mg/day prednisone within 4 weeks prior to Week 1. | Use of systemic or aerosolized antibiotics for a chronic COPD exacerbation within 4 weeks prior to Week 1. | Known selective or severe IgA deficiency.",Prior or current alpha1-proteinase inhibitor augmentation therapy allowed with washout >=25 days before Week 1; no other alpha1-PI during study participation.,ALL,F,"Disease mismatch: the trial targets alpha-1 antitrypsin deficiency, not OTC deficiency. Additionally, the patient is 3 months old (trial requires 18–80 years) and does not have the required A1AT-deficiency genotypes.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Correct: There is a hard disease mismatch (OTC deficiency vs A1AT deficiency), which alone mandates F. Additionally, the patient is 3 months old vs trial minimum 18 years, another hard exclusion. The extra genotype note wasn’t needed but doesn’t affect the grade.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04738487,0.8404600620269775,Metastatic Non-Small Cell Lung Cancer,"A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer",PHASE3,18 years,Non-Small Cell Lung Carcinoma (metastatic),"Histologically or cytologically confirmed Stage IV (M1a, M1b, or M1c) non-small cell lung cancer | Measurable disease per RECIST 1.1 | EGFR/ALK/ROS1-directed therapy not indicated; absence of ALK and ROS1 gene rearrangements | PD-L1 expression >=1% by IHC at central laboratory | ECOG performance status 0–1 | Life expectancy >=3 months | Adequate organ function","Prior systemic chemotherapy or targeted/biologic therapy for metastatic NSCLC | Prior therapy with PD-1, PD-L1, or PD-L2 agents or agents targeting CTLA-4, OX-40, or CD137 | Previous treatment with an agent targeting the TIGIT pathway | Radiotherapy within 2 weeks of start of study intervention (1-week washout permitted for <=2 weeks of palliative non-CNS radiation) | Live or live-attenuated vaccine within 30 days prior to first dose (investigational vaccines not allowed) | Participation in another investigational agent study or investigational device use within 4 weeks prior to first dose | Active or untreated CNS metastases or carcinomatous meningitis (treated, stable >=4 weeks without steroids >=14 days allowed) | Severe hypersensitivity (>=Grade 3) to pembrolizumab/vibostolimab, pembrolizumab, or excipients | Active autoimmune disease requiring systemic treatment within the past 2 years (replacement therapy allowed) | Diagnosis of immunodeficiency or chronic systemic steroids >10 mg prednisone equivalent daily or other immunosuppressive therapy within 7 days before first dose | History of non-infectious pneumonitis requiring steroids or current pneumonitis | Known interstitial lung disease | Active infection requiring systemic therapy | Known HIV infection | Known hepatitis B infection or active hepatitis C infection | Any condition, therapy, or laboratory abnormality preventing receipt of first-line platinum-doublet chemotherapy or that may confound results per investigator | Psychiatric or substance abuse disorder that would interfere with study requirements",No prior systemic therapy for metastatic NSCLC; Adjuvant/neoadjuvant or chemoradiation for nonmetastatic NSCLC allowed if completed >=6 months before metastatic diagnosis; Radiotherapy washout >=2 weeks (>=1 week for palliative non-CNS radiation <=2 weeks); Investigational agent/device washout >=4 weeks; Live vaccine washout >=30 days,ALL,F,"The trial requires no prior systemic therapy for metastatic NSCLC and that EGFR-directed therapy not be indicated, but the patient has an EGFR exon 19 deletion (EGFR therapy indicated) and has received osimertinib for metastatic disease.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Hard exclusions apply: (1) Trial requires EGFR-directed therapy not indicated; patient has EGFR exon 19 deletion, so fails a required biomarker criterion. (2) Trial excludes any prior systemic therapy for metastatic NSCLC; patient has prior osimertinib in the metastatic setting. Thus F is correct and the grader’s reasoning aligns with the rubric.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT04742673,0.5814594030380249,Dementia,Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study,PHASE2,18 years,Delirium,"Age >= 18 years | Admitted to an ICU | Receiving treatment for respiratory failure and/or shock (e.g., mechanical ventilation, NIPPV, ECMO, optiflow, vasopressors, IABP)","Allergy to guanfacine, clonidine, or dexmedetomidine | Home antipsychotic use requiring continuation in the hospital | Second- or third-degree heart block, or persistent bradycardia < 50 beats/min requiring intervention (unless treated with a pacemaker) | Expected death within 24 hours of enrollment | Acute or subacute neurologic deficit causing inability to live independently after discharge (e.g., stroke, intracranial hemorrhage, cranial trauma, intracranial malignancy, anoxic brain injury, cerebral edema) | Dementia or other chronic neurologic disease/disorder causing inability to live independently at baseline | Active substance abuse | Psychotic disorder | Blindness or deafness preventing outcome assessments | Pregnancy or breastfeeding | Cardiac surgery within the current hospitalization",(none),ALL,F,"Disease mismatch: the trial targets delirium in ICU patients, while the patient has chronic dementia.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"Correct: The trial targets delirium (ICU setting), while the patient has dementia. This is a disease mismatch, which is a hard exclusion per the rubric, warranting an F. The grader’s reasoning aligns with the rubric.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT04743661,0.7876256108283997,Recurrent Glioblastoma,Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients With Recurrent Medulloblastoma and Ependymoma,PHASE2,up to 21 years,Recurrent Medulloblastoma; Recurrent Ependymoma,"Recurrent, progressive, or refractory medulloblastoma with histologic verification (Stratum 1) | Recurrent, progressive, or refractory ependymoma with histologic verification (Stratum 2) | Evidence of disease by MRI (measurable or non-measurable) or diffuse leptomeningeal disease, or tumor cells in CSF (Stratum 1) | Tumor cells in CSF allowed with or without radiographic disease (Stratum 2) | Age < 22 years at enrollment/screening | Appropriate intraventricular access device (programmable VP shunt or Ommaya) required prior to radioimmunotherapy; willingness to place/modify device as needed | Prior craniospinal irradiation for medulloblastoma unless contraindicated or not in patient’s best interest; <= 2 prior recurrences or refractory disease (Stratum 1) | Prior focal or craniospinal irradiation for ependymoma unless contraindicated or declined (Stratum 2) | Recovery from prior myelosuppressive chemotherapy; last dose >= 21 days (>= 42 days if nitrosourea) | Recovery from prior biologic/investigational agent; last dose >= 7 days (longer if delayed AEs expected) | Recovery from prior monoclonal antibody or long half-life agents; last dose >= 21 days | Radiation washout: CSI/whole brain/TBI/>=50% pelvis or spine completed >= 24 weeks before enrollment; measurable target not irradiated within 12 weeks; focal RT to symptomatic metastases >= 14 days | Autologous stem cell transplant completed >= 3 months prior to enrollment (Stratum 1) | Neurologic deficits stable >= 1 week; seizure disorders controlled on non–enzyme-inducing anticonvulsants; no enzyme-inducing antiepileptics within 1 week | Karnofsky/Lansky >= 50% | Adequate organ function (ANC, platelets, hemoglobin, renal, hepatic, coagulation per protocol thresholds) | Hypertension well controlled (<= 95th percentile) on stable medication if applicable | HIV-infected patients on effective ART with undetectable viral load within 6 months eligible | Chronic HBV with undetectable viral load on suppressive therapy eligible | HCV infection cured or on treatment with undetectable viral load eligible | Stable or decreasing dexamethasone dose for >= 7 days prior to enrollment allowed | Off colony-stimulating factors >= 1 week (>= 2 weeks for pegfilgrastim) | Use of effective contraception during study and specified period after therapy | Ependymoma: B7-H3 (CD276) positive by CLIA-certified IHC (Stratum 2)","Pregnancy | Breastfeeding (unless agrees not to breastfeed) | Prior combination therapy with bevacizumab, irinotecan, and temozolomide (Stratum 1) | Serious or non-healing wound, ulcer, or bone fracture | History of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 6 months | Known bleeding diathesis or coagulopathy | Significant vascular disease within 6 months (e.g., aortic aneurysm requiring repair, deep venous or arterial thrombosis) | Known thrombophilia (e.g., protein C/S deficiency, antithrombin III deficiency, Factor V Leiden, Factor II G20210A mutation, homocysteinemia, antiphospholipid antibody syndrome) | New CNS hemorrhage on baseline MRI within 14 days prior to enrollment | History within 6 months of stroke, myocardial infarction, transient ischemic attack, severe or unstable angina, peripheral vascular disease, or grade II or greater congestive heart failure | Serious and inadequately controlled cardiac arrhythmia | Hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies | Current use of NSAIDs, clopidogrel, dipyridamole, or aspirin > 81 mg/day that cannot be discontinued | Clinically significant unrelated systemic illness that would compromise tolerance of therapy or study procedures | Prior or concurrent malignancy that may interfere with safety/efficacy assessment of the investigational regimen | Concurrent anti-cancer or investigational drug therapy | Use of strong or moderate CYP3A4/5 inducers or inhibitors, or CYP3A4/5 substrates with a narrow therapeutic index, that cannot be discontinued >= 7 days prior to enrollment | Use of prohibited herbal preparations (e.g., St. John's wort, kava, ephedra, ginkgo, DHEA, yohimbe, saw palmetto, black cohosh, ginseng) that cannot be stopped >= 7 days prior to enrollment | Inability or unwillingness to comply with study visits, procedures, or drug administration plan","Progression after initial surgery, radiation therapy, or other therapies for ependymoma (Stratum 2); Prior craniospinal irradiation for medulloblastoma unless contraindicated or not in patient’s best interest (Stratum 1); Last myelosuppressive chemotherapy >= 21 days prior to enrollment (>= 42 days if prior nitrosourea); Last biologic or investigational anti-neoplastic agent >= 7 days prior to enrollment (longer if delayed AEs expected); Last monoclonal antibody or long half-life agent >= 21 days prior to enrollment; Radiation washout: CSI/whole brain/TBI/>=50% pelvis or spine completed >= 24 weeks before enrollment; Focal radiation to symptomatic metastatic disease completed >= 14 days before enrollment; Autologous stem cell transplant completed >= 3 months prior to enrollment (Stratum 1); Off colony-stimulating growth factors >= 1 week (>= 2 weeks for pegfilgrastim)",ALL,F,"Disease mismatch: the trial is for recurrent medulloblastoma or ependymoma, not glioblastoma. Additionally, the trial limits age to <22 years, while the patient is 40.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,F,"There is a clear hard exclusion: disease mismatch (glioblastoma vs medulloblastoma/ependymoma). Additionally, the patient is 40 while the trial restricts to <22 years, another hard exclusion. Grade F is correct and the reasoning identifies the key factors.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT04748042,0.7527437210083008,Metastatic Castration-Resistant Prostate Cancer,"Focal Radiation With Pulsed Systemic Therapy of Abiraterone, ADT, Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON): A Phase II, Single Arm, Single Institution Study",PHASE2,18 years,Prostate Cancer (castration-sensitive),"Histologic or cytologic diagnosis of prostate adenocarcinoma | Prior radical prostatectomy or external beam radiation with curative intent to the prostate; if positive margins after prostatectomy, salvage or adjuvant radiation required | Newly diagnosed oligometastatic prostate cancer on molecular imaging (e.g., PSMA PET/CT or Axumin), with 1 to <=5 radiation treatment sites; each site up to 5 cm and may contain multiple lesions | No prior image-guided radiation to sites outside the prostate bed or pelvic lymph nodes (typically treated in salvage/adjuvant settings) | Post-prostatectomy: PSA >0.2 ng/mL confirmed >=4 weeks later with subsequent rise | After prior curative radiotherapy: meets Phoenix criteria for progression (nadir PSA + 2 ng/mL) | Medically fit for radiotherapy | All molecular positive disease sites can be safely treated with radiation per radiation oncologist | Candidate for androgen deprivation therapy and abiraterone per treating oncologist | Adequate organ and bone marrow function within 28 days before treatment per protocol | Prior ADT with or without second-generation androgen receptor inhibitors or abiraterone in the curative setting allowed if testosterone >150 ng/dL | ADT for metastatic disease allowed up to 4 weeks prior to registration; if prior curative ADT, testosterone recovery >150 ng/dL or >1 year since last curative ADT before recent ADT was resumed | ECOG <=1","Pure small cell or pure neuroendocrine prostate cancer histology | Prior orchiectomy | Prior exposure to PARP inhibitors, docetaxel, or cabazitaxel | Another malignancy within the past 3 years requiring treatment (except superficial squamous skin cancer or carcinoma in situ of bladder or head and neck) | Life expectancy <=3 years | Known parenchymal brain metastasis | Symptoms of cord compression requiring immediate radiation | Myelodysplastic syndrome or acute myeloid leukemia, or features suggestive of MDS/AML | Severe hepatic impairment (Child-Pugh Class C) | Active hepatitis B or hepatitis C infection | Concurrent use of strong or moderate CYP3A inducers (specified agents); required washout 5 weeks for phenobarbital or enzalutamide, 3 weeks for others before starting olaparib | Concurrent use of strong or moderate CYP3A inhibitors (specified agents); required washout 2 weeks before starting olaparib | Major surgery within 2 weeks prior to starting study treatment or not recovered from effects of surgery | Myocardial infarction or arterial thrombotic events (e.g., stroke) within the past 6 months | Resting EKG indicating uncontrolled, potentially reversible cardiac condition (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia) or QTcF >500 ms, or congenital long QT syndrome | Severe or unstable angina, uncontrolled atrial fibrillation, or other cardiac arrhythmia requiring therapy | Active New York Heart Association Class II–IV heart failure | History of congestive heart failure requires LVEF >=50% within 6 months | Planned or scheduled cardiac surgery or percutaneous coronary intervention | Prior revascularization procedure within the past 12 months | Uncontrolled pituitary or adrenal dysfunction | Active infection or medical condition that contraindicates prednisone use | Chronic medical condition requiring systemic corticosteroid >10 mg prednisone daily | Prior allogeneic bone marrow transplant or double umbilical cord blood transplant | Participation in another clinical study with an investigational product or device within 1 month of registration | Uncontrolled hypertension (systolic >=160 mmHg or diastolic >=95 mmHg), unless white coat hypertension documented with acceptable home readings | Known hypersensitivity to olaparib, abiraterone, planned ADT agents (e.g., leuprolide, goserelin, degarelix), their excipients, or related classes | Immunocompromised state | Serious uncontrolled medical disorder or non-malignant systemic disease making the patient a poor medical risk (e.g., uncontrolled seizure disorder, superior vena cava syndrome, severe psychiatric disorder) | Persistent toxicities from prior therapy >= Grade 2 (except alopecia or sensory peripheral neuropathy) | Unable to swallow oral medications or gastrointestinal disorders likely to interfere with absorption",Prior radical prostatectomy or curative-intent external beam radiotherapy to the prostate required; Prior ADT with or without second-generation AR inhibitors or abiraterone in the curative setting allowed if testosterone >150 ng/dL; ADT for metastatic disease allowed up to 4 weeks prior to registration,MALE,F,"The trial requires castration-sensitive, newly diagnosed oligometastatic prostate cancer, whereas the patient has metastatic castration-resistant disease with progression on enzalutamide. This is a required stage/setting mismatch, which is a hard exclusion.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,F,"The trial requires castration-sensitive, newly diagnosed oligometastatic prostate cancer, while the patient has metastatic castration-resistant disease. This is a required stage/setting mismatch listed under hard exclusions, so F is correct.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT04800874,0.4171493649482727,PMM2-CDG,An Open Label Phase 2 Study of BBP-418 in Patients With Limb Girdle Muscular Dystrophy Type 2I (MLB-01-003),PHASE2,12 years to 55 years,Limb-Girdle Muscular Dystrophy Type 2I,Body weight >30 kg | Genetically confirmed diagnosis of LGMD2I and clinically affected with limb-girdle or distal weakness | Able to complete the 10-meter walk test in <=12 seconds unaided or are severe/non-ambulatory (unable or >12 seconds) | Previous enrollment in the natural history study MLB-01-001,"Gastrointestinal disease or surgeries that may affect absorption after oral administration | Significant cardiac, pulmonary, renal, hepatic, or endocrine disease other than that associated with LGMD2I | Any condition other than LGMD2I requiring therapy with prescription medicine (unless permitted by the investigator) | Any laboratory, vital sign, ECG abnormality, or clinical history/finding that increases risk or may confound results per investigator judgment | Pregnant or breastfeeding or planning to conceive during the study and for 12 weeks after last dose | History of drug abuse or alcoholism within 2 years prior to consent | Use of ribose or other sugar alcohol-containing supplement within 60 days before Day 1 | Use of a corticosteroid within 60 days before Day 1 | Platelet or bleeding disorder or other contraindication to muscle biopsy | Actively on an experimental therapy or device or received an experimental therapy or device within 60 days before Day 1",No ribose or other sugar alcohol supplements within 60 days before Day 1; No corticosteroids within 60 days before Day 1; No experimental therapy or device within 60 days before Day 1,ALL,F,"Disease mismatch (trial enrolls LGMD2I, not PMM2-CDG) and the patient is 8 years old, below the trial’s 12–55 age range.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,"Correctly identified two hard exclusions: disease mismatch (LGMD2I trial vs PMM2-CDG patient) and age below the trial minimum (8 < 12). Per rubric, any hard exclusion → F.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT04865939,0.7750101089477539,Metastatic Urothelial Carcinoma,A Randomized Trial Comparing Intravesical Gemcitabine to Continuous Bladder Irrigation With Sterile Water to Prevent Bladder Cancer Implantation in Patients Undergoing Excision of Upper Tract Urothelial Carcinoma,PHASE3,18 years to 90 years,Urothelial Carcinoma (renal pelvis); Urothelial Carcinoma (ureter),Biopsy-proven upper tract urothelial carcinoma. | Planned excisional surgery (distal ureterectomy or nephroureterectomy) with curative intent. | Age 18–90 years. | Life expectancy > 1 year. | Agreement to use adequate contraception during study and for 90 days after.,Concurrent or prior bladder cancer with a disease-free interval < 3 years. | Synchronous bilateral upper tract urothelial carcinoma. | Planned radical cystectomy. | Bladder capacity < 100 mL. | History of allergic reactions to gemcitabine or similar agents.,(none),ALL,F,"The trial requires biopsy-proven upper tract urothelial carcinoma with planned curative excisional surgery, whereas the patient has metastatic urothelial carcinoma after second-line therapy and is not in a surgical curative setting. This is a required stage/setting mismatch.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"The trial requires a curative surgical setting for upper tract urothelial carcinoma. The patient has metastatic disease after second-line therapy, definitively lacking the required stage/setting. This constitutes a hard exclusion per the rubric. Age/sex fit and disease site specificity is unknown, but the setting mismatch alone warrants F.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT04881617,0.7164024710655212,Dementia,Establishing Evidence-based Treatment for Speech and Language in Primary Progressive Aphasia,NA,Not specified,Primary Progressive Aphasia; Logopenic Progressive Aphasia; Nonfluent Progressive Aphasia; Semantic Dementia,"Primary Progressive Aphasia diagnosis per Gorno-Tempini et al., 2011 criteria | Mini-Mental State Examination score >= 15","Other neurological or psychiatric diagnosis contributing to cognitive-linguistic deficits | Significant uncorrected visual or hearing impairment that would interfere with participation | Mini-Mental State Examination score < 15 | Prominent initial non-speech-language impairment (cognitive, behavioral, or motoric)",(none),ALL,F,"Disease mismatch: the trial targets Primary Progressive Aphasia (and its variants, including semantic dementia) requiring a PPA diagnosis per Gorno-Tempini criteria, while the patient has unspecified dementia without a PPA diagnosis. Although MMSE, age, and sex align, the core disease requirement is unmet.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"The trial specifically targets Primary Progressive Aphasia variants per Gorno-Tempini criteria, while the patient has unspecified dementia without a PPA diagnosis. This is a disease mismatch, which is a hard exclusion per the rubric, warranting grade F. The grader’s reasoning aligns with the rubric.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT04899310,0.562755823135376,Ornithine Transcarbamylase Deficiency,"A Global, Phase 1/2, Open-Label, Dose Optimization Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency",PHASE1/PHASE2,1 years,Methylmalonic Acidemia,Body weight >= 11.0 kg | Diagnosis of isolated methylmalonic acidemia due to MUT deficiency confirmed by molecular genetic testing | Blood vitamin B12 level >= lower limit of normal; elevated B12 allowed if due to supplementation per Investigator | Willing and able to provide informed consent/assent and comply with study procedures | Sexually active females of childbearing potential and males of reproductive potential agree to use highly effective contraception during the study and for 3 months after last dose | (Part 2 only) At least 1 documented metabolic decompensation event in the 12 months before consent,"Diagnosis of isolated MMA cblA, cblB, or cblD subtypes, methylmalonyl-CoA epimerase deficiency, or combined MMA with homocystinuria | Prior gene therapy for the treatment of MMA | History of organ transplantation or planned organ transplantation during study participation | Active, unstable, or clinically significant medical condition not related to MMA that could increase risk, interfere with results, or limit participation (including relevant allergies; cardiovascular, central nervous system, gastrointestinal, infectious disease; clinically significant pathology; or history of cancer) | (Part 2 only) History of hepatitis B surface antigen positivity, hepatitis C virus infection, or HIV infection; participants with resolved HBV (HBcAb positive, HBsAg negative) are eligible; HCV antibody positive allowed only if HCV RNA PCR is negative",(none),ALL,F,"Hard exclusions: The trial targets methylmalonic acidemia due to MUT deficiency with a minimum age of 1 year/≥11 kg, while the patient has ornithine transcarbamylase deficiency and is 3 months old. This represents both a disease mismatch and an age window conflict.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,Correctly identified hard exclusions: disease mismatch (OTC deficiency vs MMA due to MUT) and age below trial minimum (3 months vs ≥1 year). Either triggers an F per the rubric.,,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04919382,0.7751345634460449,Metastatic Non-Small Cell Lung Cancer,"A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab as Second or Third Line Treatment for Small Cell Lung Cancer",PHASE2,18 years,Small Cell Lung Cancer (metastatic),Age >= 18 years | ECOG performance status of 0 or 2 within 28 days prior to registration | Histologically or cytologically confirmed extensive-stage small cell lung cancer that is metastatic and/or recurrent | Progression or recurrence after platinum-based chemotherapy with immunotherapy | Maximum of 3 prior lines of systemic therapy in the metastatic setting | Measurable disease per RECIST v1.1 | ANC >= 1500/µL | Platelets >= 100000/µL | Serum bilirubin <= 1.5 x ULN or direct bilirubin <= ULN (<= 3 x ULN allowed with Gilbert syndrome) | AST <= 3 x ULN (<= 5 x ULN with liver metastases) | ALT <= 3 x ULN (<= 5 x ULN with liver metastases) | Serum creatinine <= 2.0 x ULN or creatinine clearance >= 50 mL/min | Albumin > 2.5 g/dL | INR <= 1.5 x ULN if not on therapeutic anticoagulation (stable regimen if on anticoagulation) | aPTT <= 1.5 x ULN if not on therapeutic anticoagulation (stable regimen if on anticoagulation) | Negative pregnancy test for females of childbearing potential | Ability to swallow and retain oral medication | Life expectancy > 3 months,"Prior temozolomide therapy | Participation in another investigational study with study therapy or device within 4 weeks of first dose | Prior chemotherapy, immunotherapy, targeted therapy, or radiation within 2 weeks prior to day 1 or unresolved toxicities > grade 1 (except <= grade 2 neuropathy or alopecia) | Symptomatic CNS metastases or untreated/actively progressing CNS metastases not meeting protocol criteria | History of intracranial or spinal cord hemorrhage | Recent CNS-directed therapy not meeting washout: stereotactic radiotherapy within 7 days, whole-brain radiotherapy within 14 days, or neurosurgical resection within 28 days | Ongoing requirement for corticosteroids for CNS disease at time of treatment | Active infection requiring systemic therapy, including tuberculosis, hepatitis B (HBsAg positive), active hepatitis C, or uncontrolled HIV infection | Active or history of autoimmune disease or immune deficiency requiring systemic treatment, with protocol-defined exceptions | History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or active pneumonitis | Significant cardiovascular disease within 3 months (NYHA class II or greater, myocardial infarction, cerebrovascular accident), unstable arrhythmia, or unstable angina | Live attenuated vaccine within 4 weeks prior to initiation of study treatment | Pregnant or breastfeeding | Severe allergic or anaphylactic reactions to chimeric or humanized antibodies or fusion proteins | Known hypersensitivity to Chinese hamster ovary cell products or components of atezolizumab | Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage (> once monthly) | Uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L, calcium > 12 mg/dL or corrected serum calcium > ULN) | History of leptomeningeal disease | Prior or concurrent malignancy that could interfere with safety or efficacy assessment | Psychiatric or substance abuse disorders that would interfere with protocol compliance","Progression after platinum-based chemotherapy with immunotherapy required; <=3 prior lines of systemic therapy for metastatic disease allowed; Washout >=2 weeks from prior chemotherapy, immunotherapy, targeted therapy, or radiation",ALL,F,"Disease mismatch: the trial is for metastatic/recurrent small cell lung cancer, while the patient has metastatic non-small cell lung cancer (EGFR exon 19). Therefore the patient is ineligible.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Correctly applied hard exclusion: the trial targets metastatic/recurrent small cell lung cancer, while the patient has metastatic non-small cell lung cancer. Disease mismatch mandates an F per rubric.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT04925960,0.5102982521057129,Ornithine Transcarbamylase Deficiency,"A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of Oral Epalrestat Therapy in Pediatric Subjects With Phosphomannomutase 2-congenital Disorder of Glycosylation (PMM2-CDG)",PHASE3,2 years to 17 years,Phosphomannomutase 2 Congenital Disorder of Glycosylation,Age >= 2 and < 18 years | Molecularly confirmed biallelic PMM2 pathogenic variants | Negative urine pregnancy test (females of child-bearing potential) | Agrees to effective contraception or abstinence from prior to randomization through 3 months after treatment (subjects of child-bearing potential),"Other known congenital disorders of glycosylation | Allergy to aldose reductase inhibitors | Hypersensitivity to epalrestat | AST > 5 x ULN within 6 months prior to screening | ALT > 5 x ULN within 6 months prior to screening | Total bilirubin > 2 x ULN within 6 months prior to screening | Albumin < 2.8 mmol/L at screening | Liver fibrosis by elastography (Fibroscan > 7 kPa) at screening | Serum creatinine > 0.5 mg/dL (<= 6 years) | Serum creatinine > 0.7 mg/dL (7-10 years) | Serum creatinine > 1.24 mg/dL (>= 11 years) | Platelet count < 125 x10^9/L | Hemoglobin < 10 g/dL | Any other clinically significant laboratory abnormality per investigator | Use of an investigational drug (including acetazolamide) within 28 days | Use of an investigational biologic within 12 months | Concurrent or planned participation in another interventional protocol or use of other unapproved therapeutics | Any other medical condition that interferes with protocol compliance, compromises safety, or interferes with interpretation of results",Washout from investigational drugs >= 28 days; Washout from investigational biologics >= 12 months,ALL,F,"Disease mismatch: the trial targets PMM2-CDG, not OTC deficiency. Additionally, the patient is 3 months old, below the trial’s minimum age of 2 years.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,Correct: There is a hard disease mismatch (PMM2-CDG trial vs OTC deficiency patient) and an age window conflict (trial ≥2 years vs patient 3 months). Either triggers F per rubric. The grader’s reasoning aligns with the rubric.,,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04928846,0.7737923264503479,Metastatic Non-Small Cell Lung Cancer,"A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer",PHASE3,18 years,"Non-Small Cell Lung Cancer (non-squamous, locally advanced/metastatic)","Life expectancy >= 12 weeks | c-MET overexpressing non-small cell lung cancer per IHC (VENTANA MET SP44 RxDx assay) with centrally assessed tumor tissue | Histologically or cytologically confirmed non-squamous NSCLC that is locally advanced or metastatic | Known EGFR activating mutation status | Known status of actionable gene alterations other than EGFR | Measurable disease per RECIST v1.1 | ECOG performance status 0–1 | No more than 1 prior line of systemic cytotoxic chemotherapy for locally advanced/metastatic disease | Neoadjuvant/adjuvant cytotoxic chemotherapy counts as a prior line if progression occurred within 6 months of completion | Progressed on at least 1 prior line of therapy for locally advanced/metastatic NSCLC | Without actionable gene alteration: progressed on or ineligible for platinum-based chemotherapy and an immune checkpoint inhibitor (monotherapy or in combination with chemotherapy) | With actionable gene alteration where ICI is not standard: progressed on or ineligible for targeted therapy to the driver alteration and platinum-based chemotherapy | If immune checkpoint inhibitor is standard for the actionable alteration: also progressed on or ineligible for an immune checkpoint inhibitor | Considered appropriate for docetaxel therapy by the treating physician | CNS metastases allowed if adequately treated, asymptomatic, and on stable or decreasing steroids (<= 10 mg/day prednisone equivalent) and/or anticonvulsants for >= 2 weeks before randomization","New, untreated CNS metastases | Leptomeningeal disease | Adenosquamous histology | Neuroendocrine histology | Sarcomatoid features | Actionable EGFR activating mutations (EGFR wildtype required) | Prior c-MET–targeted antibodies | Prior telisotuzumab vedotin | Prior antibody–drug conjugates targeting c-MET or containing monomethylauristatin E | Prior docetaxel therapy | History of other malignancy unless treated with curative intent and disease-free for >= 2 years, or adequately treated non-melanoma skin cancer/lentigo maligna, or carcinoma in situ without current disease | History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or active pneumonitis on screening CT (radiation pneumonitis fibrosis permitted) | Unresolved adverse event >= Grade 2 from prior anticancer therapy (except alopecia or anemia); stable replacement hormone therapy allowed | Major surgery within 21 days prior to randomization | Clinically significant medical conditions per protocol",Prior platinum-based chemotherapy required unless ineligible; Prior immune checkpoint inhibitor required unless ineligible or not standard for genotype; Prior targeted therapy to driver gene alteration required if actionable alteration present; No more than 1 prior line of systemic cytotoxic chemotherapy for advanced/metastatic disease; Neoadjuvant/adjuvant cytotoxic chemotherapy counts as a prior line if relapse within 6 months,ALL,F,"The trial explicitly requires EGFR wildtype and excludes EGFR activating mutations; the patient has an EGFR exon 19 deletion. Other aspects (metastatic NSCLC, ECOG 0, age) could fit, but EGFR status is a hard exclusion.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"The trial explicitly excludes EGFR activating mutations and requires EGFR wildtype; the patient has an EGFR exon 19 deletion. This is a hard exclusion per the rubric, so F is correct.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT04940299,0.7926715612411499,Metastatic Urothelial Carcinoma,"A Phase II Study to Assess the Safety and Efficacy of Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma",PHASE2,18 years,Melanoma (unresectable/metastatic); Urothelial Carcinoma (locally advanced/metastatic); Non-Small Cell Lung Cancer (locally advanced/metastatic),"Histologically confirmed unresectable stage III or stage IV cutaneous melanoma (Cohort 1) | Consent to BRAF testing or documented BRAF V600 mutation status (Cohort 1) | Treatment-naive for unresectable/metastatic melanoma; prior adjuvant therapy allowed (Cohort 1) | Histologically or cytologically confirmed locally advanced or metastatic urothelial carcinoma of renal pelvis, ureter, bladder, or urethra; dominant transitional cell pattern if mixed histology (Cohort 2) | Cisplatin-ineligible or patient refuses standard chemotherapy; no prior systemic therapy for inoperable locally advanced/metastatic urothelial carcinoma (Cohort 2) | Cisplatin ineligibility may be due to GFR <60 and >=15 mL/min, NYHA class >= III heart failure, grade >=2 neuropathy, ECOG PS 2, or grade >=2 hearing loss (Cohort 2) | Prior intravesical chemotherapy allowed if completed >=4 weeks before treatment (Cohort 2) | If prior adjuvant/neoadjuvant chemo or chemoradiation for urothelial carcinoma, recurrence >12 months to be considered treatment-naive; no prior immuno-oncology in adjuvant/neoadjuvant (Cohort 2) | Histologically or cytologically confirmed locally advanced/metastatic NSCLC with EGFR mutation sensitive to EGFR TKI (G719X, exon 19 deletion, L858R, L861Q) (Cohort 3) | Received exactly one prior EGFR TKI in the advanced setting (Cohort 3) | Progressed on first/second-generation EGFR TKI and T790M negative by approved assay at progression, or progressed on osimertinib; EGFR TKI must be the last therapy (Cohort 3) | ECOG performance status <=1 | Measurable disease per RECIST 1.1 | Stable brain metastases <=3 cm without need for local intervention or systemic corticosteroids within 10 days prior to first treatment | Tumor tissue available for submission (FFPE block or unstained slides) from biopsy within 3 months prior to enrollment or approved archival tissue | Age >=18 years | WOCBP negative pregnancy test within 24 hours prior to start of treatment and agree to contraception; males with WOCBP partners agree to contraception","Symptomatic interstitial lung disease or condition interfering with detection/management of pulmonary toxicity | Uveal melanoma | Active or uncontrolled medical, psychiatric, or logistical condition increasing risk or interfering with study participation | Active second malignancy within 3 years except certain curable cancers (e.g., basal/squamous skin cancer, superficial bladder cancer, carcinoma in situ of prostate, cervix, or breast) | Active autoimmune disease requiring systemic treatment (exceptions: type I diabetes, hypothyroidism on replacement, skin disorders not requiring systemic treatment, or conditions not expected to recur) | Systemic corticosteroids >10 mg prednisone equivalent daily or other immunosuppressive medication within 14 days prior to first dose (exceptions allowed as specified) | History of organ or tissue transplant requiring systemic immunosuppression | Active infection requiring systemic therapy within 14 days prior to first dose | Unstable or significant cardiac disease within 12 months (e.g., unstable angina, myocardial infarction, TIA/CVA, NYHA class III/IV heart failure, uncontrolled significant arrhythmias) | Known HIV infection | Use of an investigational agent or device within 28 days prior to first dose | Live or attenuated vaccine within 30 days before first treatment | Prior treatment with anti–PD-1, anti–PD-L1, anti–PD-L2, anti–CTLA-4, or other T-cell costimulation/checkpoint agents except permitted adjuvant use | History of life-threatening toxicity from prior immune therapy unless unlikely to recur with standard countermeasures | Use of botanical preparations intended for general health support or to treat the study disease within 2 weeks prior to treatment initiation | Allergy or hypersensitivity to study drug components or severe hypersensitivity to any monoclonal antibody | Known hypersensitivity to tocilizumab, ipilimumab, or nivolumab | Prisoners or involuntarily incarcerated individuals | Compulsory detention for treatment of psychiatric or physical illness | WBC < 2000/µL | Absolute neutrophil count < 1500/µL | Platelets < 100000/µL | Hemoglobin < 9.0 g/dL (no transfusion within 14 days to meet criteria) | Serum creatinine > 1.5 x ULN unless creatinine clearance >= 40 mL/min | AST > 3.0 x ULN | ALT > 3.0 x ULN | Total bilirubin > 1.5 x ULN (except Gilbert syndrome < 3.0 x ULN) | Positive test indicating active hepatitis B or C infection","No prior systemic therapy for unresectable or metastatic melanoma; prior adjuvant therapy allowed (Cohort 1); No prior chemotherapy for inoperable locally advanced or metastatic urothelial carcinoma (Cohort 2); Prior intravesical chemotherapy allowed if completed >= 4 weeks before treatment (Cohort 2); If prior adjuvant/neoadjuvant chemotherapy or chemoradiation for urothelial carcinoma, recurrence must be > 12 months to be considered treatment-naive; no prior immuno-oncology in adjuvant/neoadjuvant (Cohort 2); Exactly one prior line of EGFR TKI therapy in advanced NSCLC and progressed; EGFR TKI must be last therapy (Cohort 3)",ALL,F,"The urothelial carcinoma cohort requires no prior systemic therapy for inoperable locally advanced/metastatic disease (treatment-naive), but the patient is after second-line therapy, which violates this required setting.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"The trial’s urothelial carcinoma cohort requires treatment-naive status for metastatic/inoperable disease (no prior systemic therapy). The patient is after second-line therapy, definitively lacking the required setting/line. Per hard exclusions (required stage/setting mismatch), this warrants an F. The grader’s reasoning aligns with the rubric.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT04941456,0.5186991691589355,PMM2-CDG,Is Ambulation Distance on the Six-minute Walk Test Improved With the Use of Passy-Muir Valve for Patients With Tracheostomy Compared to Patients With an Open Tracheostomy?,NA,18 years,PMV; Exercise Endurance; Tracheostomy,Tracheostomy present | Able to tolerate daily 30-minute physical therapy with PMV | Oxygen saturation >=88% with exertion | Able to ambulate >=10 feet (with or without assistive device or physical assistance),Active seizures | Pregnancy | Uncontrolled hypertension | Cognitive deficits that preclude informed consent | Enteric infection control precautions | Ongoing orthostasis | Currently on decannulation protocol | Medical instability warranting hold of therapy program,(none),ALL,F,"Disease mismatch and age conflict: the trial targets adults with tracheostomy/Passy-Muir Valve use, not PMM2-CDG, and requires age ≥18 while the patient is 8.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,"Hard exclusions apply: patient age 8 is below trial minimum age 18, yielding an immediate F. The grader also noted disease mismatch, which further supports F. The assigned grade is correct.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT04995523,0.7747177481651306,Metastatic Non-Small Cell Lung Cancer,"Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC",PHASE1/PHASE2,18 years to 130 years,Non-Small-Cell Lung Carcinoma,"Age >= 18 years | Unresectable stage III or stage IV non-small cell lung cancer not amenable to curative surgery or radiation (per cohort-specific requirements) | Part A and Part B: Confirmed progression during treatment with a checkpoint inhibitor-containing regimen | Part C and Part D: No prior immune-oncology treatment for metastatic NSCLC | Part E: No prior systemic treatment for metastatic squamous NSCLC | Documented PD-L1 expression by PD-L1 IHC | ECOG performance status 0–1 | Life expectancy >= 12 weeks | At least 1 measurable lesion per RECIST v1.1 | Adequate bone marrow, liver, and kidney function","Sensitizing EGFR mutation | ALK fusion | Other actionable genomic alteration with an approved first-line targeted therapy (e.g., ROS1 fusion, NTRK fusion, BRAF V600E) | Previous treatment with anti-TIGIT therapy | Concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment | Part A and Part B: Primary or secondary resistance after treatment with >= 2 regimens including a checkpoint inhibitor | Part C and Part D: Any prior systemic immune-oncology agent (prior IO for curative intent for another malignancy permitted) | Part E: Any prior systemic treatment for metastatic NSCLC (including chemotherapy, anti-PD-1, anti-PD-L1, anti-CTLA-4) | Symptomatic central nervous system metastases | Thromboembolic event within 3 months prior to enrolment | Other invasive malignancy within 2 years prior to screening",Parts A/B: Progression on prior checkpoint inhibitor-containing regimen required; Parts C/D: No prior immune-oncology treatment for metastatic NSCLC required; Part E: No prior systemic treatment for metastatic NSCLC required; Treatment with one previous systemic chemotherapy allowed,ALL,F,"The trial explicitly excludes patients with sensitizing EGFR mutations, and the patient has an EGFR exon 19 deletion. Despite appropriate stage and ECOG, this is a hard exclusion.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"The trial lists “sensitizing EGFR mutation” as an explicit exclusion. The patient has an EGFR exon 19 deletion, which is a sensitizing EGFR mutation. This triggers a hard exclusion per the rubric, so F is correct regardless of other anchors.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT05003986,0.4257251024246216,PMM2-CDG,"A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases",PHASE2,1 years to 17 years,Alport Syndrome; Focal Segmental Glomerulosclerosis; IgA Vasculitis; Immunoglobulin A Nephropathy; Minimal Change Disease,"eGFR >=30 mL/min/1.73 m2 at screening | Mean seated blood pressure between the 5th and 95th percentile for sex and height | Population 1: Age >=1 year and <18 years at Day 1 | Population 1: UP/C >=1.5 g/g at screening | Population 1: Kidney biopsy-proven FSGS or MCD histological patterns consistent with primary disease, or genetic podocyte mutation associated with FSGS or MCD, or FSGS histological pattern with maladaptive cause | Population 2: Age >=2 years and <18 years at Day 1 | Population 2: UP/C >=0.6 g/g at screening | Population 2: Kidney biopsy-confirmed IgAN, IgAV, or AS, or AS diagnosis by qualifying COL4A3/COL4A4/COL4A5 pathogenic mutations (including digenic) | Population 3: Age >=8 years and <18 years at Day 1 | Population 3: UP/C >=1.0 g/g at screening | Population 3: Kidney biopsy-confirmed IgAN | Population 3: Weight >=40 kg | Population 3: On ACE inhibitor and/or ARB therapy for at least 12 weeks prior to screening","Weight <7.3 kg at screening | FSGS or MCD secondary to viral infections, drug toxicities, or malignancies | IgA glomerular deposits not due to primary IgAN or IgAV | Acute onset or relapse of glomerular disease requiring new or different class of immunosuppressive treatment within 6 months before screening | Chronic immunosuppressive medications (including systemic steroids) not on a stable dose for >=1 month before screening | Requires prohibited concomitant medications | Any prior organ transplantation other than corneal transplant | History of congenital or acquired heart failure (modified Ross Class II–IV) or prior hospitalization for heart failure or symptoms (unexplained dyspnea, orthopnea, paroxysmal nocturnal dyspnea, ascites, peripheral edema) | Hemodynamically significant cardiac valvular disease | Clinically significant congenital vascular disease | Jaundice, hepatitis, or known hepatobiliary disease, or ALT >2 x ULN or AST >2 x ULN at screening | History of malignancy within the past 2 years | Hematocrit <27% at screening | Hemoglobin <9 g/dL at screening | Potassium >5.5 mEq/L at screening | Any clinically significant abnormal laboratory value per investigator | History of allergic response to angiotensin II antagonists or endothelin receptor antagonists (including sparsentan) or hypersensitivity to excipients | Pregnant, planning pregnancy during the study, or breastfeeding | Females of childbearing potential not agreeing to required contraception and testing schedule | Participation in another investigational study within 28 days before screening or planning to participate during this study | Prior exposure to sparsentan | Inability to adhere to study requirements per investigator judgment | Population 3: Unable to swallow tablets whole",ACE inhibitor and/or angiotensin receptor blocker for >=12 weeks prior to screening (Population 3),ALL,F,"Disease mismatch: the trial targets pediatric proteinuric glomerular diseases (Alport, FSGS, IgAN/IgAV, MCD), while the patient has PMM2-CDG, which is not included. Therefore the patient is not eligible.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,"Disease mismatch is a hard exclusion: the trial targets specific pediatric glomerular diseases (Alport, FSGS, IgAN/IgAV, MCD), while the patient has PMM2-CDG. The grader correctly assigned F based on this.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT05005975,0.5115824937820435,Ornithine Transcarbamylase Deficiency,"A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)",PHASE3,12 years to 75 years,Erythropoietic Protoporphyria; X-Linked Protoporphyria,Completed MT-7117-G01 through Week 58 or MT-7117-A-302 through Week 58 or MT-7117-A-301 through end of treatment per protocol. | Female subjects non-lactating with negative urine pregnancy test at baseline. | Females of childbearing potential and males with partners of childbearing potential agree to use 2 effective contraception methods (one highly effective for females).,"Photodermatoses other than erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP). | Clinically significant hepatobiliary disease. | AST, ALT, or ALP >= 3 x ULN. | Total bilirubin > 1.5 x ULN (exception may apply for Gilbert's syndrome per sponsor). | Excessive alcohol intake (past 2 years). | History of melanoma. | Presence of squamous cell carcinoma, basal cell carcinoma, or other malignant skin lesions; unresolved suspicious lesions or nevi. | Clinically significant psychiatric disease. | Clinically significant renal disease or eGFR < 60 mL/min/1.73m2. | Pregnant or lactating. | Phototherapy or afamelanotide within 3 months before baseline. | Cimetidine or antioxidant agents at doses that may affect endpoints within 4 weeks before baseline. | Chronic treatment with opioids, ketamine, or medical cannabis within 4 weeks before baseline. | Any drugs or supplements that may interfere with study objectives or subject safety per investigator. | Any investigational agent other than dersimelagon within 12 weeks before screening or 5 half-lives (whichever is longer). | Hypersensitivity to dersimelagon or excipients. | Unable to swallow tablets or significant gastrointestinal disorders affecting absorption (e.g., malabsorption, gastric/small bowel resection, bariatric surgery, symptomatic IBD, bowel obstruction). | Use within 1 week of baseline of CYP3A4 narrow therapeutic index substrates or substrates of P-gp, BCRP, OATP1B1, or OATP1B3 where elevated levels pose significant risk.","Completion of prior dersimelagon studies MT-7117-G01, MT-7117-A-302, or MT-7117-A-301 as specified.; No phototherapy or afamelanotide within 3 months before baseline.; No cimetidine or high-dose antioxidant agents (e.g., beta-carotene, cysteine, pyridoxine) within 4 weeks before baseline.; No chronic opioids, ketamine, or medical cannabis within 4 weeks before baseline.; No investigational agents other than dersimelagon within 12 weeks before screening or 5 half-lives (whichever is longer).; Avoid CYP3A4 narrow therapeutic index substrates and substrates of P-gp, BCRP, OATP1B1, or OATP1B3 within 1 week before baseline.",ALL,F,"Disease mismatch: the trial is for erythropoietic protoporphyria or X-linked protoporphyria, not OTC deficiency. Additionally, the patient is 3 months old while the trial requires ages 12–75.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,Clear hard exclusions: disease mismatch (OTC deficiency vs EPP/XLP) and age below minimum (3 months vs ≥12 years). The grader correctly assigned F and identified key reasons.,,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05009992,0.8077949285507202,Recurrent Glioblastoma,"A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression",PHASE2,2 years to 39 years,Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma (H3 K27M-mutant); WHO Grade III Glioma; Recurrent Diffuse Intrinsic Pontine Glioma; Recurrent Diffuse Midline Glioma (H3 K27M-mutant); Recurrent WHO Grade III Glioma,"Age 2 to 39 years | Diagnosis of diffuse midline glioma (including spinal cord tumors) by imaging and/or pathology | Post-radiation cohorts: within 4–14 weeks of completing radiation and no additional therapy beyond radiation | Progression cohorts: evidence of progression after completing standard-of-care radiation and no prior re-irradiation | Body weight >= 10 kg | Seizure disorder allowed if well controlled | Contraception required for participants of childbearing potential | Adequate tissue available for molecular analyses (minimum 10–20 unstained slides or 1 block with >= 40% tumor content) | No dyspnea at rest or exercise intolerance due to pulmonary insufficiency | Pulse oximetry > 92% on room air | QTc < 470 msec | Karnofsky >= 50 for >16 years or Lansky >= 50 for <=16 years | For targeted therapy cohorts: tumor harbors BRAFV600E, PDGFRA alteration (point mutation or amplification with >= 5 copies), FGFR1 alteration (point mutation, fusion, or amplification with >= 5 copies), or NF1 alteration","Histone H3 wildtype grade II diffuse astrocytoma | Thalamic or cerebellar H3K27M diffuse midline glioma (with limited specified exceptions) | Prior exposure to radiation therapy (pre-radiation cohorts) | Prior exposure to re-irradiation for tumor progression (progression cohorts) | Currently receiving another investigational drug or other anti-cancer agents | Immunodeficiency or active HIV, hepatitis B, or hepatitis C infection; autoimmune disorder requiring systemic cytotoxic or immunosuppressive therapy | Uncontrolled infection or other uncontrolled systemic illness | Pregnant or breastfeeding | Active illicit drug use or diagnosis of alcoholism | Allergy to compounds of similar composition to study agents | Evidence of disseminated disease, including diffuse leptomeningeal or CSF dissemination (except allowed in specified targeted cohorts) | Additional malignancy that is progressing or requires active treatment within 3 years | Concomitant use of potent CYP3A4/5 inhibitors within 72 hours prior to and during treatment | Concomitant use of potent CYP3A4/5 inducers (including enzyme-inducing antiepileptic drugs) within 2 weeks prior to and during treatment | History of congestive heart failure or family history of long QT syndrome",Any number of prior therapies allowed; must have recovered from acute toxicities; Washout: >= 7 days after last biologic agent or beyond known AE window; Washout: >= 5 half-lives from any investigational agent; Washout: >= 4 weeks from cytotoxic therapy (>= 23 days for temozolomide; >= 6 weeks for nitrosoureas); Washout: >= 6 weeks from therapeutic antibodies (>= 21 days for bevacizumab when tumor-directed); Washout: >= 4 weeks or >= 5 half-lives (whichever is shorter) from other anti-tumor therapies; Prior temozolomide during radiation allowed at standard pediatric dosing (90 mg/m2 daily for 42 days); Bevacizumab for radiation-induced edema allowed (up to 5 doses; no required washout); Dexamethasone allowed; dose must be stable or decreasing for >= 3 days before baseline MRI,ALL,F,"Hard exclusions: the trial enrolls diffuse midline/DIPG or WHO grade III gliomas in ages 2–39, while the patient has recurrent glioblastoma (grade IV, non-DMG) and is 40 years old—both disease mismatch and age above the maximum.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,F,"Hard exclusions apply: patient age (40) exceeds trial maximum (39) and disease mismatch (trial targets DMG/DIPG/WHO grade III, not glioblastoma grade IV). Therefore F is correct per rubric.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05016219,0.5787391066551208,Dementia,Phase 2 - The Use of Rhythmic Light Therapy to Entrain Gamma Oscillations and the Circadian System in Patients With Alzheimer's Disease,NA,55 years,Mild Cognitive Impairment; Alzheimer's Disease (mild),"Mild cognitive impairment | Mild Alzheimer's disease | Montreal Cognitive Assessment score 17–25 | Sleep disturbance with Pittsburgh Sleep Quality Index > 5 | Resides at home, independent living, or assisted living",Taking sleep medication | Residence in a skilled nursing facility or long-term care | Obstructing cataracts | Macular degeneration | Blindness | Severe sleep apnea | Restless legs syndrome | History of severe epilepsy,(none),ALL,F,"The trial enrolls only Mild Cognitive Impairment or mild Alzheimer's disease, whereas the patient has moderate-stage dementia (MMSE 19) and is amyloid-negative; thus the patient’s disease is not included in the trial’s targeted diseases.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"Hard exclusion applies: the trial targets MCI or mild Alzheimer’s disease, while the patient has moderate-stage dementia and no confirmed AD diagnosis. Per rubric, disease not included in trial diseases → F. Even without hard exclusion, stage/setting would be a soft mismatch.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05081596,0.5858243703842163,Dementia,PATH-Pain: A Primary Care-Based Psychosocial Intervention To Improve Cognitive and Depression Outcomes in Older Adults With MCI and Early Stage AD,NA,60 years,Mild Cognitive Impairment; Alzheimer's Disease (early stage); Depression; Chronic Pain,"Age >= 60 years | Mild cognitive impairment (MCI) or early stage probable/possible Alzheimer's disease with MoCA 16–25 | MADRS total >= 5 | Off antidepressants, cholinesterase inhibitors, or memantine, or on a stable dosage for >= 12 weeks | Chronic pain on most days for >= 3 months and average pain intensity score >= 4 | Clinical Dementia Rating 0.5–1 | Capacity to consent | Participation of a study partner is required",Significant suicide risk | Medically or neurologically unstable to safely enroll | Psychiatrically unstable to safely enroll in randomized psychotherapy trial | Requiring psychiatric hospitalization at baseline | Lack of English fluency,"On stable dose or off antidepressants, cholinesterase inhibitors, or memantine for >= 12 weeks",ALL,F,"The trial requires MCI or early-stage Alzheimer's disease (e.g., CDR 0.5–1/MoCA 16–25), while the patient has moderate-stage dementia (MMSE 19), which is beyond the eligible stage—constituting a hard stage mismatch.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"The trial requires MCI or early-stage Alzheimer’s (e.g., CDR 0.5–1/MoCA 16–25). The patient has moderate-stage dementia (MMSE 19), definitively lacking the required stage, which is a hard exclusion per the rubric (“required ... stage/setting the patient definitively lacks”). Therefore F is appropriate.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT05083182,0.59808349609375,Rheumatoid Arthritis,"A Phase 3 Multicenter, Open-label Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr)",PHASE3,5 years to 17 years,Juvenile Psoriatic Arthritis,"Diagnosis of juvenile psoriatic arthritis by Vancouver criteria with exclusion of enthesitis-related arthritis; diagnosis made >= 3 months prior to screening | Active disease in >= 3 joints at screening and at Week 0 (swelling or loss of motion with pain and/or tenderness) | Active disease despite previous non-biologic DMARD and/or NSAID therapy (non-biologic DMARD for >= 12 weeks or intolerance; NSAID for >= 4 weeks or intolerance) | Concurrent methotrexate, sulfasalazine, leflunomide, oral corticosteroids, or NSAIDs permitted on a stable dose | Up to date with all immunizations per local guidelines for immunosuppressed patients | Prior use of anti-TNFα agents, IL-17 inhibitors and other biologics (except non-responders to IL-23 inhibitors), and JAK inhibitors permitted with sufficient washout","Enthesitis-related arthritis | History of latent or active granulomatous infection (including tuberculosis, histoplasmosis, or coccidioidomycosis) | History of, or ongoing, chronic or recurrent infectious disease | Herpes zoster infection within 8 weeks prior to Week 0 | Known history of hepatitis C infection or positive test at screening",Non-biologic DMARD for >= 12 weeks or intolerance; NSAID for >= 4 weeks or intolerance; Prior anti-TNFα therapy permitted with washout; Prior IL-17 inhibitors and other biologics permitted (except non-responders to IL-23 inhibitors); Prior JAK inhibitors permitted with washout,ALL,F,"Disease mismatch: the trial targets juvenile psoriatic arthritis, not rheumatoid arthritis, and the patient is 55 years old, outside the trial’s 5–17 year age range.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,Correct: There is a hard exclusion due to disease mismatch (rheumatoid arthritis vs juvenile psoriatic arthritis) and also an age window conflict (55 vs 5–17). Either warrants F per rubric.,,
"36 female with stage III clear cell ovarian carcinoma, who initially received optimal debulking and adjuvant carboplatin+paclitaxel +bevacizumab. After 5 months, she had a new pleural effusion that was cytology positive for ovarian carcinoma. She was found to be BRCA1 positive. What are trial options?",NCT05123807,0.7401824593544006,Recurrent Clear Cell Ovarian Carcinoma,Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study),PHASE2,18 years,"Ovarian Cancer (mucinous, recurrent)",Histologically or cytologically confirmed recurrent primary mucinous ovarian cancer | Age >= 18 years | ECOG performance status <= 2 | ANC > 1500/µL | Platelets > 100000/µL | Total bilirubin <= 1.5 mg/dL | Creatinine <= 1.5 mg/dL | AST <= 3 x ULN | ALT <= 3 x ULN | > 2 weeks from prior chemotherapy or radiation therapy (except bevacizumab requires > 6 weeks),"Receiving concurrent investigational therapy or received investigational therapy within 30 days of HIPEC | Mucinous tumors with pathologic confirmation of a non-gynecologic site of origin | Known active CNS metastases | Hypersensitivity to any component of cisplatin | Uncontrolled intercurrent illness (e.g., ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness/social situations limiting compliance) | Pregnant or nursing | Peripheral neuropathy >= grade 2 | History of allogenic transplant | History of prior HIPEC or intraperitoneal chemotherapy | Known bulky extra-abdominopelvic disease | Hearing impairment or tinnitus >= grade 2",> 2 weeks since prior chemotherapy or radiation therapy; > 6 weeks since prior bevacizumab,FEMALE,F,"The trial is restricted to recurrent primary mucinous ovarian cancer, while the patient has recurrent clear cell ovarian carcinoma. This disease/subtype mismatch is a hard exclusion.",Recurrent Clear Cell Ovarian Carcinoma,BRCA1,Stage III clear cell ovarian carcinoma; Cytology-positive pleural effusion; BRCA1 positive; Female; Age 36 years,(none),Optimal debulking surgery; Adjuvant carboplatin plus paclitaxel plus bevacizumab,Stage III,,36,years,female,(none),CORRECT,F,"Trial requires recurrent mucinous ovarian cancer, while the patient has recurrent clear cell ovarian carcinoma. This is a disease/subtype mismatch constituting a hard exclusion per the rubric, so F is appropriate.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT05144256,0.5521149039268494,Ornithine Transcarbamylase Deficiency,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Regularly Transfused, Followed by a 5-Year Open-label Extension Period",PHASE3,1 years to 17 years,Pyruvate Kinase Deficiency,"Age 1 to <18 years (12–24 months must weigh >=7 kg) | Clinical laboratory confirmation of pyruvate kinase deficiency with >=2 mutant PKLR alleles, including >=1 missense mutation | Received 6 to 26 red blood cell transfusion episodes in the 52 weeks prior to consent/assent | Complete transfusion records for the prior 52 weeks (dates, volumes, and pre-transfusion hemoglobin for >=80% of transfusions) | Receiving folic acid supplementation for >=21 days before first dose and continued during study participation | Post-menarche females or Tanner stage 2 breast development: abstinent or using 2 forms of contraception (>=1 highly effective) during study and for 28 days after last dose","Pregnant or breastfeeding | PKLR genotype homozygous R479H or two nonmissense mutations without another missense mutation | History of malignancy | Active and/or uncontrolled cardiac or pulmonary disease or clinically relevant QT prolongation within 6 months | Liver disease with histopathological evidence of cirrhosis or severe fibrosis | Clinically symptomatic cholelithiasis or cholecystitis (unless prior cholecystectomy) | History of drug-induced cholestatic hepatitis | AST >2.5 x ULN (unless due to hemolysis and/or hepatic iron deposition) | ALT >2.5 x ULN (unless due to hepatic iron deposition) | Estimated glomerular filtration rate <60 mL/min/1.73 m^2 | Nonfasting triglycerides >440 mg/dL (5 mmol/L) | Active uncontrolled infection requiring systemic antimicrobial therapy | Known active hepatitis B virus infection | Known hepatitis C virus infection | Known HIV infection | Major surgery (including splenectomy) within 6 months or planned during screening or double-blind period | Current enrollment or past participation in another interventional study within 90 days or 5 half-lives (whichever longer) before first dose | Prior exposure to gene therapy | Prior bone marrow or stem cell transplantation | Currently receiving hematopoietic stimulating agents (last dose <28 days or <5 half-lives before randomization) | Use of strong CYP3A4/5 inhibitors within <5 days or <5 half-lives before randomization | Use of strong CYP3A4 inducers within <28 days or <5 half-lives before randomization | Use of anabolic steroids, including testosterone, within <28 days before randomization | Allergy or contraindication to mitapivat or its excipients | Receiving a pyruvate kinase activator within <52 weeks before consent/assent",Received 6–26 RBC transfusion episodes in the prior 52 weeks; Folic acid supplementation for >=21 days before first dose; Hematopoietic stimulating agents stopped >=28 days or >=5 half-lives before randomization; Strong CYP3A4/5 inhibitors stopped >=5 days or >=5 half-lives before randomization; Strong CYP3A4 inducers stopped >=28 days or >=5 half-lives before randomization; Anabolic steroids (including testosterone) stopped >=28 days before randomization; Prior pyruvate kinase activator stopped >=52 weeks before consent/assent; No investigational drug/device within 90 days or >=5 half-lives before first dose,ALL,F,"Disease mismatch: the trial enrolls pyruvate kinase deficiency (PKLR-mutant, transfusion-dependent) patients, while the patient has ornithine transcarbamylase deficiency. Additionally, the patient is 3 months old, below the trial’s minimum age of 1 year.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Correct. There is a hard exclusion due to disease mismatch (OTC vs PK deficiency). Additionally, the patient is below the trial’s minimum age (3 months vs ≥1 year). Either condition triggers an F under the rubric. The grader’s reasoning aligns with the rubric.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT05152823,0.42355823516845703,PMM2-CDG,Phase I/IIa Intrathecal Gene Delivery Clinical Trial for IGHMBP2-Related Diseases,PHASE1/PHASE2,2 months to 14 years,Charcot-Marie-Tooth Disease Type 2S; Spinal Muscular Atrophy with Respiratory Distress 1,"Confirmation of two pathogenic variants in the IGHMBP2 gene from a CLIA-certified laboratory | Ambulatory status may be pre-ambulant, ambulant (able to walk 10 meters without assistance), or non-ambulant (unable to walk more than 10 meters unassisted) | Ability to cooperate with functional assessments as per PI's discretion","Prior participation in a gene or cell therapy program | Immunizations of any kind within 1 month prior to the study | Active infection based on clinical observations | Serological evidence of HIV infection, or Hepatitis B or C infection | Diagnosis of or ongoing treatment for an autoimmune disease | Persistent leukopenia or leukocytosis (WBC <= 3500/µL or >= 20000/µL) | Absolute neutrophil count < 1500/µL | Abnormal liver function: GGT > 2 x ULN (if no other laboratory abnormalities), elevated bilirubin, and/or abnormal PT/INR | Concomitant illness or requirement for chronic drug treatment that creates unnecessary risks for gene transfer per PI | AAV9 binding antibody titer > 1:50 | Abnormal laboratory values in the clinically significant range | Diagnosis of any other systemic illness that increases the risk of gene transfer or conditions that may compromise compliance, safety, or interpretability per PI | Any requirement for immunomodulatory therapy where a safe washout is not feasible | Contraindication for intrathecal injection | Positive JCV antibody test > 0.40",No prior gene or cell therapy; No immunizations within 1 month prior to study,ALL,F,"Disease mismatch: the trial targets IGHMBP2-related disorders (CMT2S/SMARD1) and requires two pathogenic IGHMBP2 variants, while the patient has PMM2-CDG with PMM2 variants. This fails the required disease/biomarker criteria despite age eligibility.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,"The trial targets IGHMBP2-related disorders (CMT2S/SMARD1), not PMM2-CDG, which is a hard disease mismatch per the rubric, triggering an F. Age and gender fit but are irrelevant once a hard exclusion applies. The grader’s reasoning correctly identified the disease mismatch (and noted the biomarker requirement mismatch, though disease mismatch alone suffices).",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT05177211,0.41827571392059326,PMM2-CDG,A Phase 2 Study of Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL),PHASE2,18 years,"Atypical Chronic Myeloid Leukemia; MDS/MPN, Unclassifiable; MDS/MPN with Ring Sideroblasts and Thrombocytosis; Chronic Neutrophilic Leukemia","Age >= 18 years | Morphologically confirmed diagnosis of Atypical Chronic Myeloid Leukemia (BCR-ABL1 negative) | Morphologically confirmed diagnosis of MDS/MPN, Unclassifiable | Morphologically confirmed diagnosis of MDS/MPN with Ring Sideroblasts and Thrombocytosis | Morphologically confirmed diagnosis of Chronic Neutrophilic Leukemia | Palpable splenomegaly >= 5 cm below left costal margin or spleen volume >= 450 cc or MPN-SAF TSS > 10 | ECOG 0–2","History of encephalopathy including Wernicke's encephalopathy | Signs or symptoms of encephalopathy; thiamine deficiency must be excluded and brain MRI may be required | Thiamine deficiency not corrected before enrollment | Concomitant use of moderate or strong CYP3A4 inducers or dual CYP3A4 and CYP2C19 inhibitors | Current treatment with chemotherapy, immunomodulatory therapy (e.g., lenalidomide, pomalidomide, thalidomide, interferon-alpha), ruxolitinib, anagrelide, or corticosteroids > 10 mg/day prednisone equivalent | Prior treatment with fedratinib | Use of myeloid growth factors (e.g., G-CSF) within 14 days prior to initiation of fedratinib | Aspirin dose > 150 mg daily | Chronic liver disease (e.g., chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis) | Active (uncontrolled, metastatic) second malignancy | Uncontrolled congestive heart failure (NYHA class 3 or 4) | Known HIV infection unless CD4+ T-cell count >= 350 cells/µL, on stable ART >= 4 weeks, and HIV viral load < 400 copies/mL | Active infectious Hepatitis B | Active Hepatitis C (unless cured or RNA negative after prior treatment) | Serious active infection requiring IV antimicrobials | Significant gastrointestinal or other disorder that would inhibit absorption of oral medication | Inability to swallow capsules | Participation in another investigational agent study within 30 days prior to start of fedratinib | Major surgery or radiation therapy within 4 weeks",Hydroxyurea allowed if on a stable dose > 14 days prior to initiation; No investigational agents within 30 days prior to fedratinib; Discontinue myeloid growth factors >= 14 days before initiation,ALL,F,"Disease mismatch: the trial targets adult MDS/MPN/CNL, not PMM2-CDG. Additionally, the patient is 8 years old, below the trial’s minimum age of 18.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,Hard exclusions apply: the patient’s disease (PMM2-CDG) is not among the trial diseases and the patient is under the minimum age (8 < 18). An F is correct per the rubric.,,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05222386,0.6775633692741394,Dementia,"Building Online Community to Improve Patient and Caregiver Outcomes in Parkinson Disease, Lewy Body Dementia and Related Disorders",NA,40 years,Corticobasal Degeneration; Dementia With Lewy Bodies; Lewy Body Parkinsonism; Multiple System Atrophy; Parkinson Disease; Parkinson Disease Dementia; Progressive Supranuclear Palsy; Vascular Parkinsonism,"Age > 40 years | Diagnosed with Parkinson disease or other causes of parkinsonism (e.g., progressive supranuclear palsy, multiple system atrophy, Lewy body dementia) by a community neurologist","Unable or unwilling to commit to study procedures | Additional medical illnesses requiring palliative services (e.g., metastatic cancer) | Already receiving palliative care or hospice services",(none),ALL,F,"The trial targets Parkinson disease/parkinsonism-related disorders (e.g., Lewy body dementia), while the patient is only described as having unspecified dementia without a diagnosis of PD/parkinsonism. This is a disease mismatch hard exclusion.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"The trial targets Parkinson disease/parkinsonism-related disorders (including DLB), while the patient only has unspecified dementia without a PD/parkinsonism diagnosis. This is a disease mismatch hard exclusion per the rubric. Age/sex are compatible but irrelevant once the hard exclusion applies. Grade F is correct.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT05300581,0.5816720724105835,Rheumatoid Arthritis,Determining the Feasibility of Outpatient Parenteral Antibiotic Therapy for Persons Who Inject Opioids,NA,18 years to 100 years,Opioid Use Disorder; Endocarditis; Osteomyelitis; Discitis; Septic Arthritis; Epidural Abscess; Staphylococcus Aureus Bacteremia,Age 18-100 years | Endocarditis (injection-related) | Osteomyelitis (injection-related) | Discitis (injection-related) | Septic arthritis (injection-related) | Epidural abscess (injection-related) | Staphylococcus aureus bacteremia (injection-related) | History of injection opioid use within the last 1 year | Evaluated by addiction medicine consult service during current inpatient admission | Started or maintained on medications for opioid use disorder (methadone or buprenorphine) during admission,,On medications for opioid use disorder (methadone or buprenorphine) during admission,ALL,F,"Disease mismatch: the trial targets injection-related infections and opioid use disorder, while the patient has rheumatoid arthritis. Therefore the patient does not meet the trial’s disease focus.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Correct: The patient has rheumatoid arthritis, while the trial targets opioid use disorder and injection-related infections. This is a hard disease mismatch per rubric, leading to an F regardless of other factors.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05333471,0.5857186913490295,Crohn's Disease,A Pilot Study of Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis,PHASE1/PHASE2,10 years to 60 years,Chronic Granulomatous Disease-associated Colitis,"Age 10–60 years | Confirmed diagnosis of chronic granulomatous disease and CGD-associated colitis (or CGD-IBD with colitis on colonoscopy) | Fecal calprotectin >=200 microgram/g | Harvey-Bradshaw Index (HBI) score >=5 | No planned change in systemic antibiotic regimen for CGD for 1 month prior to FMT | No planned escalation in CGD-IBD treatment for 1 month prior to FMT | If receiving monoclonal antibodies for CGD-IBD, stable dose for >=12 weeks with no planned escalation | Women/participants who can become pregnant agree to use highly effective contraception during the study","Acute gastrointestinal infection, including active GI abscesses | Clostridioides difficile toxin gene positive by PCR at screening | History of intestinal obstruction related to CGD-IBD | History of fistulizing CGD-IBD or intra-abdominal abscesses due to CGD-IBD | History of CGD-IBD-related non-transversable intestinal strictures | History of adverse events attributable to prior FMT | Significant liver disease, including portal hypertension or cirrhosis (e.g., biopsy-proven nodular regenerative hyperplasia) | Pregnant or breastfeeding | History of severe food allergy | Contraindication to colonoscopy under anesthesia | Any condition that, in the investigator's opinion, contraindicates study participation",Stable systemic antibiotic regimen for CGD for >=1 month prior to FMT; No planned escalation of CGD-IBD therapy for 1 month prior to FMT; Stable dose of monoclonal antibody therapy for CGD-IBD for >=12 weeks prior to FMT,ALL,F,"Disease mismatch: the trial requires chronic granulomatous disease-associated colitis, while the patient has Crohn's disease without CGD.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion: the trial requires CGD-associated colitis, while the patient has Crohn’s disease without CGD. F is appropriate per rubric.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT05345171,0.9999632239341736,Ornithine Transcarbamylase Deficiency,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Adeno-associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Patients With Late-onset OTC Deficiency",PHASE3,12 years,Ornithine Transcarbamylase Deficiency,"Confirmed clinical diagnosis of late-onset ornithine transcarbamylase (OTC) deficiency by enzymatic, biochemical, or molecular testing | Free from symptomatic hyperammonemia and no emergent active intervention for hyperammonemia within 4 weeks before screening/baseline | If on ongoing daily ammonia scavenger therapy, on a stable daily dose for >= 4 weeks prior to screening | If on a protein-restricted diet, stable total daily protein intake with <= 20% variability for >= 4 weeks prior to screening | Females of childbearing potential and fertile males agree to use highly effective contraception from consent through Visit 28","Significant hepatic inflammation or cirrhosis | Estimated glomerular filtration rate < 60 mL/min/1.73 m2 at screening | Active hepatitis B or hepatitis C infection (HBsAg positive or HCV RNA positive, or current antiviral therapy for HBV or HCV) | Active infection (viral or bacterial) | Detectable pre-existing antibodies to the AAV8 capsid | Any condition that would interfere with participation, pose undue risk, or confound interpretation of results in the opinion of the Investigator | Current or prior participation in another gene transfer study",Ammonia scavenger therapy allowed if on a stable daily dose for >= 4 weeks,ALL,F,"The patient is 3 months old, which is below the trial’s minimum age of 12 years. Additionally, the trial requires late-onset OTC deficiency, whereas the patient has a history of severe neonatal hyperammonemic crisis consistent with neonatal-onset.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Hard exclusion due to age: patient is 3 months while trial minimum age is 12 years. Additionally, the trial requires late-onset OTC deficiency, whereas the patient’s history indicates neonatal-onset, further supporting ineligibility.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT05367609,0.4274407625198364,PMM2-CDG,Personalized Perioperative Analgesia Platform (PPAP) for Pediatric Spine Fusion Surgery (sIRB),NA,10 years to 21 years,(none),,,(none),ALL,F,"Disease mismatch: the trial does not target PMM2-CDG. Additionally, the patient is 8 years old, which is below the trial’s minimum age of 10.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,"Hard exclusion applies: patient age 8 is below trial minimum age 10. Disease mismatch is also likely since the trial doesn’t target PMM2-CDG. Age alone warrants F, so the grader’s F is correct.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05393258,0.7176190614700317,Recurrent Glioblastoma,A Pilot Study of Temporally-modulated Pulsed Radiation Therapy to Reirradiate Recurrent IDH-mutant Gliomas After Prior External Beam Radiation Therapy,NA,18 years,Astrocytoma (recurrent); Oligodendroglioma (recurrent),Histologically confirmed recurrent IDH-mutant glioma (astrocytoma or oligodendroglioma) with prior external beam radiation therapy (EBRT) to the same region | Recurrent tumor may be histologically confirmed or based on clinical assessment | Maximum tumor diameter <= 7 cm | Prior EBRT completed >= 2 years ago | Region for reirradiation received >= 45 Gy from prior EBRT | Region for reirradiation received <= 75 Gy from prior EBRT | Prior EBRT may be photon-based or proton-based | Prior stereotactic radiosurgery (SRS) to the same region permitted if cumulative EBRT+SRS dose <= 75 Gy | Prior SRS completed >= 6 months ago | Life expectancy >= 12 months | Age >= 18 years | Karnofsky performance status >= 70% | Females of childbearing potential agree to use effective contraception during the study,"Leptomeningeal or metastatic involvement | Prior grade >= 3 radiation necrosis at least possibly related to prior radiotherapy | Concurrent bevacizumab or other anti-VEGF therapy during TMPRT | Medical contraindication to MRI (e.g., unsafe metallic implants, incompatible pacemaker, inability to lie still for long periods, severe to end-stage kidney disease or on hemodialysis) | Pregnant",Prior external beam radiation therapy to the same region required; Prior EBRT dose to the region between 45 Gy and 75 Gy; Prior EBRT completed >= 2 years before enrollment; Prior stereotactic radiosurgery to the same region permitted; Cumulative EBRT plus SRS dose <= 75 Gy; Prior SRS completed >= 6 months before enrollment; Bevacizumab washout >= 4 weeks before start of TMPRT,ALL,F,"The trial is for recurrent IDH-mutant astrocytoma/oligodendroglioma, while the patient has recurrent IDH-wildtype glioblastoma—both a disease and required biomarker mismatch.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,F,"Hard exclusions apply: the trial targets recurrent IDH-mutant astrocytoma/oligodendroglioma, while the patient has recurrent IDH-wildtype glioblastoma (disease mismatch) and lacks the required IDH mutation (biomarker mismatch). Thus F is appropriate.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05399888,0.6196225881576538,Dementia,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia",PHASE2,50 years to 80 years,Mild Cognitive Impairment Due to Alzheimer's Disease; Alzheimer's Disease (mild dementia),Mild cognitive impairment due to Alzheimer's disease (NIA-AA Stage 3) or mild Alzheimer's disease dementia (NIA-AA Stage 4) | RBANS Delayed Memory Index score <= 85 | Clinical Dementia Rating (global) of 0.5 for MCI due to AD or 0.5–1 for mild AD dementia | Mini-Mental State Examination (MMSE) score 21–30 | CDR Memory Box score >= 0.5 | Evidence of amyloid pathology by PET or CSF,"Known allergy or hypersensitivity to BIIB080 or its excipients | Previous participation in a study with BIIB080 | Use of symptomatic (non-disease-modifying) AD medications at unstable doses within 8 weeks prior to screening or during screening | Use of commercially available disease-modifying AD medications (e.g., anti-amyloid monoclonal antibodies) | Prior participation in active or passive anti-amyloid immunotherapy without documentation of placebo | Prior participation in passive tau immunotherapy unless last administration >= 6 months or >= 5 half-lives before screening or documentation of placebo | Prior participation in investigational tau-targeting therapy that is not passive immunotherapy without documentation of placebo | Prior participation within 12 months in any other agent with purported disease-modifying effect in AD without documentation of placebo | Prior participation in any gene therapy with purported disease-modifying effect in AD without documentation of placebo | Current or previous use of disease-modifying AD medications outside investigational studies | Any vaccination within 10 days prior to Day -1 (except as specified for COVID-19 timing) | Contraindications to brain MRI | Current enrollment or planned enrollment in another interventional clinical study within 52 weeks prior to baseline | Any medical or psychiatric contraindication or clinically significant abnormality increasing risk (LTE period)",Symptomatic Alzheimer's disease medications at stable dose >= 8 weeks before screening,ALL,F,"The trial requires evidence of amyloid pathology (positive PET or CSF), but the patient is amyloid-negative by both PET and CSF. Additionally, the patient has moderate dementia with MMSE 19, outside the trial’s MCI/mild AD (MMSE 21–30) range.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"Correct. The trial requires evidence of amyloid pathology (PET or CSF); the patient is amyloid-negative, which is a hard exclusion. The MMSE/stage also mismatches but the hard biomarker requirement alone warrants an F.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT05402332,0.4537842273712158,PMM2-CDG,"A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-Controlled, Crossover, Trial Assessing the Efficacy, Safety, and Tolerability of AVTX-801 in Subjects with Phosphoglucomutase 1 Deficiency Related Congenital Disorders of Glycosylation (PGM1-CDG)",PHASE2,18 years to 60 years,Phosphoglucomutase 1-Related Congenital Disorder of Glycosylation,Age 18 to 60 years | Genetically confirmed PGM1-CDG | Currently on a stable dose of D-galactose therapy | Non-pregnant (females of childbearing potential) | Non-lactating (females of childbearing potential) | Women of childbearing potential and non-sterile men agree to use highly effective contraception during the study and follow-up,"Aldolase B deficiency | Galactosemia | Hemolytic uremic syndrome | Severe anemia | History of galactose intolerance that precludes participation (per investigator) | Severe diarrhea from oral galactose | Severe, recurrent vomiting from oral galactose | Constipation from oral galactose | Galactosuria from oral galactose | Increased liver glycogen storage from oral galactose | Liver failure | ALT > 8 x ULN | AST > 8 x ULN | Use of investigational compounds within the previous 6 months or current enrollment in another investigational trial | Pregnancy | Hepatic impairment that would require a dose adjustment (per investigator)",Stable D-galactose therapy,ALL,F,"Disease mismatch: the trial targets PGM1-CDG with genetically confirmed PGM1, while the patient has PMM2-CDG. Additionally, the patient is 8 years old, below the trial’s minimum age of 18.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,F is correct due to hard exclusions: clear disease mismatch (trial targets PGM1-CDG; patient has PMM2-CDG) and age conflict (trial 18–60; patient is 8). The grader correctly identified these factors.,,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT05402332,0.5045496225357056,Ornithine Transcarbamylase Deficiency,"A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-Controlled, Crossover, Trial Assessing the Efficacy, Safety, and Tolerability of AVTX-801 in Subjects with Phosphoglucomutase 1 Deficiency Related Congenital Disorders of Glycosylation (PGM1-CDG)",PHASE2,18 years to 60 years,Phosphoglucomutase 1-Related Congenital Disorder of Glycosylation,Age 18 to 60 years | Genetically confirmed PGM1-CDG | Currently on a stable dose of D-galactose therapy | Non-pregnant (females of childbearing potential) | Non-lactating (females of childbearing potential) | Women of childbearing potential and non-sterile men agree to use highly effective contraception during the study and follow-up,"Aldolase B deficiency | Galactosemia | Hemolytic uremic syndrome | Severe anemia | History of galactose intolerance that precludes participation (per investigator) | Severe diarrhea from oral galactose | Severe, recurrent vomiting from oral galactose | Constipation from oral galactose | Galactosuria from oral galactose | Increased liver glycogen storage from oral galactose | Liver failure | ALT > 8 x ULN | AST > 8 x ULN | Use of investigational compounds within the previous 6 months or current enrollment in another investigational trial | Pregnancy | Hepatic impairment that would require a dose adjustment (per investigator)",Stable D-galactose therapy,ALL,F,"Disease mismatch: the trial targets PGM1-CDG, not OTC deficiency, and the patient is 3 months old while the trial requires ages 18–60.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,Correct: There is a hard disease mismatch (OTC deficiency vs PGM1-CDG) and an age hard exclusion (patient 3 months vs trial 18–60). Either triggers an F per rubric. Reasoning aligns with key factors.,,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT05402345,0.5602849721908569,Ornithine Transcarbamylase Deficiency,"A Phase II Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating Effect Of GlcNAc On Tear Production In Individuals With NGLY1-CDDG",PHASE2,1 years to 60 years,NGLY1 Deficiency,"Molecularly confirmed NGLY1-CDDG | Age 1–60 years | Non-pregnant, non-lactating females of childbearing potential must use highly effective contraception during the study; contraception not required if sterilized or postmenopausal","Hypersensitivity to any components of the placebo | Treatment with GlcNAc within 28 days prior to Visit 1 | Participation in another therapeutic drug trial during the blinded phase or within 28 days prior to Visit 1 | Shellfish allergy | Planned eye surgery within 3 months of enrollment | Pregnant, nursing, less than 6 months postpartum, or attempting to conceive",No GlcNAc within 28 days prior to Visit 1 (washout required); No participation in another therapeutic drug trial during the blinded phase and within 28 days prior to Visit 1,ALL,F,"Disease mismatch: the trial requires molecularly confirmed NGLY1 deficiency, while the patient has OTC deficiency. The patient is also 3 months old, below the trial’s minimum age of 1 year.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Correct: The trial targets NGLY1 deficiency (and requires molecular confirmation), while the patient has OTC deficiency—hard disease/biomarker mismatch. Additionally, the patient is 3 months old, below the trial minimum age of 1 year. Either hard exclusion warrants F.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05406700,0.81216961145401,Recurrent Glioblastoma,A Phase 0 Clinical Trial to Evaluate Drug Concentrations and Pharmacodynamic Parameters of Niraparib in Tumor Tissue of Patients With Surgically Accessible Recurrent IDH 1/2 Gliomas,EARLY_PHASE1,18 years,Low-Grade Glioma (recurrent),Age >= 18 years | Histologically or cytologically confirmed glioma with documented IDH1 and/or IDH2 mutation at initial diagnosis | Radiographic evidence of progression/recurrence per RANO criteria for low-grade gliomas | Surgically accessible tumor and surgical candidate | >= 12 weeks from completion of CNS radiation | Stable or decreasing dose of glucocorticoids for 7 days prior to registration | Karnofsky Performance Score >= 70% | Expected survival >= 6 months | Adequate organ function,"Major surgery <= 4 weeks prior to initiating protocol therapy or not recovered from surgical effects | Systemic anticancer therapy < 28 days prior to first study drug dose | Lomustine < 6 weeks prior to first study drug dose | Investigational agent < 28 days prior to first study drug dose | Transfusion (platelets or red blood cells) <= 4 weeks prior to initiating protocol therapy | Use of colony-stimulating factors within 4 weeks prior to initiating protocol therapy | History of Grade 3 or 4 anemia, neutropenia, or thrombocytopenia due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment | Serious, uncontrolled medical disorder or active, uncontrolled infection | Another malignancy diagnosed/treated within 2 years (except definitively treated basal/squamous cell skin cancer or cervical cancer) | Pregnant or breastfeeding | Known hypersensitivity to niraparib components | Known HIV infection or active hepatitis B or C | Conditions limiting oral drug ingestion or absorption (e.g., dysphagia, short-gut syndrome, gastroparesis) | Radiation therapy encompassing > 20% bone marrow within 2 weeks, or any radiation therapy within 1 week prior to Day 1 | Known or symptomatic leptomeningeal metastases",">= 12 weeks since completion of CNS radiation; No systemic anticancer therapy within 28 days before first dose; No lomustine within 6 weeks before first dose; No investigational agents within 28 days before first dose; Recovered from clinically relevant toxic effects of prior surgery, radiotherapy, or other anticancer therapy; No transfusions within 4 weeks before initiating protocol therapy; No colony-stimulating factors within 4 weeks before initiating protocol therapy; No radiation therapy encompassing > 20% bone marrow within 2 weeks before Day 1; No any radiation therapy within 1 week before Day 1",ALL,F,"The trial requires recurrent low-grade glioma with an IDH1/2 mutation, while the patient has recurrent IDH-wildtype glioblastoma. This is both a disease and required-biomarker mismatch, constituting a hard exclusion.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,F,"Trial requires recurrent low-grade IDH-mutant glioma; patient has recurrent IDH-wildtype glioblastoma. This is both a disease mismatch and a required biomarker mismatch, each a hard exclusion. F is appropriate.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05413304,0.8199051022529602,Recurrent Glioblastoma,Feasibility of Evaluating Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis,PHASE1,18 years to 39 years,High-Grade Glioma (recurrent); Diffuse Midline Glioma,Recurrent high-grade glioma or diffuse midline glioma based on clinical and/or radiologic findings | For cortical high-grade glioma: prior intra-operative pathology confirming disease | Age 18–39 years at enrollment | Ability to swallow tablets/pills | Karnofsky >= 50% within 14 days prior to enrollment | Adequate organ function per protocol-defined laboratory parameters,"Unable to safely undergo biopsy due to contraindications | Pregnant or breastfeeding | Serious preexisting medical conditions precluding participation (e.g., interstitial lung disease, severe dyspnea requiring oxygen, severe renal impairment, history of major gastric/small bowel resection impairing absorption, Crohn's disease, ulcerative colitis, or chronic condition causing baseline grade >=2 diarrhea) | Uncontrolled intercurrent illness (e.g., symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, active bleeding diathesis, renal transplant) | History of syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin, or sudden cardiac arrest | Active systemic bacterial, fungal, or viral infection (including active hepatitis B or C; certain controlled HIV may be eligible) | Requires strong or moderate CYP3A inhibitors or inducers | Inability to undergo MRI or contraindication to MRI | Refractory nausea/vomiting limiting oral drug administration | Known severe hypersensitivity to abemaciclib, temozolomide, or their excipients | Prior treatment with abemaciclib or another CDK4/6 inhibitor | Investigator deems participation not appropriate",>=4 weeks since any major surgery with recovery and no active infection; Recovered from chemotherapy to CTCAE <=1 (except alopecia or grade 2 neuropathy); Washout from last disease-directed therapy: >=14 days or >=4 half-lives (whichever is shorter) before treatment; Completed radiotherapy with recovery; >=14-day washout before treatment,ALL,F,"The disease and recurrent setting match, but the trial restricts enrollment to ages 18–39 and the patient is 40 years old, which is outside the allowed range.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,F,"Age exceeds trial maximum (40 vs 39), which is a hard exclusion per rubric. Grader correctly assigned F and cited the age window conflict. Disease/setting otherwise match but are moot due to hard exclusion.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT05422911,0.7360905408859253,Metastatic Castration-Resistant Prostate Cancer,"A Phase 2 Randomized Study of YONSA® (Abiraterone Acetate), Enzalutamide or Apalutamide as First Line Therapy in Veterans With Castrate-sensitive Prostate Cancer",PHASE2,Not specified,Prostate Cancer (castrate-sensitive),"Age >= 18 years | ECOG performance status 0–1 | Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine, signet-cell, or small-cell features | Receiving or will receive androgen-deprivation therapy with a GnRH agonist/antagonist or have undergone bilateral orchiectomy | High-risk disease with >= 3 rising PSA values at least 1 week apart | PSA >= 2 ng/mL | PSA doubling time <= 9 months during continuous androgen-deprivation therapy | Has not received abiraterone acetate, enzalutamide, or apalutamide at enrollment | Predicted life expectancy > 12 months | For patients on bisphosphonates or denosumab, dose stable for >= 4 weeks before randomization | AST <= 2.5 x ULN | ALT <= 2.5 x ULN | Creatinine clearance >= 30 mL/min or serum creatinine <= 1.8 mg/dL | Absolute neutrophil count >= 1000/µL | Platelet count >= 100000/µL | Hemoglobin > 9 g/dL","Prior cytotoxic chemotherapy for prostate cancer | Prior aminoglutethimide or ketoconazole for prostate cancer | Prior abiraterone acetate, apalutamide, or enzalutamide for prostate cancer | Prior participation in a clinical trial of an investigational androgen receptor or androgen synthesis inhibitor (unless placebo) | Hormonal therapy for prostate cancer within 4 weeks of randomization (other than GnRH agonist/antagonist) | Biologic therapy for prostate cancer within 4 weeks of randomization (other than approved bone-targeting agents) | Active second malignancy except disease-free >= 3 years, completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma | History of seizure or condition predisposing to seizure (e.g., prior cortical stroke, significant brain trauma) | Deep vein thrombosis or pulmonary embolism within the past 3 months causing medical instability | Concurrent investigational agents",Androgen-deprivation therapy with a GnRH agonist/antagonist or prior bilateral orchiectomy required; Bisphosphonates or denosumab allowed if on a stable dose for >= 4 weeks before randomization,MALE,F,"The trial explicitly excludes prior abiraterone or enzalutamide; this patient has received both and has mCRPC, whereas the study is for first-line castrate-sensitive disease.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,F,"Explicit exclusion: trial excludes prior abiraterone or enzalutamide; patient has received both. That alone triggers a hard exclusion. Additionally, the study is for first-line castrate-sensitive disease while the patient has mCRPC, reinforcing ineligibility.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT05443906,0.5792176723480225,Dementia,Study of Adapted Exercise and Mindfulness Interventions to Improve Motor Function and Sleep Quality in Individuals with Neurodegenerative Disease,NA,5 years to 75 years,Adrenomyeloneuropathy; Cerebellar Ataxia; Leukoencephalopathy with Brainstem and Spinal Cord Involvement and Lactate Elevation; Leukodystrophy; Neurodegenerative Disease,"Males: X-linked adrenoleukodystrophy confirmed by biochemical determination or genetic testing | Females: X-linked adrenoleukodystrophy confirmed by biochemical determination, genetic testing, or pedigree analysis | Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL): confirmed DARS2 mutation by genetic analysis | Cerebellar ataxia due to stroke, tumor, or degeneration; genetically confirmed cerebellar disorders should provide genetic testing | Other similar neurodegenerative diseases as determined by chart review and clinical exam | Able to stand for 30 seconds without upper extremity support | Ambulatory (including use of a cane or a walker) | Able to walk for 2 minutes",Uncontrolled hypertension | Orthopedic conditions that interfere with safe participation | Diabetes that interferes with safe participation | Seizure disorder that interferes with safe participation | Peripheral vestibular loss that interferes with safe participation | Severe aphasia | Dementia | Pregnancy | Other medical or psychological conditions that would interfere with acquiring study information or performing exercises safely,(none),ALL,F,"The trial explicitly excludes participants with dementia, which the patient has. Therefore the patient is ineligible despite meeting age and sex criteria.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"The trial explicitly lists dementia as an exclusion criterion, which the patient has. This is a hard exclusion per rubric, so grade F is correct regardless of other matches.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT05489523,0.5061975717544556,Ornithine Transcarbamylase Deficiency,"An Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation",PHASE4,18 years to 90 years,Transthyretin Cardiac Amyloidosis,Orthotopic heart transplantation for transthyretin cardiac amyloidosis >= 12 months prior to screening (combined hepatic and/or renal transplantation with adequate allograft function allowed). | Stable immunosuppressive regimen and <= 10 mg prednisone (or equivalent) at enrollment. | Karnofsky performance status >= 70%.,"Prior inotersen within 180 days. | Prior patisiran within 90 days. | Prior tafamidis within 14 days. | Prior diflunisal within 14 days. | Participating in a clinical trial for ATTR-targeted therapies. | Estimated glomerular filtration rate (eGFR) <= 15 mL/min/1.73 m2. | Known leptomeningeal or AL amyloidosis. | Active post-transplant lymphoproliferative disease. | Active malignancy (excluding non-melanoma skin cancer). | Active infection with hepatitis B, hepatitis C, human immunodeficiency virus, or cytomegalovirus (exceptions for prior treated CMV disease on stable antiviral therapy). | Cardiac allograft dysfunction with left ventricular ejection fraction < 50% by echocardiogram within the past 3 months. | Treated acute cellular or antibody-mediated rejection in the past 3 months. | Meets ISHLT CAV3 criteria for severe coronary allograft vasculopathy.",No inotersen within 180 days.; No patisiran within 90 days.; No tafamidis within 14 days.; No diflunisal within 14 days.; Stable immunosuppressive regimen required.,ALL,F,"Disease mismatch: the trial targets transthyretin-mediated amyloidosis post heart transplant, not OTC deficiency. Additionally, the patient is 3 months old, outside the trial’s 18–90 year age range.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion (OTC deficiency vs transthyretin amyloidosis). Additionally, the patient’s age (3 months) is outside the trial’s 18–90 year range, another hard exclusion. The grader correctly assigned F and identified the key factors.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT05549219,0.5490914583206177,Ornithine Transcarbamylase Deficiency,"A Phase 2, Randomized, Open-Label, 24-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult, Adolescent, and Pediatric Participants With PMM2-CDG",PHASE2,2 years to 65 years,Phosphomannomutase 2 Deficiency,"Age 2–65 years (cohort dependent) | Molecularly confirmed PMM2-CDG (biallelic pathogenic/likely pathogenic PMM2 variants, or bi-allelic variants plus deficient PMM2 enzyme activity)","Diagnosis of a congenital disorder of glycosylation other than PMM2-CDG | Active infection requiring parenteral antibiotics/antivirals/antifungals or systemic steroids within 7 days prior to screening | Active COVID-19 or positive SARS-CoV-2 test at screening | ALT >3 x ULN | AST >3 x ULN | Total bilirubin >2 x ULN | INR >1.5 | History of severe allergic reaction to GLM101 or its excipients | Known poor venous access | History of liver transplant | Drug or alcohol use disorder within 12 months | Major surgery within 30 days prior to screening | Clinically significant lab abnormalities not related to PMM2-CDG | Positive pregnancy test (female) | Breastfeeding (female) | Hepatitis B surface antigen positive or hepatitis C antibody positive | Any illness that might impact infusion safety or evaluability per investigator/medical monitor | QTc >=450 ms or clinically significant ECG abnormalities | Uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric, or other significant disease | Participation in another interventional study or investigational product within 30 days or 5 half-lives | Weight >75 kg",(none),ALL,F,"Disease mismatch: the trial targets PMM2-CDG, not OTC deficiency. Additionally, the patient is 3 months old (trial requires ≥2 years) and lacks the required PMM2 genetic diagnosis.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Hard exclusions apply: disease mismatch (OTC vs PMM2-CDG), age below minimum (3 months vs ≥2 years), and required biomarker mismatch (requires PMM2-CDG). The grader correctly assigned F and identified key factors.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05636293,0.6105717420578003,Crohn's Disease,"Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib to Prevent Gluten-induced Celiac Enteropathy and Symptoms in Celiac Disease Patients in Remission",PHASE2,18 years to 75 years,Celiac Disease,Age 18 to 75 years | Body mass index >=17 and <40 | Body weight >45 kg | Well-controlled biopsy-proven celiac disease on a gluten-free diet for >=6 months with resolution of symptoms | Celiac serology normalized (<= 2 x ULN) | Screening histology Marsh 0–2 | HLA-DQ2.5 and/or HLA-DQ8 positive | Negative SARS-CoV-2 molecular test at screening and required pre-endoscopy timepoints,"History of gluten-triggered acute symptoms (<=24 hours after exposure), severe symptoms (e.g., abdominal pain interfering with daily activities, diarrhea >5 stools/day), or prolonged symptoms (>7 days) | Abdominal or pelvic surgery within <3 months before enrollment | Imminent need for surgery or elective surgery scheduled during the study | Positive or borderline IgA anti-tissue transglutaminase at screening (>= 2 x ULN) | Screening histology Marsh 3a–3c | Diagnosis of any other inflammatory gastrointestinal disorder | Ongoing immunosuppression or treatment within 3 months that might alter T cell repertoire or phenotype | Confirmed SARS-CoV-2 infection within the previous 2 months | History of untreated or inadequately treated latent or active tuberculosis, current treatment for TB, evidence of active TB on chest x-ray, or close contact with active TB | Positive screening for HIV, hepatitis B, or hepatitis C",(none),ALL,F,"Disease mismatch: the trial targets celiac disease only, while the patient has Crohn's disease. This is a hard exclusion.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,Disease mismatch is a hard exclusion per rubric: patient has Crohn’s disease while the trial targets celiac disease only. The grader correctly assigned F with appropriate reasoning.,,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT05669430,0.42039793729782104,PMM2-CDG,An Open-Label Phase 1/2A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Advanced and/or Refractory Solid Tumor Malignancies,PHASE1/PHASE2,18 years,Endometrial Carcinoma; Head and Neck Squamous Cell Carcinoma; Cutaneous Melanoma; Non-Small Cell Lung Cancer; Colorectal Adenocarcinoma (pMMR/MSS),Age >= 18 years | Histologically confirmed advanced solid malignancy with progressive disease | Refractory or intolerant to standard therapy | Not eligible for or declined standard-of-care therapy | Measurable disease per RECIST 1.1 | Documented disease progression after prior checkpoint inhibitor if previously treated | ECOG performance status 0-1 | Life expectancy >= 12 weeks (Parts A and C) or >= 24 weeks (Parts B and D) | Disease-free of active second malignancy for >= 2 years | Eligible tumor types for expansion cohorts include: endometrial carcinoma; head and neck squamous cell carcinoma; cutaneous melanoma; non-small cell lung cancer; pMMR/MSS colorectal adenocarcinoma (Parts C and D),"Acute leukemia or chronic lymphocytic leukemia (Parts A and B) | Clinically significant heart disease or unstable arrhythmia | Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy | Active autoimmune disease or other conditions requiring chronic systemic steroids or immunosuppressive therapy | History of major organ transplant | History of bone marrow transplant | Symptomatic central nervous system malignancy or metastasis | Serious nonmalignant disease that could interfere with study participation | Pregnant or nursing | Treatment with PD-1 or equivalent immune modulators prior to first dose | Major surgery prior to first dose of study medication | Receipt of another investigational agent within 4 weeks before first dose | Any anticancer treatment within 2 weeks before first dose | Radiation for symptomatic lesions must be completed prior to first dose | Liver metastases unless approved by the Sponsor | History of immune-related adverse event >= Grade 3 attributed to prior cancer immunotherapy | Additional malignancy that is progressing or required active treatment within 2 years before C1D1 | Radiation therapy to the lung > 30 Gy within 6 months prior to C1D1 for NSCLC (Parts C and D) | Severe hypersensitivity (>= Grade 3) to pembrolizumab or its excipients (Parts C and D) | History of non-infectious pneumonitis/interstitial lung disease requiring steroids or current pneumonitis/ILD (Parts C and D) | Any condition or laboratory abnormality that could confound results or interfere with participation (Parts C and D) | Active substance abuse",Prior standard therapy required; refractory or intolerant to standard therapy; Prior checkpoint inhibitor allowed with documented progression; No investigational agents within 4 weeks before first dose; No anticancer treatments within 2 weeks before first dose; Radiation for symptomatic lesions must be completed before first dose,ALL,F,"Disease mismatch: the trial is for specific advanced solid tumors, while the patient has PMM2-CDG. Additionally, the patient is 8 years old and the trial requires age ≥18.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,"Two hard exclusions apply: disease mismatch (patient has PMM2-CDG, trial is for specified advanced solid tumors) and age window conflict (patient is 8; trial requires >=18). Under the rubric, any hard exclusion → F. The grader’s reasoning and grade are correct.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT05703178,0.6053727269172668,Rheumatoid Arthritis,Web-based Pain Coping Skills Training to Improve Pain and Poor Adherence Caused by Aromatase Inhibitor-Associated Arthralgia In Breast Cancer Survivors (SKIP-Arthralgia): A Randomized Controlled Trial,PHASE3,18 years,Breast Cancer; Arthralgia; Chronic Pain,"Female sex | Age >= 18 years | Stage 0–III hormone receptor positive breast cancer | Completed primary cancer treatment (surgery, chemotherapy, and/or radiation therapy) | Postmenopausal | Currently taking aromatase inhibitor therapy (letrozole, exemestane, or anastrozole) | Musculoskeletal pain that developed or worsened since starting aromatase inhibitor therapy | >= 15 days of pain in the past 30 days | Worst pain rating >= 4/10 in the past week | ECOG performance status 0-2 | Stable analgesic regimen for >= 14 days prior to enrollment with no planned upward titration during the study","Metastatic disease | Other active cancer (except non-melanoma skin cancer) | Chemotherapy or radiation therapy completed < 4 weeks prior to enrollment | Major surgery completed < 8 weeks prior to enrollment (minor surgeries may be allowed) | Diagnosed or suspected condition interfering with consent or study activities (e.g., significant cognitive impairment or uncorrected hearing/vision)","Completed primary cancer treatment (surgery, chemotherapy, and/or radiation therapy); Currently receiving aromatase inhibitor therapy; Stable analgesic regimen >= 14 days before enrollment; No chemotherapy or radiation therapy within 4 weeks prior to enrollment; No major surgery within 8 weeks prior to enrollment",FEMALE,F,"The trial is for postmenopausal hormone receptor–positive breast cancer survivors on aromatase inhibitors with AI-associated arthralgia, whereas the patient has rheumatoid arthritis; this disease mismatch is a hard exclusion.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Disease mismatch is a hard exclusion: the trial targets breast cancer survivors with AI-associated arthralgia, while the patient has rheumatoid arthritis. F is appropriate per rubric.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05726396,0.5327533483505249,Crohn's Disease,A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis,PHASE2,18 years,Immune-Related Colitis,"Solid tumor treated with immune checkpoint inhibitor (PD-1/PD-L1 with or without CTLA-4) with at least two doses | ICI used as single agent or in combination with cytotoxic chemotherapy or targeted therapy | Last ICI treatment within 6 weeks of onset of IMDC symptoms | Steroid-refractory IMDC per protocol definitions (persistent Grade >= 2 diarrhea after high-dose steroids and/or after biologic agent, or relapse during/after steroid taper as specified) | Adequate organ function within 14 days prior to enrollment | Well-controlled diabetes with HbA1c < 8 within 6 months of screening | Euvolemic on physical examination | Stable vital signs at screening and enrollment (temperature 95.8–99.9 F, heart rate 60–100/min, blood pressure 90–140/60–90 mm Hg) | On standard antidiarrheal supportive care for at least 1 day prior to starting study treatment | Age >= 18 years | Body weight > 30 kg | Expected survival >= 6 months","Concomitant infectious colitis based on standard stool screening (ova and parasites, C. difficile PCR, enteric bacterial and viral PCR panel) | Last cytotoxic chemotherapy or targeted therapy < 3 weeks prior to screening | Anticipated need for cytotoxic chemotherapy or targeted therapy through 30 days after first dose of study drug | Current pregnancy or breastfeeding | Receiving another investigational agent or received an investigational agent within 60 days of enrollment | Uncontrolled Grade >= 3 infection at the time of enrollment (systemic antibiotics for non-GI infections allowed) | History of chronic diarrhea from non-IMDC causes (e.g., Crohn's disease, ulcerative colitis) | Dysphagia or inability to swallow capsules (CTCAE v5 Grade >= 2) | Known risk of aspiration | Known sensitivity to any component of study therapy | On intravenous biologic agents for other baseline autoimmune conditions | Other uncontrolled immune-related adverse events requiring systemic corticosteroids or biologic immunomodulatory agents | Chronic systemic antibiotic therapy (>= 60 consecutive days within 12 weeks of enrollment) | Receipt of over-the-counter probiotics in the last 4 weeks | Receipt of live attenuated vaccination within 30 days of study treatment | Psychiatric or social conditions limiting compliance or informed consent",Prior immune checkpoint inhibitor therapy (>= 2 doses of PD-1/PD-L1 with or without CTLA-4); Washout from cytotoxic chemotherapy or targeted therapy >= 3 weeks before screening,ALL,F,"Disease mismatch: the trial targets immune checkpoint inhibitor-related colitis in cancer patients, not Crohn's disease. Additionally, the trial explicitly excludes patients with chronic diarrhea from non-IMDC causes, including Crohn's disease.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Correct: The trial targets immune checkpoint inhibitor-related colitis and explicitly excludes Crohn’s disease. This is both a disease mismatch hard exclusion and an explicit exclusion, so F is appropriate.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT05734196,0.5502026081085205,Ornithine Transcarbamylase Deficiency,"The ENERGY Study: An Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 in Infants With Ectonucleotide Pyrophosphatase/ Phosphodiesterase 1 (ENPP1) Deficiency or ATP-binding Cassette Sub-family C Member 6 (ABCC6) Deficiency",PHASE1,up to 1 years,ENPP1 Deficiency; ABCC6 Deficiency; Generalized Arterial Calcification of Infancy,Confirmed post-natal molecular genetic diagnosis of ENPP1 Deficiency or ABCC6 Deficiency with biallelic mutations | Clinical manifestations of Generalized Arterial Calcification of Infancy (GACI) or GACI-2 | Age from birth to <1 year at Baseline (Day 1) | Weight >=0.5 kg at first dose,"Clinically significant disease or laboratory abnormality unrelated to ENPP1 or ABCC6 deficiency that may preclude participation, including uncontrolled thyroid disease or unrelated connective tissue, bone, mineral, or muscle disease | Care withdrawn or receiving end of life care or hospice only | Known malignancy | Known intolerance to INZ-701 or any excipients | Concurrent participation in another non-Inozyme interventional study | Receipt of any non-Inozyme investigational new drug within 5 half-lives or within 4 weeks prior to first dose, whichever is longer, or use of an investigational device",No investigational drug within 5 half-lives or 4 weeks prior to first dose,ALL,F,"Disease mismatch: the trial is for ENPP1 or ABCC6 deficiency (GACI), while the patient has ornithine transcarbamylase (OTC) deficiency. Age and sex fit, but the required disease cohort is not met.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Correct: The patient has OTC deficiency, while the trial targets ENPP1 or ABCC6 deficiency (GACI). This is a hard disease mismatch per rubric, warranting an F regardless of age/sex fit.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT05756569,0.7725739479064941,Metastatic Urothelial Carcinoma,Phase II Single-Arm Study of Enfortumab Vedotin (EV) Plus Pembrolizumab in the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology,PHASE2,18 years,Bladder Adenocarcinoma; Bladder Squamous Cell Carcinoma; Bladder Cancer (locally advanced); Bladder Cancer (metastatic); Renal Pelvis Carcinoma; Ureter Carcinoma; Urethral Carcinoma; Urachal Adenocarcinoma,"Age >= 18 years | ECOG 0–1 | Metastatic disease or unresectable locally advanced disease | Variant or non-urothelial bladder cancer of epithelial origin; predominant > 50% variant or non-urothelial in mixed tumors | Eligible primary sites include ureter, urethra, urachus, or renal pelvis | Measurable disease per RECIST 1.1 | Adequate organ and marrow function within 28 days of C1D1 | Tumor tissue available for submission or agree to undergo biopsy | Female of childbearing potential: negative pregnancy test prior to therapy | Use of effective contraception during treatment and for 6 months after last dose | Completion of all prior cancer therapy >= 4 weeks before start of study therapy | Life expectancy > 12 weeks","Neuroendocrine histology (small cell or large cell) or non-epithelial bladder tumors (e.g., bladder sarcoma, carcinosarcoma, paraganglioma, melanoma, primary lymphoma, lymphoepithelioma-like carcinoma) | Chemotherapy or radiotherapy within 4 weeks prior to study entry or unresolved >= grade 2 toxicities from prior treatment (except alopecia) | Receipt of other investigational agents or an investigational device within 21 days before first dose | Allergic reactions to compounds of similar chemical or biologic composition to study agents | Ongoing sensory or motor neuropathy grade >= 2 | Prior treatment with enfortumab vedotin or PD-1/PD-L1 inhibitors (including maintenance) | Uncontrolled diabetes mellitus with HbA1c >= 8% or HbA1c 7% to < 8% with symptomatic polyuria or polydipsia | Active central nervous system metastases | Another active malignancy within 24 months except for permitted in-situ or localized cancers | Currently receiving systemic antimicrobial therapy for active infection or high-dose steroids (> 10 mg prednisone equivalent) | Pregnancy or positive pregnancy test at baseline | Breastfeeding | Active autoimmune disease requiring systemic treatment within the past 2 years | Hepatitis B surface antigen positive | Active hepatitis C virus infection (HCV RNA detected) | Active tuberculosis | History of active keratitis or corneal ulcerations | History of allogeneic tissue or solid organ transplant | Congestive heart failure NYHA class III or IV, unstable angina, or serious cardiac arrhythmias within 6 months prior to first dose | Other uncontrolled illness (including cardiac arrhythmia or psychiatric illness) that would limit compliance","Any number of prior systemic therapies allowed (including untreated); Washout >= 4 weeks from prior surgery, radiotherapy, chemotherapy, immunotherapy, or investigational therapy; Washout >= 21 days from other investigational agents",ALL,F,"The trial requires variant or non-urothelial epithelial bladder cancer (>50% variant), while the patient has metastatic urothelial carcinoma. This is a required histologic subtype mismatch and a hard exclusion.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"The trial explicitly requires variant or non-urothelial epithelial bladder cancer (>50% variant in mixed tumors). The patient has metastatic urothelial carcinoma, which definitively does not meet this required histologic subtype. This is a hard exclusion per the rubric (required biomarker/subtype mismatch), so F is correct.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT05767034,0.6438535451889038,Rheumatoid Arthritis,"A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)",PHASE3,50 years to 100 years,Polymyalgia Rheumatica,"Age >= 50 years. | Male or non-pregnant, non-lactating female. | Diagnosis of polymyalgia rheumatica per ACR/EULAR criteria with bilateral shoulder pain and elevated CRP (>= 10 mg/L) and/or ESR (>= 30 mm/hr). | ACR/EULAR optional classification criteria totaling >= 4 points: morning stiffness > 45 min; hip pain or restricted range of motion; absence of rheumatoid factor and/or anti-citrullinated protein antibodies; absence of other joint involvement. | Treated with prednisone >= 10 mg/day (or equivalent) for at least 8 consecutive weeks at any time prior to screening. | At least one PMR relapse while tapering prednisone >= 5 mg/day within the past 12 weeks prior to baseline, with relapse defined by recurrence of bilateral shoulder/hip girdle pain and inflammatory stiffness not due to mimicking diseases, and elevated ESR (>= 30 mm/hr) and/or CRP (> ULN) attributable to PMR at relapse and/or screening. | Following the latest PMR relapse, treated per local recommendations and on prednisone 7.5–25 mg/day at screening and during screening.","Evidence or history of giant cell arteritis (cranial symptoms, extremity claudication, suggestive imaging and/or temporal artery biopsy). | Concurrent rheumatoid arthritis, other inflammatory arthritis, or other connective tissue diseases (e.g., systemic lupus erythematosus, systemic sclerosis, vasculitis, myositis, mixed connective tissue disease, ankylosing spondylitis). | Concurrent diagnosis or history of neuropathic muscular diseases or fibromyalgia. | Inadequately treated hypothyroidism (e.g., persistent symptoms or non-normalized TSH despite replacement). | Previous exposure to secukinumab or other biologics directly targeting IL-17 or the IL-17 receptor. | Treatment with tocilizumab or other IL-6/IL-6 receptor inhibitors within 12 weeks or within 5 half-lives (whichever is longer) prior to baseline; non-responders or those who relapsed during such treatment are excluded.",Prior prednisone >= 10 mg/day for >= 8 consecutive weeks.; On prednisone 7.5–25 mg/day at screening.; Washout from IL-6/IL-6 receptor inhibitors >= 12 weeks or >= 5 half-lives prior to baseline.,ALL,F,"Disease mismatch: the trial targets polymyalgia rheumatica and explicitly excludes patients with rheumatoid arthritis, while the patient has seropositive rheumatoid arthritis.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Correct: There is a hard exclusion due to disease mismatch (trial is for PMR, patient has RA) and an explicit exclusion listing concurrent rheumatoid arthritis. Grade F is appropriate.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05786404,0.553044319152832,Crohn's Disease,"A Randomized, Open-label, Pilot Study to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis",PHASE1,18 years,Ulcerative Colitis (active),Active ulcerative colitis: Partial Mayo score >= 3 with each subscore > 1 | Sexually active males and females of childbearing potential agree to use effective contraception during the study | Females of childbearing potential must have a negative urine pregnancy test at enrollment and on Week 1 Day 1 prior to dosing,"Severe ulcerative colitis (Mayo score > 7) | Unable to take retention enema or multiple oral capsules | Pregnant, breastfeeding, or planning pregnancy during the study | Receipt of systemic non-topical antibiotics within 14 days before Day 1 | Active HIV infection | Active hepatitis B infection | Active hepatitis C infection | History of recurrent Clostridioides difficile infection | Prior fecal microbiota transplantation within 6 months | Other active gastrointestinal conditions (e.g., irritable bowel syndrome, microscopic colitis, celiac disease, short gut syndrome, colostomy, colectomy, gastrointestinal fistulae or strictures, chronic parasitic infections, diverticulitis) | Known bile acid diarrhea | Compromised immune system (primary immune disorders or clinical immunosuppression) | Current systemic corticosteroids at prednisone > 20 mg/day or equivalent | History of active cancer and/or ongoing chemotherapy (superficial non-metastatic cancers and maintenance chemotherapy are permitted) | Use of an investigational drug within 90 days before screening | Significant uncontrolled systemic disease | Life expectancy < 1 year | Absolute neutrophil count < 500/µL",(none),ALL,F,"Disease mismatch: the trial targets ulcerative colitis, while the patient has Crohn's disease. Additionally, the trial excludes patients with gastrointestinal fistulae, and the patient has an active perianal fistula.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Correct: This is a hard exclusion due to disease mismatch (trial is for ulcerative colitis; patient has Crohn’s). Additionally, the trial explicitly excludes gastrointestinal fistulae, and the patient has an active perianal fistula. F is appropriate.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT05818553,0.42532360553741455,PMM2-CDG,"A Phase 2,Double-Blind,Randomized Clinical Trial to Explore the Safety,Tolerability,Efficacy, and Pharmacokinetics of PRAX-562 in Pediatric Participants With Developmental and Epileptic Encephalopathies Followed by Open-Label Extension(OLE)",PHASE2/PHASE3,2 years to 18 years,SCN2A Encephalopathy; SCN8A Encephalopathy,"Documented rare missense variant in SCN2A with seizure onset in the first 3 months of life, or documented de novo missense variant in SCN8A with seizure onset in the first 6 months of life. | At least 8 countable motor seizures in the 4 weeks immediately prior to Screening. | At least 8 countable motor seizures during the 28-day Baseline Observation Period.","Clinically significant or known pathogenic/likely pathogenic genetic variant other than in SCN2A or SCN8A, or a genetic variant that may explain or contribute to epilepsy and/or developmental disorder. | Documented, functionally characterized loss-of-function missense variant, or presumed loss-of-function variant (nonsense or frameshift), or clinical evidence that prior exposure to a sodium channel blocker worsened seizures. | Two or more episodes of convulsive status epilepticus requiring hospitalization and intubation in the 6 months prior to Screening.",(none),ALL,F,"The trial is for SCN2A or SCN8A encephalopathy with specific genetic requirements, while the patient has PMM2-CDG with PMM2 variants—constituting a disease and required biomarker mismatch. The trial also excludes participants with pathogenic variants other than SCN2A/SCN8A.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,"Disease mismatch (PMM2-CDG vs SCN2A/SCN8A encephalopathy) is a hard exclusion. The trial also requires SCN2A or SCN8A variants and explicitly excludes other pathogenic variants, which the patient has (PMM2). Grade F is correct per rubric.",,
"What are trial options for a 66 year old male with hx hypertension, afib, T2DM and mCRPC, now progressing on enzalutamide? He has been on Lupron+Zytiga for 3 years, with new liver and bone metastases which are all PSMA PET avid. He’s tolerated therapy well overall except for grade 2 fatigue.",NCT05832086,0.7620301246643066,Metastatic Castration-Resistant Prostate Cancer,Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes,PHASE2,Not specified,"Prostate Adenocarcinoma (metastatic, castrate-sensitive)","Metastatic castrate-sensitive prostate adenocarcinoma confirmed by biopsy | Metastatic disease confirmed by biopsy or MRI | Receiving or planning to start first-line intensified androgen deprivation therapy within 30 days with abiraterone, apalutamide, enzalutamide, or darolutamide | Current or prior chemotherapy permitted","Allergy to any ingredients on the Xentigen Ingredient List | Diabetes not on stable doses of antihyperglycemic medication for >= 6 months or without physician consent to safely hold antihyperglycemics during the 5 days of FMD | Regularly practicing a fasting diet that would impact study participation | Significant cardiac, pulmonary, liver disease, or ongoing alcohol/drug abuse precluding enrollment | Body mass index < 20 kg/m2 | Actively trying to lose weight | Use of weight loss medications (e.g., naltrexone/bupropion, liraglutide, orlistat) | Planning to receive weight loss surgery in the next 6 months | Self-reported weight loss >= 10% in the last 6 months","Receiving or planning first-line intensified ADT with abiraterone, apalutamide, enzalutamide, or darolutamide within 30 days of registration; Prior or current chemotherapy allowed",MALE,F,"The trial enrolls metastatic castrate-sensitive prostate cancer patients starting first-line intensified ADT, while the patient has metastatic castration-resistant disease after progression on enzalutamide—an explicit disease/setting mismatch.",Metastatic Castration-Resistant Prostate Cancer,PSMA PET avid,Age 66 years; Male sex; Metastatic castration-resistant prostate cancer; Progression on enzalutamide; PSMA PET avid liver and bone metastases,(none),Progression on enzalutamide; Prior abiraterone (Zytiga) with leuprolide (Lupron) for 3 years,metastatic,,66,years,male,(none),CORRECT,F,"The trial requires metastatic castrate-sensitive prostate cancer initiating first-line intensified ADT, while the patient has metastatic castration-resistant disease after enzalutamide. This is a required stage/setting mismatch (hard exclusion), so F is appropriate.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05849012,0.7246365547180176,Crohn's Disease,A Pilot Study Examining Low Sulfur Diet as Treatment for Persistent Symptoms in Quiescent Crohn's Disease,NA,18 years,Crohn's Disease (remission),"Prior diagnosis of Crohn's disease based on endoscopic, radiographic, and/or histologic findings | Quiescent Crohn's disease defined by fecal calprotectin < 150 mcg/g stool and/or absence of inflammation on colonoscopy within 30 and 90 days of enrollment, respectively | Persistent symptoms defined by abdominal pain and/or diarrhea T-scores >= 55 on the NIH PROMIS-GI scale",Prior total colectomy | Presence of an end ileostomy or colostomy | Changes in immunosuppressive medications within the past 4 weeks | Use of antibiotics or probiotics within the past 4 weeks | Active or suspected gastrointestinal stricture or stenosis | Habitual vegetarian or vegan diet | Unable or unwilling to follow a low sulfur diet | Underweight (BMI < 18.5 kg/m2) or significant unintentional weight loss (> 7.5% in the past 3 months) | Currently pregnant or breastfeeding,(none),ALL,F,"The trial requires quiescent Crohn's disease (remission) with objective evidence, whereas the patient has active moderate-to-severe, fistulizing Crohn's disease (CDAI 350), a definitive stage/setting mismatch.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Trial requires quiescent (remission) Crohn’s, while the patient has active moderate-to-severe, fistulizing disease—this is a required stage/setting the patient definitively lacks, which is a HARD EXCLUSION per the rubric. Age/sex fit, but the setting mismatch alone warrants F. The grader’s reasoning aligns.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT05857969,0.8032944202423096,Recurrent Glioblastoma,Adopting a Functional Precision Medicine Approach For Individualized Pediatric Cancer Treatments,PHASE1,1 days to 21 years,"Acute Lymphoblastic Leukemia (recurrent); Acute Myeloid Leukemia (recurrent); Brain Tumor (recurrent); Brainstem Glioma (recurrent); Ependymoma (recurrent); Gliosarcoma (recurrent); Large Cell Lymphoma (recurrent); Lymphoblastic Lymphoma (recurrent); Rhabdomyosarcoma (recurrent); Soft Tissue Sarcoma (recurrent); Acute Lymphoblastic Leukemia (refractory); Hodgkin Lymphoma (refractory); Malignant Germ Cell Tumor (refractory); Chronic Myelogenous Leukemia, BCR-ABL1 Positive (refractory)",Age <=21 years | Recurrent or refractory cancer (suspected or confirmed) | Scheduled for or recently had tumor biopsy/excision or bone marrow aspirate | Willing to provide blood or buccal swab for genetic testing,No malignant tissue available or accessible | Insufficient malignant tissue for ex vivo drug testing and/or genomic profiling | Newly diagnosed tumors | Tumors with high (>90%) cure rate with safe standard therapy,(none),ALL,F,"The trial restricts enrollment to age ≤21 years, while the patient is 40, which is outside the allowed age range. Thus, the patient is ineligible despite having a recurrent brain tumor.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,F,"Age is a hard exclusion: trial allows ≤21 years, patient is 40. This alone mandates grade F regardless of other factors. The grader correctly identified and applied this.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT05867329,0.541721761226654,Crohn's Disease,A Sequential Multiple Assignment Randomized Trial (SMART) Feasibility Pilot Developing and Optimizing Patient-Tailored Adaptive Treatment Strategies (ATS) for Acute Severe Ulcerative Colitis (ASUC),PHASE4,18 years to 75 years,Ulcerative Colitis (acute severe),"Age 18–75 years | Diagnosis of ulcerative colitis confirmed by clinical history, endoscopy, and histology | Current hospitalization for ulcerative colitis treatment with expected initiation of IV corticosteroids | Acute severe ulcerative colitis: >= 4 bloody bowel movements/day plus at least one of the following—temperature > 37.5 C, pulse > 90 BPM, hemoglobin < 10.5 g/dL, ESR >= 30 mm/h, weight loss > 5 lb over 3 months, CRP >= 3.0 mg/dL, fecal calprotectin > 782 mg/kg (within 4 weeks), or oral corticosteroid use for >= 14 days at a dose equivalent to >= 30 mg/day | Prior exposure to at least one anti-TNF agent (adalimumab, certolizumab, infliximab, or golimumab; originator or biosimilar) | Able to take oral medication and adhere to the study regimen | Females of reproductive potential: negative pregnancy test at admission and agreement to use highly effective contraception during the 3-month follow-up","Indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical features suggestive of Crohn's disease | Receiving continuous IV corticosteroids for >= 72 hours prior to enrollment | Pregnant or breastfeeding | Toxic megacolon during current admission | Hypersensitivity to methylprednisolone, cyclosporine, tofacitinib, or upadacitinib | Prior exposure to upadacitinib | Ongoing severe infection, including untreated or inadequately treated latent or active tuberculosis | Active CMV colitis defined as > 5 inclusion bodies per high powered field at baseline (unless allowed with concomitant antiviral therapy per teams) | Investigational agent or procedure within 30 days or five half-lives prior to baseline | Current malignancy except non-metastatic basal cell or squamous cell carcinoma of the skin | History of colectomy (total or subtotal), ileoanal pouch, Kock pouch, or ileostomy, or planned bowel surgery | Neutropenia (ANC < 1200/µL) or total white blood cell count < 2500/µL | Hemoglobin < 8 mg/dL | Platelet count < 80000/µL | eGFR < 30 mL/min/1.73 m2 | ALT >= 2 x ULN or AST >= 2 x ULN | Cirrhosis with Child-Pugh score >= 5 | Uncontrolled hypertension (systolic > 160 mmHg or diastolic > 100 mmHg despite therapy) | Recent (within 6 months) cerebrovascular accident, myocardial infarction, or coronary stenting | Recent (within 6 months) moderate-to-severe congestive heart failure (NYHA class III–IV) | Inherited or acquired thrombophilia (e.g., antiphospholipid syndrome, Factor V Leiden, prothrombin G20210A, deficiencies of antithrombin, protein C, protein S, heparin cofactor II, PAI-1/plasminogen disorders, dysfibrinogenemia, Factor XII deficiency) | Total cholesterol < 80 mg/dL at baseline | Chronic HBV infection with positive HBsAg and detectable DNA not on suppressive therapy; HCV RNA positive; or HIV with CD4 < 350/µL or AIDS-defining opportunistic infection | Solid organ or bone marrow transplant within 1 year or expected within 6 months | History of more than one episode of herpes zoster, disseminated zoster, or disseminated herpes simplex | Current use of medications increasing venous thromboembolism risk (e.g., hormone replacement therapy, testosterone, tamoxifen) | Live or attenuated live vaccines within 6 weeks prior to baseline or scheduled during study or within 140 days after last dose | History of lymphoproliferative disorder, lymphoma, leukemia, myeloproliferative disorder, multiple myeloma, or signs/symptoms of current hematologic disease | History of spontaneous gastrointestinal perforation (other than appendicitis or mechanical injury), diverticulitis, or significantly increased risk of GI perforation per investigator | Concomitant strong CYP3A4 inducers or inhibitors, including grapefruit or grapefruit juice | Conditions affecting oral drug absorption (e.g., gastrectomy, significant diabetic gastroenteropathy, gastric bypass; gastric banding permitted) | Any clinically significant medical condition or other reason that, in the investigator’s opinion, would interfere with participation or pose risk","Prior exposure to at least one anti-TNF agent (adalimumab, certolizumab, infliximab, or golimumab; originator or biosimilar)",FEMALE,F,"Disease mismatch: the trial targets acute severe ulcerative colitis and excludes Crohn’s disease. Additionally, the trial is restricted to females, whereas the patient is male.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,Hard exclusions apply: disease mismatch (Crohn’s vs trial for acute severe ulcerative colitis) and sex restriction (trial limited to females; patient is male). F is correct per rubric.,,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT05885412,0.4850372076034546,PMM2-CDG,A Phase 1 Dose Escalation Trial Evaluating an Intravenously Administered Recombinant Adeno-Associated Virus Serotype rh.74 (AAVrh.74) Vector Containing the Human Plakophilin-2a (PKP2a) Coding Sequence (RP-A601; AAVrh.74-PKP2a) in Subjects With Arrhythmogenic Cardiomyopathy Arising From Pathogenic PKP2 Variants (PKP2-ACM),PHASE1,18 years,Arrhythmogenic Cardiomyopathy (PKP2),Age >= 18 years | Clinical diagnosis of arrhythmogenic cardiomyopathy per 2010 revised Task Force Criteria | Pathogenic or likely pathogenic truncating variant in PKP2 | Implantable cardioverter-defibrillator in place for >= 6 months | Premature ventricular contraction frequency >= 500 per 24 hours by ambulatory monitoring | Left ventricular ejection fraction >= 50%,Anti-AAVrh.74 neutralizing antibody titer > 1:40 | Cardiomyopathy due to a genetic etiology other than PKP2 truncating variant | Previous participation in a gene transfer or gene editing study | Severe right ventricular dysfunction | New York Heart Association Class IV heart failure,(none),ALL,F,"The trial targets arrhythmogenic cardiomyopathy with pathogenic PKP2 variants and requires adults ≥18, while the patient has PMM2-CDG with PMM2 variants and is 8 years old. This is a clear disease, biomarker, and age mismatch.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,"Clear hard exclusions: disease mismatch (PMM2-CDG vs trial for PKP2-related ACM), age window conflict (8 < 18), and required biomarker mismatch (PKP2 truncating variants required; patient has PMM2). Grader’s F and reasoning are correct.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT05886049,0.42416977882385254,PMM2-CDG,A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged Disease.,PHASE1,18 years to 75 years,"Acute Myeloid Leukemia (NPM1 mutated, FLT3 wildtype); Acute Myeloid Leukemia (KMT2A rearranged)","Age 18-75 years with untreated acute myeloid leukemia that is NPM1-mutated/FLT3-ITD wildtype and FLT3-TKD wildtype, or KMT2A-rearranged, and candidate for intensive induction chemotherapy | ECOG performance status <= 2 (Karnofsky >= 60%) | Total bilirubin <= 2 x ULN (except Gilbert's syndrome) | AST <= 3 x ULN | ALT <= 3 x ULN | Glomerular filtration rate >= 60 mL/min | HIV infection allowed if on effective antiretroviral therapy with undetectable viral load within 6 months | Chronic hepatitis B allowed if viral load undetectable on suppressive therapy | History of hepatitis C allowed if treated and cured, or on treatment with undetectable viral load | Prior or concurrent malignancy allowed if it will not interfere with assessment of the investigational regimen | If cardiac disease/history of cardiotoxic therapy: NYHA class 2B or better | Left ventricular ejection fraction >= 50% (or >= 45% if no CHF or cardiac symptoms) by TTE or MUGA | White blood cells < 25 x 10^9/L; hydroxyurea and leukapheresis permitted prior to enrollment and must stop within 24 hours before protocol therapy | Previously untreated AML with no prior therapy other than hydroxyurea (or ATRA given for suspected APL that is later ruled out)","Allergic reactions to compounds similar to SNDX-5613 (revumenib), daunorubicin, or cytarabine | Uncontrolled intercurrent illness making participation unsafe | Use of strong or moderate CYP3A4 inhibitors, strong CYP3A4 inducers (except antifungal as specified), or sensitive/narrow therapeutic index MATE1 substrates within 7 days of enrollment | Pregnancy or breastfeeding | Isolated myeloid sarcoma without blood or marrow AML involvement | Acute promyelocytic leukemia (FAB M3) | Active central nervous system involvement by AML | Uncontrolled symptomatic disseminated intravascular coagulopathy with active bleeding or thrombosis | QTcF >= 450 ms at screening or factors conferring high risk of QT prolongation/arrhythmia (unless cleared by cardiology as specified) | Projected to exceed lifetime anthracycline exposure > 550 mg/m^2 daunorubicin equivalent (> 400 mg/m^2 with prior mediastinal radiation) | Upper gastrointestinal conditions that may affect oral drug absorption or ingestion (e.g., gastric bypass, gastroparesis) | Cirrhosis with Child-Pugh class B or C | Down syndrome | Myelodysplastic syndromes previously treated with intensive induction regimens similar to 7+3",No prior AML therapy except hydroxyurea; All-trans retinoic acid allowed if given for suspected APL that is later ruled out; Hydroxyurea and leukapheresis permitted for WBC control prior to enrollment (must stop within 24 hours before protocol therapy); Antiretroviral therapy allowed if HIV viral load is undetectable,ALL,F,"The trial enrolls adults (18–75) with specific subtypes of acute myeloid leukemia, while the patient is an 8-year-old with PMM2-CDG, so both disease and age do not meet required criteria.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,Hard exclusions apply: disease mismatch (PMM2-CDG vs AML cohorts) and age outside 18–75 window. F is correct and the reasoning identifies both key exclusions.,,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT05907746,0.41780155897140503,PMM2-CDG,A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency,PHASE2,6 years to 70 years,GATA2 Deficiency,"Age 6–70 years | Germline deleterious mutation in GATA2 confirmed by targeted sequencing | Clinical manifestations consistent with GATA2 deficiency (e.g., severe/recurrent infections; monocytes <190/µL, B cells <61/µL, NK cells <126/µL; myelodysplastic syndrome by WHO) | Early-stage GATA2 deficiency: hypocellular marrow for age, <5% blasts, and normal/favorable cytogenetics (good/very good risk groups plus trisomy 8) | Availability of suitable donor: 8/8 HLA-matched related or unrelated, 7/8 HLA-matched unrelated, or haploidentical related donor | Karnofsky or Lansky performance status >= 40% | Left ventricular ejection fraction > 40% | Total bilirubin <= 2.5 x ULN | AST and ALT <= 5 x ULN | Adult creatinine <= 2.0 mg/dL and creatinine clearance >= 30 mL/min | Pediatric creatinine < 1.5 mg/dL and creatinine clearance > 30 mL/min/1.73m^2 | Pulmonary function: FEV1 and adjusted DLCO > 30%; if unable to perform due to age, no dyspnea at rest and no supplemental oxygen requirement | HBV or HCV seropositive allowed if HBV DNA <100 IU/mL or HCV RNA undetectable and hepatology approval","Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) score > 8 | Receipt of investigational agents within 4 weeks before treatment initiation (except virus-specific T cells for treatment of viral infection/reactivation prior to allogeneic HCT) | History of hematologic malignancy (e.g., AML, CMML); MDS allowed | History of allergic reactions to compounds similar to study agents (fludarabine, cyclophosphamide, tacrolimus, mycophenolate, G-CSF) | Presence of active malignancy (virus-driven malignancies allowed); MDS allowed | HIV infection | Pregnancy | Uncontrolled intercurrent illness or social situations limiting compliance with study requirements",No investigational agents within 4 weeks before treatment initiation (except virus-specific T cells for viral infection/reactivation),ALL,F,"Disease mismatch: the trial is for GATA2 deficiency with a required germline GATA2 mutation, while the patient has PMM2-CDG with PMM2 variants. This fails the trial’s disease/biomarker requirement.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,"Clear hard exclusion: the trial targets GATA2 deficiency and requires a germline GATA2 mutation, while the patient has PMM2-CDG with PMM2 variants. Disease and required biomarker mismatch → F. Grader applied rubric correctly.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT05907746,0.5549944043159485,Ornithine Transcarbamylase Deficiency,A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency,PHASE2,6 years to 70 years,GATA2 Deficiency,"Age 6–70 years | Germline deleterious mutation in GATA2 confirmed by targeted sequencing | Clinical manifestations consistent with GATA2 deficiency (e.g., severe/recurrent infections; monocytes <190/µL, B cells <61/µL, NK cells <126/µL; myelodysplastic syndrome by WHO) | Early-stage GATA2 deficiency: hypocellular marrow for age, <5% blasts, and normal/favorable cytogenetics (good/very good risk groups plus trisomy 8) | Availability of suitable donor: 8/8 HLA-matched related or unrelated, 7/8 HLA-matched unrelated, or haploidentical related donor | Karnofsky or Lansky performance status >= 40% | Left ventricular ejection fraction > 40% | Total bilirubin <= 2.5 x ULN | AST and ALT <= 5 x ULN | Adult creatinine <= 2.0 mg/dL and creatinine clearance >= 30 mL/min | Pediatric creatinine < 1.5 mg/dL and creatinine clearance > 30 mL/min/1.73m^2 | Pulmonary function: FEV1 and adjusted DLCO > 30%; if unable to perform due to age, no dyspnea at rest and no supplemental oxygen requirement | HBV or HCV seropositive allowed if HBV DNA <100 IU/mL or HCV RNA undetectable and hepatology approval","Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) score > 8 | Receipt of investigational agents within 4 weeks before treatment initiation (except virus-specific T cells for treatment of viral infection/reactivation prior to allogeneic HCT) | History of hematologic malignancy (e.g., AML, CMML); MDS allowed | History of allergic reactions to compounds similar to study agents (fludarabine, cyclophosphamide, tacrolimus, mycophenolate, G-CSF) | Presence of active malignancy (virus-driven malignancies allowed); MDS allowed | HIV infection | Pregnancy | Uncontrolled intercurrent illness or social situations limiting compliance with study requirements",No investigational agents within 4 weeks before treatment initiation (except virus-specific T cells for viral infection/reactivation),ALL,F,"Disease mismatch: the trial targets GATA2 deficiency with a required GATA2 germline mutation, while the patient has OTC deficiency with an OTC mutation. Additionally, the patient is 3 months old, outside the trial’s 6–70 years age range.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,Hard exclusions apply: disease mismatch (OTC vs GATA2) and age outside trial range (3 months vs 6–70 years). Grader correctly assigned F and reasoning aligns with rubric.,,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT06008093,0.8135332465171814,Metastatic Non-Small Cell Lung Cancer,"A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for First-line Treatment in Metastatic Non-small Cell Lung Cancer Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)",PHASE3,18 years to 130 years,"Non-Small Cell Lung Cancer (non-squamous, metastatic)","Histologically or cytologically confirmed Stage IV non-squamous NSCLC not amenable to curative surgery or radiation | Tumor harbors STK11 or KEAP1 or KRAS mutation (co-mutations allowed) | Tumor lacks activating EGFR mutations and lacks ALK fusions | No prior chemotherapy or other systemic therapy for metastatic NSCLC | Prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation allowed if progression > 6 months from end of last therapy | No prior exposure to immune-mediated therapy (excluding therapeutic anti-cancer vaccines) within 6 months of randomization | ECOG performance status 0–1 | Life expectancy >= 12 weeks | At least one measurable lesion per RECIST 1.1 (>= 10 mm) not previously irradiated and suitable for repeated measurements | Adequate organ and bone marrow function | Negative pregnancy test for women of childbearing potential | Use of effective contraception (male and female) | Body weight > 30 kg","Acute or uncontrolled diseases or history of allogeneic organ transplant | Mixed small cell lung cancer and NSCLC histology | Major surgery within 28 days prior to first dose or need for major surgery during study | Active or prior autoimmune or inflammatory disorders (exceptions: vitiligo, alopecia, stable hypothyroidism on replacement, chronic skin conditions not requiring systemic therapy, inactive disease > 5 years after consultation, celiac disease controlled by diet) | Medical contraindication to platinum-based doublet chemotherapy | History of another malignancy except curatively treated with no active disease >= 2 years or adequately resected non-melanoma skin cancer or curatively treated in situ disease | Persistent CTCAE Grade >= 2 toxicities from prior therapy (except alopecia and vitiligo); Grade <= 2 neuropathy may be allowed per investigator | Spinal cord compression unless asymptomatic and stable | Significant cardiac disease (e.g., symptomatic CHF, unstable angina, uncontrolled significant arrhythmias, symptomatic/uncontrolled atrial fibrillation, sustained ventricular tachycardia) | Concurrent anticancer chemotherapy, investigational product, biologic, or hormonal therapy (non-cancer hormonal therapy allowed) | Radiation therapy not meeting allowed criteria (definitive >= 6 months prior; or specific palliative settings) | Untreated or unstable brain metastases (must be treated and stable; not RECIST target lesions) | History of leptomeningeal carcinomatosis | Active tuberculosis infection | Active hepatitis: HBsAg positive or anti-HBc with detectable HBV DNA; HCV antibody positive with detectable HCV RNA; HBV/HCV or HBV/HDV coinfection | HIV infection not well controlled | Immunosuppressive medication within 14 days before first dose (exceptions: local/topical/inhaled steroids; physiologic doses <= 10 mg/day prednisone equivalent; premedication/single palliative dose) | Receipt of live attenuated vaccine within 30 days before first dose | Concurrent enrollment in another interventional clinical study (except observational or follow-up) | Hypersensitivity to study drugs or excipients | Pregnant or breastfeeding or planning pregnancy; breastfeeding restrictions apply during and after therapy",No prior systemic therapy for metastatic NSCLC; Prior platinum-containing adjuvant/neoadjuvant or definitive chemoradiation allowed if progression > 6 months from last therapy; No prior immune-mediated therapy within 6 months before randomization,ALL,F,The trial requires tumors to lack activating EGFR mutations and to be treatment-naïve for metastatic disease; the patient has an activating EGFR exon 19 deletion and has received osimertinib. These are explicit exclusion conflicts.,Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"The trial explicitly excludes tumors with activating EGFR mutations and requires no prior systemic therapy for metastatic NSCLC. The patient has an EGFR exon 19 deletion and received osimertinib, triggering hard exclusions. Grade F is correct.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06041789,0.5785478353500366,Dementia,Effect of Acetylcholinesterase Inhibitors on Bone Metabolism and Fracture Risk Factors Among Older Adults With Mild to Moderate Alzheimer's Disease,PHASE2,50 years,Osteoporosis; Alzheimer's Disease (mild to moderate),"Diagnosis of cognitive impairment (clinical, radiographic, or laboratory biomarker assessment) | Female: age >55 years or <55 years and >=12 months postmenopausal | Male: age >50 years | Geriatric Depression Scale score <6","Current use of acetylcholinesterase inhibitor or memantine | History of bradycardia, heart block, long QT, unexplained syncope, or other contraindication to donepezil | ECG: heart rate <50 bpm, PR interval >200 ms, QTc >440 ms (men) or >460 ms (women), or atrioventricular block | Current use of osteoporosis medications (e.g., bisphosphonates, SERM, denosumab, teriparatide, abaloparatide, calcitonin) | Bisphosphonate use within the last 5 years | Use within the last 6 months of estrogens, testosterone, androgen deprivation therapy, aromatase inhibitors, antiepileptics, heparin, or thiazolidinediones | Disorders associated with secondary osteoporosis (e.g., collagen vascular disease, malabsorption, inflammatory bowel disease, severe liver disease/cirrhosis, hyperthyroidism) | History of low-trauma fracture of the humerus, wrist, or vertebra | History of hip fracture, hip replacement, or non-ambulatory status | Long-term corticosteroid use (>6 months) | History of Parkinson's disease, HIV, or Huntington's disease | History of solid organ transplantation | History of bariatric surgery or planned weight loss by bariatric surgery or weight loss medication in the next 12 months | Severe renal impairment (eGFR <30 mL/min) | Active malignancy undergoing chemotherapy, surgery, or radiation therapy (except non-melanoma skin cancer) | Estimated 1-year mortality >25%",(none),ALL,F,"The trial targets mild to moderate Alzheimer's disease, while the patient’s listed condition is dementia without an Alzheimer's diagnosis (amyloid PET and CSF amyloid are negative). This is a disease mismatch per the trial’s disease focus.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion. The trial targets Alzheimer’s disease (mild–moderate), while the patient is listed with dementia without an AD diagnosis; amyloid-negative profile further argues against AD. Thus F per rubric; no need to assess anchors.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT06046820,0.5366018414497375,Ornithine Transcarbamylase Deficiency,"The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children With Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency",PHASE3,1 years to 12 years,Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency,Biallelic ENPP1 mutations confirmed by a CAP/CLIA-certified (or regional equivalent) laboratory | Age >=1 and <13 years at Study Day 1 | Open growth plates of the distal femur and proximal tibia in both legs | Plasma pyrophosphate (PPi) <1400 nM at screening | 25-hydroxyvitamin D >=12 ng/mL at screening | Radiographic evidence of skeletal abnormalities with RSS >=2 | Negative serum pregnancy test for females of childbearing potential | Use of highly effective contraception for participants of childbearing potential during the study,"Clinically significant disease or laboratory abnormality not associated with ENPP1 Deficiency that would preclude participation or confound results | Use of prohibited medications: systemic corticosteroids >5 mg prednisone equivalent per day, anti-FGF23 agents, or oral/IV bisphosphonates | Unable or unwilling to discontinue calcitriol or other active vitamin D analogs within 7 days prior to Study Day 1 | Unable or unwilling to discontinue oral phosphate supplements within 36 hours prior to Study Day 1 if randomized to INZ-701 | Planned orthopedic surgery during the 52-week randomized treatment period | Known intolerance to INZ-701 or its excipients | Positive COVID-19 test within 5 days prior to randomization (if required per local policy) | Previous treatment with INZ-701 | Concurrent participation in another interventional clinical study or receipt of an investigational drug within 5 half-lives or 4 weeks prior to randomization (whichever is longer), or use of an investigational device",Discontinue calcitriol or other active vitamin D analogs >=7 days prior to Study Day 1; Discontinue oral phosphate supplements >=36 hours prior to Study Day 1; No investigational drugs within 5 half-lives or 4 weeks prior to randomization (whichever is longer),ALL,F,"Disease mismatch: the trial targets ENPP1 deficiency requiring biallelic ENPP1 mutations, while the patient has OTC deficiency with an OTC mutation. Additionally, the patient is 3 months old, below the trial’s minimum age of 1 year.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,Correct: There is a hard disease mismatch (ENPP1 deficiency vs patient’s OTC deficiency) and the patient is below the trial’s minimum age (3 months vs ≥1 year). Either triggers F.,,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT06067802,0.5342826843261719,Ornithine Transcarbamylase Deficiency,"A Phase II, Escalating Dose, Open Label Study to Evaluate the Safety of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)",PHASE2,16 years,Medium-Chain Acyl-CoA Dehydrogenase Deficiency,"Diagnosis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency with molecular confirmation. | Age >= 16 years. | Negative pregnancy test for females of childbearing potential. | Effective contraception required for females of childbearing potential and males, or abstinence.","Use of any investigational drug within 30 days of screening. | Active infection (viral or bacterial) or other intercurrent illness at screening. | Evidence of liver disease: AST or ALT > 1.5 x ULN at screening. | Pregnant, planning to become pregnant, breastfeeding, or lactating. | Diagnosis of pancreatic insufficiency or use of pancreatic lipase inhibitors (e.g., orlistat). | Type 1 or type 2 diabetes, or use of medications that can cause hypoglycemia. | Any clinical or laboratory abnormality or medical condition that increases risk in the investigator's judgment.",No investigational drugs within 30 days prior to screening.,ALL,F,"Hard exclusions: the trial targets MCAD deficiency, not OTC deficiency, and the minimum age is 16 years while the patient is 3 months old.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Correct: There is a hard disease mismatch (trial is for MCAD, patient has OTC deficiency) and a hard age conflict (trial min age 16 years vs patient 3 months). Either triggers F. The grader identified both.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT06139172,0.5058239698410034,Ornithine Transcarbamylase Deficiency,Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities,NA,2 years to 12 years,"Angelman Syndrome; Chromosome 15q Partial Deletion; Creatine Deficiency (X-linked); Fragile X Syndrome; Hamartoma Syndrome, Multiple; Rett Syndrome; Telomeric 22q13 Monosomy Syndrome; Tuberous Sclerosis","Age 2-12 years at enrollment | Existing genetic syndrome confirmed by clinical or genetic diagnosis | Documented global developmental delay or intellectual disability | Estimated intellectual disability in any range | Disruptive behavior appropriate for remote, parent-implemented coaching per clinician judgment | Stable psychosocial and psychiatric treatments for 3 months prior to baseline",High levels of aggression precluding remote or outpatient treatment or ABC Irritability score > 20 | Medical or psychiatric instability that may limit participation | Meaningful change in medication or psychosocial interventions within 3 months prior to baseline,Stable psychosocial and psychiatric treatments for >=3 months prior to baseline,ALL,F,"Disease mismatch: the trial targets specific syndromic developmental disorders, not ornithine transcarbamylase deficiency. Additionally, the patient is 3 months old, below the trial's 2–12 year age range.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Correct: The trial does not include OTC deficiency (disease mismatch), and the patient is 3 months old vs trial minimum age 2 years. Either constitutes a hard exclusion, so F is appropriate.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT06147037,0.7607053518295288,Metastatic Urothelial Carcinoma,"A Phase 1, First-in-human, Multicentre, Open-label, Dose Escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours",PHASE1,18 years,Gastric Cancer; Head and Neck Squamous Cell Carcinoma; Metastatic Colorectal Carcinoma; Non-small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma; Renal Cell Carcinoma,"Histologically or cytologically confirmed solid tumor that is metastatic, locally advanced, recurrent, or inoperable | Disease progressed despite prior treatment and no additional effective standard therapy available, contraindicated, not tolerable, or refused | Measurable disease per RECIST v1.1 | ECOG performance status 0–1 | Adequate organ function","Previous treatment with any systemic radiopharmaceutical | Prior anti-cancer therapy unless adequate washout and recovery from toxicities | Contraindications to or inability to perform required imaging procedures | Radiation therapy within 28 days prior to the first dose of [111In]-FPI-2107 | Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (>= once per month) | Known CNS metastatic disease unless treated and stable",Prior anti-cancer therapy permitted with adequate washout and recovery; Prior radiation therapy permitted if >28 days before first [111In]-FPI-2107 dose,ALL,F,"Disease mismatch: the trial targets gastric, head and neck SCC, metastatic colorectal, NSCLC, pancreatic ductal, and renal cell cancers; urothelial carcinoma is not listed. Therefore the patient’s metastatic urothelial carcinoma is not eligible.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion: trial diseases targeted do not include metastatic urothelial carcinoma. Despite broad inclusion text, the provided diseases_targeted list governs per rubric. F is correct.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06159673,0.5766936540603638,Dementia,"A Master Protocol for Three Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled Efficacy and Safety Studies of ACP-204 in Adults With Alzheimer's Disease Psychosis",PHASE2/PHASE3,55 years to 95 years,Alzheimer's Disease Psychosis,"Age >=55 and <=95 years | Possible or probable Alzheimer's disease per 2011 NIA-AA criteria | Psychosis meeting International Psychogeriatrics Association criteria in major or mild neurocognitive disorder | Evidence of amyloid plaque deposition by blood-based biomarker, PET, or CSF consistent with Alzheimer's disease | Prior brain MRI or CT consistent with Alzheimer's disease | MMSE score >=6 and <=24 | Psychotic symptoms for >=2 months | Stable dose of a cholinesterase inhibitor or memantine, if applicable","Psychotic symptoms primarily attributable to delirium, substance abuse, or a medical or psychiatric condition other than dementia | History of cerebral amyloid angiopathy | History of epilepsy | History of central nervous system neoplasm | History of unexplained syncope | Atrial fibrillation | Symptomatic orthostatic hypotension | Protocol-defined exclusionary clinical laboratory findings | Treatment with anti-tau therapy or donanemab within 2 months prior to screening | In hospice receiving end-of-life palliative care or bedridden",Stable dose of cholinesterase inhibitor; Stable dose of memantine,ALL,F,"The trial requires evidence of amyloid plaque deposition consistent with Alzheimer's disease, whereas the patient’s PET and CSF amyloid are negative. This fails a required biomarker criterion.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"The trial requires evidence of amyloid plaque deposition; the patient’s PET and CSF amyloid are explicitly negative, indicating the required biomarker is definitively lacking. This triggers a HARD EXCLUSION, so F is correct.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT06173505,0.7711784243583679,Metastatic Non-Small Cell Lung Cancer,"A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer",PHASE1/PHASE2,18 years,Nonsquamous Non-small Cell Lung Cancer,"Histologically confirmed locally advanced (unresectable) or metastatic nonsquamous non-small cell lung cancer | Documented absence of tumor-activating EGFR mutation, ALK rearrangement, ROS1 rearrangement, and other actionable driver alterations with approved first-line targeted therapies | PD-L1 IHC TPS < 49% | No prior systemic treatment for advanced/metastatic NSCLC | Measurable disease per RECIST 1.1 | ECOG performance status 0–1 | Life expectancy >= 3 months | Adequate liver function | Adequate kidney function | Adequate thyroid function | Adequate bone marrow function","Active central nervous system metastases or carcinomatous meningitis (treated, radiologically stable brain metastases allowed) | Active known or suspected autoimmune disease | Systemic corticosteroids or other immunosuppressive medications within 14 days prior to first dose | Symptomatic interstitial lung disease | HIV infection with CD4+ T-cell count < 350 cells/µL, HIV viral load > 400 copies/mL, history of AIDS-defining opportunistic infection within 12 months, or not on stable ART >= 4 weeks | Positive test for hepatitis C RNA | Positive hepatitis B surface antigen or positive hepatitis B core antibody unless HBV DNA negative with ongoing monitoring | Clinically unstable or uncontrolled disorder or disease that could pose risk or interfere with study",No prior systemic therapy for advanced/metastatic NSCLC,ALL,F,"Ineligible: the trial requires documented absence of activating EGFR mutations, whereas the patient has an EGFR exon 19 deletion, and it is restricted to first-line therapy with no prior systemic treatment for metastatic disease, but the patient has received osimertinib.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Correct: The trial requires absence of activating EGFR mutations and no prior systemic therapy for advanced/metastatic disease. The patient has an EGFR exon 19 deletion and prior osimertinib. These are hard exclusions, so F is appropriate.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06189963,0.6000585556030273,Dementia,"A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's Disease",PHASE1/PHASE2,40 years to 85 years,Alzheimer Disease (moderate),Diagnosis of Alzheimer's dementia per 2011 NIA-AA guidelines | Age 40 to 85 years | At least 6 years of formal education and fluency in test language | Females of childbearing potential: negative urine pregnancy test at screening and before first dose | Participants of reproductive potential agree to abstinence or effective contraception during treatment and for 30 days after last dose | Positive amyloid PET of the brain within the past 6 months | CDR-SB score >= 9.5 and < 16.0,"Substantial concomitant cerebrovascular disease (Fazekas Grade 3) | History of stroke or intracranial hemorrhage temporally related to worsening cognition | Substance use disorder not in remission for at least 12 months | History of cancer (except basal cell carcinoma) or cancer treatment within the last 5 years | Uncontrolled cardiovascular illness (e.g., chronic congestive heart failure, tachycardia, arrhythmias, uncontrolled hypertension) | Cerebrovascular accident, transient ischemic attack, or unexplained loss of consciousness within the last year | Significant pulmonary disease predisposing to hypoxia | Significant ischemic heart disease, myocardial infarction within the last 2 years and/or residual angina, orthopnea, conduction defects, or NYHA class III or IV heart disease | Significant liver disease (e.g., cirrhosis, active hepatitis B or C, primary or metastatic liver neoplasm) | ALT, AST, or alkaline phosphatase > 3 x ULN | Significant gastrointestinal disorders (e.g., GI bleeding within 2 years, malabsorption syndromes, post-gastrectomy, active peptic ulcer disease) | Clinically significant immunological disorders (e.g., significant allergies, lupus erythematosus, scleroderma) | Uncontrolled or unstable hematological disease (e.g., refractory anemia, refractory myelosuppression) | Neurological diseases affecting cognition (e.g., primary Lewy body dementia, Huntington's disease, Parkinson's disease, encephalitis, epilepsy, vascular or multi-infarct dementia, stroke, congenital mental deficiency, multiple sclerosis) | Psychiatric disorders impacting cognition (e.g., schizophrenia, intellectual disability) | Unstable or uncontrolled major depression or anxiety within the last 12 months | History of seizures in the past 3 years | Uncontrolled endocrine disease (e.g., uncontrolled diabetes mellitus, manifest hyperthyroidism) | Severe renal impairment (GFR < 30 mL/min/1.73 m2) | Infection with HIV, hepatitis B, hepatitis C, or any other active infection or active systemic disease | Current treatment with anticoagulants (except aspirin at or below a prophylactic dose) | Use of memantine or acetylcholinesterase inhibitors above recommended dose range or not on a stable dose for 30 days prior to enrollment | Any contraindication to brain MRI and/or amyloid PET | Any condition that, in the investigator's opinion, puts the participant's safety at risk | Medically unstable or uncontrolled conditions | Any suicidal behavior in the past 2 years | Suicidal ideation type 4 or 5 on C-SSRS in the past 3 months",Stable dose of memantine or acetylcholinesterase inhibitors for >=30 days prior to enrollment,ALL,F,"The trial requires a positive amyloid PET (and AD per NIA-AA), but the patient has negative amyloid PET and CSF amyloid, constituting a required biomarker mismatch. Age and stage otherwise fit, but this hard exclusion applies.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"The trial requires a positive amyloid PET; the patient has negative amyloid PET (and CSF amyloid negative), which is a definitive required biomarker mismatch. This is a HARD EXCLUSION per the rubric, so grade F is correct. Other factors (age, stage) do not override the hard exclusion.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT06222580,0.424068808555603,PMM2-CDG,Safety and Efficacy of Dual Menin and FLT3 Inhibition in Patients With Relapsed/Refractory FLT3- Mutated Acute Myeloid Leukemia Containing a Concurrent MLL-Rearrangement or NPM1 Mutation: A Phase I (Ph I) Study of SNDX-5613 + Gilteritinib,PHASE1,18 years,Acute Myeloid Leukemia (relapsed/refractory); Acute Myeloid Leukemia With FLT3 Mutation; Acute Myeloid Leukemia With NPM1 Mutation; Acute Myeloid Leukemia With KMT2A Rearrangement,"Age >= 18 years | Morphologically confirmed relapsed/refractory acute myeloid leukemia (WHO 2022) | Refractory disease after >= 2 cycles intensive induction or >= 2 cycles HMA + venetoclax with persistent >= 5% marrow blasts and/or reappearance of peripheral blasts | FLT3 mutation (ITD or TKD) AND concurrent NPM1 mutation or KMT2A (MLL) rearrangement or other mutation causing HOXA-MEIS1 overexpression (e.g., NUP98, UBTF-TD, MLL-PTD) | Receiving itraconazole, ketoconazole, posaconazole, or voriconazole for antifungal prophylaxis >= 24 hours prior to enrollment and during treatment; no other strong CYP3A4 inhibitors/inducers | Not suitable for immediate myeloablative/intensive chemotherapy | ECOG performance status 0-2 | AST <= 3 x ULN | ALT <= 3 x ULN | Total bilirubin <= 1.5 x ULN (except Gilbert syndrome) | eGFR >= 60 mL/min | Left ventricular ejection fraction >= 50% by echocardiogram or MUGA | Able to swallow oral medications | Prior treatment-related toxicities resolved to <= grade 1 (except <= grade 2 neuropathy or alopecia) | Required washouts from prior therapies per protocol | Prior gilteritinib allowed","Acute promyelocytic leukemia | Extramedullary AML or myeloid sarcoma (WHO 2022) | Suspected CNS involvement unless cleared or receiving active CNS-directed therapy | Active second malignancy requiring anticancer therapy (therapy-related neoplasms not eligible) | Known allergy or hypersensitivity to gilteritinib or revumenib | Active uncontrolled HIV, HBV, or HCV infection (controlled/treated cases with undetectable viral load are eligible) | QTcF > 450 ms at screening | Clinically significant ventricular arrhythmia (e.g., VT, VF, Torsades de pointes) | Unstable angina, serious cardiac arrhythmia, myocardial infarction within 2 months, or NYHA class III/IV heart failure | Uncontrolled infection | Psychiatric illness preventing informed consent | Pregnant or breastfeeding | Malabsorption syndrome or condition precluding enteral administration | Any condition that, in the investigator’s opinion, would adversely affect participation or interpretation of results","Prior gilteritinib permitted; Radiation: >= 60 days from TBI/craniospinal or >= 50% pelvic radiation; >= 14 days from local palliative RT; HSCT: >= 60 days post-transplant; DLI: >= 4 weeks; Immunotherapy (vaccines, checkpoint inhibitors): >= 42 days; CAR-T or other modified T-cell therapy: >= 21 days; Antileukemia therapy (small molecule or cytotoxic/myelosuppressive): >= 14 days or 5 half-lives (whichever is shorter); Hydroxyurea for cytoreduction allowed before and during treatment (with approval); Prophylactic intrathecal chemotherapy allowed; Hematopoietic growth factors: >= 7 days (short-acting) or >= 14 days (long-acting); Antineoplastic biologics: >= 90 days or 5 half-lives (whichever is shorter); Systemic steroids: >= 7 days unless physiologic dosing",ALL,F,"Disease mismatch: the trial targets relapsed/refractory FLT3-mutated AML, while the patient has PMM2-CDG. Additionally, the trial requires age ≥18 years and the patient is 8 years old.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,There is a clear disease mismatch (patient has PMM2-CDG; trial is for R/R FLT3-mutated AML with specific co-mutations) and an age hard exclusion (trial requires ≥18; patient is 8). Either triggers an F. The grader’s reasoning correctly identified these hard exclusions.,,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06257706,0.7592913508415222,Crohn's Disease,An Interventional Study to Evaluate Treating to a Target of Transmural Healing in Patients With Moderately to Severely Active Crohn's Disease,PHASE4,18 years to 80 years,Crohn Disease (moderately to severely active),Age 18 to 80 years | Moderately-to-severely active Crohn disease: CDAI 220 to 450 and SES-CD >= 6 (or >= 4 if isolated ileal disease) | C-reactive protein >= 5 mg/L and/or fecal calprotectin >= 250 µg/g at screening | Bowel wall thickness on intestinal ultrasound > 4.0 mm in the ileum or any colonic segment (excluding rectum) | Biologic-naive or prior exposure to no more than 1 advanced therapeutic (approved biologic or small molecule) for Crohn disease | Stable dose of 5-ASA initiated >= 4 weeks prior to screening may be continued | Persons of childbearing potential: negative serum pregnancy test prior to randomization and use of highly effective contraception during study,"Prior treatment with vedolizumab, etrolizumab, or natalizumab | Previously exposed to 2 or more advanced therapeutics (approved biologic or small molecule) for Crohn disease | Change in oral corticosteroid dose within 2 weeks prior to randomization or prednisone > 40 mg (or equivalent) at randomization | Inflammation only proximal to terminal ileum not reachable by ileocolonoscopy | Crohn disease complication requiring procedural intervention (e.g., symptomatic small bowel stricture with > 3 cm prestenotic dilatation) | Previous extensive colonic resection or missing > 2 of 5 segments; ileorectal anastomosis; proctocolectomy | Ostomy or ileoanal pouch | Short bowel syndrome | Fibrotic-only stricture in ileum or colon without active inflammation, including any impassable stenosis | Abscess > 2 cm detected by intestinal ultrasound (participants with draining fistulas are not excluded) | Serious underlying disease other than Crohn disease that may interfere with participation or compromise safety | Positive stool test for Clostridioides difficile toxin | Known HIV infection | Known hepatitis B or hepatitis C infection | Known active or latent tuberculosis | Other systemic or opportunistic infection (including cytomegalovirus), any other clinically significant extraintestinal infection, or recurring infection within 6 months of randomization | Active cerebral or meningeal disease, signs, symptoms, or any history of progressive multifocal leukoencephalopathy | Hypersensitivity, allergy, or intolerance to vedolizumab excipients or any contraindication to vedolizumab | Active severe infection such as sepsis, cytomegalovirus, listeriosis, or opportunistic infection | Unwilling to withhold protocol-prohibited medications during the trial | Participation in another clinical trial with investigational therapy within 30 days or 5 half-lives (whichever is longer) prior to randomization | History of alcohol or drug abuse that may interfere with compliance | Prior enrollment in the current study and received study treatment | Pregnant, lactating, or intending pregnancy; or intending to donate ova or sperm during and up to 18 weeks after last dose | Live or live-attenuated vaccine within 4 weeks prior to randomization or planned during the study",Biologic-naive or <= 1 prior advanced therapeutic for Crohn disease allowed; Stable 5-ASA for >= 4 weeks prior to screening allowed; No change to oral corticosteroid dosing within 2 weeks prior to randomization,ALL,F,"The patient has received two prior advanced therapies (infliximab and ustekinumab), while the trial excludes participants previously exposed to ≥2 advanced therapeutics and allows ≤1. Although age and disease activity align, this explicit exclusion makes the patient ineligible.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Patient has prior exposure to two advanced therapies (infliximab and ustekinumab), and the trial explicitly excludes those with ≥2 prior advanced therapeutics. This is a hard exclusion under the rubric, so grade F is correct.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06264362,0.715561032295227,Dementia,Developing a Nonpharmacological Pain Intervention for Community-dwelling Older Adults With Dementia,NA,60 years,Dementia (mild); Knee Osteoarthritis,Age >= 60 years | Mild or very mild dementia | Knee pain lasting >= 3 months | Average knee pain intensity >= 2/10,Life expectancy < 1 year | Recent changes to pain or psychotropic medications within 60 days | Knee surgery within the past 1 year | Medical condition that contraindicates exercise | Currently receiving rehabilitation services,(none),ALL,F,"The trial requires mild or very mild dementia, but the patient has moderate-stage dementia (MMSE 19), which fails a required inclusion criterion. Age and sex fit; knee pain requirements are unknown but do not offset the stage mismatch.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"The trial explicitly requires mild/very mild dementia; the patient has moderate-stage dementia, a required stage/severity the patient definitively lacks. This qualifies as a hard exclusion per the rubric. Age and sex fit; knee pain/OA status is unknown and not used to penalize. F is correct.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT06377384,0.5966877937316895,Rheumatoid Arthritis,"A Pilot and Feasibility Study Focusing on Lifestyle, Environmental Modifications, and Transdisciplinary Clinical Care for Children With Chronic Illness: Protocol for the FLIGHT Study",PHASE1,2 years to 15 years,Juvenile Idiopathic Arthritis; Asthma; Eczema; Allergies; Crohn's Disease; Ulcerative Colitis; Lupus; Obesity; Type 2 Diabetes; Autism Spectrum Disorder; Attention-Deficit/Hyperactivity Disorder; Depression; Obsessive-Compulsive Disorder; Anxiety Disorder,"Diagnosis in immune/autoimmune conditions (e.g., juvenile idiopathic arthritis, juvenile rheumatoid arthritis, asthma, eczema, atopic illness, allergies, Crohn's disease, ulcerative colitis, lupus) | Diagnosis in conditions of metabolic dysregulation (e.g., obesity, type 2 diabetes) | Diagnosis in mood/behavioral/developmental conditions (e.g., autism spectrum disorder, ADHD/ADD, depression, obsessive-compulsive disorder, anxiety)","Condition severe enough to preclude participation in an intensive, multi-modal lifestyle intervention | Pregnancy",(none),ALL,F,"Disease mismatch: the trial targets pediatric conditions (juvenile idiopathic/rheumatoid arthritis), not adult rheumatoid arthritis. Age window conflict: the trial enrolls ages 2–15, while the patient is 55.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Correct: There is a hard age window conflict (trial ages 2–15 vs patient 55) and a disease mismatch (trial lists juvenile arthritis, not adult rheumatoid arthritis). Either triggers F. The grader’s reasoning aligns with the rubric.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT06430385,0.45872366428375244,PMM2-CDG,"A Phase 1-2, Double-Blind, Sham-Controlled Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Patients With MECP2 Duplication Syndrome",PHASE1/PHASE2,2 years to 65 years,MECP2 Duplication Syndrome,Males age 2 to 65 years (cohort-dependent; Group A: 8–65 years; Group B: 2–7 years). | Documented MECP2 Duplication Syndrome with genetic confirmation of MECP2 duplication. | Stable doses of concomitant medications for >= 3 months prior to baseline (or per investigator judgment). | Completed Part 1/MAD to enroll in Part 2.,"Complex MECP2 duplication/triplication or clinical features suggesting complex variant if structure unknown (e.g., seizures onset < age 5 for those >=5 years, oxygen dependence, microcephaly). | Clinically significant vital sign or ECG abnormality at screening (e.g., HR < 45 bpm; SBP < 90 mmHg; confirmed BP > 170/105 mmHg). | Known brain or spinal disease interfering with lumbar puncture, CSF circulation, or safety of the procedure. | Any concomitant disease/condition or finding making participation unsuitable or posing unacceptable risk, per investigator. | Treatment with an investigational drug/biologic/device within 30 days or 5 half-lives, whichever is longer. | Previous treatment with an oligonucleotide (including siRNA) within 4 months (single dose) or 12 months (multiple doses); centrally administered ASOs require >= 12 months washout. | Currently enrolled in another clinical trial of an investigational agent/device or used any investigational agent within 5 half-lives. | History of gene therapy, cell transplantation, or experimental brain surgery. | Active infection requiring systemic antiviral/antimicrobial therapy not completed before baseline. | Status epilepticus within the past 6 months.","Washout from investigational agents: 30 days or 5 half-lives, whichever is longer.; Washout from oligonucleotides (including siRNA): >= 4 months after single dose; >= 12 months after multiple doses; centrally administered ASOs: >= 12 months.",MALE,F,"Hard exclusions: the trial targets MECP2 Duplication Syndrome with required MECP2 duplication and enrolls males only, whereas the patient has PMM2-CDG with PMM2 variants and is female. Age fits, but disease, biomarker, and sex criteria do not.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,Correct: There is a hard disease mismatch (trial is for MECP2 Duplication Syndrome; patient has PMM2-CDG) and a sex restriction conflict (trial male-only; patient female). Either triggers an immediate F. Age fit is irrelevant. The grader’s reasoning appropriately identified these hard exclusions.,,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT06452277,0.7686145305633545,Metastatic Non-Small Cell Lung Cancer,"A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations",PHASE3,18 years,"Non-Small Cell Lung Cancer (non-squamous, advanced/metastatic)",Age >= 18 years | Histologically or cytologically confirmed locally advanced non-squamous non-small cell lung cancer not suitable for definitive therapy or metastatic non-squamous non-small cell lung cancer (Stage III–IV) | Activating HER2 mutation in the tyrosine kinase domain confirmed by tissue molecular test in an accredited laboratory | No prior systemic therapy for locally advanced or metastatic disease | No prior HER2 exon 20 insertion–targeted therapy | Prior adjuvant or neoadjuvant therapy allowed if completed >= 12 months before screening | Eligible to receive platinum-pemetrexed doublet chemotherapy and pembrolizumab per product information,"Prior malignancy unless curatively treated with no recurrence for 5 years (specific in situ cancers, superficial bladder cancer, limited-stage prostate cancer, and basal or squamous skin cancers allowed if appropriately treated) | Tumors harboring other targetable alterations with approved available therapy (except HER2 mutation in the TKD) | Inability to discontinue chronic systemic corticosteroids | Pre-existing peripheral neuropathy Grade >= 2 (CTCAE v5.0) | History of severe hypersensitivity reaction to a monoclonal antibody | Radiotherapy outside of the brain within 21 days prior to start of study intervention or unresolved radiation-related toxicities or requirement for corticosteroids",No prior systemic therapy for locally advanced or metastatic disease; No prior HER2 exon 20 insertion–targeted therapy; Adjuvant or neoadjuvant therapy allowed if completed >= 12 months before screening,ALL,F,"The trial requires a HER2-activating mutation and first-line (no prior systemic) therapy, and excludes tumors with other targetable alterations; the patient has an EGFR exon 19 deletion and has already received osimertinib, which explicitly violates these criteria.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,"Correct. Although HER2 status is unknown, the trial explicitly excludes tumors with other targetable alterations with approved therapy; the patient has an EGFR exon 19 deletion (targetable) and has received osimertinib. This is a hard exclusion, so F is appropriate.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06456593,0.7965657711029053,Crohn's Disease,"A Phase 2b, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease",PHASE2,18 years to 75 years,Crohn Disease (moderate to severe),"Age 18 to 75 years | Confirmed Crohn disease by endoscopy and histology | Moderately to severely active Crohn disease: CDAI 220–450 | SES-CD >= 6 for ileo-colonic or colonic disease, or SES-CD >= 4 for isolated ileal disease (per central reading) | Documented inadequate response, loss of response, or intolerance to at least one: corticosteroids, immunosuppressants, biologic or biosimilar therapies, or JAK inhibitors","Ulcerative colitis or indeterminate colitis | Crohn disease without ileal and/or colonic involvement | Untreated active external or perianal fistula or abscess (recent abscess must be drained and adequately treated per protocol timelines) | Symptomatic bowel stricture or stenosis not passable on endoscopy | Current stoma or ileoanal pouch | More than two missing complete segments among terminal ileum, right colon, transverse colon, left colon, and sigmoid/rectum | Combined prior small bowel resections > 100 cm | Surgical bowel resection within 3 months prior to baseline | Any manifestation likely to require surgery during the study | Use of prohibited concomitant therapies for Crohn disease | Prior natalizumab or any other alpha4beta1 integrin agonist | Failure of more than three advanced therapies for Crohn disease, or failure of two different mechanisms of action of advanced therapies | History of or active malignancy (except subjects with >= 5-year disease-free survival) | History of colonic cancer or dysplasia adenomatous polyps, or evidence of such polyps at screening endoscopy | Primary sclerosing cholangitis, autoimmune hepatitis, or primary biliary cirrhosis | Serious illness requiring hospitalization (not related to Crohn disease) within 4 weeks prior to screening | Chronic or recurrent grade 3–4 infection within 2 months prior to screening or history of opportunistic infection while not on immunosuppressive therapy | Herpes zoster reactivation within 2 months prior to screening | Active infection at screening or major infection requiring hospitalization or IV antibiotics within 1 month prior to or during screening | Positive stool assay or culture for pathogens requiring treatment or positive Clostridioides difficile toxin at screening | HIV infection | Acute or chronic hepatitis B infection | Acute or chronic hepatitis C infection (unless successfully treated with no detectable HCV RNA for >= 1 year) | Active tuberculosis or untreated latent tuberculosis | Uncontrolled ischemic heart disease or history of congestive heart failure | Congenital or acquired long QT syndrome or marked baseline prolonged QTc | History of torsade de pointes | Clinically relevant pulmonary, hepatic, or renal abnormality; encephalopathy; neuropathy; unstable CNS pathology including seizure disorder; or other significant medical problems | Live vaccine within 3 months prior to screening or planned during the study | Acute or chronic pancreatitis | Hemoglobin <= 8.0 g/dL | Absolute neutrophil count < 750/µL | Platelets < 100,000/µL | eGFR < 60 mL/min | Total bilirubin > 1.5 x ULN (except Gilbert syndrome) | AST > 2 x ULN or ALT > 2 x ULN | Did not meet protocol-specified washout periods prior to screening endoscopy | Use of any investigational or nonregistered product within 3 months or within 5 half-lives prior to baseline, whichever is longer | Prior obefazimod exposure or known hypersensitivity to obefazimod or excipients | Illicit drug or alcohol abuse or dependence | Any condition that could compromise safety or adherence in the investigator's opinion","Inadequate response, loss of response, or intolerance to at least one of: corticosteroids, immunosuppressants, biologic or biosimilar therapies, or JAK inhibitors for Crohn disease; No investigational or nonregistered product within 3 months or 5 half-lives prior to baseline; Meet protocol-specified washout periods before screening endoscopy",ALL,F,"Explicit exclusion: the trial excludes subjects with failure of two different mechanisms of advanced therapies; this patient is refractory to infliximab (anti-TNF) and ustekinumab (anti–IL-12/23), meeting that exclusion.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"The trial explicitly excludes patients with failure of two different mechanisms of advanced therapies. The patient is refractory to infliximab (anti-TNF) and ustekinumab (anti–IL-12/23), satisfying this exclusion. Thus, a hard exclusion applies and F is correct.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT06557512,0.799019455909729,Recurrent Glioblastoma,A Pilot Trial of Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma (SRS-AIM),NA,18 years,Meningioma; Recurrent Meningioma,Age >= 18 years | Histologic diagnosis of newly diagnosed WHO grade 2 meningioma or recurrent WHO grade 1 meningioma with radiographic evidence of recurrence and WHO grade 1 histology at most recent resection | Gross-total surgical resection (Simpson grade I–III) within 180 days of enrollment | ECOG 0–1 (Karnofsky >= 70%) | Post-operative MRI indicating anatomy suitable for hypofractionated stereotactic radiosurgery,Extensive multifocal meningiomas (>= 3) or metastatic disease | Tumor within 2 mm of the optic apparatus or brainstem | Another active primary malignancy unless complete remission achieved >= 2 years prior and no additional therapy required during the study period | Pregnancy | Underlying medical or psychiatric condition that would interfere with evaluation of study treatment or interpretation of safety/results | Uncontrolled seizures (>3 disabling seizures per day while on anti-epileptic drugs) | Prior intracranial radiotherapy overlapping the planned stereotactic radiosurgery target,Gross-total surgical resection (Simpson grade I–III) required within 180 days prior to enrollment,ALL,F,"Disease mismatch: the trial targets WHO grade 2 meningioma or recurrent grade 1 meningioma, while the patient has recurrent glioblastoma (IDH-wildtype). Thus, the patient is not eligible.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion: the trial is for meningioma (grade 2 or recurrent grade 1), while the patient has recurrent glioblastoma. The grader correctly assigned F based on this.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06588855,0.5418388843536377,Crohn's Disease,"A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis",PHASE3,16 years to 80 years,Ulcerative Colitis (moderately to severely active),"Confirmed diagnosis of ulcerative colitis | Moderately to severely active ulcerative colitis assessed by modified Mayo Score | Body weight >= 40 kg | Up to date colorectal cancer screening per local standards | Inadequate response, loss of response, or intolerance to at least one conventional or advanced ulcerative colitis therapy","Complications of ulcerative colitis (e.g., fulminant colitis, toxic megacolon) | Crohn's disease, indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or radiation colitis | Presence of an ostomy or ileoanal pouch | Primary sclerosing cholangitis | Pregnancy or breastfeeding | Past or current colonic dysplasia, adenomas, or neoplasia not completely removed | Malignancy within 5 years except adequately treated non-metastatic basal cell or squamous cell skin cancer or in situ cervical cancer | Infection with Clostridioides difficile, cytomegalovirus, HIV, hepatitis B, or hepatitis C | Active tuberculosis or latent/inadequately treated tuberculosis | Prior exposure to anti-TL1A therapy or other protocol-prohibited medicines","Inadequate response, loss of response, or intolerance to at least one conventional or advanced ulcerative colitis therapy",ALL,F,"The patient has Crohn's disease, while the trial targets ulcerative colitis and explicitly excludes Crohn's disease. This is a hard disease mismatch exclusion.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Disease mismatch: patient has Crohn’s disease while the trial is for ulcerative colitis, and the trial explicitly excludes Crohn’s disease. This is a hard exclusion, so F is correct.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT06600321,0.7556034922599792,Metastatic Urothelial Carcinoma,A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma,PHASE1,18 years,Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma,"Histologic, cytologic, or AASLD clinical diagnosis of hepatocellular carcinoma | At least one prior line of systemic therapy for unresectable advanced or metastatic disease | At least one WNT-pathway activating mutation | Child-Pugh class A or B7",Fibrolamellar hepatocellular carcinoma | Sarcomatoid hepatocellular carcinoma | Mixed cholangiohepatocellular carcinoma | Symptomatic extrahepatic disease | Received anti-cancer therapy or investigational drugs <= 3 weeks prior to first dose,At least one prior line of systemic therapy for unresectable advanced or metastatic disease; Washout >= 3 weeks from prior anti-cancer therapy or investigational drugs,ALL,F,"Disease mismatch: the trial enrolls patients with advanced/metastatic hepatocellular carcinoma, while the patient has metastatic urothelial carcinoma. This is a hard exclusion regardless of other factors.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),CORRECT,F,"Disease mismatch: patient has metastatic urothelial carcinoma; trial is only for advanced/metastatic hepatocellular carcinoma. This is a hard exclusion per rubric, so F is correct.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT06623240,0.5978066921234131,Rheumatoid Arthritis,"A Randomized, Double-Blind, Phase 2, Efficacy and Safety Cross-Over Study of Allogeneic HB-adMSCs vs Placebo for the Treatment of Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis",PHASE2,2 years to 16 years,(none),,,(none),ALL,F,"The trial targets juvenile idiopathic arthritis and enrolls ages 2–16, while the patient has adult rheumatoid arthritis and is 55 years old—both constitute hard exclusions (disease mismatch and age out of range).",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Correct: The trial is for juvenile idiopathic arthritis (not rheumatoid arthritis) and restricts age to 2–16, while the patient has RA and is 55. Both are hard exclusions (disease mismatch and age out of range), warranting F.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT06666712,0.7177515029907227,Recurrent Glioblastoma,Chronic Convection Enhanced Delivery of Topotecan for Recurrent Malignant Glioma,PHASE1,18 years,"Malignant Glioma (recurrent, WHO grade III–IV)","Recurrent malignant glioma, IDH-mutant, WHO grade 3–4; progression on imaging with suspicion of histologic recurrence | Patients with prior WHO grade 2 IDH-mutant glioma now demonstrating high-grade (WHO grade 3–4) features | Failed standard-of-care treatment | MRI within 30 days showing an enhancing mass without significant mass effect | Tumor volume <32 cc and stereotactically accessible | Karnofsky performance status >=70% | Age >=18 years | Adequate organ and marrow function per protocol thresholds | Women of childbearing potential: negative pregnancy test within 7 days of entry and use of birth control; men and women must use contraception per protocol timelines","Diffuse subependymal or cerebrospinal fluid disease | Tumors involving the cerebellum or both cerebral hemispheres | Active infection requiring treatment or unexplained febrile illness | Known HIV, hepatitis B, or hepatitis C positivity | Systemic diseases conferring unacceptable anesthetic/operative risk | Prior systemic topotecan for the tumor | Inability to undergo MRI or PET imaging | Allergy to topotecan, other topoisomerase inhibitors, or gadolinium compounds | Concomitant use of drugs metabolized solely by CYP3A4/5 with a narrow therapeutic index or strong CYP2C8 inhibitors, or agents with QT prolongation risk that are CYP3A substrates (must discontinue >=2 weeks before treatment) | Uncontrolled intercurrent illness (e.g., congestive heart failure, unstable angina, cardiac arrhythmia, significant psychiatric illness) | Positive pregnancy test within 7 days of registration | Breastfeeding",Failed standard-of-care therapy for malignant glioma,ALL,F,"The trial requires IDH-mutant recurrent malignant glioma, but the patient has IDH-wildtype glioblastoma—a required biomarker mismatch that is a hard exclusion.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,F,"The trial explicitly requires IDH-mutant recurrent malignant glioma, while the patient is IDH-wildtype. This is a required biomarker mismatch, which is a hard exclusion per the rubric, warranting grade F. The grader’s reasoning correctly identifies this.",,
"I have a 40 year old patient with non-smallcell lung cancer. Diagnosed de novo metastatic disease (bone, liver) with EGFR exon 19 deletion. He has been on Osimertinib for 2 years with complete response. Unfortunately, began having headaches and recent MRI shows numerous lesions. Otherwise no past medical issues and ECOG 0. Are there any trial options?",NCT06692738,0.7787777185440063,Metastatic Non-Small Cell Lung Cancer,"A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)",PHASE3,18 years,"Non-small Cell Lung Cancer (squamous, metastatic)",Histologically or cytologically confirmed squamous non-small cell lung cancer. | Stage IV metastatic NSCLC not amenable to curative treatment. | No actionable driver oncogenes with approved first-line targeted therapies per local testing. | Tumor PD-L1 expression on tumor cells (TC) >= 1%. | At least one measurable lesion by RECIST 1.1 not previously irradiated (>= 10 mm longest diameter; lymph nodes short axis >= 15 mm) suitable for repeated measurements by CT or MRI. | Adequate organ and bone marrow function.,"Presence of small cell or neuroendocrine histology components. | Active or uncontrolled brain metastases; allowed only if asymptomatic, stable, off steroids and anticonvulsants >= 7 days; >= 2 weeks since local therapy with recovery from acute effects. | Any prior systemic therapy for advanced or metastatic NSCLC. | Any prior treatment with an anti-PD-1 or anti-PD-L1 agent. | Any prior exposure to anti-TIGIT therapy or other anticancer therapy targeting immune-regulatory receptors or mechanisms. | History of another primary malignancy unless treated with curative intent with no active disease for >= 2 years and low risk of recurrence. | Active or prior autoimmune or inflammatory disorders requiring chronic steroids or other immunosuppressive treatment. | Active primary immunodeficiency or active infectious disease(s). | Active tuberculosis infection.",No prior systemic therapy for advanced/metastatic NSCLC,ALL,F,"The trial requires no prior systemic therapy for advanced/metastatic NSCLC and absence of actionable driver oncogenes; the patient has received osimertinib and harbors an EGFR exon 19 deletion, both of which are explicit exclusions.",Metastatic Non-Small Cell Lung Cancer,EGFR exon 19 deletion,"Non-small cell lung cancer; De novo metastatic disease (bone, liver); EGFR exon 19 deletion; ECOG 0; Age 40 years",(none),Osimertinib,metastatic,,40,years,male,(none),CORRECT,F,Hard exclusions apply: the trial excludes any prior systemic therapy for advanced/metastatic NSCLC and requires no actionable driver oncogenes; the patient has prior osimertinib and an EGFR exon 19 deletion. The grader correctly assigned F and cited the right reasons.,,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT06717438,0.5156973004341125,PMM2-CDG,"A Phase 2 Randomized, Double-blind, Placebo-controlled, Study of Zatolmilast (BPN14770) in Subjects With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome)",PHASE2,9 years to 45 years,PPP2R5D Neurodevelopmental Disorder,Age 9–45 years | Confirmed PPP2R5D Neurodevelopmental Disorder | Current treatment with no more than 3 prescribed psychotropic medications,"Body weight <25 kg | Clinically significant abnormalities in safety laboratory tests, vital signs, or ECG at screening | Concurrent major psychiatric condition (e.g., major depressive disorder, schizophrenia, bipolar disorder); autism spectrum disorder or anxiety disorder allowed | Planning to commence psychotherapy or cognitive behavior therapy during the study or initiated within 4 weeks prior to screening",No psychotherapy or cognitive behavior therapy initiated within 4 weeks prior to screening; Concomitant use of <=3 prescribed psychotropic medications allowed,ALL,F,"Disease and biomarker mismatch: the trial requires confirmed PPP2R5D neurodevelopmental disorder, while the patient has PMM2-CDG with PMM2 variants. Additionally, the patient is 8 years old, below the trial’s minimum age of 9.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,"Disease mismatch (PMM2-CDG vs PPP2R5D neurodevelopmental disorder) is a hard exclusion, and the patient is younger than the trial’s minimum age (8 < 9), another hard exclusion. Either mandates grade F. The grader correctly identified these factors.",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT06738017,0.5008717179298401,Ornithine Transcarbamylase Deficiency,"A Randomized, Double-Blind, Placebo-Controlled, Single Oral Dose Study Evaluating the Safety and Pharmacokinetics of BMN 349 in Homozygous for the Z Mutation of Alpha 1 Antitrypsin Gene (PiZZ) and Heterozygous for the Z Mutation (PiMZ/MASH)",PHASE1,18 years to 75 years,Alpha 1-Antitrypsin Deficiency,Confirmation of PiZZ or PiMZ genotype | Age 18 to 75 years | Nonsmoker for >= 6 months prior to screening (no tobacco or nicotine-containing products),INR > 1.2 | ALT > 125 U/L | AST > 125 U/L | Current or recent use of alpha-1 antitrypsin augmentation therapy | Diagnosis of pneumonia within the last 3 months,(none),ALL,F,"Disease mismatch: trial targets Alpha-1 antitrypsin deficiency, not OTC deficiency. Additionally, the patient is 3 months old, outside the trial’s 18–75 year age range.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Disease mismatch (OTC deficiency vs Alpha-1 antitrypsin deficiency) is a hard exclusion, and the patient’s age (3 months) is outside the trial’s 18–75 range—another hard exclusion. F is correct.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06741969,0.5398619174957275,Crohn's Disease,"A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults With Moderate to Severe Sjogren's Disease (SjD)",PHASE3,18 years,Sjogren's Disease,"Medically stable on exam, history, vital signs, clinical laboratory tests, and 12-lead ECG at screening | Meets 2016 ACR/EULAR classification criteria for Sjogren's disease | Seropositive for antibodies to Ro/SSA (Ro60 and/or Ro52) at screening | Total ClinESSDAI score >= 5 at screening | Negative pregnancy tests for participants of childbearing potential (serum at screening; urine at Week 0 prior to randomization)","History of severe, progressive, and/or uncontrolled hepatic, gastrointestinal, renal, pulmonary, cardiovascular, psychiatric, neurological, or musculoskeletal disorder, hypertension, or other uncontrolled autoimmune disorder, or clinically significant abnormalities in screening laboratory tests | Known allergy, hypersensitivity, or intolerance to nipocalimab or excipients in nipocalimab or placebo formulations | Confirmed or suspected clinical immunodeficiency syndrome not related to treatment of Sjogren's disease, or family history of congenital or hereditary immunodeficiency | Previous severe immediate hypersensitivity reaction (e.g., anaphylaxis) to therapeutic proteins (e.g., monoclonal antibodies, intravenous immunoglobulin) | Unstable or progressive manifestations of Sjogren's disease likely to warrant escalation in therapy beyond permitted background medications",(none),ALL,F,"Disease mismatch: the trial targets Sjogren's disease, while the patient has Crohn's disease. Therefore, the patient is ineligible regardless of other factors.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Disease mismatch (Crohn’s vs Sjogren’s) is a hard exclusion per the rubric, so F is correct regardless of other factors.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06750432,0.574731707572937,Dementia,"A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PMN310 in Patients With Early Alzheimer's Disease",PHASE1,50 years,Alzheimer Disease (early),Age >= 50 years | Ambulatory with adequate vision and hearing for assessments | MCI due to Alzheimer’s disease or mild AD dementia per NIA-AA (Stage 3–4) | Global CDR 0.5–1.0 and memory box score >= 0.5 at Screening and Baseline | Objective episodic memory impairment (>= 1 SD below age-adjusted mean on WMS-IV Logical Memory II) | MMSE 20–28 inclusive at Screening | Positive amyloid PET scan within 6 months of Screening or during Screening | Body mass index 18.5–35 kg/m2 inclusive | Patients of reproductive potential agree to use effective contraception during treatment and for 120 days after last dose | Females of childbearing potential: negative pregnancy tests; not breastfeeding | Postmenopausal or surgically sterile patients are eligible | Reliable caregiver available for study visits and assessments | Adequate venous access for IV infusions and blood collection | Stable dose (>= 3 months) of acetylcholinesterase inhibitors or memantine allowed,"Residing in a continuous care or long-term care nursing facility | Other neurodegenerative or neurological disorders contributing to cognitive impairment (e.g., Parkinson’s disease, Huntington’s disease, frontotemporal dementia, dementia with Lewy bodies) | QTcF > 450 msec (males) or > 470 msec (females) | ALT >= 2 x ULN, AST >= 2 x ULN, or total bilirubin >= 1.5 x ULN | Creatinine clearance < 30 mL/min | Clinically significant physical or psychiatric illness posing risk or affecting study completion (including suicidal risk/behavior) | Unstable or clinically significant cardiovascular disease within 1 year (e.g., unstable angina, myocardial infarction, chronic heart failure, significant conduction abnormalities) | Clinically significant hepatic or renal impairment; positive hepatitis B surface antigen or hepatitis C antibody | Poorly managed hypertension (systolic > 160 mmHg and/or diastolic > 95 mmHg) or hypotension (systolic < 90 mmHg and/or diastolic < 60 mmHg) | Uncontrolled diabetes (HbA1c > 7.5%) or insulin-dependent diabetes | Significant systemic illness within 30 days before first dose | Seizure within 3 years prior to Screening | Prior malignancy (except adequately treated non-melanoma skin cancer or cervical carcinoma in situ) | Brain MRI findings: > 4 microhemorrhages; > 1 lobar microhemorrhage; superficial siderosis; subarachnoid hemorrhage; any other hemorrhage > 10 mm; > 2 lacunar infarcts or cortical infarct; severe perivascular spaces or multisport-pattern white matter hyperintensities (PI review required) | History of stroke or TIA within 12 months | Contraindication to PET or brain MRI | Negative amyloid PET scan within 6 months of Screening or during Screening | Pregnant or breastfeeding | Alcohol or substance abuse within 12 months prior to dosing | Positive alcohol breath test or positive illicit drug screen at Screening | HIV antibody positive | COVID-19 infection within 2 weeks of Screening or ongoing symptoms at Screening | Currently receiving anti-amyloid treatment or received within 9 months prior to Screening (marketed or investigational); investigational placebo recipients are not excluded | Contraindication to lumbar puncture (e.g., INR > 1.4, platelet count < 120,000/µL, local infection, anticoagulant use except low-dose aspirin, significant spinal abnormalities) | Blood or blood product donation within 56 days prior to first dose | Received an investigational active agent within 30 days or 5 half-lives (whichever is longer) | History of severe hypersensitivity to PMN310 components",Stable dose of acetylcholinesterase inhibitors or memantine for >= 3 months allowed; Washout from anti-amyloid therapy >= 9 months prior to Screening; Washout from investigational active agents >= 30 days or 5 half-lives (whichever is longer),ALL,F,"The trial requires early AD with a positive amyloid PET (and excludes negative PET); the patient has a documented negative amyloid PET/CSF amyloid. Additionally, the MMSE 19 and moderate-stage dementia conflict with the trial’s mild-stage (MMSE 20–28) requirement.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"Trial requires positive amyloid PET (and excludes negative); patient definitively lacks this required biomarker (amyloid PET and CSF amyloid negative), which is a hard exclusion. Age/sex okay; MMSE and stage also mismatch but F is already triggered by biomarker.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT06789913,0.4244210720062256,PMM2-CDG,"A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation",PHASE2,2 years,PIK3CA-Related Overgrowth Spectrum (PROS); CLOVES Syndrome; Klippel-Trenaunay Syndrome; Megalencephaly-Capillary Malformation Polymicrogyria Syndrome (MCAP); Vascular Malformation; Lymphatic Malformation,Clinical diagnosis of PIK3CA-related overgrowth spectrum (PROS) or a malformation within the ISSVA classification | One or more documented activating PIK3CA mutation(s) in lesional tissue and/or cell-free DNA from the lesion or blood; some participants may be eligible without a documented PIK3CA mutation if no other genetic driver is documented | Lansky (<16 years) or Karnofsky (>=16 years) performance status >=50 | Willing to provide archived lesional fluid/tissue or undergo pretreatment lesional biopsy to assess PIK3CA status,"History of hypersensitivity to PI3K inhibitors | Factors that increase the risk of QTc prolongation or risk of arrhythmic events | Clinically significant, uncontrolled cardiovascular disease | Systemic therapy or antibody within 5 half-lives before first dose of study drug | Local therapy including radiation, surgery, or other procedures within 28 days before first dose; lesion(s) must have demonstrated progression after the procedure",(none),ALL,F,"Disease mismatch: the trial targets PIK3CA-related overgrowth spectrum and requires an activating PIK3CA mutation. The patient has PMM2-CDG with PMM2 biallelic variants, so they do not meet the disease/biomarker criteria.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,"Disease mismatch is a hard exclusion: the trial targets PROS-related conditions and PIK3CA-driven lesions, while the patient has PMM2-CDG with PMM2 variants. This triggers an immediate F per rubric. The grader’s reasoning reflects this correctly.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT06820528,0.5697106719017029,Rheumatoid Arthritis,Trapeziectomy and Suture Suspensionplasty for Thumb Carpometacarpal Arthritis - Is In-Clinic Therapy Needed?,NA,18 years,CMC Arthritis; Hand Arthritis,Age > 18 years | Undergoing CMC arthroplasty | Ability to read and write in English | Ability to provide informed consent,Revision CMC arthroplasty | Acute traumatic dislocation of the CMC joint as indication for surgery | Concomitant treatment of MCP hyperextension,(none),ALL,F,"Disease mismatch hard exclusion: the trial targets CMC/hand arthritis in patients undergoing CMC arthroplasty, whereas the patient has rheumatoid arthritis and no indication of CMC arthritis or planned CMC arthroplasty.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Disease mismatch is a hard exclusion. The trial targets CMC/hand arthritis (with requirement of undergoing CMC arthroplasty), while the patient is listed only with rheumatoid arthritis; we cannot infer CMC/hand arthritis. Thus F is appropriate per rubric.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06821568,0.5948872566223145,Dementia,Long-term Home-based Transcranial Electrical Stimulation for Cognitive and Motor Function in Older Adults With an Increased Risk of Dementia: a Randomized Controlled Trial,NA,65 years to 90 years,Alzheimer Disease and Related Dementias; Cognition; Mobility Disability,Age 65-90 years | Subjective cognitive complaints per screening questions | Montreal Cognitive Assessment (MoCA) score >=21 | Slow gait speed defined as usual walking speed >=1 SD below age- and sex-adjusted means on 4-Meter walk | Able to walk unassisted for at least 2 minutes and Functional Activities Questionnaire (FAQ) score <9,"Formal education less than 8th grade | Previous physician diagnosis of dementia | Current diagnosis of a major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depressive disorder) | Moderate-to-severe depressive symptoms (Geriatric Depression Scale-15 score >=9) | History of head trauma with prolonged loss of consciousness | History of fainting spells of unknown etiology that might constitute seizures | History of seizures, epilepsy, or first-degree family history of epilepsy (except a single benign seizure per neurologist judgment) | Hospitalization within the past 3 months due to acute illness or musculoskeletal injury significantly affecting gait or balance | Unstable or uncontrolled medical conditions that may pose risk with potential provoked seizure (e.g., cardiac malformation, dysrhythmia, asthma) | Substance use disorder within the past 6 months | Hairstyle or headdress preventing electrode contact with the scalp or interfering with stimulation (e.g., thick braids, hair weave, afro, wig) | Chronic vertigo | Myocardial infarction within the past 6 months | Active cancer receiving chemotherapy or radiation therapy | Legal blindness | Visual hallucinations (history or self-report) | Pacemaker | Contraindications to MRI or tDCS (e.g., unprovoked seizure within past 2 years, risk of ferromagnetic objects, implanted medical devices such as deep brain stimulator, infusion pump, cochlear implant, pacemaker; active dermatological condition on the scalp) | History of REM sleep behavior disorder | Medical history and CNS-active medications deemed unsafe by study physician based on dose, recent changes, duration, or combinations",(none),ALL,F,"The trial explicitly excludes participants with a prior physician diagnosis of dementia, and this patient has moderate-stage dementia. Other criteria (e.g., MoCA ≥21, slow gait, FAQ <9) are unknown, but the explicit exclusion makes the patient ineligible.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"Explicit exclusion applies: the trial excludes individuals with a prior physician diagnosis of dementia, and the patient has moderate-stage dementia. Therefore, F is correct regardless of other unknown criteria.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06864403,0.6816847324371338,Crohn's Disease,Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch,PHASE4,18 years to 80 years,Chronic Pouchitis; Crohn's-like Disease of the Pouch,"Age >=18 and <=80 years | Diagnosis of chronic pouchitis or Crohn's-like disease of the pouch | Chronic antibiotic-dependent pouchitis: symptoms responsive to antibiotics but relapse after stopping, requiring continuous antibiotics | Chronic antibiotic-refractory pouchitis: lack of response or minimal improvement with standard antibiotics | Crohn's-like disease of the pouch: fistula >=12 months post-IPAA, stricture of pouch body or pre-pouch ileum, or pre-pouch ileitis (pouchitis may coexist) | History of ulcerative colitis and prior IPAA (1, 2, modified -2, or 3 stage) with ileostomy takedown | Provider is considering initiating mirikizumab for treatment","Prior exposure to mirikizumab | Known hypersensitivity to mirikizumab or its metabolites | Current Clostridioides difficile infection | Known HIV infection or active hepatitis B or C | Clinically significant liver disease (PSC allowed if liver function tests <1.5 x ULN) | Severe hepatic impairment (Child-Pugh class C) | Decreased kidney function with eGFR <45 mL/min/1.73 m^2 | History of malignancy except basal cell carcinoma, non-metastatic squamous cell carcinoma of the skin, or prior malignancy cured >=5 years before screening without recurrence | Clinically significant laboratory abnormalities at screening or baseline per investigator | Pregnant or breastfeeding, or of childbearing potential without highly effective contraception | Participation in another interventional clinical trial within 30 days before screening | Any disorder that may jeopardize safety or protocol compliance per investigator",(none),ALL,F,"Disease mismatch: the trial targets chronic pouchitis/Crohn's-like disease of the pouch in post-IPAA patients, whereas the patient has Crohn's disease with perianal fistula and no evidence of having a pouch or UC/IPAA.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Correct F. The trial targets chronic pouchitis/Crohn’s-like disease of the pouch (post-IPAA), not general Crohn’s disease. Patient’s disease is Crohn’s disease with perianal fistula; this is not among trial diseases, triggering the Hard Exclusion for disease mismatch.",,
"A 55-year-old female has severe, seropositive rheumatoid arthritis refractory to methotrexate and two prior biologic agents (adalimumab and tocilizumab). She has active disease with a DAS28 score of 5.5. Critically, she has a history of treated Hepatitis B (HBsAg negative, anti-HBc positive) and moderate chronic kidney disease with an eGFR of 45 mL/min/1.73m². What are trial options for her?",NCT06876350,0.5765183568000793,Rheumatoid Arthritis,Patient Satisfaction for Post-Operative Carpometacarpal Arthroplasty: Wood Casting Versus Thermoplastic Splint,NA,18 years,Carpometacarpal Joint Arthritis,Age >= 18 years | Intact medical decision-making capacity | Eligible for surgical intervention,Pregnancy,(none),ALL,F,"Disease mismatch: the trial targets carpometacarpal joint arthritis patients undergoing surgical arthroplasty, not rheumatoid arthritis. Even though age and sex fit, the patient’s disease is not included.",Rheumatoid Arthritis,(none),Age 55 years; Female; Seropositive rheumatoid arthritis; Active disease (DAS28 5.5),(none),Refractory to methotrexate; Prior adalimumab; Prior tocilizumab; Failed two prior biologic agents,,,55,years,female,(none),CORRECT,F,"Hard exclusion applies due to disease mismatch: trial targets carpometacarpal joint arthritis (post-op arthroplasty) while the patient has rheumatoid arthritis, with no indication of CMC arthritis. Per rubric, this is an immediate F. The grader’s reasoning aligns with the rubric.",,
"40 year old man with recurrent glioblastoma. Diagnosed 1 year ago, underwent gross total resection with confirmation of GBM, IDH wildtype. Completed adjuvant radiation + concurrent temozolomide and then adjuvant temozolomide. Three months after completing adjuvant therapy, MRI shows recurrence. ECOG 1 and no other medical issues. What are trial options?",NCT06914479,0.7583947777748108,Recurrent Glioblastoma,"A Phase 1 Study of a Combined Cytotoxic and Immune-Stimulatory Therapy in Pediatric and Young Adult Patients With Recurrent, Primary Malignant Brain Tumors",PHASE1,3 years to 39 years,Malignant Brain Tumor (recurrent); Diffuse Hemispheric Glioma (H3 G34-mutant),"Age 3-25 years with malignant primary brain tumor at recurrence/relapse/progression after completion of up-front standard therapy | Age 26-39 years with diffuse hemispheric glioma, H3 G34-mutant, at recurrence/relapse/progression after completion of up-front standard therapy | Weight >= 10 kg and BSA > 0.5 m^2 | On stable or decreasing corticosteroid dose for >= 3 days prior to baseline MRI | Surgical resection of recurrence/relapse/progression is clinically indicated | Willing to provide archival FFPE and/or frozen tissue specimens, if available | Recovered from acute side effects of prior therapy | Therapy washouts from start of study treatment: >= 7 days after last biologic agent or beyond known AE window; 5 half-lives from any investigational agent; 4 weeks from cytotoxic therapy (23 days for temozolomide; 6 weeks for nitrosoureas); 6 weeks from antibody therapy (21 days for bevacizumab); 6 weeks from cellular therapy; 4 weeks or 5 half-lives (whichever shorter) from other antitumor therapies | Prior radiotherapy: >= 28 days from focal RT; >= 150 days from craniospinal irradiation | Bevacizumab for RT-induced edema allowed (up to 5 doses; no washout required) | Prior temozolomide during radiation at standard pediatric dosing allowed; prior dexamethasone allowed | ANC >= 1000/µL | Platelets >= 100000/µL (transfusion independent) | Creatinine clearance or GFR >= 70 mL/min/1.73 m^2 or serum creatinine within normal limits for age | Bilirubin <= 2 x ULN | ALT <= 3 x ULN | Serum albumin <= 2 g/dL | Performance score >= 60 (Karnofsky if >16 years; Lansky if <=16 years) | Females of child-bearing potential and males agree to use adequate contraception during treatment and for 30 days after last dose","Not clinically appropriate for tumor resection per neurosurgeon | Disseminated disease including diffuse leptomeningeal disease or CSF dissemination | Primary brainstem or primary spinal tumors | History of prior gene therapy | Ongoing valacyclovir therapy that cannot be stopped due to a medical condition | Known allergy to valacyclovir | Concurrent use of other investigational agents (non-diagnostic) | Currently receiving anti-cancer agents | Known disorders affecting immune system (e.g., HIV, hepatitis B or C) or autoimmune disorder requiring systemic cytotoxic or immunosuppressive therapy | Uncontrolled infection or other uncontrolled systemic illness | Current diagnosis of bipolar disorder or major depressive disorder | Congenital immune deficiency syndrome or acquired autoimmune disease | Pregnant or breastfeeding; FOCBP must have negative pregnancy test prior to therapy | Active illicit drug use or diagnosis of alcoholism | History of kidney transplant | History of allogeneic stem cell transplantation | Another malignancy that is progressing or requires active treatment within 3 years","Completed up-front standard-of-care therapy required; Washout: >= 7 days since last biologic agent or beyond known AE window; Washout: 5 half-lives from any investigational agent; Washout: 4 weeks from cytotoxic therapy (23 days for temozolomide; 6 weeks for nitrosoureas); Washout: 6 weeks from antibody therapy (21 days for bevacizumab); Washout: 6 weeks from cellular therapy (e.g., modified T cells, NK cells, dendritic cells); Washout: 4 weeks or 5 half-lives (whichever is shorter) from other antitumor therapies; Prior radiotherapy: >= 28 days from focal RT; >= 150 days from craniospinal irradiation; Bevacizumab for RT-induced edema allowed (<= 5 doses; no washout required); Prior temozolomide during radiation at standard pediatric dosing allowed; Prior dexamethasone allowed",ALL,F,"The patient is 40 years old, which exceeds the trial’s maximum age of 39, creating an age window hard exclusion. Additionally, for adults the trial requires H3 G34-mutant diffuse hemispheric glioma, which is not specified for this patient.",Recurrent Glioblastoma,IDH wildtype,Age 40 years; Male; Recurrent glioblastoma; IDH wildtype; Status post gross total resection; Completed radiation with concurrent temozolomide and adjuvant temozolomide; ECOG 1; No other medical issues,(none),Gross total resection; Adjuvant radiation with concurrent temozolomide; Adjuvant temozolomide,recurrent,,40,years,male,(none),CORRECT,F,"Age 40 exceeds the trial’s max age of 39, which is a hard exclusion per the rubric. Thus F is correct. The additional note about the adult cohort’s H3 G34-mutant requirement is not needed once the age exclusion applies, but does not change the outcome.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06937229,0.5847024917602539,Dementia,"A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-3)",PHASE3,55 years to 90 years,Alzheimer Disease (agitation),Completed study CN012-0023 or CN012-0024 per protocol | One identified caregiver with approximately 10 hours/week or more contact,"Clinically significant cardiovascular (e.g., untreated or unstable hypertension, clinically significant tachycardia), pulmonary, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any condition that could jeopardize participant safety or study validity in the investigator’s opinion",(none),ALL,F,"Disease mismatch: the trial enrolls patients with agitation associated with Alzheimer’s disease (and requires completion of specific parent studies), while the patient has unspecified dementia with amyloid-negative biomarkers and no stated AD diagnosis or prior parent-study completion.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,F is correct due to hard exclusion: disease mismatch. The trial targets Alzheimer’s disease (agitation) and requires prior parent-study completion; the patient has unspecified dementia without confirmed AD and did not complete the parent studies. Disease mismatch alone justifies F per rubric.,,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT06937658,0.46146345138549805,PMM2-CDG,Remote Alert Pathway To Optimize CaRe of Cardiac Implantable Electrical Devices,NA,18 years,Pacemaker DDD; Implantable Defibrillator User,"Age > 18 years | Clinically stable | Has a wireless cardiac implantable electronic device (pacemaker or implantable cardioverter-defibrillator), including single, dual-chamber, biventricular, subcutaneous/extravascular, or leadless systems | Device from Medtronic, Boston Scientific, Abbott, or Biotronik | Currently enrolled in remote monitoring | Primary clinical electrophysiology follow-up at the enrolling center",Presence of an insertable cardiac monitor (alone or in combination with any other CIED) | Listed for cardiac transplantation prior to enrollment,(none),ALL,F,"Disease mismatch: the trial is for patients with cardiac implantable electronic devices, not PMM2-CDG. Additionally, the patient is 8 years old while the trial requires age >18.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,"Correct F: There is a hard disease mismatch (trial targets CIED users, not PMM2-CDG) and an age hard exclusion (trial ≥18, patient 8). The grader’s reasoning aligns with the rubric.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06986382,0.6890472769737244,Crohn's Disease,"Phase 1b/2a Trial of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset (EO), Medically Refractory (MR) Crohn Disease (CD)",PHASE1/PHASE2,2 years to 30 years,"Crohn Disease (medically refractory, early-onset or monogenic)","Monogenic cause of inflammatory bowel disease with a causative mutation for which HSCT is known to be curative (e.g., IL10/IL10RA/IL10RB, XIAP, IPEX, WAS, CD40L, CGD, LRBA, CTLA4, DOCK8, SCID syndromes) | Known monogenic cause of Crohn disease expressed in lymphohematopoietic cells where HSCT has not been previously performed, with moderate disease activity and failure/toxicity to at least two treatment pathways | Suspected monogenic cause of Crohn disease with a rare deleterious variant in a lymphohematopoietic-expressed gene and moderate disease activity or corticosteroid-dependence despite trials of at least two biologic/small molecule therapies of different mechanisms or significant toxicity | Medically refractory Crohn disease with suspected strong genetic component, with moderate or severe activity and corticosteroid-dependence despite trials of at least two biologic/small molecule therapies or significant toxicity | Disease severity unlikely to be tolerable long-term (e.g., not amenable to surgery without risk of short bowel syndrome or permanent ileostomy; requirement for long-term parenteral nutrition; intolerable extraintestinal symptoms) | Features suggesting high genetic contribution (e.g., parental consanguinity, strong family history in first-degree relatives, diagnosis <6 years, extraintestinal manifestations, family history of IBD or autoimmune disease) | Age >2 years and <30 years | Donor and recipient identical at least one allele at HLA-A, HLA-B, HLA-C, HLA-DQB1, and HLA-DRB1 by high-resolution typing | Karnofsky/Lansky performance status >=50%","Ulcerative colitis | Crohn disease responsive to medical therapy without corticosteroid-dependence or significant toxicity | Deleterious mutation in a gene expressed in epithelial or stromal cells but not in lymphohematopoietic cells (e.g., TTC7A), or mutation expected to be more deleterious outside lymphohematopoietic cells | Active hemophagocytic lymphohistiocytosis | Hepatic dysfunction: ALT >5 x ULN, AST >5 x ULN, or direct bilirubin >3 x ULN | Cirrhosis with bridging fibrosis (grade F3 or greater) or sclerosing cholangitis | Severe cardiovascular disease (e.g., left ventricular ejection fraction <40% or severe diastolic dysfunction) | Severe renal dysfunction: serum creatinine >1.5 x ULN or 24-hour creatinine clearance <50 mL/min/m2 | HIV infection or chronic hepatitis B or hepatitis C infection | Past exposure to therapeutic radiation | Previous allogeneic HSCT | Active malignancy or history of malignancy within 2 years (except nonmelanoma skin cancer or carcinoma in situ) | Pregnant or lactating | Severe concurrent uncontrolled disease increasing risk from study participation","Failure or significant toxicity after at least two biologic or small-molecule therapies with different mechanisms (e.g., TNF inhibitors, anti-IL12/23 antibodies, JAK inhibitors, anti-integrin); Corticosteroid dependence despite prior biologic/small-molecule therapies",ALL,F,"The patient is 32 years old, which is outside the trial’s age range (>2 and <30 years). Although the disease matches, the age window is a hard exclusion.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Age is a hard exclusion: patient is 32, exceeding trial maximum age of 30. Per rubric, age window conflict triggers F regardless of other matches. The grader correctly identified this and assigned F.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT06991114,0.5377060770988464,Crohn's Disease,"An Open-label Phase 2a Study to Evaluate the Safety and Efficacy of AlloNK®, an Allogeneic Cord Blood-derived NK Cell Therapy, in Combination With Rituximab in Relapsing Forms of B-cell Dependent Rheumatologic Diseases",PHASE2,18 years,Rheumatoid Arthritis; Sjögren's Disease; Idiopathic Inflammatory Myopathy; Systemic Sclerosis,Rheumatoid arthritis diagnosis per 2010 ACR/EULAR criteria | Rheumatoid factor (RF) or anti-citrullinated protein antibody (ACPA) positive | High-sensitivity C-reactive protein (hs-CRP) > 3 mg/L or erythrocyte sedimentation rate (ESR) > 28 mm/hr | Prior biologic DMARD treatment for >= 12 weeks and deemed refractory by treating physician | >= 6 swollen joints and >= 6 tender joints on assessment | Primary Sjögren's disease per 2016 ACR/EULAR criteria with confirmatory diagnosis within 24 weeks before screening | ClinESSDAI > 6 | Stimulated salivary flow rate > 0.1 mL/min | Idiopathic inflammatory myopathy with positive autoantibody (ANA > 1:80 or RNP or SSA/SSB or other myositis-specific autoantibody) | Refractory IIM: inadequate response or intolerance to >= 3 months of glucocorticoids and/or at least one other immunosuppressive | Muscle biopsy or muscle MRI confirming IIM within 12 months prior to enrollment | Systemic sclerosis diagnosis per 2013 ACR/EULAR criteria | Modified Rodnan skin score (mRSS) > 10 | Initial confirmatory SSc diagnosis within 8 years of screening | Refractory SSc: inadequate response or intolerance to >= 3 months of glucocorticoids and/or at least one other immunosuppressive,,Prior biologic DMARD for rheumatoid arthritis for >= 12 weeks; Prior glucocorticoids and/or at least one immunosuppressive for IIM for >= 3 months; Prior glucocorticoids and/or at least one immunosuppressive for systemic sclerosis for >= 3 months,ALL,F,"Disease mismatch: the trial only enrolls rheumatoid arthritis, Sjögren's, idiopathic inflammatory myopathy, or systemic sclerosis, while the patient has Crohn's disease. Therefore the patient is not eligible despite appropriate age and sex.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion: the trial targets RA, Sjögren’s, IIM, or systemic sclerosis, while the patient has Crohn’s disease. F is correct regardless of age/sex compatibility.",,
"What are trial options for a 68-year-old male with a two-year history of progressive cognitive decline? His MMSE score is 19, consistent with moderate-stage dementia. An amyloid PET scan was performed and was negative. CSF analysis was also negative for amyloid plaques but showed elevated p-tau. His family is seeking disease-modifying therapies.",NCT06995638,0.622193455696106,Dementia,Web-based Technology and Cognitive Training: Improving Executive Control in Cognitively Healthy Older Adults: the MUltitasking STrategy (MUST) Study,NA,60 years to 75 years,Healthy Aging; Alzheimer&#39;s Disease (AD),Age 60-75 | Adequate English proficiency | Willingness to attend 2 in-person assessments | Willingness to attend a blood test | Willingness to attend online intervention sessions | Willingness to attend an online follow-up assessment,"Montreal Cognitive Assessment score < 26 | History of cognitive impairment, dementia, stroke, seizure disorder, or other neuropsychiatric condition judged to impact cognitive performance | Taking medications known to influence cognitive performance | Sensory impairment (e.g., visual, auditory) incompatible with use of a standard computer workstation | Physical impairment (e.g., severe arthritic, orthopedic, neurologic) incompatible with use of a standard computer workstation | Enrollment in a concurrent study that could affect the outcome of this study",(none),ALL,F,"The trial is for cognitively healthy older adults and explicitly excludes participants with a history of cognitive impairment or dementia. The patient has moderate-stage dementia (MMSE 19), triggering an explicit exclusion.",Dementia,Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,Age 68 years; Male; Two-year history of progressive cognitive decline; MMSE score 19; Moderate-stage dementia; Amyloid PET negative; CSF amyloid negative; Elevated CSF p-tau,(none),(none),moderate-stage,,68,years,male,(none),CORRECT,F,"Explicit exclusion applies: the trial excludes anyone with a history of cognitive impairment or dementia, and the patient has moderate-stage dementia. Grade F is correct per hard exclusion rule.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT07015671,0.4264090657234192,PMM2-CDG,Bioavailability and Bioequivalence (BA/BE) Study of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Subjects,PHASE3,18 years to 45 years,Bioequivalence Study in Healthy Subjects; PK/PD,"Age 18–45 years | Weight: men >=50 kg; women >=45 kg; BMI 18.50–29.99 kg/m2 | Non-smoker (abstinent >=1 year) and no tobacco use | Healthy with no significant disease and no clinically significant abnormalities on history, exam, labs, ECG, and chest X-ray | Negative for HIV 1/2, hepatitis B, hepatitis C, and syphilis | Women of childbearing potential and male participants agree to use two effective contraceptive methods during the study and for 2 weeks after last dose; postmenopausal or surgically sterile women eligible","Significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, musculoskeletal, or psychiatric disease | History of asthma, urticaria, or allergic-type reactions after taking torsemide, spironolactone, or other drugs; gastric/duodenal ulcer; gastrointestinal bleeding; jaundice within past 6 months; internal bleeding | Hypersensitivity or allergy to torsemide, spironolactone, or excipients | Alcohol or drug abuse within the past year | Family history of bleeding disorders | History of urinary retention, difficulty voiding, or incontinence | Blood donation >=500 mL within 90 days before first dose | Difficulty with venous access for cannulation or blood sampling | Positive breath alcohol test at screening/check-in | Positive urine drug screen at screening/check-in | Positive screening for hepatitis B, hepatitis C, HIV, or syphilis | Difficulty swallowing tablets | Use of any medication (including OTC) or herbal products within 14 days before first dose | Use of enzyme-modifying drugs within 30 days before first dose | History of dehydration from diarrhea or vomiting within 24 hours before first check-in | Consumption of xanthine-containing products (chocolate, tea, coffee, cola) within 48 hours before first check-in | Consumption of grapefruit or its products within 48 hours before first check-in | Pregnant or lactating females",No medications (including OTC) or herbal products within 14 days before first dose; No enzyme-modifying drugs within 30 days before first dose,ALL,F,"This study enrolls only healthy adults aged 18–45, whereas the patient is an 8-year-old with PMM2-CDG. Both the disease and age fall outside the trial’s eligibility criteria.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,"Hard exclusions apply: disease mismatch (trial enrolls only healthy subjects, not PMM2-CDG) and age 8 < 18. The grader correctly assigned F and cited the key conflicts.",,
"55 year old male with metastatic urothelial carcinoma, now progressing after second line therapy. Initially diagnosed with MIBC 3 years ago. He received neoadjuvant gemcitabine/cisplatin x 4 cycles and then cystectomy with pCR. 6 months later he presented with new bone metastases. Biopsy confirmed metastatic urothelial cancer. He was started on EV+pembrolizumab and after 6 cycles, scans showed worsening osseous mets and now new liver lesions. He has a hx of T2DM, COPD, and CKD with eGFR 35. What are trial options?",NCT07048457,0.8283127546310425,Metastatic Urothelial Carcinoma,A Phase II Study of Consolidative Local Therapy in Patients With Locally Advanced or Oligo-metastatic Urothelial Carcinoma (la/mUC) Following Treatment Response to Systemic Therapy With or Without Metastasis-directed Radiotherapy,PHASE2,18 years,Urothelial Carcinoma (locally advanced); Urothelial Carcinoma (oligo-metastatic),"Age >= 18 years | ECOG performance status 0–1 | Surgical candidate for extirpative surgery of primary site with bilateral pelvic lymph node dissection and urinary diversion | If applicable, surgical candidate for resection of non-irradiated metastatic lesion(s) | Histologically confirmed urothelial carcinoma, locally advanced or oligo-metastatic (<= 5 distinct metastatic lesions) | Variant histology < 50% with urothelial carcinoma predominant | Received first-line enfortumab vedotin-based systemic therapy started >= 3 months prior to surgery and total treatment duration <= 6 months | Most recent restaging scan shows stable disease, partial response, or complete response by investigator-assessed RECIST v1.1","Systemic anti-cancer therapy within 3 weeks prior to surgery | Radiotherapy within 2 weeks prior to surgery | Positive pregnancy test or breastfeeding | History of central nervous system or leptomeningeal metastases | Concurrent medical, surgical, or psychiatric condition that may confound study interpretation or prevent completion of study procedures | Any medical condition posing undue risk to participation per investigator judgment",First-line enfortumab vedotin-based systemic therapy initiated >= 3 months before surgery; total duration <= 6 months; Metastasis-directed radiotherapy allowed,ALL,F,"The trial requires patients in the consolidative setting after a response to first-line enfortumab vedotin-based therapy, whereas the patient is post–second-line therapy, which does not meet the required treatment setting.",Metastatic Urothelial Carcinoma,(none),(none),(none),(none),metastatic,after second line therapy,55,years,male,(none),INCORRECT,D,"Wrong line/setting is a soft mismatch, not a hard exclusion. The trial requires consolidative post–first-line enfortumab vedotin response; the patient is post–second-line, which mismatches Core Anchor 2 (line/prior) and likely stage/setting, but it’s not an explicit exclusion. Other required elements (oligo-metastatic status, surgical candidacy, EV exposure) are unknown, so no hard exclusion applies. Correct grade: D.",,
I'm looking for trial options for an 8-year-old female with PMM2-CDG (Congenital Disorder of Glycosylation). She has confirmed biallelic pathogenic variants in PMM2 and exhibits moderate cerebellar dysfunction with a recent ICARS score of 35. Her family is highly motivated for research participation.,NCT07054515,0.4910292625427246,PMM2-CDG,"18-month Double-blind, Randomized, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease and in Late-infantile and Juvenile-onset Forms of GM1 Gangliosidosis or GM2 Gangliosidosis",PHASE3,4 years,GM1 Gangliosidosis; GM2 Gangliosidosis; Niemann-Pick Type C Disease,"Age >= 4 years | Diagnosis of Niemann-Pick type C disease (late-infantile or juvenile form) | Diagnosis of GM1 gangliosidosis (late-infantile or juvenile onset) | Diagnosis of GM2 gangliosidosis (Tay-Sachs, Sandhoff, or GM2AB variant; late-infantile or juvenile onset)",,(none),ALL,F,"Disease mismatch: the trial targets Niemann-Pick type C and GM1/GM2 gangliosidoses, not PMM2-CDG. The patient’s condition is not included among the eligible diseases.",PMM2-CDG,PMM2 biallelic pathogenic variants,Diagnosis of PMM2-CDG; Confirmed biallelic pathogenic variants in PMM2; ICARS score 35 (moderate cerebellar dysfunction); Age 8 years,(none),(none),,,8,years,female,(none),CORRECT,F,"The trial targets Niemann-Pick type C and GM1/GM2 gangliosidoses, while the patient has PMM2-CDG. This is a hard disease mismatch per rubric, triggering an immediate F. The grader’s reasoning and grade are correct.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT07075536,0.5438545942306519,Crohn's Disease,A Web-based Contraceptive Decision Support Tool for Individuals With Health Conditions: A Cluster Randomized Controlled Trial With Mixed Methods,NA,18 years to 49 years,"Contraceptive Usage; Contraceptive Behavior; Chronic Disease; Chronic Condition; Chronic Conditions, Multiple","Age 18-49 years | Assigned female sex at birth | Presumed fertile (intact uterus/tube/ovary; premenopausal) | Has at least one health condition, prior adverse pregnancy outcome, taking a teratogenic medication, or taking a medication that interacts with hormonal contraception | Able to read English | Access to a mobile phone, computer, or tablet with internet | Not currently pregnant | Desires to discuss starting, switching, or adding contraception to prevent pregnancy","Trying to get pregnant in the next 12 months | Presumed infertile due to surgical or medical reasons (e.g., postmenopausal, hysterectomy, chemotherapy)",(none),FEMALE,F,"Hard exclusion: The trial is restricted to individuals assigned female sex at birth, while the patient is male. Although age fits, the sex restriction makes the patient ineligible.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"Hard exclusion applies: trial restricts to individuals assigned female at birth, while patient is male. Therefore F is correct. (Disease focus also mismatches, but sex restriction alone is sufficient.)",,
What are trial options for a 3-month-old male infant with genetically confirmed Ornithine Transcarbamylase (OTC) deficiency? He presented on day 3 of life with a severe hyperammonemic crisis (ammonia 720 μmol/L) and is now stable on a regimen of dietary protein restriction and ammonia scavengers.,NCT07125066,0.48826688528060913,Ornithine Transcarbamylase Deficiency,"An Individual Patient, Open Label Study to Use ACER-001 to Treat Combined D,L-2-hydroxyglutaric Aciduria (C-2HGA)",PHASE1,Not specified,"Combined D,L-2-Hydroxyglutaric Aciduria","Diagnosis of Combined D,L-2-hydroxyglutaric aciduria | Parental permission at start of protocol | Parents willing to adhere to the protocol",Refusal or withdrawal of consent | Drug intolerance,(none),MALE,F,"Disease mismatch: the trial targets combined D,L-2-hydroxyglutaric aciduria, while the patient has ornithine transcarbamylase deficiency.",Ornithine Transcarbamylase Deficiency,OTC mutation,Genetically confirmed ornithine transcarbamylase (OTC) deficiency; History of severe neonatal hyperammonemic crisis; Currently clinically stable on therapy; Male; Age 3 months,(none),Dietary protein restriction; Ammonia scavengers,,,3,months,male,(none),CORRECT,F,"Disease mismatch is a hard exclusion per rubric. Trial targets Combined D,L-2-hydroxyglutaric aciduria; patient has OTC deficiency. F is appropriate, and the grader’s reasoning aligns with the rubric.",,
"A 32-year-old male has moderate-to-severe fistulizing Crohn's disease, refractory to both infliximab and ustekinumab, with a CDAI score of 350. He recently completed IV antibiotic treatment for a perianal abscess and still has an active, draining seton in place. What are his clinical trial options?",NCT07138898,0.5736960172653198,Crohn's Disease,Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty,PHASE2,18 years,Rheumatoid Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Systemic Lupus Erythematosus; Juvenile Idiopathic Arthritis; Spondyloarthritis; Polymyalgia Rheumatica; Giant Cell Arteritis; Vasculitis; Granulomatosis With Polyangiitis; Dermatomyositis; Polymyositis; Inflammatory Bowel Disease-Associated Arthritis,"Age >= 18 years | Diagnosis of rheumatic disease (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, juvenile idiopathic arthritis, spondyloarthritis, polymyalgia rheumatica, giant cell arteritis, vasculitis, granulomatosis with polyangiitis, dermatomyositis, polymyositis, inflammatory bowel disease-associated arthritis) | On active immunosuppression for >= 3 months prior to scheduled surgery | Scheduled for elective total shoulder arthroplasty",Active infection | Active malignancy | Shoulder arthroplasty indication is fracture or tumor | Pregnancy or breastfeeding | Severe systemic lupus erythematosus with marked activity,On active immunosuppression for >= 3 months,ALL,F,"Disease mismatch: the study enrolls patients with specified rheumatic diseases (including IBD-associated arthritis) undergoing elective total shoulder arthroplasty, while the patient has Crohn's disease without IBD-associated arthritis.",Crohn's Disease,(none),Moderate-to-severe Crohn's disease; Fistulizing disease; CDAI score 350; Active perianal fistula with draining seton in place,(none),Refractory to infliximab; Refractory to ustekinumab,,,32,years,male,(none),CORRECT,F,"The trial targets rheumatic diseases (including IBD-associated arthritis) in patients undergoing elective total shoulder arthroplasty. The patient has Crohn’s disease without documented IBD-associated arthritis, so this is a disease mismatch—a hard exclusion per the rubric—warranting grade F.",,
